





Drug Expenditure in Canada, 1985 to 2011



Our Vision

Better data. Better decisions. Healthier Canadians.

Our Mandate

To lead the development and maintenance of comprehensive and integrated health information that enables sound policy and effective health system management that improve health and health care.

Our Values

Respect, Integrity, Collaboration, Excellence, Innovation

Table of Contents

Executive Summary	V
Introduction	1
National Drug Expenditure Overview	3
The Share of Drugs in Total Health Expenditure	3
Total Drug Expenditure	6
Total Drug Expenditure per Capita	7
Drug Expenditure: Prescribed and Non-Prescribed Drugs	8
Prescribed Drug Expenditure by Source of Finance	10
Drug Expenditure in the Provinces and Territories	17
The Share of Drugs in Total Health Expenditure	18
Total Drug Expenditure by Source of Finance	20
Total Drug Expenditure per Capita by Source of Finance	21
Drug Expenditure by Type of Drug and by Source of Finance	22
International Comparisons	29
Comparability of Health Expenditure Across Countries	29
Share of Drugs in Total Health Expenditure	29
Share of Public Expenditure in Total Expenditure on Drugs	32
Share of Drugs in Public Expenditure on Health	33
Factors Affecting Drug Expenditure in Canada	35
Methodological Notes	39
Background	39
Data Limitations	43
Collection and Non-Response	45
Sources of Data	52
Series A—Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, Canada, 1985 to 2011	55
Series B—Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, by Province/Territory, 1985 to 2011	61
Series C—International Comparisons	115
Appendix A—Comparison of Provincial and Territorial Drug Subsidy Programs	121
References	143

List of Figures

Figure 1	Total Drug Expenditure as a Percentage of Total Health Expenditure, Canada, 1985 to 2011	3
Figure 2	Annual Growth Rate for Total Drug Expenditure and Total Health Expenditure, Canada, 1985 to 2011	4
Figure 3	Total Health Expenditure, by Use of Funds, Canada, 2011	5
Figure 4	Total Drug Expenditure, Canada, 1985 to 2011	6
Figure 5	Total Drug Expenditure per Capita, Current and Constant Dollars, Canada, 1985 to 2011	7
Figure 6	Total Drug Expenditure, by Type (Prescribed and Non-Prescribed), Canada, 1985 to 2011	9
Figure 7	Total Drug Expenditure, by Source of Finance and Type of Expenditure, Canada, 2011	10
Figure 8	Prescribed Drug Expenditure, by Source of Finance, Canada, 1985 to 2011	11
Figure 9	Annual Growth Rate for Prescribed Drug Expenditure, by Source of Finance, Canada, 1985 to 2011	12
Figure 10	Prescribed Drug Expenditure, by Private-Sector Source of Finance, Canada, 1988 to 2011	14
Figure 11	Drug Expenditure as a Percentage of Total Health Expenditure, by Province/ Territory and Canada, 1985 and 2011	19
Figure 12	Percentage of Total Drug Expenditure by Source of Finance, by Province/ Territory and Canada, 2011	20
Figure 13	Total Drug Expenditure per Capita, by Type and by Source of Finance, by Province/Territory and Canada, 2011	21
Figure 14	Annual Growth Rate for Public- and Private-Sector Prescribed and Non-Prescribed Drug Expenditure per Capita, by Province/Territory and Canada, 2011	23
Figure 15	Average Annual Growth Rate for Prescribed Drug Expenditure per Capita, by Source of Finance, by Province/Territory and Canada, Between 1985 and 2011	24
Figure 16	Public-Sector Prescribed Drug Expenditure as a Percentage of Total Prescribed Drug Expenditure, by Province/Territory, 1985 to 2011	25
Figure 17	Drug Expenditure per Capita, Selected OECD Comparator Countries, 1985 to 2009	31
Figure 18	Composition of Total Health Expenditure, by Source of Finance	40
Figure 19	Patented Medicine Price Index (PMPI), Consumer Price Index (CPI) and Industrial Product Price Index (IPPI), 1985 to 2011 (1987 = 100)	45

List of Tables

Table 1	Distribution of Prescribed Drug Expenditure, by Source of Finance, Canada, 1988 and 2011	13
Table 2	Drug Expenditure Summary, by Province/Territory and Canada, 2011	17
Table 3	Total Expenditure on Pharmaceutical Goods per Capita and as a Percentage of Total Health Expenditure, Selected OECD Comparator Countries, 2009	30
Table 4	Public Expenditure on Pharmaceutical Goods per Capita and as a Percentage of Total Expenditure on Pharmaceutical Goods, Selected OECD Comparator Countries, 2009	33
Table 5	Public Expenditure on Pharmaceutical Goods per Capita and as a Percentage of Public-Sector Health Expenditure, Selected OECD Comparator Countries, 2009	34
Table 6	Provincial/Territorial Government Drug Expenditure Data	46
Table 7	Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2011	. 122

Executive Summary

Total expenditure on drugsⁱ in Canada was \$29.6 billionⁱⁱ in 2009, and is forecast to have reached \$32.0 billion in 2011. Between 1985 and 2009, the share of drugs in total health expenditure increased from 9.5% to 16.2%. It is forecast to have slightly decreased to 16.0% in 2011. Since 1997, among major categories of health expenditure, drugs have accounted for the second-largest share, after hospitals.¹

At the national level, 2010 and 2011 forecast data indicates that

- The share of drugs in total health expenditure is forecast to have stabilized in 2010 and 2011 at 16.0%.
- Total drug expenditure is forecast to have reached \$30.8 billion in 2010 and \$32.0 billion in 2011, representing annual increases of 4.2% and 4.0%, respectively.
- Total drug expenditure per capita in Canada is expected to have reached \$903 in 2010 and \$929 in 2011, representing annual rates of increase of 3.0% and 2.8%, respectively.
- The share of prescribed drugs in total drug expenditure is forecast to have reached 84.3% in 2010 and 84.8% in 2011.
- Expenditure on prescribed drugs is expected to have reached \$26.0 billion in 2010 and \$27.2 billion in 2011, representing growth rates of 4.7% in both years.
- Expenditure on non-prescribed drugs is forecast to have reached \$4.8 billion in 2010 and \$4.9 billion in 2011, representing increases of 1.7% and 0.5%, respectively.
- Public-sector expenditure on prescribed drugs is forecast to have reached \$11.8 billion in 2010 and \$12.1 billion in 2011, representing annual growth rates of 2.4% and 2.2%, respectively. Private-sector expenditure on prescribed drugs is forecast to have reached \$14.2 billion in 2010 and \$15.1 billion in 2011, with corresponding annual growth rates of 6.6% and 6.8%.

Drug expenditure data in this report is obtained from the National Health Expenditure Database (NHEX) and is composed of
estimates that represent the final costs to Canadian consumers, including dispensing fees, markups and appropriate taxes.
Total drug expenditure, in this report, includes expenditure on prescribed drugs and non-prescribed drugs (over-the-counter
drugs and personal health supplies). For more information on over-the-counter drugs and personal health supplies, see the
General Methods section of the Methodological Notes.

ii. All figures are in current dollars (unadjusted for inflation) unless otherwise stated.

At the provincial level, 2011 forecast data indicates that

- Total drug expenditure per capita is forecast to have ranged from \$702 in British Columbia and \$849 in Manitoba to \$1,116 in New Brunswick and \$1,139 in Nova Scotia.
- The share of prescribed drug spending in total drug expenditure is forecast to have ranged from 82.0% in British Columbia and 83.0% in Alberta to 88.2% in Quebec and 89.1% in Newfoundland and Labrador.
- The proportion of prescribed drugs financed by the public sector in 2011 varied across the provinces and is forecast to have ranged from 29.7% in New Brunswick and 34.2% in Prince Edward Island to 48.3% in Alberta and 49.0% in Saskatchewan.

At the international level in 2009, the most recent year for which data was available, among eight Organisation for Economic Co-operation and Development (OECD) comparator countriesⁱⁱⁱ

- Canada had the second-highest level of total drug expenditure per capita, after the United States.
- The public sector funded 38.8% of total drug expenditure in Canada. This was
 the second-lowest share, ahead of the United States (31.1%). The share of public drug
 expenditure in total drug expenditure was highest in the United Kingdom, at 84.7%.
- Public drug expenditure accounted for 9.4% of public-sector health expenditure in Canada.
 This proportion places Canada ahead of the United States (7.8%) and New Zealand (7.5 %).
 The share of public drug expenditure in public-sector health expenditure was highest in Japan, at 17.3%.

Factors affecting drug expenditure:

Numerous factors, many of which are interrelated, may influence drug expenditure. Since
drug prices, as measured by several price indices, have been relatively stable over the past
10 years, factors affecting increased drug spending in Canada essentially relate to the volume
of drug use and the entry of new drugs (typically introduced to the market at higher prices).

iii. Comparator countries are Australia, Canada, France, Germany, Japan, New Zealand, the United Kingdom and the United States.

iv. 2008 data has been used for the United Kingdom due to unavailability of current data.

Introduction

Pharmaceutical drugs play an essential role in modern medicine. Through the treatment of various diseases, they have become an increasingly significant component of the Canadian health care system.

Drug expenditure data in this report is primarily obtained from the National Health Expenditure Database (NHEX) maintained by the Canadian Institute for Health Information (CIHI). This database contains a historical series of macro-level health expenditure statistics by province and territory, beginning in 1975. Drug expenditure data in NHEX is macro-level data and does not allow for decomposition of prescription costs or drug classes.

The Drugs category in NHEX is intended to measure final consumption, outside an institutional setting, of drugs purchased by consumers or third-party payers on their behalf, generally from retail outlets. Drug expenditure data in NHEX consists of estimates that represent the final costs to Canadian consumers, including dispensing fees, markups and appropriate taxes. NHEX data does not include drug expenditure by non-Canadian residents. This classification system used in NHEX is consistent with international standards developed by the Organisation for Economic Co-operation and Development (OECD).

Drug expenditure estimates within NHEX provide insight into total drug expenditure by public and private payers and by type of drugs (prescribed and non-prescribed) at the provincial/ territorial and national levels. All drug expenditure estimates stated in this report are in current dollars (unadjusted for inflation) unless otherwise stated.

Drug Expenditure in Canada, 1985 to 2011 is an annual publication and provides updated information on drug expenditure trends in Canada. This publication includes

- National drug expenditure;
- Provincial and territorial drug expenditure;
- International comparisons; and
- Factors that may affect drug expenditure.

For more information on drug expenditure and the methods used in the preparation of this document, contact the Pharmaceuticals department at CIHI by phone at 613-241-7860 or by email at drugs@cihi.ca.


v. Total drug expenditure in this report includes expenditure on prescribed drugs and non-prescribed drugs. Non-prescribed drugs consist of over-the-counter drugs (such as cold remedies, cough remedies and headache remedies) and personal health supplies (such as antiperspirants, dental floss and disposable diabetic syringes). For more information on over-the-counter drugs and personal health supplies, see the General Methods section of the Methodological Notes.

National Drug Expenditure Overview

The Share of Drugs in Total Health Expenditure

Outlook-2010 and 2011

The share of drugs in total health expenditure is forecast to be 16.0% in both 2010 and 2011 (Figure 1).



Source


Highlights—2009

Drugs have been one of the fastest growing components of total health expenditure in Canada. From 1985 to 2009, total health spending grew at an average annual rate of 6.5%. During this period, total drug expenditure increased at an average annual rate of 8.9%. In every year prior to 2005, the annual rate of growth for drugs exceeded the rate for total health expenditure (Figure 2). Drug spending grew particularly rapidly during the 1990s, when many blockbuster drug classes were established and/or expanded in terms of use and cost. From 2005 to 2009, the annual rate of growth for drugs was slightly less than the rate for total health expenditure every year, with the exception of 2006 and 2009. The growth in drug spending during this time period slowed to an average rate of 6.3% per year.

Expenditure, Canada, 1985 to 2011 18.0% 16.0% 14.0% 12.0% 10.0% 8.0% 6.0% 4.0% 2.0% 0.0% Drug Expenditure Health Expenditure Forecast Forecast

Figure 2: Annual Growth Rate for Total Drug Expenditure and Total Health

Source



Notes

f: forecast.

\$ billions; percentage share of total health expenditure.

Source

National Health Expenditure Database, 2011, Canadian Institute for Health Information.

NHEX provides an overview of all health spending in Canada by spending category and source of funding. Total health expenditure comprises nine major spending categories. Since 1997, among major categories of health expenditure, drugs have accounted for the second-largest share, after hospitals (Figure 3).

Between 1985 and 2009, total drug expenditure grew at an average annual rate of 8.9%, while total hospital expenditure and total physician expenditure grew at average annual rates of 5.0% and 6.1%, respectively.

Total drug expenditure grew faster than total hospital expenditure every year between 1985 and 2006. From 2007 until 2009, total hospital expenditure had a higher rate of growth than total drug expenditure.


Total drug expenditure grew at a higher rate than total physician expenditure every year between 1985 and 2006, with the exception of 2005. From 2007 until 2009, total physician expenditure had a higher rate of growth than total drug expenditure.

See the data tables in Series A for more data on national drug expenditure from 1985 to 2011.

Total Drug Expenditure

Outlook—2010 and 2011

Total drug expenditure is forecast to have reached \$30.8 billion^{vi} in 2010 and \$32.0 billion in 2011, representing annual increases of 4.2% and 4.0%, respectively.



Source

National Health Expenditure Database, 2011, Canadian Institute for Health Information.

Highlights—2009

Canada's total drug expenditure increased steadily from \$3.8 billion in 1985 to \$29.6 billion in 2009 (Figure 4). The average annual rate of growth during this period was 8.9%.

See the data tables in Series A for more data on national drug expenditure from 1985 to 2011.

vi. All figures are in current dollars (unadjusted for inflation) unless otherwise stated.

Total Drug Expenditure per Capita

Outlook—2010 and 2011

Total drug expenditure per capita in Canada is expected to have reached \$903 in 2010 and \$929 in 2011, representing annual rates of increase of 3.0% and 2.8%, respectively.

Figure 5: Total Drug Expenditure per Capita, Current and Constant* Dollars, Canada, 1985 to 2011 \$1,000 \$900 \$800 \$700 \$600 \$500 \$400 \$300 \$200 \$100 Current Dollars ▲ Constant Dollars → Forecast

Note

Sources

National Health Expenditure Database, 2011, Canadian Institute for Health Information; Consumer Price Index, Statistics Canada.

Highlights—2009

Per capita drug expenditure trends are similar to those of total drug spending. Total drug expenditure increased from \$147 per capita in 1985 to \$877 in 2009 (Figure 5). The average annual growth rate during this period was 7.7%.

^{*} Figures are deflated using the Consumer Price Index to reflect 1985 dollars.

Typically, expenditure is deflated by a price index to measure change in quantity. There is no authoritative composite price index for all drugs sold in Canada. However, measuring drug expenditure in constant dollars (adjusted for inflation) using the CPI reported by Statistics Canada gives a sense of change in drug expenditure in the context of economy-wide inflation. Readers should cautiously interpret inflation-adjusted trends in expenditure, since drug-specific inflation may differ from that depending upon the broad basket of goods and services purchased by Canadians.

In terms of constant (1985) dollars, per capita drug expenditure increased from \$147 in 1985 to \$483 in 2009, reflecting an average annual growth rate of 5.1%. Trends in per capita drug expenditure measured in constant dollars are similar to those of per capita drug expenditure measured in current dollars, though growth between 1985 and 2009 is less pronounced when it is considered relative to economy-wide inflation (Figure 5).

See the data tables in Series A for more data on national drug expenditure from 1985 to 2011.

Drug Expenditure: Prescribed and Non-Prescribed Drugs Outlook—2010 and 2011

Expenditure on prescribed drugs^{ix} is expected to have reached \$26.0 billion in 2010 and \$27.2 billion in 2011, representing growth rates of 4.7% in both years. Expenditure on non-prescribed drugs is forecast to have reached \$4.8 billion in 2010 and \$4.9 billion in 2011, representing increases of 1.7% and 0.5%, respectively.

Non-prescribed drugs, which are typically financed by consumers (households), include over-the-counter drugs (such as cold remedies, cough remedies and headache remedies) and personal health supplies (such as antiperspirants, dental floss and disposable diabetic syringes). Since NHEX consists of macro-level health expenditure data, some over-the-counter drugs and personal health supplies that are covered under some drug benefit plans may be counted as prescribed drug expenditures. A

Prescribed drugs are expected to have accounted for 84.3% of total drug expenditure in Canada in 2010 and 84.8% in 2011. Conversely, the share of non-prescribed drugs in total drug expenditure is expected to have accounted for 15.7% in 2010 and 15.2% in 2011.

vii. For more information on drug prices, see the Data Limitations section of the Methodological Notes.

viii. A measure of the average percentage change over time in the cost of a fixed basket of goods and services purchased by Canadian consumers.

ix. A prescribed drug is a substance considered to be a drug under the *Food and Drugs Act*, which is sold for human use as the result of a prescription from a health professional.

x. For more information on over-the-counter drugs and personal health supplies, see the General Methods section of the Methodological Notes.

xi. For example, diabetic test strips, where covered under drug benefit plans, may be included in prescribed drug expenditure, subject to source of data.




Figure 6: Total Drug Expenditure, by Type (Prescribed and Non-Prescribed),

Notes

f: forecast.

Prescribed drug expenditure is based on drugs sold as the result of a prescription from a health professional. This expenditure can be financed by either the public or the private sector.

Non-prescribed drug expenditure includes spending on over-the-counter drugs and personal health supplies.

This expenditure is financed by the private sector, typically out-of-pocket by consumers (households).

For detailed definitions, please refer to the Methodological Notes.

National Health Expenditure Database, 2011, Canadian Institute for Health Information.

Highlights—2009

From 1985 to 2009, expenditure on prescribed drugs grew from \$2.6 billion to \$24.8 billion, at an average annual rate of 9.9%. Spending on non-prescribed drugs increased from \$1.2 billion to \$4.8 billion, at an average of 5.8% per year (Figure 6). During this period, with the exception of 1987 and 1994, annual growth in drug spending was higher in prescribed drugs than in non-prescribed drugs. As a result, prescribed drugs captured a larger share of total drug spending, rising from 67.5% in 1985 to 83.9% in 2009.

Non-prescribed drug expenditure represented 16.1% of total drug expenditure in 2009. Over-the-counter drugs accounted for \$2.7 billion, or 9.1% of total drug expenditure, and personal health supplies accounted for \$2.1 billion, or 6.9%.

See the data tables in Series A for more data on national drug expenditure from 1985 to 2011.

Prescribed Drug Expenditure by Source of Finance

While non-prescribed drugs are typically financed out-of-pocket by consumers (households), multiple payers are involved in the financing of prescribed drugs. In the public sector, these payers include provincial/territorial and federal drug subsidy programs and social security funds (such as workers' compensation boards, or WCBs). In the private sector, they include private insurers and households.

In 2011, \$12.1 billion in prescribed drugs are expected to have been financed by the public sector, while expenditure by the private sector is for both prescribed drugs (\$15.1 billion) and non-prescribed drugs (\$4.9 billion). In the private sector, prescribed drugs financed by private insurers are expected to have been \$10.2 billion, with the remainder financed by Canadian households (\$4.9 billion). Non-prescribed drugs are composed of over-the-counter drugs (\$2.7 billion) and personal health supplies (\$2.1 billion) (Figure 7).

Canada, 2011 Private Sector (Non-Prescribed Drugs) \$4.9; 15.2% Insurers \$10.2; 32.0% Private Sector (Prescribed Drugs) \$15.1; 47.2% **Public Sector** (Prescribed Drugs) Out-of-Pocket \$12.1; 37.6% \$4.9; 15.2%

Figure 7: Total Drug Expenditure, by Source of Finance and Type of Expenditure,

Notes

f: forecast.

\$ billions; percentage share of total drug expenditure.

Prescribed drug expenditure is based on drugs sold as the result of a prescription from a health professional.

Non-prescribed drugs include over-the-counter drugs and personal health supplies.


For detailed definitions, please refer to the Methodological Notes.

Source

Outlook—2010 and 2011

Public-sector expenditure on prescribed drugs is forecast to have reached \$11.8 billion in 2010 and \$12.1 billion in 2011 (Figure 8), representing annual growth rates of 2.4% and 2.2%, respectively. Private-sector expenditure on prescribed drugs is forecast to have reached \$14.2 billion in 2010 and \$15.1 billion in 2011, with corresponding annual growth rates of 6.6% and 6.8%.

The share of prescribed drug expenditure financed by the public sector is forecast to be 45.5% in 2010 and 44.4% in 2011.



Notes


Prescribed drug expenditure is based on drugs sold as the result of a prescription from a health professional. This expenditure can be financed by either the public or the private sector.

For detailed definitions, please refer to the Methodological Notes.

Source

Highlights—2009

The intersections of the two series depicted in Figure 9 (excluding forecasts for 2010 and 2011) identify four distinct periods of growth in publicly and privately financed prescribed drug expenditure.



Notes

Prescribed drug expenditure is based on drugs sold as the result of a prescription from a health professional. This expenditure can be financed by either the public or the private sector.

For detailed definitions, please refer to the Methodological Notes.

Source

National Health Expenditure Database, 2011, Canadian Institute for Health Information.

Between 1985 and 1992, expenditure on prescribed drugs in the public sector grew by an average annual rate of 14.6%, while this rate was 12.0% for prescribed drug expenditure financed by the private sector. Consequently, the share of prescribed drugs financed from public sources increased from 43.6% in 1985 to 47.7% in 1992.

From 1992 to 1997, spending on prescribed drugs by the private sector grew at an average annual rate of 9.1%, more than twice the 4.3% average annual rate of growth in publicly financed prescribed drug expenditure. Fiscal restraint introduced in several provinces led to negative growth in publicly financed prescribed drug expenditure in 1996. By 1997, the share of prescribed drugs financed from public sources had declined to 42.2%, below its share in 1985 (43.6%).

Between 1997 and 2005, expenditure on prescribed drugs by the public sector grew at an average annual rate of 12.0%, compared with 9.5% in the private sector. The share of prescribed drug expenditure financed by the public sector reached 46.6% in 2005.

From 2006 to 2009, the public and private sectors changed places each year in terms of leading the annual growth rate for prescribed drug expenditure. The annual growth rate was higher in the private sector in 2006 and 2008, while it was higher in the public sector in 2007 and 2009. As a result, the share of prescribed drug expenditure financed by the public sector remained relatively stable, at 46.5%, in 2009 compared with its share in 2005 (46.6%).

See the data tables in Series A for more data on national drug expenditure from 1985 to 2011.

Two levels of government—provincial/territorial and federal—as well as social security funds, such as workers' compensation boards (WCBs) and the premium component of the Fonds de l'assurance médicaments (Drug Insurance Fund) in Quebec, xii finance spending on prescribed drugs by the public sector. Private-sector expenditure on prescribed drugs is financed by two sources: private insurers and households (out-of-pocket). Table 1 shows the distribution of prescribed drug expenditure by these sources of finance.

Expenditure by private insurers and out-of-pocket spending by households were available separately for the first time in 1988.

Table 1: Distribution of Prescribed Drug Expenditure, by Source of Finance, Canada, 1988 and 2011^f

	1988		2011 ^f		
	\$ Millions	Percentage	\$ Millions	Percentage	
Provincial/Territorial Governments	1,592.7	42.6	10,391.5	38.2	
Federal Direct	89.3	2.4	664.6	2.5	
Social Security Funds:					
Workers' Compensation Boards	20.8	0.6	212.9	0.8	
Quebec Drug Insurance Fund* (Premium Component)	N/A	N/A	793.5	2.9	
Subtotal Public Sources	1,702.8	45.6	12,062.5	44.4	
Private Insurers	1,130.3	30.2	10,244.9	37.7	
Households (Out-of-Pocket)	903.7	24.2	4,874.2	17.9	
Subtotal Private Sources	2,034.0	54.4	15,119.1	55.6	
Total All Sources	3,736.8	100.0	27,181.6	100.0	

Notes

Source


^{*} Data not available prior to January 1, 1997, when the program was first introduced in Quebec.

f: forecast.

xii. Since July 1, 2002, the public plan has been financed both by the expenditure allocated to this program by the Quebec government (provincial government sector) and by the amounts collected by the Drug Insurance Fund as premiums and proceeds (social security funds sector). The premium component of the Quebec Drug Insurance Fund is considered to be a social security scheme, while the remaining portion of the program that is paid through the ministère de la Santé et des Services sociaux is included as a provincial government expenditure. For more information, see the General Methods section of the Methodological Notes.

Provincial/territorial government expenditure on prescribed drugs was almost \$1.6 billion in 1988, accounting for 42.6% of total expenditure on prescribed drugs. By 2011, provincial/territorial government expenditure is forecast to have grown to \$10.4 billion, while its share of total expenditure on prescribed drugs is expected to have diminished to 38.2%. All provinces/territories provide some form of prescribed drug coverage to seniors and social assistance recipients (see Appendix A for an overview of provincial and territorial drug subsidy programs).

Federal direct expenditure was \$89.3 million in 1988, equivalent to 2.4% of total expenditure on prescribed drugs. Federal direct expenditure is forecast to have increased to \$664.6 million in 2011, representing 2.5% of total expenditure on prescribed drugs. The federal government provides drug benefits to Aboriginal Canadians, veterans, members of the military and the RCMP, prisoners in federal correctional facilities and refugees.



Note

^{*} Expenditure by private insurers and out-of-pocket spending by households were available separately for the first time in 1988. **Source**

Expenditure by social security funds was \$20.8 million in 1988, equivalent to 0.6% of total prescribed drug expenditure. In 2011, expenditure by social security funds is forecast to have reached \$1.0 billion and to have accounted for 3.7% of total expenditure on prescribed drugs. Social security funds' figures have largely represented spending by the premium component of the Quebec Drug Insurance Fund since its institution in 1997. Seniors (65 and older) and other residents (those who do not receive social assistance benefits and are not covered by private group insurance) are required to pay a premium. The amount of the premium varies according to net family income.

Expenditure on prescribed drugs by private insurers amounted to more than \$1.1 billion in 1988, or 30.2% of prescribed drug expenditure. Private insurers' spending increased to \$10.2 billion in 2011, and their share of prescribed drug expenditure increased to 37.7%. Private insurers include group and individual insurance. Many employers offer group benefit plans covering prescribed drugs for employees and their families. In some cases, individuals will continue to be covered by a group plan even after they retire.

Out-of-pocket spending by households was an estimated \$0.9 billion in 1988, representing 24.2% of total expenditure on prescribed drugs. By 2011, out-of-pocket prescribed drug expenditure is estimated to have risen to \$4.9 billion, while its share of prescribed drug expenditure will have decreased to 17.9% (Figure 10).

See the data tables in Series A for more data on national drug expenditure from 1985 to 2011.

Drug Expenditure in the Provinces and Territories

There is considerable variation in the level and growth of drug expenditure across the provinces and territories. These variations are influenced by several factors, including differences in provincial/territorial drug subsidy programs (see Appendix A for an overview of provincial and territorial drug subsidy programs), the extent of private insurance coverage, age and sex distribution of provincial/territorial populations, the health needs of targeted populations and the manner in which health care is delivered (including the balance between institutional and ambulatory care).² Other possible sources of variation in drug expenditure are described in the section Factors Affecting Drug Expenditure in Canada.

Table 2 provides an overview of provincial/territorial drug expenditure forecast for 2011.

Table 2: Drug Expenditure Summary, by Province/Territory and Canada, 2011 ^f									
	Total Drug Expenditure per Capita			Prescribed Drug Expenditure per Capita			Public Prescribed Drug Expenditure per Capita		
	Amount (Dollars)	Percentage Change Over 2010	Percentage of Total Health Exp. per Capita	Amount (Dollars)	Percentage Change Over 2010	Percentage of Total Drug Exp. per Capita	Amount (Dollars)	Percentage Change Over 2010	Percentage of Prescribed Drug Exp. per Capita
N.L.	1,032.66	8.2	15.0	920.35	9.4	89.1	319.74	9.0	34.7
P.E.I.	950.11	3.1	15.5	790.73	4.5	83.2	270.14	0.2	34.2
N.S.	1,138.91	5.6	18.1	984.67	6.4	86.5	372.86	1.6	37.9
N.B.	1,116.34	4.7	17.6	936.92	5.1	83.9	278.70	-2.7	29.7
Que.	1,034.04	3.7	19.7	912.46	4.6	88.2	414.18	-2.1	45.4
Ont.	939.46	1.5	16.2	785.00	2.0	83.6	353.37	1.7	45.0
Man.	849.46	2.8	13.1	710.37	3.4	83.6	319.17	1.9	44.9
Sask.	929.60	6.3	14.5	799.35	7.4	86.0	391.37	1.2	49.0
Alta.	873.00	4.6	13.3	724.86	5.9	83.0	350.42	5.8	48.3
B.C.	701.83	1.4	12.9	575.49	1.4	82.0	236.89	2.2	41.2
Y.T.	809.34	2.8	9.0	677.45	4.7	83.7	417.66	2.3	61.7
N.W.T.	702.58	0.9	6.9	587.12	1.0	83.6	376.72	0.1	64.2
Nun.	672.19	2.8	5.6	572.50	5.8	85.2	335.48	0.2	58.6
Canada	928.75	2.8	16.0	787.82	3.5	84.8	349.62	1.0	44.4

Notes

f: forecast.

Total drug expenditure consists of prescribed drugs and non-prescribed products purchased outside an institutional setting.

Prescribed drug expenditure is based on drugs sold as the result of a prescription from a health professional. This expenditure can be financed by either the public or the private sector.

Public prescribed drug expenditure is the amount of prescribed drug expenditure financed by provincial, territorial and federal governments, as well as spending from social security funds.

For detailed definitions please refer to the Methodological Notes.

Sources

National Health Expenditure Database, 2011, Canadian Institute for Health Information; Population, Statistics Canada.

In 2011, per capita expenditure on drugs is forecast to have accounted for 16.0% of total per capita health expenditure in Canada. Among the provinces, the share of drugs in total health expenditure per capita is expected to have ranged from 12.9% in British Columbia and 13.1% in Manitoba to 18.1% in Nova Scotia and 19.7% in Quebec. The three territories were expected to have lower shares than all the provinces, ranging from 5.6% in Nunavut to 9.0% in Yukon.

Total drug expenditure per capita in Canada is expected to have been \$929 in 2011. Per capita spending on drugs in the provinces is forecast to have ranged from \$702 and \$849 in British Columbia and Manitoba, respectively, to \$1,116 and \$1,139 in New Brunswick and Nova Scotia, respectively. Per capita spending on drugs in the territories is forecast to have ranged from \$672 in Nunavut to \$809 in Yukon.

Prescribed drug expenditure per capita is forecast to have accounted for 84.8% of total per capita expenditure on drugs in Canada in 2011. Among the provinces and territories, the share of prescribed drugs in total drug expenditure is forecast to have ranged from 82.0% in British Columbia and 83.0% in Alberta to 88.2% in Quebec and 89.1% in Newfoundland and Labrador.

In 2011, the proportion of prescribed drugs in Canada financed by the public sector is expected to have been 44.4%. Among the provinces, it is forecast that the proportion will have been highest in Saskatchewan and Alberta, at 49.0% and 48.3%, respectively, and the lowest in Prince Edward Island and New Brunswick, at 34.2% and 29.7%, respectively. The proportion is forecast to have been higher in the territories than in the provinces, ranging from 64.2% in the Northwest Territories to 58.6% in Nunavut.

The Share of Drugs in Total Health Expenditure

The share of drugs in total health expenditure is forecast to have been higher in 2011 than in 1985 in all provinces and territories except Prince Edward Island, Newfoundland and Labrador and the Northwest Territories and Nunavut (Figure 11). It should be noted that in Newfoundland and Labrador between 1986 and 2011, the share of drug expenditure in total health expenditure is expected to have grown.

In 1985, expenditure on drugs accounted for 9.5% of total health expenditure in Canada. Newfoundland and Labrador, Prince Edward Island, Nova Scotia, New Brunswick and Ontario exceeded the national average. Prince Edward Island had the highest share, at 18.0%, followed by Newfoundland and Labrador, at 16.3%, while among the provinces with a lower share than the national average, shares ranged from 8.0% in Alberta to 9.3% in Manitoba. The territories also had a lower share than the national average (8.0% in Yukon and 7.1% in the Northwest Territories and Nunavut).




Figure 11: Drug Expenditure as a Percentage of Total Health Expenditure,

Notes

On April 1, 1999, Nunavut was formed from the eastern part of the Northwest Territories.

f: forecast.

Source


National Health Expenditure Database, 2011, Canadian Institute for Health Information.

In 2011, Nova Scotia, New Brunswick, Quebec and Ontario are forecast to have had drug expenditure as a percentage of total health expenditure above the Canadian average (16.0%), with Quebec (19.7%) and Nova Scotia (18.1%) having the highest shares. Newfoundland and Labrador, Prince Edward Island, Manitoba, Saskatchewan, Alberta and British Columbia are expected to have been below the Canadian average, with British Columbia (12.9%) and Manitoba (13.1%) having the lowest shares among the provinces. Yukon and the combined territories of the Northwest Territories and Nunavut are forecast to have had lower shares than the provinces, at 9.0% and 6.3%, respectively.

See the data tables in Series B for more data on drug expenditure by province/territory from 1985 to 2011.

Total Drug Expenditure by Source of Finance

In 2011, among the provinces, Quebec (40.1%), Saskatchewan (42.1%) and Alberta (40.1%) are forecast to have had public shares of total drug expenditure that exceeded the national average (37.6%). The three territories also are forecast to have had public shares of total drug expenditure that exceeded the national average, ranging from 53.6% in the Northwest Territories to 49.9% in Nunavut. Among the provinces with shares below the national average, the share of total drug expenditure funded by the public sector is expected to have ranged from 37.6% in Ontario to 25.0% in New Brunswick (Figure 12).



Note

f: forecast.

Source

Total Drug Expenditure per Capita by Source of Finance

In 2011, total drug expenditure per capita in Canada is forecast to have been \$929. Per capita prescribed drug spending financed by the public and private sectors is forecast to have amounted to \$350 and \$438, respectively (Figure 13).

by Province/Territory and Canada, 2011 \$132 \$115 \$100 N.W.T. Nun. \$112 \$414 \$391 \$319 \$350 \$498 \$408 \$391 \$374 \$122 \$126 \$148 \$130 \$139 Ont. Que. \$159 B.C. Alta. Sask. Man. \$353 \$432 N.S. \$154 N.B. \$612 \$154 Public Rx \$179 Private Rx Private Non-Rx

Figure 13: Total Drug Expenditure per Capita, by Type and by Source of Finance, by Province/Territory and Canada. 2011[†]

Notes

f: forecast.

Prescribed drug expenditure (Rx) is based on drugs sold as the result of a prescription from a health professional. This expenditure can be financed by either the public or the private sector.

Non-prescribed drug expenditure (Non-Rx) includes spending on over-the-counter drugs and personal health supplies.

This expenditure is financed by the private sector, typically out-of-pocket by consumers (households).

For detailed definitions, please refer to the Methodological Notes.

Sources

National Health Expenditure Database, 2011, Canadian Institute for Health Information; Population, Statistics Canada.

In 2011, among the provinces, per capita spending on drugs by the public sector is forecast to have ranged from \$237 in British Columbia and \$270 in Prince Edward Island to \$391 in Saskatchewan and \$414 in Quebec. In the territories, per capita spending on drugs by the public sector is forecast to have ranged from \$335 in Nunavut to \$418 in Yukon. Along with Quebec, Saskatchewan and Yukon, it is expected that Nova Scotia (\$373), Ontario (\$353), Alberta (\$350) and the Northwest Territories (\$377) will also have had publicly financed drug expenditure per capita above the Canadian average (\$350).

Among the provinces, prescribed drug expenditure per capita financed by the private sector is expected to have ranged from \$339 in British Columbia and \$374 in Alberta to \$612 in Nova Scotia and \$658 in New Brunswick. In addition to New Brunswick and Nova Scotia, Newfoundland and Labrador (\$601), Prince Edward Island (\$521) and Quebec (\$498) are also forecast to have had privately financed prescribed drug expenditure per capita higher than the Canadian average (\$438). In the three territories, prescribed drug expenditure per capita financed by the private sector is forecast to have been below the average of all the provinces, ranging from \$210 in the Northwest Territories to \$260 in Yukon.

It should be noted that public spending per capita may or may not accurately reflect the amount spent per person eligible for coverage because the proportion of the population eligible for coverage by the public sector varies significantly across provinces and territories.

See the data tables in Series B for more data on drug expenditure by province/territory from 1985 to 2011.

Drug Expenditure by Type of Drug and by Source of Finance

Public- and Private-Sector Prescribed and Non-Prescribed Drug^{xiii} Expenditure


In 2011, in all provinces and territories except British Columbia, the annual growth rate for prescribed drug spending per capita is forecast to have been higher in the private sector than in the public sector (Figure 14).

Among the provinces, the annual growth rate for prescribed drug spending per capita in the private sector ranged from 0.9% in British Columbia and 2.2% in Ontario to 10.9% in Quebec and 14.1% in Saskatchewan. Among the territories, this same rate ranged from 2.8% in the Northwest Territories to 14.9% in Nunavut. The annual growth rate for prescribed drug spending per capita in the public sector ranged from -2.7% in New Brunswick and -2.1% in Quebec to 5.8% in Alberta and 9.0% in Newfoundland and Labrador.

xiii. Non-prescribed drugs consist of over-the-counter drugs (such as cold remedies, cough remedies and headache remedies) and personal health supplies (such as antiperspirants, dental floss and disposable diabetic syringes). For more information on over-the-counter drugs and personal health supplies, see the General Methods section of the Methodological Notes.

In 2011, three provinces (Prince Edward Island, New Brunswick and Quebec) and two territories (the Northwest Territories and Nunavut) are expected to have had annual growth of publicly financed prescribed drug expenditure per person below the Canadian average (1.0%).

Figure 14: Annual Growth Rate for Public- and Private-Sector Prescribed and Non-Prescribed Drug Expenditure per Capita, by Province/Territory and Canada, 2011^f



Notes

f: forecast.

Prescribed drug expenditure (Rx) is based on drugs sold as the result of a prescription from a health professional.

This expenditure can be financed by either the public or the private sector.

Non-prescribed drug expenditure (Non-Rx) includes spending on over-the-counter drugs and personal health supplies.

This expenditure is financed by the private sector, typically out-of-pocket by consumers (households).

For detailed definitions, please refer to the Methodological Notes.

Sources

National Health Expenditure Database, 2011, Canadian Institute for Health Information; Population, Statistics Canada.

The analysis of annual growth rates should be interpreted cautiously. The actual change in drug spending associated with a given growth rate varies based on the initial level of expenditure. For example, a 10% growth rate for a higher initial level of expenditure would translate into a larger growth in dollar amounts than for a lower initial level of expenditure.

Public- and Private-Sector Prescribed Drug Expenditure

Between 1985 and 2011, publicly financed prescribed drug expenditure per capita grew at a lower average annual rate than privately financed prescribed drug expenditure per capita in Nova Scotia, New Brunswick, Saskatchewan and British Columbia (Figure 15). During this period, among the provinces, average annual growth in public-sector prescribed drug spending per capita ranged from 6.5% in British Columbia and 6.7% in Saskatchewan to 9.7% in Alberta and 10.7% in Prince Edward Island. Prescribed drug expenditure per capita financed by the public sector grew at a faster rate in Yukon (12.1%) than in all the provinces.

Per capita prescribed drug expenditure financed by the private sector grew at average annual rates ranging from 4.8% in Prince Edward Island and 5.7% in Newfoundland and Labrador to 10.7% in Nova Scotia and 11.1% in Saskatchewan.




Figure 15: Average Annual Growth Rate for Prescribed Drug Expenditure per Capita, by Source of Finance, by Province/Territory and Canada,

* On April 1, 1999, Nunavut was formed from the eastern part of the Northwest Territories.

f: forecast.

Prescribed drug expenditure (Rx) is based on drugs sold as the result of a prescription from a health professional.


This expenditure can be financed by either the public or the private sector.

For detailed definitions, please refer to the Methodological Notes.

Sources

National Health Expenditure Database, 2011, Canadian Institute for Health Information; Population, Statistics Canada.

Figure 16 illustrates provincial/territorial trends in the share of publicly financed prescribed drug expenditure as a percentage of prescribed drug expenditure, from 1985 to 2009, with forecasts to 2011.



25

Expenditure, by Province/Territory, 1985 to 2011 (cont'd) Alberta British Columbia 80.0% 80.0% 70.0% 70.0% 60.0% 60.0% 50.0% 50.0% 40.0% 40.0% 30.0% 30.0% 20.0% 20.0% 10.0% 10.0% 0.0% 0.0% 2005 2011 2011 1985 1990 1995 2000 2005 1990 1995 2000 1985 → Forecast — Actual → Forecast --- Actual Northwest Territories* Yukon 80.0% 80.0% 70.0% 70.0% 60.0% 60.0% 50.0% 50.0% 40.0% 40.0% 30.0% 30.0% 20.0% 20.0% 10.0% 10.0% 0.0% 0.0% 1985 1990 1995 2000 2005 2011 2011 1990 1995 2000 2005 1985 → Actual ---- Forecast -----Forecast → Actual Nunavut* 80.0% 70.0% 60.0% 50.0% 40.0% 30.0% 20.0% 10.0% 0.0% 1990 1995 2000 2005 2011 1985 → Actual —Forecast

Figure 16: Public-Sector Prescribed Drug Expenditure as a Percentage of Total Prescribed Drug

Note

* On April 1, 1999, Nunavut was formed from the eastern part of the Northwest Territories.

Between 1985 and 2009, the share of prescribed drug expenditure financed by the public sector increased in Newfoundland and Labrador, Prince Edward Island, Quebec, Ontario, Manitoba, Alberta, Yukon and the Northwest Territories. Increases in the provinces ranged from 3.8 and 7.0 percentage points in Ontario and Manitoba, respectively, to 16.4 and 24.9 percentage points in Newfoundland and Labrador and Prince Edward Island, respectively. The Northwest Territories had a lower increase than the provinces, at 3.6 percentage points, while Yukon had a higher increase than the provinces, at 35.3 percentage points. Decreases in the share of prescribed drug expenditure financed by the public sector occurred in Nova Scotia, New Brunswick, Saskatchewan and British Columbia. Decreases ranged from 12.2 percentage points in British Columbia to 19.8 percentage points in Saskatchewan.

In 2011, the share of prescribed drug expenditure financed by the public sector in Canada is expected to have been 44.4%. This is forecast to have been exceeded by Quebec (45.4%), Ontario (45.0%), Manitoba (44.9%), Saskatchewan (49.0%), Alberta (48.3%), Yukon (61.7%), the Northwest Territories (64.2%) and Nunavut (58.6%).

International Comparisons

Comparability of Health Expenditure Across Countries

There are 29 countries with health expenditure information that most closely follows the health care boundary proposed in the Organisation for Economic Co-operation and Development (OECD) manual *A System of Health Accounts* (SHA). The OECD states that the data for those countries is believed to be fairly comparable, although some deviations from SHA definitions may still exist among the sub-aggregate variables of total health expenditure.

In general, international comparisons should be interpreted with caution, as variation exists between countries with regard to reporting, inclusion and classification of health expenditure. Level of income, institutional characteristics and service delivery across countries also cause differences in the share of drugs in total health expenditure.

Drug expenditure data from 8 of the 29 OECD comparator countries is covered in this section: Canada, Australia, France, Germany, Japan, New Zealand, the United Kingdom and the United States.

Share of Drugs in Total Health Expenditure

The OECD maintains a comparative database on health-related statistics, including health expenditure. This database captures information on expenditure for pharmaceuticals and other medical non-durables outside an institutional setting (equivalent to drugs purchased in retail establishments in Canada). Pharmaceutical and other medical non-durables comprise prescribed drugs, over-the-counter drugs and a wide range of medical non-durables such as bandages, elastic stockings, incontinence articles, condoms and other mechanical contraceptive devices.

In 1985, drug expenditure in Canada represented 9.6%^{xiv} of total health expenditure. Japan had the largest share of drug expenditure in total health expenditure, at 18.0%, and the United States had the lowest, at 8.7%. By 2009, the most recent year for which data was available, drug expenditure in Canada had increased its share in total health expenditure by just more than seven percentage points, to 17.0%. Japan had the highest share of drug expenditure in total health expenditure, at 19.4%, and New Zealand had the lowest, at 9.3% (Table 3).

xiv. OECD data is standardized for international comparability; consequently, figures calculated from this data may differ from those calculated from the national health accounts of member countries. Specific to Canada, expenditure on health research and the training of health care workers with concomitant care of patients is included in the national health accounts but excluded from OECD health expenditure data.

Table 3: Total Expenditure on Pharmaceutical Goods per Capita and as a Percentage of Total Health Expenditure, Selected OECD Comparator Countries, 2009

	GDP pe	r Capita	Exper	Drug nditure Capita		Health Iditure apita	Total Drug Expenditure as a Percentage of Total Health Expenditure	
Country	(CA\$, PPP)*	Rank	(CA\$, PPP)*	Rank	(CA\$, PPP)*	Rank	Percentage	Rank
Australia [†]	47,798	2	602	6	4,125	6	14.6	5
Canada [‡]	45,771	3	890	2	5,223	2	17.0	2
France	40,423	6	767	3	4,763	4	16.1	3
Germany	43,493	4	752	4	5,050	3	14.9	4
Japan [†]	38,828	7	668	5	3,445	8	19.4	1
New Zealand	34,703	8	330	8	3,571	7	9.3	8
United Kingdom [§]	42,689	5	457	7	4,175	5	11.6	7
United States	54,830	1	1,145	1	9,530	1	12.0	6

Notes

- * Converted to Canadian dollars using purchasing power parities (PPPs) for gross domestic product (GDP).
- † 2008 data used for Total Drug Expenditure per Capita, Total Health Expenditure per Capita and Total Drug Expenditure as a Percentage of Total Health Expenditure.
- ‡ Canadian data reported by the OECD is as of November 2010. In November 2011, updated and revised Canadian data was released in Canada. This updated information will not be incorporated into the OECD database until the summer of 2012.
- § 2008 data used for Total Drug Expenditure per Capita and Total Drug Expenditure as a Percentage of Total Health Expenditure. **Source**

Organisation for Economic Co-operation and Development, OECD Health Data 2011 (Paris, France: OECD, June 2011).

Figure 17 illustrates the trends of drug expenditure per capita (constant 2000 CA\$, PPP)^{xv} in the eight selected OECD comparator countries.




Figure 17: Drug Expenditure per Capita,* Selected OECD Comparator Countries, 1985 to 2009^{†, ‡}

Notes

- * Converted to constant 2000 Canadian dollars using purchasing power parity (PPP) for gross domestic product (GDP).
- † 2009 data not available for Australia, Japan and the United Kingdom.
- ‡ Derived values have been used where data was not available for some countries in certain years: (Germany: 1991; France: 1986–1989; New Zealand: 1998–2003; United Kingdom: 1998–1999).

Source

Organisation for Economic Co-operation and Development, OECD Health Data 2011 (Paris, France: OECD, June 2011).

Between 1985 and 2009, among comparator countries, Australia, Canada and the United States had the highest average annual rate of growth in per capita drug expenditure, with rates of 5.5%, 5.3% and 5.2%, respectively. The remaining five countries experienced a lower average annual rate of growth in per capita drug expenditure, ranging from 2.4% in Germany to 3.3% in the United Kingdom.

To eliminate the differences in price levels between countries, purchasing power parities (PPPs) are used. To make useful comparisons of trends in drug expenditure per capita over time, it is necessary to deflate nominal drug expenditure through the use of a suitable price index to derive real spending per capita. Due to the unavailability of a specific pharmaceutical price index, the gross domestic product (GDP) is used by the OECD. It should be kept in mind that prices of patented medicines in Canada usually experience lower inflation than the economy as a whole, due to the regulation of patented drug prices in Canada.

xv. For purpose of this comparison, the constant 2000 CA\$ PPP has been used. The figures are calculated from US\$ at a 2000 GDP price level that have been adjusted to CA\$ at 2000 PPP rates.

Share of Public Expenditure in Total Expenditure on Drugs

The OECD database on health contains statistics on total expenditure on pharmaceutical goods and public expenditure on pharmaceutical goods. In Canada, drug expenditure by the public sector rose from 29.4% of total expenditure on pharmaceutical goods in 1985 to 38.8% in 2009.

In OECD countries, with the exception of those in North America, the entire population usually has coverage for prescribed drugs through public insurance. Most countries have formularies restricting the number of drugs covered under public insurance and impose cost-sharing (deductibles, co-insurance or copayments) with waivers for certain groups of beneficiaries.

Table 4 shows that, among the eight selected OECD comparator countries in 2009, Germany had the highest level of public drug spending per capita (\$583), the United States had the highest level of total drug expenditure per capita (\$1,145) and the United Kingdom had the highest public share of total drug spending (84.7%).

The high share of total drug expenditure financed by the public sector in some European countries (for example, Germany) reflects the inclusion of drug benefits provided through employment-related social security funds in publicly financed drug expenditure (see Series C for more data on international comparisons). These funds are social insurance programs covering the entire community or large sections of the community, and are imposed or controlled by a government authority. They generally involve compulsory contributions by employees, employers or both, and the government authority determines the terms upon which benefits are paid to recipients. In some European countries, expenditure by social security funds represents the major share of public expenditure on drugs (for example, 94.7% in Germany and 98.2% in France in 2009).³

By contrast, in Canada, until 1996, drug benefits under social security funds included only spending by WCBs and they represented less than 2% of public expenditure on drugs in retail establishments. Starting in 1997, they also included expenditure by the premium component of the Quebec Drug Insurance Fund. The share of social security funds in public expenditure on drugs in Canada increased from 5.9% in 1997 to 8.0% in 2009. The premium component of the Quebec Drug Insurance Fund is financed by the mandatory payment of premiums by seniors (65 and older) and other residents not covered by private group insurance. Social assistance recipients are not required to pay a premium.

Group insurance plans offered by employers, unions and professional associations that resemble the European model do exist in Canada; however, since a government authority does not impose group health insurance in Canada, and policy-holders may voluntarily opt out (except in Quebec), they are considered privately financed. Private health insurance, composed mainly of group insurance, accounted for 30.4% of total drug expenditure in retail establishments in Canada in 2009.

xvi. Since July 1, 2002, the public plan has been financed both by the expenditure allocated to this program by the Quebec government (provincial government sector) and by the amounts collected by the Drug Insurance Fund as premiums and proceeds (social security funds sector). The premium component of the Quebec Drug Insurance Fund is considered to be a social security scheme, while the remaining portion of the program that is paid through the ministère de la Santé et des Services sociaux is included as a provincial government expenditure. For more information, see the General Methods section of the Methodological Notes.

Table 4: Public Expenditure on Pharmaceutical Goods per Capita and as a Percentage of Total Expenditure on Pharmaceutical Goods, Selected OECD Comparator Countries, 2009

	Public Expen per C	diture		Expenditure apita	Public Drug Expenditure as a Percentage of Total Drug Expenditure		
Country	(CA\$, PPP)*	Rank	(CA\$, PPP)*	Rank	Percentage	Rank	
Australia [†]	324	7	602	6	53.8	6	
Canada [‡]	346	6	890	2	38.8	7	
France	511	2	767	3	66.7	4	
Germany	583	1	752	4	77.6	2	
Japan [†]	482	3	668	5	72.1	3	
New Zealand	217	8	330	8	65.6	5	
United Kingdom [†]	387	4	457	7	84.7	1	
United States	356	5	1,145	1	31.1	8	

Notes

- * Converted to Canadian dollars using purchasing power parities (PPPs) for gross domestic product (GDP).
- † 2008 data.
- ‡ Canadian data reported by the OECD is as of November 2010. In November 2011, updated and revised Canadian data was released in Canada. This updated information will not be incorporated into the OECD database until the summer of 2012.

Source

Organisation for Economic Co-operation and Development, OECD Health Data 2011 (Paris, France: OECD, June 2011).

Share of Drugs in Public Expenditure on Health

In Canada, drugs accounted for only 3.8% of health expenditure by the public sector in 1985. This proportion increased to 9.4% in 2009, reflecting substantially higher growth in drug expenditure than in other types of public-sector health expenditure between 1985 and 2009. In 1985, among the comparator countries, the share of drugs in public-sector health expenditure ranged from 1.8% in the United States to 15.4% in Japan. In 2009, the share of drugs in public-sector health expenditure ranged from 7.5% in New Zealand to 17.3% in Japan (Table 5).

In 2009, the share of drug spending in public-sector health expenditure was lower than the share of drug spending in total health expenditure in most of the selected countries (the exceptions were Germany and the United Kingdom), reflecting generally higher cost-sharing for drugs than for other health expenditure. In the case of Canada, the low share of drugs in total public expenditure on health (9.4% in 2009), compared with the share of drugs in total health expenditure (17.0% in 2009), also reflects the absence of universal coverage of prescribed drugs by public insurance, while there exists universal and full coverage of medically necessary hospital and physician services.

Table 5: Public Expenditure on Pharmaceutical Goods per Capita and as a Percentage of Public-Sector Health Expenditure, Selected OECD Comparator Countries, 2009

	_	Expenditure apita		ctor Health e per Capita	Public Drug Expenditure as a Percentage of Public- Sector Health Expenditure		
Country	(CA\$, PPP)*	Rank	(CA\$, PPP)*	Rank	Percentage	Rank	
Australia [†]	324	7	2,805	7	11.6	5	
Canada [‡]	346	6	3,689	4	9.4	6	
France	511	2	3,712	3	13.8	3	
Germany	583	1	3,882	2	15.0	2	
Japan [†]	482	3	2,783	8	17.3	1	
New Zealand	217	8	2,873	6	7.5	8	
United Kingdom [§]	387	4	3,513	5	12.0	4	
United States	356	5	4,543	1	7.8	7	

Notes

- * Converted to Canadian dollars using purchasing power parities (PPPs) for gross domestic product (GDP).
- † 2008 data.
- ‡ Canadian data reported by the OECD is as of November 2010. In November 2011, updated and revised Canadian data was released in Canada. This updated information will not be incorporated into the OECD database until the summer of 2012.
- § 2008 data used for Public Drug Expenditure per Capita and Public Drug Expenditure as a Percentage of Public Sector Health Expenditure.

Source

Organisation for Economic Co-operation and Development, OECD Health Data 2011 (Paris, France: OECD, June 2011).

Factors Affecting Drug Expenditure in Canada

Numerous factors, many of which are interrelated, may influence drug expenditure. Since drug prices, as measured by several price indices, xvii have been relatively stable over the past 10 years, factors affecting increased drug spending in Canada essentially relate to the volume of drug use and the entry of new drugs (typically introduced to the market at higher prices).

The following review of some of the factors affecting drug expenditure is intended to facilitate discussion and is not meant to be a systemic review of all relevant literature.

Price-Related Factors

Although the ingredient prices of drugs, once on the market, are relatively stable, the introductory price and overall cost of drugs may be influenced by several factors. These factors include international pricing, inflation, changes in retail or wholesale markups and other market forces. Market forces can be competitive forces (for example, the introduction of new products can increase drug expenditures while generics can decrease drug expenditure by offering a lower-priced alternative) or regulatory forces (for example, changes in price controls or extending patent legislation that prevents a less expensive alternative from coming to the market).

Quantity-Related Factors

There are many factors that can affect the quantity of drugs dispensed. A change in quantity can be the result of a change in the number of users or in the volume of drugs used (for example, an increase or decrease in dosage prescribed or length of treatment).

Population-Related Factors

Population size affects the number of potential users in an area (for example, Prince Edward Island versus Ontario). Demographics such as age, gender and ethnic distribution also influence drug utilization. For example, the number of drugs people take, and in turn drug spending, increases with age.⁴ Drug use can also be influenced by changes in the health status of the population, which can be the result of the emergence of new diseases, epidemics and changes in the prevalence or severity of existing disease. Healthier populations may use fewer drugs.

xvii. For more information on price indices, see the Data Limitations section of the Methodological Notes.

Health System-Related Factors

The health system also plays a role in drug expenditure. Changes in policies and programs, including regulations around drug plan eligibility and co-insurance, the extent of formulary listings and the availability of and access to third-party insurance coverage can all affect drug spending.⁵ In general, the more accessible and more generous insurance coverage is, the less costly drugs are to the end consumer and the more likely people are to consume drugs.

New Drugs

New drugs introduced to the market may influence drug expenditure. New drugs can also result in switching between classes of drugs used to treat similar conditions or switching between drugs within a class. Provided there is a difference in price, any switching will affect drug expenditure.

New drugs may be safer or have fewer potential side effects than existing drugs. As well, they may offer an alternative to, or even a replacement for, existing non-drug therapies (for example, surgery). In addition, new drugs may be used to treat or slow the progression of diseases or symptoms of diseases that were previously undertreated or untreatable.

Generic Drugs

Generic drugs are usually introduced to the market following the expiration of patents for brand name drugs. They provide a lower-priced alternative, which often results in switching from the brand name to the generic product.

Other Factors

Changes in clinical practice guidelines can influence the types of drugs being used by recommending drugs as first- or second-line therapies. They may also influence the volume of use by recommending that more or fewer people be treated with certain drugs.

New indications for marketed drugs may influence drug expenditure. New indications can also result in switching between classes of drugs used to treat similar conditions or switching between drugs within a class. Provided there is a difference in price, any switching will affect drug expenditure.

Pharmaceutical companies promote their products to prescribers (for example, physicians, dentists and nurse practitioners) and pharmacists through a practice known as detailing, as well as by advertising to the general public, known as direct-to-consumer advertising (DTCA). Although DTCA is regulated in Canada, Canadians are exposed to it through international media. These practices can influence prescribing practices and consumer preferences, which can in turn influence drug utilization and spending.

Other factors include changes in pharmaceutical care practices, which can improve patients' compliance with treatment regimens, or the adoption of primary prevention strategies, such as improved diet, exercise or other forms of healthy living, which can improve the health status of the population.

What We Know

- Drug expenditure rose every year between 1985 and 2011, with an average annual growth rate of 8.5%.
- Since 2005, drug spending has grown more slowly than hospital spending, physician spending and total health care spending.
- Slowed growth has been due, at least in part, to recent patent expiries of some high-use drugs.⁶
- The generic share of the Canadian prescription drug market is expected to increase in the coming years, as drugs with patents that expired or will expire between 2010 and 2014 accounted for more than one-third (38.2%) of all wholesale spending on prescription drugs in Canada in 2009.⁶
- Some public drug programs have recently implemented changes to generic pricing policies. ^{7,8}
- Increased volume of use (related to increases in either the proportion of the population taking
 prescription drugs or the amount of drugs people are taking) and changes in the mix of
 treatments being used (related to patients switching to more expensive drugs) were the
 primary drivers of drug spending growth over the past decade. Population growth and aging
 also contributed to increased drug spending during the decade, though to a lesser degree.⁶
- The prices of patented drugs, which made up two-thirds of retail spending, are regulated in Canada and cannot grow in excess of the consumer price index (CPI) for extended periods.
- New drugs are often introduced at much higher prices than those of existing therapies. However, some new drugs have reduced overall medical expenditures. 10, 11
- The number of new chemicals marketed in Canada has declined in the past decade compared with the 1990s.⁶
- Cancer drugs and immunosuppressants have been the fastest growing drug classes in the
 past five years. Trends in drug development suggest that these classes may continue to drive
 drug spending in the years to come.⁶
- An increasing number of drug therapies are being administered outside of the hospital setting, thereby shifting costs from hospitals^{xviii} to the community (for example, in-home cancer treatments).¹²

What We Don't Know

- Whether increases in total drug expenditure negatively or positively affect overall health outcomes.
- How drug use impacts spending in other sectors of health care (for example, decreased hospitalization).
- How DTCA affects the marketplace, prescribing practices, physician—patient communication and the public's understanding of drug therapy in Canada.¹³
- The impact generic pricing policy changes will have on drug spending.

xviii. Drugs paid through hospital budgets are not identified separately in the NHEX database but are classified as hospital expenditure.

Methodological Notes

Background

Drug expenditure data in this report is obtained from the National Health Expenditure Database (NHEX), which is maintained by the Canadian Institute for Health Information (CIHI). This database contains a historical series of macro-level health expenditure statistics by province and territory, beginning in 1975. Drug expenditure data in NHEX is macro-level data and does not allow for decomposition of prescription costs or drug classes.

The Drugs category in NHEX is intended to measure final consumption, outside an institutional setting, of drugs purchased by consumers or third-party payers on their behalf, generally from community pharmacies. Drug expenditure data in NHEX consists of estimates that represent the final costs to Canadian consumers, which include dispensing fees, markups and appropriate taxes. NHEX data does not account for drug expenditure by non-Canadians (for example, Americans' purchases from Canadian pharmacies). The classification system employed is consistent with international standards developed by the Organisation for Economic Co-operation and Development (OECD).

National Health Expenditure Database

The mandate of the NHEX database is twofold:


- 1. To support the development and evaluation of health programs in Canada by all levels of government and within the private sector.
- 2. To compile information on health expenditure that will accurately portray the importance of health care as a component of national expenditure.

Health Expenditure—Includes any type of expenditure for which the primary objective is to improve or prevent the deterioration of health status.

This definition allows economic activities to be measured according to primary purpose and secondary effects. Activities that are undertaken with the direct purpose of improving or maintaining health are included. Other activities are not included, even though they may impact health. For example, housing and income support policies have social welfare goals as their primary purpose and are not considered to be health expenditure, yet they are recognized as powerful factors in determining population health.

Source of Finance

National health expenditures are reported based on the principle of *responsibility for payment* rather than on the source of the funds. It is for this reason, for example, that federal health transfers to the provinces/territories are included in the provincial/territorial government sector, since it is the responsibility of provincial/territorial governments to expend federal transfers on health services. The exception to this principle is that provincial/territorial government health transfers to municipal governments are included in the provincial/territorial government sector. The following figure depicts the composition of total health expenditure by source of finance.



Note

* The remaining funds in the Quebec Drug Insurance Fund are financed through the Consolidated Revenue Fund; these expenditures are captured under the provincial government sector.

Public Sector—Includes health care spending by governments and government agencies. it is subdivided into provincial government sector and other public sector, as described below:

- 1. The *provincial government sector* includes health spending from provincial/territorial government funds, federal health transfers to the provinces/territories and provincial/territorial government health transfers to municipal governments.
- The federal direct sector refers to direct health care spending by the federal government in relation to health care services for special groups, such as Aboriginal People, the Canadian Forces and veterans, as well as expenditures for health research, health promotion and health protection. Federal direct health expenditure does not include federal health transfers to the provinces.
- 3. The municipal government sector expenditure includes health care spending by municipal governments for institutional services, public health, capital construction and equipment, and dental services provided by municipalities in the provinces of Nova Scotia, Manitoba and British Columbia. Designated funds transferred by provincial governments for health purposes are not included in the municipal sector but are included with provincial government expenditure. Currently, no estimates of drug spending are included in this sector.

xix. Statistics Canada (Public Sector Statistics Division) publishes estimates of government health expenditure as part of its comprehensive reporting system of all government expenditure, the Financial Management System (FMS). The FMS public-sector health spending estimates are lower than those reported by CIHI because different classification methods are applied and a narrower definition of health expenditure is used in the FMS.

- 4. Social security funds are social insurance programs that are imposed and controlled by a government authority. They generally involve compulsory contributions by employees, employers or both, and the government authority determines the terms upon which benefits are paid to recipients. Social security funds are distinguished from other social insurance programs, the terms of which are determined by mutual agreement between individual employers and their employees. In Canada, social security funds include the health care spending by workers' compensation boards (WCBs) and the premium component of the Quebec Drug Insurance Fund.
 - Health spending by WCBs includes what the provincial boards commonly refer to as medical aid. Non-health related items often reported by the WCBs as medical aid expenditure—such as funeral expenses, travel and clothing—are removed.
 - On January 1, 1997, the government of Quebec created a basic drug insurance plan with the objective of ensuring the population of Quebec has access to drugs as required by health status. All residents of Quebec must be covered by drug insurance, whether by private group insurance or by the public plan administered by the Régie de l'assurance maladie du Québec (RAMQ). At the beginning of the plan, the Drug Insurance Fund was the chosen mechanism to pay all drug and pharmaceutical service costs provided to subscribers** insured by the RAMQ, as well as their children. Since July 1, 2002, the Drug Insurance Fund has also covered persons age 65 or older and social assistance recipients insured by the RAMQ. Accordingly, the public plan has been financed since then both by the expenditure allocated to this program by the Quebec government (provincial government sector) and by the amounts collected by the Drug Insurance Fund as premiums and proceeds (social security funds sector). The premiums are paid by the subscribers of the Quebec Drug Insurance Fund and by persons age 65 or older insured by this plan.

Private Sector—Includes health care spending by individuals and private sources as described below:

- 1. Non-consumption includes non-patient revenues received by health care institutions, such as donations and investment income, private spending on health-related capital construction and equipment, as well as health research funded by private sources. Currently, no estimates of drug spending are included in this portion of the private sector.
- 2. Out-of-pocket includes health expenditures made by individuals for health care goods and services.
- 3. Private health insurance includes health expenditure paid by commercial and not-for-profit insurance firms, as well as the cost of administering those claims.

xx. Subscribers are defined as Quebec residents younger than age 65 who do not receive social assistance benefits and who do not have access to private group insurance.

Hierarchy of Classification

National health expenditure in Canada is based on a system of classification that is consistent with international standards developed by the OECD for reporting health expenditure.

National health expenditure is grouped within the broad categories of personal health care or other health expenses:

- Personal health care consists of expenditure for health goods and services used by individuals.
- Other health expenses consist of expenditure on behalf of society, such as public health; expenditure made as investments for purposes of future consumption, such as capital expenditure; the administrative expenses of planning and managing the health care system; and research.

Personal health expenditure is classified within categories that describe the type of health care used. Certain categories overlap. The hierarchy of classification that is used to allocate overlapping categories of expenditure is as follows:

- Institutional setting—Health care services consumed in hospitals or other institutions are
 allocated to the institutional category if the institution purchases the services on behalf of
 its patients. For example, drugs paid through hospital budgets are classified as hospital
 expenditure. This allocates expenditure to the supplier actually paid by patients or
 their agents in the form of government or insurance companies. It also reflects
 data availability.
- **Self-employed provider of service—**For example, all expenses of physicians' practices are considered to be expenditure for physician services, even though some of these expenses would be for employment of other health professionals, drugs or personal health supplies.
- Type of good or service—Drugs and personal health supplies are examples.

One of the categories of health expenditure within NHEX is Drugs. Other categories include Hospitals, Other Institutions, Physicians, Other Professionals, Capital, Public Health and Administration, and Other Health Spending. In NHEX, these categories are also named Use of Funds.

Below is a description of the Drugs category within NHEX; it is not a definition supplied by the OECD.

- Drugs—At the aggregate level, include expenditure on prescribed drugs and non-prescribed products purchased in retail stores. Estimates represent the final costs to consumers, including dispensing fees, markups and appropriate taxes. The breakdown of prescribed drugs, over-the-counter drugs and personal health supplies in NHEX is parallel with the breakdown in the OECD. This category has been disaggregated at the Canada level in the data tables to provide information on the following sub-categories:
 - Prescribed drugs—substances considered as drugs under the Food and Drugs Act and sold for human use as the result of a prescription from a health professional.

- Non-prescribed drugs^{xxi}—include two sub-components: over-the-counter drugs and personal health supplies.
- Over-the-counter drugs—therapeutic drug products not requiring a prescription and purchased as such.
- Personal health supplies—include items used primarily to promote or maintain health; for example, oral hygiene products, diagnostic items such as diabetic test strips and medical items such as incontinence products.

The Drugs category in NHEX does not include drugs dispensed in hospitals and generally in other institutions. These are included in health expenditure figures for Hospitals or Other Institutions.

Other Terms

Gross domestic product (GDP)¹⁴—GDP implicit price index (in 1997 dollars) is used to compare annual percentage change of drug expenditure with inflation in the Canadian economy. GDP is the unduplicated value of production originating within the boundaries of Canada, regardless of the ownership of the factors of production.

Purchasing power parity (PPP)¹⁵—PPPs are the rates of currency conversion that equalize the purchasing power of different currencies. This means that a given sum of money, when converted into different currencies at the PPP rates, will buy the same basket of goods and services in all countries. Thus PPPs are the rates of currency conversion, which eliminate differences in price levels between countries.

Data Limitations

Data contained in NHEX is estimated. The data is collected from diverse sources and includes varying classes of financial information. The data is collected and classified according to methods established by a review committee. CIHI analysts and external experts continue to improve the comprehensiveness, accuracy and currency of the data in order to provide the most complete and objective estimates possible. Notwithstanding these improvements, national health expenditure data consists of estimates and should be used accordingly.

Most private-sector expenditure is estimated from survey data. Prior to 1996, the Family Expenditure Survey by Statistics Canada, ¹⁶ an important source of private-sector data, was not carried out annually; therefore, trend data was imputed for years between surveys. Private-sector data was revised following a methodology review in the early 1990s. The revised private-sector data incorporated information estimated directly from new sources for 1988 and subsequent years. Prior years were estimated using trend data. As a result, readers should use caution when using the private-sector expenditure data for small provinces and for years prior to 1988.

xxi. For more information on over-the-counter drugs and personal health supplies, see the General Methods section of the Methodological Notes.

Drugs in Hospitals

The NHEX database at CIHI uses a classification system that is consistent with international standards developed by the OECD for the reporting of health expenditure. Similar to the functional category Pharmaceutical and Other Medical Non-Durables in the OECD System of Health Accounts, the Drugs category in NHEX is intended to measure final consumption, outside an institutional setting, of drugs purchased by consumers or third-party payers on their behalf, generally from retail outlets. Drugs in hospitals are considered as inputs (intermediate consumption) to the production of health care in hospitals. Consequently, drugs paid through hospital budgets are not identified separately in NHEX but are classified as hospital expenditure. Similarly, drugs purchased by residential care facilities for their residents are classified as institutional expenditure. All expenses of physicians' and dentists' practices, including drugs, are considered to be expenditure for physicians' and dentists' services. Some drug expenditure is also included in the NHEX category of public health (for example, vaccines). While the above hierarchy of classification is essential in allocating overlapping categories of expenditure, it also reflects data availability. For example, data on expenditure by provincial/territorial governments is usually extracted from provincial/territorial government public accounts. In the accounts, it is generally not possible to isolate drug spending from other categories of expenditure within program areas (for example, hospitals or public health). Although other possible data sources exist, the use of a single data source for the different categories of provincial government health expenditure—such as the provincial/territorial public accounts—has the major advantage of minimizing the risk of double counting.

Measuring Drug Prices

There is no authoritative composite price index for all drugs sold in Canada. The difficulty lies in the fact that traditional statistical measurement considers the price of tablets or capsules rather than measuring the nature of the product itself (that is, its therapeutic properties). In pure economic terms, the price of a drug is the price per unit of health gain attained. From a practical perspective, however, people buy tablets, capsules or other forms of medication, some of which may contain multiple active ingredients.




Figure 19: Patented Medicine Price Index (PMPI), Consumer Price Index (CPI) and Industrial Product Price Index (IPPI), 1985 to 2011 (1987 = 100)

Sources

Consumer Price Index and Industrial Product Price Index, Statistics Canada; Patented Medicine Price Index, Patented Medicine Prices Review Board.

There are several commonly accepted price indices that can potentially be used to measure shifts in drug prices at the retail level. These include the Consumer Price Index (CPI), the pharmaceutical component of the Industrial Product Price Index (IPPI [pharma]) and the Patented Medicine Price Index (PMPI). Each index is built upon a unique set of assumptions pertaining to inclusion criteria, definitions, updating and weighting methodologies. As a result, these indices produce differing results (Figure 19).

It is important to determine whether two different products with similar therapeutic elements used to treat similar health conditions are essentially different. Several price indices assume they are different products. The consequence is that when new products enter the market, price indices do not compare their prices to existing products; they are simply added to the basket of goods.

Collection and Non-Response

The definitions and methods used in the preparation of this document are for the most part based on those adopted in 1994 by the National Health Expenditure Methodology Review Committee. This committee included representation from Health Canada, Statistics Canada, the Quebec ministère de la Santé et des Services sociaux, the Canadian Medical Association and the Canadian Healthcare Association. Some of the recommendations for change made during that process are still under development.

General Methods

The following is intended as a general overview of the methods applied to calculate estimates of drug expenditure in Canada. More detailed information can be obtained by contacting the National Health Expenditures program area by phone at 613-241-7860, by fax at 613-241-8120 or by email at nhex@cihi.ca.

Provincial/Territorial Government

Provincial/territorial government expenditure principally includes drugs that are dispensed through provincial/territorial drug subsidy programs (see Appendix A). This drug expenditure data is extracted predominantly from audited and consolidated provincial/territorial documents detailing provincial government expenditure (Table 6).

Provincial/territorial government drug spending figures include spending by the provincial/territorial ministry responsible for health, as well as by other departments that may provide drug coverage. CIHI's estimates of provincial and territorial government drug expenditure were submitted to provincial and territorial departments of health for review and validation.

Provincial/territorial government figures identified as forecasts are based on the growth rates of major programs reported in provincial and territorial government main estimates and budgets.

Table 6: Provincia	Table 6: Provincial/Territorial Government Drug Expenditure Data									
Province/Territory		Description								
Newfoundland and Labrador	Drug Expenditure Data Source	Drug expenditure data is collected from the Provincial Public Accounts Volume III, <i>Consolidated Revenue Fund</i> Supplementary Statements and Schedules for three drug programs: indigents, seniors and the special drug programs.								
Prince Edward Island	Drug Expenditure Data Source	The Drug Cost Assistance Program is reported under the Provincial Pharmacy program in the Queens Region Health and Community Services operating statement, which is reported in the P.E.I. Provincial Public Accounts Volume II.								
Nova Scotia	Drug Expenditure Data Source	Drugs data is extracted from three sources: the <i>Nova Scotia Estimates</i> Supplementary Detail, special tabulations from the N.S. Seniors' Pharmacare Program and the N.S. Department of Community Services, Income Assistance and Employment Support Services.								
New Brunswick	Drug Expenditure Data Source	Drugs data is provided through special reports from the Department of Health and the Department of Social Development. A small component of drug expenditure by the provincial government is from the N.B. Public Accounts Volume 2, under Payments to Vendors and Grants and Contribution Payments.								
Quebec	Drug Expenditure Data Source	Provincial government expenditure is extracted from Volume 2 of the Quebec provincial public accounts. Spending on drugs by the provincial government is represented by total transfers of Program 5, Régie de l'assurance maladie du Québec, for "médicaments et services pharmaceutiques." See also the section below on social security funds and the Quebec Drug Insurance Fund.								

Table 6: Provincia	al/Territorial Gov	ernment Drug Expenditure Data (cont'd)
Province/Territory		Description
Ontario	Drug Expenditure Data Source	Data is collected from Volume 1 of the Ontario Provincial Public Accounts. Information is collected for the drug programs provided by the Ministry of Health and Long-Term Care (Ontario Drug Benefit Program, Trillium Drug Program, Special Drug Program) and by the Ministry of Community and Social Services, under Social Assistance and Employment under the Adult and Children's Service Program.
Manitoba	Drug Expenditure Data Source	Data is from Manitoba Health's Pharmacare Program under the Health Services Insurance Fund. Data is also collected from the annual report of the Manitoba Department of Family Services under Income Assistance of the Employment and Income Assistance Program.
Saskatchewan	Drug Expenditure Data Source	Data sources include the Saskatchewan Public Accounts Volume 2 and the Saskatchewan Health Annual Statistical Report for the Drug Plan and Extended Benefits Branch. Data is collected for the Saskatchewan Prescription Drug Plan from the annual report. A total for the Supplementary Health Program (SHP) is also extracted from the annual report. The distribution of detailed expenditure of the SHP provided in the Statistical Report for the Drug Plan and Extended Benefits Branch is applied to the total for the SHP extracted from the public accounts. One of the components of the SHP that is also collected is "non-formulary drugs." Drug expenditure amounts are collected under the Ministry of Social Services in the Supplier Payments section of the public accounts.
Alberta	Drug Expenditure Data Source	Drug expenditure data from Alberta Health and Wellness is extracted from its annual report. Detailed claims summary data is provided by Alberta Blue Cross Non-Group Benefits. The largest single expenditure component of Alberta Blue Cross Non-Group Benefits is drug benefits. The detailed claims distribution is applied to the total for Blue Cross Non-Group Benefits under Practitioner Services, extracted from the annual report of the Ministry of Health and Wellness. Drug expenditure information is also collected from Children's Services, the Department of Community Development and the Department of Human Resources and Employment. Drug expenditure amounts are compiled from various income assistance programs, including Income Support to Individuals and Families, Social Support to Individuals and Families
British Columbia	Drug Expenditure Data Source	and Services to Persons With Disabilities. Data is received in the <i>Financial Management Reports</i> (FMRs) from the Ministry of Health Services. Control totals for major programs are from the public accounts. With few exceptions, expenditure items from the FMRs sum to the control totals. The Ministry of Health Services administers drug subsidization for all targeted groups (seniors, income assistance recipients and families) under the Medical Services Program.
Yukon	Drug Expenditure Data Source	Control totals on major programs are extracted from Yukon's public accounts. Additional details are in a special tabulation provided by the territorial Ministry of Health and Social Services on spending for pharmacare, prescription drugs, under the Chronic Disease Program and Extended Health Benefits for Seniors.
Northwest Territories	Drug Expenditure Data Source	Drug expenditure data is provided by the Finance Division of the Department of Health and Social Services under the Extended Health Benefits of the Supplementary Health Programs.
Nunavut	Drug Expenditure Data Source	The government of Nunavut is unable to provide drug expenditure amounts to CIHI. The method used to estimate expenditure in Nunavut was to allocate the same proportion that drugs were in the Northwest Territories of the aggregate of individual programs in the Northwest Territories that make up the Supplementary Health Benefits Program in Nunavut.

Federal Direct

Prescribed drug data is derived from information provided by federal government organizations supplemented with information from the national public accounts. Federal government health care spending is generally provided according to the province in which the expenditure was made. Some data, however, is provided only at the national level; in these cases, it is distributed by the appropriate provincial or territorial population.

Social Security Funds

Social security funds are financially autonomous social insurance schemes that are imposed and controlled by a government authority. They generally involve compulsory contributions by employees, employers or both, and the government authority determines the terms by which benefits are paid to recipients. Social security funds are distinguished from other social insurance programs, the terms of which are determined by mutual agreement between individual employers and their employees. In Canada, social security funds include the health care spending by WCBs and the premium component of the Quebec Drug Insurance Fund.

Workers' compensation boards—Prescribed drug expenditure for the WCBs and the Commission de la santé et de la sécurité du travail du Québec is collected through special tabulations from contacts in each provincial or territorial WCB.

Quebec Drug Insurance Fund—On January 1, 1997, the government of Quebec created a basic drug insurance plan with the objective of ensuring the population of Quebec has access to drugs as required by health status. All residents of Quebec must be covered by drug insurance, whether by private group insurance or by the public plan administered by the Régie de l'assurance maladie du Québec (RAMQ). At the beginning of the plan, the Drug Insurance Fund was the chosen mechanism to pay all drug and pharmaceutical service costs provided to subscribers insured by the RAMQ, as well as their children. Since July 1, 2002, the Drug Insurance Fund has also covered persons age 65 or older and social assistance recipients insured by the RAMQ. Accordingly, the public plan has been financed since then, both by the expenditure allocated to this program by the Quebec government (provincial government sector) and by the amounts collected by the Drug Insurance Fund as premiums and proceeds (social security funds sector). The premiums are paid by the subscribers of the Quebec Drug Insurance Fund and by persons age 65 or older insured by this plan.

The premium component of the Quebec drug program is considered to be a social security scheme, while the remaining portion of the program that is paid through the ministère de la Santé et des Services sociaux (MSSS) is included as a provincial government expenditure.

xxii. Subscribers are defined as Quebec residents younger than age 65 who do not receive social assistance benefits and who do not have access to private group insurance.

Private Sector

Private-sector drug data was revised in 1995 following a methodology review that began in the early 1990s. Private-sector data under the revised methodology incorporated information estimated directly from new sources for 1988 and subsequent years. Expenditure amounts prior to 1988 were estimated using trend data. Therefore, readers should exercise caution when using the private-sector expenditure data for small provinces and for years prior to 1988.

The recommendations pertaining to prescribed and non-prescribed drugs that were ultimately implemented included the following:

- Data on drug benefits paid by private insurers was to be estimated based on information provided by the Canadian Life and Health Insurance Association (CLHIA) and from surveys of non-profit insurers.
- Out-of-pocket expenditure on prescribed drugs was to be estimated from Statistics Canada's Family Expenditure in Canada survey (FAMEX), renamed in 1997 to the Survey of Household Spending (SHS).
- Non-prescribed drug estimates would include two components: over-the-counter drugs and personal health supplies. Estimates would be based on information from the market research firm The Nielsen Company.

As part of the original agreement with the not-for-profit insurance firms that provide data to NHEX, the administrators of NHEX agreed not to report the components of the private sector—insurance and out-of-pocket expenditure—at the provincial/territorial level. The purpose was to protect the proprietary nature of the information of the not-for-profit insurance firms. Consequently, CIHI only reports the private-sector sum of components by province and the out-of-pocket and insurance components of the private sector at the national level.

The data sources and methodologies related to these recommendations are described below.

Health insurance drug claims paid are collected from nine not-for-profit insurance companies and the CLHIA. The CLHIA data is based on its survey of member companies. Currently, drug spending that may occur by insurance companies providing casualty insurance is not included in the estimates.

Out-of-pocket prescribed drug expenditure is based on purchased data from the SHS fielded by Statistics Canada. Specifically, average household costs associated with question 220, in Section PH of the SHS 2008 Questionnaire, relating to medicines, drugs and pharmaceutical products **prescribed by a doctor** are the basis of the estimates. The average household expenditure of prescribed drugs is multiplied by the number of estimated households reported in the survey.

The SHS is an annual survey that began in 1996. Prior to 1996, full surveys that included both urban and rural areas were carried out in 1986 and 1992. In 1990, a survey was conducted that included only metropolitan areas. For the years in which complete surveys were carried out, data is available for the 10 provinces and for 17 urban centres. Two of the urban centres, Yellowknife and Whitehorse, were used to derive estimates of expenditure in the territories. Metropolitan expenditure per household tends to be somewhat higher than provincial estimates.

All relevant categories were updated in complete survey years. For the years in which only urban surveys were carried out, the percentage changes in urban expenditure within each province or territory were used to update category estimates from complete survey years. Between 1992 and 1996, when no surveys were conducted, historical provincial growth rates of the SHS variables of drug and drug sundries were used to impute missing years.

The non-prescribed drug estimate is based on data from the market research firm The Nielsen Company, which tracks consumer sales of non-prescribed drugs sold in Canada at retail. Each year, The Nielsen Company reports retail sales data for two consistent years for more than 48 non-prescribed drug categories. Data is reported by sales channel, xxiii total dollar sales volume and regional sales distribution for five regions that include nine provinces. Newfoundland and Labrador and the territories are not included. The data is processed by classifying the non-prescribed drug categories as either over-the-counter drugs or personal health supplies. Regional sales amounts are separated into nine provinces, and estimates for Newfoundland and Labrador and the territories are calculated using provincial distributions of "direct costs for health care" from the SHS. Appropriate provincial and federal sales taxes are incorporated into the estimates.

The following list provides the various drug classes that are supplied to CIHI by The Nielsen Company. The choice of classes to be included in the non-prescribed drug expenditure estimate and the classification according to which drugs are included as over-the-counter or personal health supplies was made by the NHEX Drug Expenditure Review Committee during the NHEX methodology review and adopted in 1995.

Over-the-Counter Drugs	Personal Health Supplies
Analgesic rubs	Adhesive bandages and dressing strips
Anti-fungals (external)	Antiperspirants
Athletes' foot products (included in	Artificial sweeteners
anti-fungals in later years)	Athletic supports/braces
Cold remedies	Condoms
Cough remedies	Contact lens preparations
Diarrhea remedies	Cotton swabs
Dietary aids	Cover and tape products
Headache remedies	Dental floss
Headache remedies—child's acetaminophen	Dentifrice
Hemorrhoidal remedies	Denture adhesives
Infant feeding products	Denture cleansers
Laxatives	Diabetic test strips
Medical nutritional supplements	Disposable diabetic syringes
Milk-intolerant products	Elastic bandages
Nasal preparations	Eye drops and lotions
Oral backache remedies	Feminine hygiene products
Pediculicides	Fever thermometers

xxiii. As a general rule, Statistics Canada definitions govern the classification of stores by class of trade. Sales channels include drug stores; food stores with pharmacies; grocery banners; and mass merchandiser and warehouse clubs, which are estimated from The Nielsen Company's household panel data.

Over-the-Counter Drugs	Personal Health Supplies
Personal lubricants	Incontinence products
Premenstrual products	Medical supports/braces
Sleeping aids	Oral antiseptics
Throat remedies	Pregnancy test kits
Topical wound care	Sanitary pads
Upset stomach remedies	Selected hot/cold compresses
Vitamins—children's	Selected insoles
Vitamins—adults'	Tampons
Wart removers	Toothbrushes (includes denture brushes)

Calculation Methods

Calculation of Average Annual Rate of Growth

The average annual rate of growth is the constant annual rate necessary for a value at the beginning of a period to grow to a value at the end of a period over the number of compounding years in the period. The formula used to calculate the average annual rate of growth is

$$= e^{\frac{\ln(\text{value at end of period}) - \ln(\text{value at beginning of period})}{T}} - 1$$

Where the constant e equals 2.718, which is the base of the natural logarithm, and T equals the number of years in the period (that is, year at end of period – year at beginning of period).

Calculation of Calendar Year

Some information sources provide data in fiscal years. Calendar-year data was derived by adding three-quarters of one fiscal year to one-quarter of the previous fiscal year.

Calculation of per Capita Dollars

Per capita expenditure was calculated using the most recent revised population estimates and forecasts from the Demography Division of Statistics Canada. These take into account the results of the census adjustment for net census under-count, non-permanent residents and returning Canadians.

Calculation of Total Health Expenditure

"Total health expenditure" refers to the sum of the public and private sectors. "Canada" refers to the sum of the 10 provinces and three territories. "Canada average" is the sum of provincial and territorial expenditure divided by the sum of provincial and territorial data of another variable, such as population.

Calculation of Deflated Drug Expenditure per Capita Using CPI

Where drug expenditure per capita is presented in constant 1985 dollars, constant dollar drug expenditure per capita was calculated using the CPI, provided by Statistics Canada. A more complete explanation of the methodology for calculating the CPI is available from Statistics Canada.¹⁷

Forecasting Methods

Provincial government–sector drug spending forecasts are based on the growth rates of drug subsidy programs of provincial health departments reported in provincial main estimates and budgets. In the case of territorial government forecasts of the Northwest Territories and Nunavut, estimates were based on amounts reported in their main estimates. In other sectors, the figures for these two territories were calculated by developing a forecast for the Northwest Territories, including Nunavut. The share of Nunavut spending in the last year of actual data of the combined total of the Northwest Territories and Nunavut was used as a proxy to break out the forecasts for the Northwest Territories and Nunavut.

Forecasts for federal direct, WCBs and private sector were entirely based on econometric analysis of time series trends. For each series, up to 40 different univariate forecasting specifications were evaluated, and the best one (based on the root mean square error of prediction) was selected. The functional forms studied included the exponential smoothing family (simple, double, Holt, Brown, Winters, damped trend, etc.); time trends; and ARIMA specifications. Logarithmic transformations were used when the data warranted their use.

Forecasts of health expenditure are identified in the figures by special symbols and in the data tables by the letter *f*.

Sources of Data

Drug expenditure estimates from NHEX are compiled based on information from the following sources.

Provincial Government Sector

- Provincial public accounts and main estimates
- Provincial departments of health annual reports and statistical supplements, where available
- Annual reports of various foundations, agencies and commissions
- Special tabulations and specific information from various provincial departments reporting health expenditure

Federal Direct Sector

- Public Accounts of Canada
- Special tabulations and information from
 - Health Canada
 - Veterans Affairs Canada

- Department of National Defence
- Solicitor General of Canada
- Statistics Canada
- Citizenship and Immigration Canada

Social Security Funds Sector

- Special tabulations on medical aid spending provided by the provincial and territorial WCBs
- Annual reports of provincial and territorial WCBs
- Annual report of the RAMQ

Private Sector

- Private insurance component:
 - The not-for-profit portion is captured from special tabulations provided by the not-for-profit insurance companies.
 - The commercial portion is captured by a special tabulation provided by the CLHIA.
- Out-of-pocket component:
 - SHS, Statistics Canada (formerly the FAMEX)
 - Over-the-Counter Drugs and Personal Health Supplies—Market Review of Selected Drug Categories at Retail, a special tabulation purchased from The Nielsen Company Canada

Economic and Demographic Data

- Gross domestic product:
 - Purchased from National Accounts and Environment Division, Statistics Canada, for all years except the latest
 - Purchased from The Conference Board of Canada (GDP growth rates) for the latest year
- Population—purchased from Demography Division, Statistics Canada
- Provincial government expenditure—special tabulation purchased from Public Institutions Division, Statistics Canada
- Price indices:
 - PMPI: from Patented Medicine Prices Review Board
 - CPI and Industrial IPPI: purchased from the Prices Division, Statistics Canada

Series A—Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, Canada, 1985 to 2011

Table A Canada—Total

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, Canada, 1985 to 2011

			Dub-#-		Prescribed	l Drugs	Dubra 4-				Prescribed Dru	
	Provincial/ Territorial	Federal	WCBs	urity Funds Drug Insurance Funds	Subtotal Public	Insurers	Out of Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	te (Out of Pock Personal Health Supplies	Total Non-Presc. Drugs
Year			(Pro	emium Component)		(\$ Millions	s)			Drugs		
1985 1986 1987 1988	1,048.1 1,240.6 1,406.7 1,592.7	58.0 63.3 68.2 89.3	12.6 15.2 17.8 20.8		1,118.7 1,319.2 1,492.7 1,702.8	 1,130.3	 903.7	1,447.7 1,698.8 1,800.4 2,034.0	2,566.5 3,018.0 3,293.1 3,736.8			1,235.9 1,399.0 1,621.7 1,784.9
1989 1990	1,838.0 2,120.2	110.0 130.3	22.9 27.5		1,970.9 2,278.0	1,260.6 1,466.8	1,031.4 1,127.0	2,292.0 2,593.9	4,262.9 4,871.8			1,975.6 2,058.7
1991 1992 1993	2,428.0 2,710.7 2,817.0	145.6 159.7 187.6	33.2 38.1 40.2		2,606.7 2,908.5 3,044.9	1,671.5 1,947.3 2,089.3	1,190.4 1,244.9 1,469.4	2,861.9 3,192.3 3,558.7	5,468.7 6,100.7 6,603.5	1,290.0 1,373.0	1,128.1 1,203.1	2,236.6 2,418.1 2,576.0
1994	2,845.0 3,099.7	207.1	35.5 37.8		3,087.6 3,365.3	2,105.2 2,350.1	1,568.2 1,683.6	3,673.3 4,033.8	6,760.9 7,399.0	1,475.1	1,288.9	2,764.0 2,788.4
1996 1997	3,052.3 3,133.4	234.0 252.5	41.4 42.7	169.1	3,327.7 3,597.7	2,476.6 2,785.2	1,796.7 2,148.0	4,273.3 4,933.2	7,601.0 8,530.9	1,508.0 1,569.2	1,338.8 1,407.6	2,846.7 2,976.8
1998 1999	3,462.5 3,914.2	283.7 321.0	47.9 53.7	213.4 262.4	4,007.5 4,551.3	3,220.5 3,387.0	2,223.0 2,302.0	5,443.5 5,689.0	9,451.1 10,240.3	1,661.7 1,782.1	1,509.7 1,576.7	3,171.3 3,358.8
2000	4,559.3	343.3	64.8	327.8	5,295.2	3,866.8	2,562.5	6,429.3	11,724.6	1,815.3	1,605.0	3,420.3
2001 2002	5,228.8 5,839.0	392.0 448.2	75.8 86.5	367.4 433.2	6,064.1 6,807.0	4,489.0 5,009.4	2,613.5 2,934.4	7,102.5 7,943.9	13,166.6 14,750.9	1,882.4 1,972.2	1,654.0 1,712.5	3,536.4 3,684.7
2003 2004	6,376.6 6,996.6	508.2 528.6	102.6 121.1	577.8 615.5	7,565.2 8,261.8	5,692.6 6,229.2	3,155.9 3,364.8	8,848.5 9,594.0	16,413.7 17,855.8	2,047.6 2,159.3	1,714.6 1,770.9	3,762.2 3,930.2
2005 2006	7,594.9 8,188.6	564.4 609.9	133.4 148.5	618.7 669.0	8,911.5 9,616.0	6,714.3 7,269.4	3,484.1 3,945.5	10,198.4 11,214.9	19,109.9 20,830.9	2,245.5 2,348.8	1,838.5 1,914.4	4,084.0 4,263.2
2007	8,672.0	626.7	157.3	712.1	10,168.0	7,896.8	3,934.9	11,831.7	21,999.6	2,478.3	1,961.7	4,439.9
2008 2009	9,188.4 9,954.3	639.8 650.7	168.9 179.2	774.7 744.0	10,771.8 11,528.2	8,467.2 8,976.9	4,167.8 4,302.1	12,634.9 13,279.0	23,406.8 24,807.3	2,531.9 2,704.0	1,983.8 2,052.4	4,515.7 4,756.5
2010 ^f 2011 ^f	10,176.7 10,391.5	652.3 664.6	195.1 212.9	779.0 793.5	11,803.1 12,062.5	9,555.6 10,244.9	4,603.0 4,874.2	14,158.6 15,119.1	25,961.7 27,181.6	2,748.0 2,733.0	2,091.1 2,129.3	4,839.1 4,862.4
1985	***					(Annual Percentag	e Change)		***	***		
1986 1987	18.4 13.4	9.2 7.7	20.9 16.9		17.9 13.2			17.3 6.0	17.6 9.1			13.2 15.9
1988 1989	13.2 15.4	30.9 23.2	16.6 10.0		14.1 15.7	 11.5	 14.1	13.0 12.7	13.5 14.1			10.1
1990	15.4	18.4	20.0		15.6	16.4	9.3	13.2	14.3			4.2
1991 1992	14.5 11.6	11.7 9.7	20.8 14.8		14.4 11.6	14.0 16.5	5.6 4.6	10.3 11.5	12.3 11.6			8.6 8.1
1993 1994	3.9 1.0	17.5 10.4	5.7 -11.9	***	4.7 1.4	7.3 0.8	18.0 6.7	11.5 3.2	8.2 2.4	6.4 7.4	6.6 7.1	6.5 7.3
1995 1996	9.0 -1.5	10.0 2.7	6.5 9.6		9.0 -1.1	11.6 5.4	7.4 6.7	9.8 5.9	9.4 2.7	-0.1 2.3	2.0 1.9	0.9 2.1
1997 1998	2.7 10.5	7.9 12.4	3.2 12.0	26.2	8.1 11.4	12.5 15.6	19.6 3.5	15.4 10.3	12.2 10.8	4.1 5.9	5.1 7.3	4.6 6.5
1999	13.0	13.1	12.1	23.0	13.6	5.2	3.6	4.5	8.4	7.2	4.4	5.9
2000 2001	16.5 14.7	7.0 14.2	20.7 17.0	24.9 12.1	16.3 14.5	14.2 16.1	11.3 2.0	13.0 10.5	14.5 12.3	1.9 3.7	1.8 3.1	1.8 3.4
2002 2003	11.7 9.2	14.3 13.4	14.1 18.7	17.9 33.4	12.3 11.1	11.6 13.6	12.3 7.5	11.8 11.4	12.0 11.3	4.8 3.8	3.5 0.1	4.2 2.1
2004	9.7	4.0	18.0	6.5	9.2 7.9	9.4	6.6	8.4	8.8 7.0	5.5	3.3	4.5 3.9
2005 2006	8.6 7.8	6.8 8.1	10.2 11.3	0.5 8.1	7.9	7.8 8.3	3.5 13.2	6.3 10.0	9.0	4.0 4.6	3.8 4.1	4.4
2007 2008	5.9 6.0	2.7 2.1	5.9 7.4	6.4 8.8	5.7 5.9	8.6 7.2	-0.3 5.9	5.5 6.8	5.6 6.4	5.5 2.2	2.5 1.1	4.1 1.7
2009 2010 ^f	8.3 2.2	1.7 0.2	6.1 8.9	-4.0 4.7	7.0 2.4	6.0 6.4	3.2 7.0	5.1 6.6	6.0 4.7	6.8 1.6	3.5 1.9	5.3 1.7
2011 ^f	2.1	1.9	9.1	1.9	2.2 (Percent	7.2 tage Share of Total	5.9 Drug Expendit	6.8 ture)	4.7	-0.5	1.8	0.5
1985 1986	27.6 28.1	1.5 1.4	0.3 0.3		29.4 29.9			38.1 38.5	67.5 68.3			32.5 31.7
1987 1988	28.6 28.8	1.4 1.6	0.4 0.4		30.4 30.8	20.5	 16.4	36.6 36.8	67.0 67.7			33.0 32.3
1989	29.5	1.8	0.4		31.6	20.2	16.5	36.7	68.3			31.7
1990 1991	30.6 31.5	1.9 1.9	0.4 0.4		32.9 33.8	21.2 21.7	16.3 15.4	37.4 37.1	70.3 71.0			29.7 29.0
1992 1993	31.8 30.7	1.9 2.0	0.4 0.4		34.1 33.2	22.9 22.8	14.6 16.0	37.5 38.8	71.6 71.9	15.1 15.0	13.2 13.1	28.4 28.1
1994	29.9	2.2	0.4		32.4	22.1	16.5	38.6	71.0	15.5	13.5	29.0
1995 1996	30.4 29.2	2.2	0.4		33.0 31.9	23.1 23.7	16.5 17.2	39.6 40.9	72.6 72.8	14.5 14.4	12.9 12.8	27.4 27.2
1997 1998	27.2 27.4	2.2 2.2	0.4 0.4	1.5 1.7	31.3 31.7	24.2 25.5	18.7 17.6	42.9 43.1	74.1 74.9	13.6 13.2	12.2 12.0	25.9 25.1
1999 2000	28.8 30.1	2.4	0.4	1.9 2.2	33.5 35.0	24.9 25.5	16.9 16.9	41.8 42.5	75.3 77.4	13.1 12.0	11.6 10.6	24.7 22.6
2001	31.3	2.3	0.5	2.2	36.3	26.9	15.6	42.5	78.8	11.3	9.9	21.2
2002 2003	31.7 31.6	2.4 2.5	0.5 0.5	2.4	36.9 37.5	27.2 28.2	15.9 15.6	43.1 43.9	80.0 81.4	10.7 10.1	9.3 8.5	20.0 18.6
2004	32.1 32.7	2.4	0.6	2.8 2.7	37.9 38.4	28.6 28.9	15.4 15.0	44.0 44.0	82.0 82.4	9.9 9.7	8.1 7.9	18.0 17.6
2006	32.6	2.4	0.6	2.7	38.3	29.0	15.7	44.7	83.0	9.4	7.6	17.0
2007 2008	32.8 32.9	2.4 2.3	0.6 0.6	2.7 2.8	38.5 38.6	29.9 30.3	14.9 14.9	44.7 45.3	83.2 83.8	9.4 9.1	7.4 7.1	16.8 16.2
2009 2010 ^f	33.7 33.0	2.2	0.6	2.5 2.5	39.0 38.3	30.4 31.0	14.6 14.9	44.9 46.0	83.9 84.3	9.1 8.9	6.9	16.1 15.7
2011 [†] f: forecast.	32.4	2.1	0.7	2.5	37.6	32.0	15.2	47.2 National He	84.8 alth Expenditure Dat	8.5 tabase, 2011, Cana	6.6 dian Institute for H	15.2 Health Information.

Table A Canada—Total

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, Canada, 1985 to 2011 (cont'd)

Share of Drugs in Public, Private and All Drugs Private Health Expenditure Total Health Expenditures Year (\$ Millions) (Percentage Share) 1985 2,683.6 3,802.3 30,095.5 9,746.9 39,842.4 27.5 9.5 1,118.7 1986 1.319.2 3.097.9 4.417.1 32.529.4 10.808.7 43.338.1 4.1 28.7 10.2 1987 1,492.7 3,422.2 35,055.7 11,733.5 46,789.2 29.2 10.5 1988 1.702.8 3.818.9 5.521.7 38.163.7 12.796.4 50.960.1 4.5 29.8 10.8 1,970.9 4,267.7 6,238.5 41,911.9 14,184.3 56,096.2 4.7 30.1 1990 2 278 0 4 652 5 6.930.5 45 449 2 15 577 1 61 026 3 5.0 29 9 11.4 11.6 1991 2,606.7 5,098.5 7,705.3 49,382.9 16,906.9 66,289.8 5.3 30.2 1992 2.908.5 5.610.4 8.518.8 51.637.9 18.112.0 69.749.9 5.6 31.0 12.2 1994 3.087.6 6.437.4 9.524.9 20.574.2 73.111.4 5.9 31.3 13.0 6,822.2 74,086.4 6.4 1995 3,365.3 10,187.4 52,716.3 21,370.1 31.9 13.8 1996 3.327.7 7.120.0 10.447.8 52.803.4 21.910.5 74.713.9 32.5 14.0 1997 3,597.7 11,507.7 55,201.3 23,533.1 78,734.4 6.5 33.6 1998 4.007.5 8.614.9 12.622.4 59.186.0 24.897.9 84.083.9 6.8 34.6 15.0 4,551.3 9,047.9 13,599.2 63,182.8 27,180.7 90,363.4 33.3 2000 5 295 2 9 849 6 15 144 8 69 253 9 29.335.2 98 589 1 7.6 33 6 15.4 6,064.1 6,807.0 32,216.8 35,147.5 107,208.3 115,093.2 79,945.7 2002 11,628.6 18,435.6 8.5 33.1 16.0 2003 2004 7,565.2 8,261.8 12,610.7 13,524.2 20,176.0 21,786.0 86,653.0 92,271.2 37,025.4 39,515.9 123,678.4 131,787.1 34.1 34.2 16.3 16.5 9.0 14,282.4 23,193.8 98,603.9 42,049.5 2005 2006 9,616.0 15,478.1 25,094.1 105,121.3 45,802.3 150,923.6 9.1 33.8 16.6 10,168.0 10,771.8 16,271.6 26,439.6 47,916.3 50,772.2 2008 17,150.6 27,922.4 121,451.3 172,223.5 8.9 33.8 16.2 2009 11,528.2 18,035.5 29,563.7 129,089.4 53,023.3 182,112.7 8.9 34.0 16.2 2010 18 997 7 30 800 8 136 857 2 55 996 7 192 853 9 16.0 11.803.1 8.6 33.9 2011^f 12,062.5 32,043.9 140,968.4 200,499.1 (Annual Percentage Change) 1985 ---15.4 17.9 8.1 10.9 8.8 16.2 1986 1987 1988 13.2 14.1 10.5 11.6 11.3 12.3 7.8 8.9 8.6 9.1 8.0 8.9 1989 15.7 11.8 13.0 9.8 10.8 10.1 11.1 1990 15.6 9.0 8.4 9.8 8.8 14.4 11.6 8.7 4.6 1992 10.0 10.6 5.2 1993 9.3 4.9 7.8 3.8 0.6 1.2 2.5 2.3 6.0 4.4 11.1 8.9 9.0 -1.1 1995 0.3 3.9 1996 2.6 0.2 2.5 0.8 1997 10.1 9.7 7.7 4.5 7.2 7.4 5.4 6.8 1999 13.6 5.0 6.8 9.2 7.5 2000 16.3 8.9 11.4 9.6 7.9 9.1 2001 14.5 12.3 10.3 10.4 8.7 7.4 7.5 8.0 9.3 8.4 7.2 8.3 6.6 9.8 9.1 2003 11.1 9.4 8.4 5.3 2004 9.2 8.0 6.5 6.6 2005 2006 7.9 7.9 6.5 8.2 6.4 8.9 5.6 8.4 6.9 6.6 6.7 7.3 6.3 7.3 5.7 2007 5.7 5.1 5.4 5.4 7.0 4.6 2008 7.9 6.3 6.0 4.4 2009 7.0 5.2 5.9 2.4 5.3 4.2 6.0 5.6 5.9 2011 22 5.2 4.0 3.0 6.3 4.0 (Percentage Share of Total Drug Expenditure) 29.4 100.0 1985 70.6 1986 1987 29.9 30.4 70.1 69.6 100.0 100.0 1988 30.8 69.2 100.0 1989 31.6 1990 32.9 33.8 67.1 66.2 100.0 1991 100.0 34.1 33.2 1992 65.9 100.0 1993 66.8 100.0 1994 32.4 67.6 100.0 67.0 33.0 100.0 1995 31.9 31.3 68.1 68.7 1996 100.0 1998 31.7 68.3 100.0 66.5 2000 35.0 65.0 100.0 2001 36.3 100.0 63.7 2002 36.9 63 1 100.0 2003 2004 37.9 62.1 100.0 38.4 2005 61.6 100.0 2006 38.3 38.5 61.7 61.5 100.0 100.0 38.6 2008 61.4 100.0 61.0 100.0 2011^f 37.6 62.4 100.0

f: forecast.

Table A Canada—Per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Canada, 1985 to 2011

					Prescribed	Drugs					Prescribed Dru	
	Provincial/ Territorial	Federal	Public Social Security WCBs Dru	Funds g Insurance Funds	Subtotal Public	Insurers	Private Out of Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	te (Out of Pock Personal Health Supplies	Total Non-Presc. Drugs
Year			(Premi	ım Component)		(\$ per Capi	ta)			Drugs		
1985 1986 1987 1988	40.56 47.53 53.18 59.44	2.24 2.43 2.58 3.33	0.49 0.58 0.67 0.78		43.29 50.54 56.44 63.55	 42.18	33.72	56.02 65.09 68.07 75.91	99.31 115.63 124.51 139.46			47.82 53.60 61.32 66.61
1989 1990 1991	67.37 76.55 86.62	4.03 4.70 5.19	0.84 0.99 1.18		72.24 82.24 92.99	46.21 52.96 59.63	37.81 40.69 42.47	93.65 102.10	156.25 175.89 195.09			72.42 74.33 79.79
1992 1993 1994	95.56 98.22 98.11	5.63 6.54 7.14	1.34 1.40 1.22		102.53 106.16 106.47	68.65 72.84 72.59	43.89 51.23 54.08	112.53 124.07 126.67	215.07 230.23 233.14	45.48 47.87 50.87	39.77 41.95 44.45	85.24 89.81 95.31
1995 1996 1997 1998	105.78 103.08 104.77 114.81	7.78 7.90 8.44 9.41	1.29 1.40 1.43 1.59	5.65 7.08	114.85 112.38 120.30 132.89	80.20 83.64 93.13 106.79	57.46 60.68 71.82 73.71	137.66 144.32 164.95 180.51	252.51 256.70 285.24 313.39	50.31 50.93 52.47 55.10	44.85 45.21 47.07 50.06	95.16 96.14 99.53 105.16
1999 2000 2001 2002	128.74 148.57 168.56 186.12	10.56 11.19 12.64 14.29	1.77 2.11 2.44 2.76	8.63 10.68 11.84 13.81	149.70 172.55 195.48 216.97	111.40 126.00 144.71 159.68	75.71 83.50 84.25 93.53	187.12 209.50 228.96 253.21	336.81 382.04 424.44 470.18	58.61 59.15 60.68 62.86	51.86 52.30 53.32 54.59	110.47 111.45 114.00 117.45
2003 2004 2005	201.31 218.68 235.05	16.04 16.52 17.47	3.24 3.79 4.13	18.24 19.24 19.15	238.83 258.22 275.79	179.71 194.69 207.80	99.63 105.17 107.83	279.34 299.86 315.62	518.17 558.08 591.42	64.64 67.49 69.49	54.13 55.35 56.90	118.77 122.84 126.39
2006 2007 2008 2009	251.37 263.35 275.80 295.20	18.72 19.03 19.20 19.30	4.56 4.78 5.07 5.31	20.54 21.62 23.25 22.06	295.19 308.78 323.32 341.88	223.15 239.81 254.15 266.22	121.11 119.49 125.10 127.58	344.27 359.30 379.25 393.80	639.45 668.08 702.57 735.68	72.10 75.26 76.00 80.19	58.77 59.57 59.54 60.87	130.87 134.83 135.54 141.06
2010 ^f 2011 ^f	298.36 301.18	19.12 19.26	5.72 6.17	22.84 23.00	346.04 349.62	280.15 296.94 (Annual Percentag	134.95 141.27 e Change)	415.10 438.21	761.14 787.82	80.57 79.21	61.31 61.72	141.87 140.93
1985 1986	 17.2	 8.1	 19.7		 16.8			 16.2	 16.4			 12.1
1987 1988 1989	11.9 11.8 13.3	6.3 29.2 21.0	15.4 15.1 8.1		11.7 12.6 13.7	 9.5	 12.1	4.6 11.5 10.7	7.7 12.0 12.0			14.4 8.6 8.7
1990 1991 1992 1993	13.6 13.2 10.3 2.8	16.7 10.4 8.4 16.2	18.2 19.4 13.4 4.5		13.8 13.1 10.3 3.5	14.6 12.6 15.1 6.1	7.6 4.4 3.3 16.7	11.5 9.0 10.2 10.3	12.6 10.9 10.2 7.1	 5.3	 5.5	2.6 7.3 6.8 5.4
1994 1995 1996 1997	-0.1 7.8 -2.6 1.6	9.2 8.9 1.6 6.8	-12.8 5.4 8.5 2.2		0.3 7.9 -2.1 7.0	-0.3 10.5 4.3 11.3	5.6 6.3 5.6 18.4	2.1 8.7 4.8 14.3	1.3 8.3 1.7 11.1	6.3 -1.1 1.2 3.0	6.0 0.9 0.8 4.1	6.1 -0.2 1.0 3.5
1998 1999 2000	9.6 12.1 15.4	11.4 12.2 6.0	11.1 11.2 19.6	25.2 22.0 23.7	10.5 12.6 15.3	14.7 4.3 13.1	2.6 2.7 10.3	9.4 3.7 12.0	9.9 7.5 13.4	5.0 6.4 0.9	6.4 3.6 0.9	5.7 5.1 0.9
2001 2002 2003 2004	13.5 10.4 8.2 8.6	13.0 13.1 12.3 3.0	15.7 12.8 17.5 16.9	10.9 16.6 32.1 5.5	13.3 11.0 10.1 8.1	14.8 10.3 12.5 8.3	0.9 11.0 6.5 5.6	9.3 10.6 10.3 7.3	11.1 10.8 10.2 7.7	2.6 3.6 2.8 4.4	1.9 2.4 -0.8 2.3	2.3 3.0 1.1 3.4
2005 2006 2007 2008	7.5 6.9 4.8 4.7	5.7 7.2 1.6 0.9	9.1 10.4 4.8 6.1	-0.5 7.2 5.3 7.5	6.8 7.0 4.6 4.7	6.7 7.4 7.5 6.0	2.5 12.3 -1.3 4.7	5.3 9.1 4.4 5.6	6.0 8.1 4.5 5.2	3.0 3.8 4.4 1.0	2.8 3.3 1.4 0.0	2.9 3.5 3.0 0.5
2009 2010 ^f 2011 ^f	7.0 1.1 0.9	0.5 -0.9 0.7	4.8 7.7 7.9	-5.1 3.5 0.7	5.7 1.2 1.0	4.7 5.2 6.0	2.0 5.8 4.7	3.8 5.4 5.6	4.7 3.5 3.5	5.5 0.5 -1.7	2.2 0.7 0.7	4.1 0.6 -0.7
1985 1986	14.4	5.3	 16.9	(Annual	Percentage Cha	ange in Excess of Ir	nflation in the C	anadian Econo	omy) 13.6			9.3
1987 1988 1989	7.1 7.2 8.8	1.6 24.7 16.4	10.6 10.6 3.5		6.9 8.1 9.1			-0.2 7.0 6.1	2.9 7.5 7.5			9.7 4.1 4.1
1990 1991 1992 1993	10.6 10.4 9.1 1.3	13.6 7.6 7.1 14.7	15.2 16.6 12.2 3.1		10.8 10.3 9.0 2.1	 		8.4 6.3 9.0 8.8	9.5 8.2 9.0 5.6	 3.8	 4.0	-0.4 4.6 5.6 3.9
1994 1995 1996	-1.2 5.5 -4.2	8.1 6.5 0.0	-13.9 3.0 6.8		-0.8 5.5 -3.8			1.0 6.3 3.2	0.2 6.0 0.0	5.2 -3.4 -0.4	-1.4 -0.9	5.0 -2.5 -0.6
1997 1998 1999 2000	0.6 10.0 10.3 11.3	5.8 11.9 10.4 1.9	1.2 11.6 9.4 15.5	25.6 20.2 19.6	6.1 10.9 10.8 11.2			13.3 9.9 1.9 7.9	10.1 10.3 5.7 9.3	2.0 5.5 4.6	3.1 6.8 1.8	2.5 6.1 3.2 -3.2
2001 2002 2003 2004	12.1 9.4 5.3 6.0	11.6 12.0 9.4 0.4	14.4 11.7 14.6 14.3	9.5 15.6 29.2 2.9	11.9 9.9 7.2 5.5			7.9 9.5 7.4 4.8	9.7 9.7 7.3 5.1	1.2 2.6 -0.1 1.8	0.6 1.3 -3.7 -0.3	0.9 2.0 -1.8 0.8
2005 2006 2007 2008	4.5 4.1 1.1 -0.1	2.7 4.4 -2.0 -4.0	6.1 7.6 1.1 1.3	-3.5 4.4 1.6 2.7	3.8 4.2 0.9 -0.2			2.2 6.3 0.7 0.7	3.0 5.3 0.8 0.3	0.0 1.0 0.7 -3.9	-0.2 0.5 -2.3 -4.9	-0.1 0.7 -0.7 -4.3
2008 2009 2010 ^f 2011 ^f	-0.1 9.7 -1.9 -3.0	-4.0 3.2 -3.9 -3.3	1.3 7.5 4.7 3.9	2.7 -2.4 0.6 -3.3	-0.2 8.4 -1.7 -3.0			0.7 6.5 2.5 1.6	0.3 7.4 0.5 -0.5	-3.9 8.2 -2.5 -5.7	-4.9 4.9 -2.2 -3.3	-4.3 6.8 -2.4 -4.7
f: forecast.								National He	alth Expenditure Dat	abase, 2011, Canad	dian Institute for F	lealth Information.

Table A Canada—Per Capita

GDP Implicit

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Canada, 1985 to 2011 (cont'd)

All Drugs Private Health Expenditure Private Price Index—Canada Public Public (1997 = 100) Year (\$ per Capita) 1985 43.29 103.84 147.13 1.164.56 377.16 1.541.72 73.6 50.54 56.44 169.23 185.82 1,246.28 1,325.41 414.11 443.63 1,660.39 1,769.04 75.6 79.2 1986 118.69 1987 129.39 1988 1989 63.55 142 52 206.07 228.67 1 424 26 477.56 1,901.82 82.8 519.92 167.98 181.89 562.40 603.14 2,203.31 2,364.84 1990 82.24 250.22 1,640.91 89.2 1991 92.99 274.88 1,761.70 91.6 1992 1993 102.53 106.16 300.31 320.05 2,458.85 2,492.87 92.8 94.1 197.78 1,820.36 638.49 1994 106 47 221.98 328.46 1,811.68 709 48 2,521.16 95.2 1995 114.85 232.82 347.67 1,799.05 729.30 2,528.35 97.4 1996 1997 112.38 120.30 240.45 264.48 352.84 384.78 1,783.24 1,845.74 739.95 786.87 2,523.19 2,632.61 99.0 100.0 1998 132.89 285.67 418 56 1,962.59 825.61 2,788.20 996 2,972.10 101.4 172.55 195.48 955.88 1,038.54 3,212.52 3,455.96 2000 320.95 493.49 2.256.63 105.5 2001 342.96 538.44 2,417.42 2002 216.97 370.66 587.63 2.548.27 1.120.32 3.668.59 108.1 238.83 258.22 2,735.60 2,883.91 111.2 3,904.47 422.69 1.235.06 4.118.96 2004 680.92 2005 275.79 442.01 717.81 3,051.61 1,301.36 4,352.97 117.5 2006 295.19 475.14 770.32 3.226.95 1.406.01 4.632.96 120.8 802.91 3,417.31 1,455.11 4,872.41 2008 323.32 514.79 838.11 3.645.44 1.523.96 5.169.40 131.3 2009 876.74 3,828.25 1,572.45 5,400.70 127.8 2010^t 346.04 556 97 903.02 4.012.38 1.641.71 5 654 09 131 5 349.62 579.14 4,085.79 1,725.42 928.75 5,811.22 136.8 (Annual Percentage Change) 1985 16.8 11.7 14.3 9.8 7.7 6.5 2.8 9.0 6.3 4.7 1987 9.8 12.6 13.7 10.2 7.5 8.1 10.9 7.5 7.9 11.0 8.9 4.6 1989 6.8 7.4 3.3 -0.6 1990 13.8 1991 13.1 8.3 9.9 7.2 7.3 2.8 1992 10.3 8.7 8.1 9.3 6.6 4.0 1.4 1.1 1993 6.9 1994 0.3 3.8 2.6 0.1 3.9 1.1 4.9 -0.7 2.8 2.3 1995 7.9 5.8 0.3 1996 1997 -2.1 7.0 3.3 10.0 1.5 -0.9 3.5 1.5 6.3 -0.2 4.3 1.7 1.0 8.0 4.2 -0.4 1.8 1998 10.5 8.8 6.3 5.9 4.9 5.9 6.9 8.3 2000 15.3 7.8 10.3 8.6 6.9 8.1 7.6 4.1 7.1 5.4 7.4 1.4 2001 13.3 6.9 9.1 9.1 8.6 2003 10.1 7.4 8.4 4.3 6.4 2.9 2004 6.2 5.4 5.7 5.5 2005 6.8 4.6 5.4 5.8 5.4 5.7 3.0 2006 7.0 7.5 7.3 8.0 6.4 2.8 2007 4.6 4.0 4.2 5.9 3.5 3.7 6.1 4.5 2008 4.2 4.4 4.6 6.7 5.0 2009 5.7 3.9 3.2 -2.7 2010¹ 3.0 4.8 4.7 2.9 1.2 4.4 2011¹ 1.0 4.0 2.8 1.8 5.1 2.8 4.0 (Annual Percentage Change in Excess of Inflation in the Canadian Economy) 1985 4.9 1.8 1986 1987 14.0 11.5 4.3 12.2 5.1 7.0 2.4 4.2 1.6 6.9 1988 8.1 5.6 6.4 2.9 3.0 9.1 5.2 6.4 3.3 4.3 3.6 1990 1991 10.8 10.3 4.4 5.5 6.4 7.1 3.8 4.6 5.1 4.5 4.1 4.6 1992 9.0 7.5 8.0 2.1 4.6 2.7 -2.0 -1.0 6.7 5.1 1.5 1994 -0.8 2.8 0.0 -2.1 -1.9 3.3 1995 5.5 2.5 3.5 -3.0 0.5 1996 1997 -3.8 6.1 1.6 9.0 -0.2 8.1 -2.6 2.5 -0.2 5.3 1998 10.9 8.4 9.2 6.8 4.1 5.4 6.3 4.8 1999 2.4 2000 11.2 3.7 5.5 7.0 4.5 3.6 6.2 4.5 2.8 4.0 6.2 5.1 3.5 2.9 11.9 7.8 2001 5.8 7.3 8.1 5.5 4.3 2002 9.9 4.4 6.8 1.4 7.2 5.5 4.5 2.8 2005 2006 3.8 4.2 1.6 4.7 2.4 4.5 2.8 2.9 2.4 5.2 2.7 3.6 2007 0.9 0.3 0.5 2.2 -0.2 1.5 1.2 2009 8.4 6.6 7.3 7.7 5.9 7.2 2010¹ -1.7 1.2 0.1 1.9 1.5 1.7 2011^f -2.2 f: forecast. National Health Expenditure Database, 2011, Canadian Institute for Health Information.

CA



Series B—Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditure, by Province/Territory, 1985 to 2011

Table B N.L.—Total

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, Newfoundland and Labrador, 1985 to 2011

			Public		Prescribed	Drugs	Private				Prescribed Drugs e (Out of Pocket)	
Provinc	ial	Federal	Social Security WCBs Drug	Funds Insurance Funds	Subtotal Public	Insurers*	Out of Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	Personal Health Supplies	Total Non-Presc. Drugs
				m Component)		(\$ Million	15)		Drugs	Drugs	Supplies	Diugs
	18.0	2.3	0.1		20.4			82.8	103.2			24.9
	21.4	2.7	0.2		24.4			51.6	76.0			28.2
	24.7 28.2	3.1 1.6	0.3 0.4		28.1 30.2			55.1 58.7	83.2 88.9			32.7 32.3
	31.2	1.3	0.4		32.9			62.5	95.4			32.0
	35.3	1.6	0.6		37.5			64.7	102.2			34.3
	40.3	1.7	0.8		42.8			65.8	108.5			37.8
	43.9	1.7 2.2	1.1 1.2		46.6			72.9 76.1	119.5	20.6	17.9 18.2	38.6
	47.8 52.1	2.2	1.2		51.1 55.8			76.1 77.9	127.2 133.7	21.7 22.9	18.2	39.9 41.2
	54.5	2.8	1.5		58.8			85.6	144.4	22.5	19.9	42.3
	54.5	2.7	1.8		59.0			90.0	149.0	24.7	21.9	46.7
	53.6	3.3	1.9		58.8			87.9	146.7	21.4	18.9	40.3
	56.1 60.0	3.7 4.1	2.4 2.8		62.1 66.9			93.7 103.3	155.8 170.2	23.3 25.6	21.0 22.5	44.3 48.1
	68.0 77.9	5.8 6.6	3.8 4.2		77.6 88.7			119.9 129.2	197.5 217.9	26.1 25.8	22.2 22.6	48.3 48.3
	86.9	7.4	5.0		99.3			150.2	249.5	26.6	23.0	49.7
	96.0	8.1	4.7		108.9			169.0	277.8	27.0	22.5	49.5
	101.7	7.8	4.8		114.4			178.4	292.7	27.8	23.1	50.9
	106.0	8.0	5.1		119.0			196.7	315.8	27.4	22.3	49.7
	108.1 116.9	7.7 7.3	5.1 5.1		121.0 129.4			208.4 241.2	329.4 370.6	28.3 29.6	23.0 23.3	51.3 52.8
	122.3	7.1	5.2		134.5			229.2	363.7	29.6	23.1	52.7
	128.7	7.5	6.2		142.4			250.9	393.3	32.4	24.5	57.0
	135.8	7.6	6.2		149.6			279.4	429.0	32.6	24.8	57.5
	148.0	7.8	6.8		162.6			305.4	467.9	32.0	25.1	57.1
					(Annual Percenta	ge Change)					
	19.2 15.4	20.4 13.5	35.5 34.3		19.4 15.3			-37.6 6.7	-26.3 9.4			13.2 16.0
	13.9	-48.0	50.0		7.4			6.6	6.8			-1.0
	10.6	-20.2	14.5		9.0			6.6	7.4			-1.0
	13.4	21.5	38.7		14.0			3.4	7.1			7.1
	14.1	9.6	25.5		14.1			1.7	6.2			10.3
	8.8 8.9	-3.5 31.4	40.5 9.2		8.9 9.7			10.8 4.5	10.1 6.5	5.4	1.1	2.0 3.4
	9.1	12.4	7.4		9.2			2.3	5.1	5.3	0.8	3.3
	4.6	12.3	22.5		5.4			9.9	8.0	-1.8	8.6	2.8
	0.0	-2.7	18.8		0.4			5.1	3.2	10.1	10.3	10.2
	-1.6	23.0	3.4		-0.4			-2.3	-1.5	-13.4	-14.0	-13.7
	4.6 7.0	10.5 12.0	28.6 16.0		5.6 7.7			6.5 10.3	6.2 9.3	8.8 9.9	11.5 7.0	10.0 8.5
	13.4 14.5	40.7 15.5	37.7 8.8		16.1 14.3			16.0 7.8	16.0 10.3	2.2 -1.4	-1.4 1.7	0.5 0.1
	11.5	11.9	19.9		12.0			16.2	14.5	3.3	2.1	2.8
	10.6	8.3	-4.9		9.6			12.5	11.4	1.2	-2.3	-0.4
	5.9	-3.0	2.2		5.1			5.5	5.4	3.2	2.5	2.8
	4.2	1.8	4.5		4.1			10.3	7.9	-1.6	-3.2	-2.3
	2.0 8.1	-3.1 -5.0	1.5 -0.7		1.7 6.9			5.9 15.7	4.3 12.5	3.4 4.4	2.9 1.3	3.2 3.0
	4.6	-3.5	1.0		4.0			-5.0	-1.9	0.2	-0.6	-0.2
	5.2	5.6	20.7		5.8			9.5	8.1	9.5	6.1	8.0
	5.5	1.9	-1.0		5.0			11.4	9.1	0.6	1.3	0.9
	9.0	1.9	10.6		8.7			9.3	9.1	-2.0	1.1	-0.6
						age Share of Tota						
	14.0 20.6	1.8	0.1		15.9 23.4			64.6	80.6 73.0			19.4 27.0
	21.3	2.6 2.7	0.2 0.2		23.4			49.6 47.5	73.0 71.8			27.0
	23.2	1.3	0.3		24.9			48.4	73.3			26.7
	24.4	1.0	0.3		25.8			49.1	74.9			25.1
	25.9	1.2	0.4		27.5			47.4	74.9			25.1
	27.5	1.2	0.5		29.2			44.9	74.2			25.8
	27.8 28.6	1.1 1.3	0.7 0.7		29.5 30.6			46.1 45.6	75.6 76.1	13.0 13.0	11.4 10.9	24.4 23.9
	29.8	1.4	0.7		31.9			44.6	76.5	13.1	10.5	23.5
	29.2	1.5	0.8		31.5			45.9	77.3	12.0	10.6	22.7
	27.9	1.4	0.9		30.2			46.0	76.2	12.6	11.2	23.8
	28.7	1.8	1.0		31.4			47.0	78.5	11.4	10.1	21.5
	28.0 27.5	1.8 1.9	1.2 1.3		31.0 30.6			46.8 47.3	77.9 78.0	11.6 11.7	10.5 10.3	22.1 22.0
	27.7 29.3	2.3 2.5	1.6 1.6		31.6 33.3			48.8 48.5	80.3 81.8	10.6 9.7	9.0 8.5	19.7 18.2
	29.0	2.5	1.7		33.2			50.2	83.4	8.9	7.7	16.2
	29.3	2.5	1.4		33.3			51.6	84.9	8.2	6.9	15.1
	29.6	2.3	1.4		33.3			51.9	85.2	8.1	6.7	14.8
	29.0	2.2	1.4		32.6			53.8	86.4	7.5	6.1	13.6
	28.4 27.6	2.0	1.4		31.8 30.6			54.7 57.0	86.5 87.5	7.4 7.0	6.0	13.5 12.5
	29.4	1.7 1.7	1.2 1.2		30.6			57.0 55.0	87.5 87.3	7.0	5.5 5.6	12.5 12.7
	28.6	1.7	1.4		31.6			55.7	87.3	7.2	5.4	12.7
	27.9	1.6	1.3		30.7			57.4	88.2	6.7	5.1	11.8

f. forecast.

* Confidentiality precludes reporting provincial-level insurance data.

National Health Expenditure Database, 2011, Canadian Institute for Health Information.

Table B N.L.—Total

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, Newfoundland and Labrador, 1985 to 2011 (cont'd)

			eaith Expenditu		oundland and Labrador, 1985 to 2		UTT (CONT 0) Share of Drugs in Public, Private and Total Health Expenditures		i
	Public	All Drugs Private	Total	Public	Ith Expenditure Private	Total		Private	Total
Year 1985	20.4	107.7	(\$ Million 128.1	588.8	197.1	785.8	(Percentag 3.5	e Share) 54.6	16.3
1986	24.4	79.8	104.2	642.9	169.6	812.5	3.8	47.1	12.8
1987 1988	28.1 30.2	87.8 91.0	115.9 121.2	693.6 733.8	188.0 197.1	881.6 930.9	4.1 4.1	46.7 46.2	13.1 13.0
1989	32.9	94.6	127.4	787.7	203.9	991.6	4.2	46.4	12.9
1990	37.5	99.0	136.5	875.9	220.6	1,096.4	4.3	44.9	12.4
1991 1992	42.8 46.6	103.6 111.4	146.4 158.0	905.7 928.3	247.5 269.1	1,153.2 1,197.4	4.7 5.0	41.8 41.4	12.7 13.2
1993	51.1	116.0	167.1	924.9	284.2	1,209.1	5.5	40.8	13.8
1994	55.8	119.1	174.9	948.1	301.1	1,249.3	5.9	39.6	14.0
1995 1996	58.8 59.0	128.0 136.7	186.7 195.6	973.1 974.4	296.4 279.0	1,269.4 1,253.4	6.0 6.1	43.2 49.0	14.7 15.6
1997	58.8	128.2	187.0	1,020.8	284.5	1,305.4	5.8	45.1	14.3
1998 1999	62.1 66.9	138.0 151.4	200.1 218.3	1,107.8 1,250.8	325.6 332.5	1,433.4 1,583.3	5.6 5.3	42.4 45.5	14.0 13.8
2000 2001	77.6 88.7	168.2 177.5	245.8 266.2	1,318.7 1,415.5	368.6 387.4	1,687.2 1,802.9	5.9 6.3	45.6 45.8	14.6 14.8
2002	99.3	199.8	299.1	1,510.0	416.0	1,926.1	6.6	48.0	15.5
2003 2004	108.9 114.4	218.5 229.2	327.3 343.6	1,591.3 1,628.9	470.5 509.2	2,061.8 2,138.1	6.8 7.0	46.4 45.0	15.9 16.1
2005	119.0	246.4	365.5	1,684.8	550.4	2,235.2	7.1	44.8	16.4
2006	121.0	259.7	380.7	1,783.2	561.5	2,344.7	6.8	46.3	16.2
2007 2008	129.4 134.5	294.0 281.9	423.4 416.4	1,926.8 2,096.8	632.3 638.2	2,559.2 2,735.0	6.7 6.4	46.5 44.2	16.5 15.2
2009	142.4	307.9	450.3	2,313.8	686.6	3,000.4	6.2	44.8	15.0
2010 ^f	149.6	336.9	486.5	2,540.0	757.6	3,297.5	5.9	44.5	14.8
2011 ^f	162.6	362.5	525.0	2,694.7	805.3	3,500.0	6.0	45.0	15.0
1985			(Annual Percenta	ge Change)					
1985	19.4	-25.9	-18.6	9.2	-13.9	3.4			
1987	15.3	9.9	11.2	7.9	10.9	8.5			
1988 1989	7.4 9.0	3.7 3.9	4.6 5.1	5.8 7.4	4.8 3.4	5.6 6.5			
1990	14.0	4.7	7.1	11.2	8.2	10.6			
1991	14.1	4.7	7.3	3.4	12.2	5.2			
1992 1993	8.9 9.7	7.6 4.1	8.0 5.8	2.5 -0.4	8.7 5.6	3.8 1.0			
1994	9.2	2.7	4.7	2.5	6.0	3.3			
1995	5.4	7.4	6.8	2.6	-1.6	1.6			
1996	0.4	6.8	4.8	0.1	-5.9	-1.3			
1997 1998	-0.4 5.6	-6.2 7.6	-4.4 7.0	4.8 8.5	2.0 14.4	4.1 9.8			
1999	7.7	9.7	9.1	12.9	2.1	10.5			
2000	16.1	11.1	12.6	5.4	10.8	6.6			
2001 2002	14.3 12.0	5.6 12.6	8.3 12.4	7.3 6.7	5.1 7.4	6.9 6.8			
2003	9.6	9.3	9.4	5.4	13.1	7.0			
2004	5.1	4.9	5.0	2.4	8.2	3.7			
2005 2006	4.1 1.7	7.5 5.4	6.4 4.2	3.4 5.8	8.1 2.0	4.5 4.9			
2007	6.9	13.2	11.2	8.1	12.6	9.1			
2008 2009	4.0 5.8	-4.1 9.2	-1.6 8.1	8.8 10.3	0.9 7.6	6.9 9.7			
2010 ^f	5.0	9.4	8.0	9.8	10.3	9.9			
2010 2011 ^f	8.7	7.6	7.9	6.1	6.3	6.1			
		Share of Total Drug I							
1985 1986	15.9 23.4	84.1 76.6	100.0 100.0						
1987	24.3	75.7	100.0						
1988 1989	24.9 25.8	75.1 74.2	100.0 100.0						
1990	27.5	72.5	100.0						
1991	29.2	70.8	100.0						
1992 1993	29.5 30.6	70.5 69.4	100.0						
1993	31.9	68.1	100.0 100.0						
1995	31.5	68.5	100.0						
1996	30.2	69.8	100.0						
1997 1998	31.4 31.0	68.6 69.0	100.0 100.0						
1999	30.6	69.4	100.0						
2000	31.6	68.4	100.0						
2001 2002	33.3 33.2	66.7 66.8	100.0 100.0						
2003	33.3	66.7	100.0						
2004	33.3	66.7	100.0						
2005	32.6	67.4	100.0						
2006 2007	31.8 30.6	68.2 69.4	100.0 100.0						
2008	32.3	67.7	100.0						
2009	31.6	68.4	100.0						
2010 ^f 2011 ^f	30.7 31.0	69.3 69.0	100.0 100.0						
	55	00.0							

f: forecast.

National Health Expenditure Database, 2011, Canadian Institute for Health Information.

Table B N.L.—Per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Newfoundland and Labrador, 1985 to 2011

Prescribed Drugs

Non-Prescribed Drugs
Private (Out of Pocket) Public Private Over Provincial Federal Social Security Funds Subtotal Insurers' Subtotal Total Total WCBs Pocket Health Drug Insurance Public Private Prescribed the-Non-Presc. Funds Drugs Counter Supplies Drugs ium Component) Drugs Year (\$ per Capita) 31.05 37.19 1985 3.94 0.24 35.23 142.89 42.96 1986 4.77 42.28 89.58 1987 43.00 5.42 0.44 48.86 95.77 144.63 56.82 ---165.56 55.53 1989 54.05 2.25 0.75 57.04 108.52 1990 61.11 2.72 1.03 64.87 111.92 176.79 59.30 1991 69.56 2.97 1.30 73.83 113.48 187.30 65.26 1992 30.94 1993 82.36 3.77 1.99 88.12 131.28 219.40 37.46 31.30 68.77 2.15 39.83 1995 96.05 4.86 2.67 103.58 150.89 254.47 39.59 35.02 74.61 1996 4.80 160.78 266.15 1997 97.30 6.00 3.38 106.67 159.58 266.25 38.85 34.22 73.08 103.81 288.47 7.67 42.18 90.14 1999 112.49 5.20 125.36 193.70 319.07 47.96 128.84 2001 149.21 12.73 7.97 169.91 247.46 417.37 49.41 43.21 92.63 167.25 14.32 289.07 480.24 535.94 44.35 95.65 95.42 185.27 15.54 2003 9.15 209.96 325.97 52.01 2004 196.64 15.11 9.37 221.13 344.79 565.91 53.78 44.57 98.35 2005 206.17 15.48 9.86 231.51 382.64 614.15 53.25 43.42 96.67 645.53 100.48 2007 230.95 14.47 10.09 255.51 476.27 731.78 58.39 45.95 104.34 452.73 493.82 2008 241.59 13.97 10.19 265.75 718.49 58.53 45.67 104.20 112.12 14.70 2009 2010^f 14.93 841.60 2011^f 291.08 15.26 13.40 319.74 600.61 920.35 62.89 49.42 112.31 Percentage Change) 1985 1986 19.8 21.0 36.2 20.0 -37.3 -26.0 13.8 1988 14.0 -48.0 50.0 6.6 6.9 -1.0 1989 10.3 -20.4 14.2 8.7 6.3 7.1 -1.3 1990 13.1 21.2 38.3 13.7 3.1 6.8 6.8 1991 1992 8.7 -3.5 40.4 8.8 10.7 10.0 1.9 31.4 13.4 1.2 1.8 1993 1994 8.9 10.1 9.3 8.4 4.5 3.3 5.4 6.3 3.4 4.3 10.2 6.1 1995 13.7 24.1 11.2 -0.6 1996 1.4 -1.3 20.4 1.7 6.6 4.6 11.6 11.8 11.7 -12.3 12.3 1997 -0.1 6.7 25.0 1.2 7.8 0.0 -12.0 -12.6 13.8 12.8 31.2 8.7 11.0 1998 8.3 1999 8.4 13.4 17.4 9.0 11.7 10.6 11.2 8.3 9.8 14.5 42.2 39.1 17.2 17.2 17.2 1.5 2000 3.2 -0.4 2001 12.5 2002 12.1 20.4 12.5 16.8 15.1 3.8 2.6 3.3 2004 6.1 -2.8 2.5 5.3 5.8 5.6 3.4 2.7 3.1 4.8 4.7 -1.7 2005 2.5 5.1 11.0 -1.0 -2.6 2006 2.8 9.0 -2.4 -4.2 2.3 2.4 4.2 3.6 3.9 2007 7.8 16.6 2008 4.6 -3.5 1.0 4.0 -4.9 -1.8 0.3 -0.6 -0.1 20.2 9.1 0.2 -1.7 2010^f 5.2 1.6 -1.3 4.7 11.0 1.0 1.4 0.6 9.0 -0.4 2011^f 10.9 9.6 (Annua Percentage Change in Excess of Inflation in the Canadian Economy) 1985 1986 17.0 17.2 11.0 1987 10.9 9.0 29.9 10.8 2.2 4.9 11.5 1988 9.4 5.7 -52.5 45.5 2.9 4.1 2.1 1.7 2.3 -5.5 -5.8 -25.0 9.6 2.6 1989 10.0 35.3 10.7 0.1 3.8 1991 11.1 6.6 22.4 11.1 -1.4 3.2 7.3 7.4 7.5 -4.8 39.1 29.9 4.0 -0.3 1993 7.8 8.3 3.0 2.0 1994 9.0 12.3 7.3 9.1 2.2 5.0 5.2 0.7 3.2 1.7 1995 3.6 11.4 21.7 4.3 8.9 7.0 -2.9 7.6 -0.3 -1.1 7.1 -3.0 24.0 0.1 10.0 -13.3 1996 1997 2.9 -1.0 -13.0 -13.6 8.3 7.2 1998 13.2 31.7 9.1 8.8 11.4 14.2 12.7 1999 9.9 9.4 2000 10.4 38.1 35.0 13.1 13.1 13.1 -0.9 -2.6 14.5 11.0 7.9 3.5 2001 15.4 8.8 14.2 11.5 10.3 -1.6 1.5 -0.1 2.8 -1.5 0.8 194 15.8 9.9 14 0 22 5.6 -5.4 -3.1 0.5 6.9 8.7 3.0 -5.0 0.1 2004 -0.1 3.2 1.8 2.1 1.7 -4.0 -4.7 2005 8.0 5.5 2006 0.0 -5.2 -0.5 -0.4 3.9 2.3 1.4 0.8 1.1 2007 -7.9 2008 -0.3 -8.3 -3.8 -0.9 -9.8 -6.7 -4.6 -5.5 -5.0 2009 7.5 7.9 22.9 8.1 11.8 10.4 11.8 8.4 10.3 2010^f 2.2 8.1 -2.7 -1.4 -4.3 1.8 5.8 -2.0 -2.4

* Confidentiality precludes reporting provincial-level insurance data.

National Health Expenditure Database, 2011, Canadian Institute for Health Information.

Table B N.L.—Per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Newfoundland and Labrador, 1985 to 2011 (cont'd)

GDP Implicit
Price Index—Canada

		All Drugs		He	alth Expenditure		Price Index—Canada
	Public	Private	Total	Public	Private	Total	
Year			(\$ per Ca	pita)			(1997 = 100)
1985	35.23	185.85	221.08	1,016.34	340.16	1,356.50	73.6
1986	42.28	138.46	180.75	1,115.18	294.15	1,409.34	75.6
1987 1988	48.86 52.48	152.59 158.33	201.45 210.81	1,205.91 1,276.14	326.89 342.81	1,532.79 1,618.95	79.2 82.8
1989	57.04	164.05	221.09	1,366.63	353.75	1,720.39	86.6
1990	64.87	171.22	236.09	1,515.29	381.55	1,896.84	89.2
1991	73.83	178.73	252.56	1,562.86	427.13	1,989.99	91.6
1992	80.30	192.14	272.44	1,600.38	463.99	2,064.37	92.8
1993	88.12	200.04	288.16	1,594.84	489.99	2,084.83	94.1
1994	97.12	207.33	304.44	1,650.45	524.20	2,174.65	95.2
1995	103.58	225.50	329.08	1,714.87	522.27	2,237.14	97.4
1996 1997	105.37 106.67	244.12 232.65	349.49 339.33	1,740.60 1,852.68	498.31 516.33	2,238.91 2,369.01	99.0 100.0
1998	115.01	255.52	370.54	2,051.73	603.02	2,654.75	99.6
1999	125.36	283.85	409.21	2,344.87	623.44	2,968.31	101.4
2000	146.98	318.50	465.48	2,497.29	698.00	3,195.28	105.5
2001	169.91	340.09	510.00	2,711.82	742.15	3,453.96	106.9
2002	191.17	384.72	575.89	2,907.00	800.89	3,707.89	108.1
2003 2004	209.96 221.13	421.39 443.14	631.36 664.27	3,069.40 3,148.88	907.53 984.26	3,976.93 4,133.15	111.2 114.1
2005 2006	231.51 237.10	479.31 508.91	710.82	3,276.97	1,070.49	4,347.46	117.5 120.8
2006	237.10 255.51	508.91 580.61	746.01 836.12	3,494.28 3,805.10	1,100.28 1,248.76	4,594.56 5,053.85	120.8 125.2
2008	265.75	556.94	822.69	4,142.32	1,260.69	5,403.02	131.3
2009	280.21	605.93	886.14	4,553.46	1,351.20	5,904.66	127.8
2010 ^f	293.39	660.96	954.35	4,982.90	1,486.15	6,469.05	131.5
2011 ^f	319.74	712.92	1,032.66	5,300.01	1,583.83	6,883.84	136.8
				Annual Percentage Cha	nge)		
1985							
1986	20.0	-25.5	-18.2	9.7	-13.5	3.9	2.8
1987 1988	15.6 7.4	10.2 3.8	11.5 4.6	8.1 5.8	11.1 4.9	8.8 5.6	4.7 4.5
1989	8.7	3.6	4.9	7.1	3.2	6.3	4.6
1990		4.4					
1990	13.7 13.8	4.4	6.8 7.0	10.9 3.1	7.9 11.9	10.3 4.9	3.0 2.8
1992	8.8	7.5	7.9	2.4	8.6	3.7	1.3
1993	9.7	4.1	5.8	-0.3	5.6	1.0	1.4
1994	10.2	3.6	5.6	3.5	7.0	4.3	1.1
1995	6.7	8.8	8.1	3.9	-0.4	2.9	2.3
1996	1.7	8.3	6.2	1.5	-4.6	0.1	1.7
1997 1998	1.2 7.8	-4.7 9.8	-2.9 9.2	6.4 10.7	3.6 16.8	5.8 12.1	1.0 -0.4
1999	9.0	11.1	10.4	14.3	3.4	11.8	1.8
2000	17.2	12.2	13.7	6.5	12.0	7.6	4.1
2001	15.6	6.8	9.6	8.6	6.3	8.1	1.4
2002	12.5	13.1	12.9	7.2	7.9	7.4	1.0
2003	9.8	9.5	9.6	5.6	13.3	7.3	2.9
2004	5.3	5.2	5.2	2.6	8.5	3.9	2.6
2005	4.7	8.2	7.0	4.1	8.8	5.2	3.0
2006 2007	2.4 7.8	6.2 14.1	4.9 12.1	6.6 8.9	2.8 13.5	5.7 10.0	2.8 3.7
2008	4.0	-4.1	-1.6	8.9	1.0	6.9	4.9
2009	5.4	8.8	7.7	9.9	7.2	9.3	-2.7
2010 ^f	4.7	9.1	7.7	9.4	10.0	9.6	2.9
2011 ^f	9.0	7.9	8.2	6.4	6.6	6.4	4.0
				Inflation in the Canadia	•		
1985 1986	 17.2	-28.3	-21.0	6.9	-16.3	1.1	
1986	17.2	-28.3 5.5	-21.0 6.7	3.4	-16.3 6.4	1.1 4.0	
1988	2.9	-0.8	0.1	1.3	0.4	1.1	
1989	4.1	-1.0	0.3	2.5	-1.4	1.7	
1990	10.7	1.3	3.8	7.9	4.8	7.2	
1991	11.1	1.6	4.2	0.4	9.2	2.2	
1992 1993	7.5 8.3	6.2 2.7	6.6 4.3	1.1 -1.8	7.4 4.2	2.5 -0.4	
1994	9.1	2.5	4.6	2.4	5.9	3.2	
1005	4.3	6.4	5.8	1.6	-2.7	0.5	
1995 1996	4.3 0.1	6.6	4.5	-0.2	-2.7 -6.3	-1.6	
1997	0.2	-5.7	-3.9	5.4	2.6	4.8	
1998	8.3	10.3	9.6	11.2	17.2	12.5	
1999	7.2	9.3	8.6	12.5	1.6	10.0	
2000	13.1	8.1	9.6	2.4	7.9	3.5	
2001	14.2	5.4	8.2	7.2 6.2	5.0	6.7	
2002 2003	11.5 6.9	12.1 6.6	11.9 6.7	6.2 2.7	6.9 10.4	6.3 4.4	
2004	2.7	2.6	2.6	0.0	5.9	1.3	
2005	1.7	5.2	4.0	1.1	5.8	2.2	
2006	-0.4	3.4	2.2	3.8	0.0	2.9	
2007	4.1	10.4	8.4	5.2	9.8	6.3	
2008 2009	-0.9 8.1	-8.9 11.5	-6.5 10.4	4.0 12.6	-3.9 9.9	2.0 12.0	
		11.5					
2010 ^t 2011 ^f	1.8 5.0	6.1 3.9	4.8 4.2	6.5 2.4	7.0 2.6	6.6 2.4	
	5.0	3.3	4.4	2.4	2.0		
f: forecast.						National	Health Expenditure Database, 20

N.L

Table B P.E.I.—Total

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, Prince Edward Island, 1985 to 2011

			Public		Prescribed		Private			Priva	Prescribed Dru te (Out of Pock	(et)
	Provincial	Federal	Social Security WCBs Dru	Funds g Insurance Funds	Subtotal Public	Insurers*	Out of Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	Personal Health Supplies	Total Non-Presc. Drugs
Year			(Premiu	ım Component)		(\$ Millior)			Drugs		
1985	1.7	0.8	0.0		2.5	(\$ WIIIIOI		19.5	22.0			10.7
1986	2.1	0.9	0.1		3.1			12.9	16.0			12.1
1987 1988	3.5 4.6	1.0 0.6	0.1 0.1		4.6 5.3			10.2 12.4	14.7 17.7			14.0 11.8
1989	5.5	0.5	0.1		6.0			15.0	21.0			9.9
1990	6.5	0.6	0.1		7.3			18.0	25.3			10.6
1991 1992	7.4 7.6	0.7 0.7	0.1 0.4		8.2 8.6			17.1 18.8	25.3 27.5	8.6	7.8	13.5 16.4
1993	7.5	0.8	0.3		8.6			21.8	30.5	9.0	8.4	17.4
1994	7.7	0.9	0.3		8.9			23.8	32.8	9.2	8.7	17.9
1995 1996	8.5 8.5	1.0 1.0	0.4 0.4		9.8 9.8			28.4 29.7	38.3 39.5	8.5 6.8	8.3 6.3	16.8 13.1
1997	9.1	1.0	0.4		10.6			28.8	39.4	7.1	6.9	14.0
1998 1999	10.4 12.0	1.2 1.4	0.5 0.6		12.2 13.9			33.0 33.6	45.1 47.6	8.6 9.1	8.5 8.5	17.1 17.6
2000	14.0	2.3	0.7		17.0			36.0	53.0	8.8	8.0	16.8
2001	15.7	2.7	0.8		19.1			43.0	62.2	9.7	8.4	18.1
2002 2003	16.9 18.4	2.7 2.9	0.7 0.7		20.3 22.0			38.1 43.7	58.4 65.7	10.4 10.7	9.0 9.0	19.4 19.7
2004	19.9	2.9	0.7		23.4			47.8	71.2	10.7	8.9	19.6
2005	22.3	2.9	0.7		25.9			52.2	78.1	10.2	8.3	18.5
2006 2007	24.2 25.8	2.8 2.8	0.8		27.8 29.4			56.8 56.9	84.6 86.3	10.6 11.3	8.7 9.0	19.3 20.4
2008	28.7	2.8	0.9		32.4			56.7	89.1	12.2	9.6	21.8
2009	32.4	2.8	0.9		36.0			63.7	99.7	12.5	9.5	22.0
2010 [†] 2011 [†]	34.7 34.8	2.8 2.8	0.9 0.9		38.3 38.6			69.3 74.3	107.7 112.9	13.2 12.8	10.2 10.0	23.4 22.8
						(Annual Percenta	ge Change)					
1985												
1986 1987	27.8 63.7	16.1 12.6	44.0 39.7		24.4 48.5			-34.1 -21.0	-27.5 -7.6			13.2 16.0
1988	32.4	-40.9	20.2		16.1			21.5	19.8			-16.1
1989	17.9	-17.4	0.9		13.7			21.5	19.1			-16.1
1990 1991	19.8 13.5	30.7 7.0	20.5 -0.4		20.7 12.7			19.8 -4.7	20.1 0.3			7.5 27.3
1992	2.5	-4.5	218.0		5.2			10.0	8.5			21.5
1993 1994	-1.7 2.8	24.8 12.0	-13.7 -1.5		-0.3 3.5			15.9 9.2	10.8 7.6	4.9 1.7	7.8 3.7	6.3 2.7
1995	10.2	8.6	9.8		10.0			19.2	16.7	-7.1	-5.1	-6.1
1996	0.0	-3.8	4.4		-0.2			4.3	3.2	-20.6	-24.1	-22.3
1997 1998	7.4 14.6	8.3 16.2	14.7 21.0		7.8 15.1			-3.0 14.5	-0.3 14.6	5.4 21.2	9.2 23.2	7.2 22.2
1999	14.7	14.0	11.9		14.5			2.0	5.4	5.7	0.1	3.0
2000	16.8	66.4	26.3		22.1			7.2	11.6	-3.7	-6.0	-4.8
2001 2002	12.4 7.7	16.8 0.7	4.4 -9.4		12.6 6.0			19.4 -11.5	17.2 -6.1	10.0 7.4	5.3 7.2	7.7 7.3
2003	9.2	6.4	-1.6		8.4			14.8	12.6	2.5	0.2	1.4
2004	7.7	0.4	-2.8		6.5			9.3	8.3	0.6	-0.9	-0.1
2005 2006	12.4 8.2	-0.1 -1.4	7.6 9.7		10.7 7.1			9.3 8.8	9.8 8.2	-5.2 4.3	-6.5 4.7	-5.8 4.5
2007	6.6	-1.0	7.0		5.9			0.3	2.1	7.0	3.4	5.4
2008 2009	11.3 12.8	-1.5 0.6	10.8 -7.9		10.1 11.2			-0.4 12.4	3.2 11.9	7.4 2.8	6.5 -1.4	7.0 0.9
2010 ^f	7.2	0.2	-1.8		6.5			8.9	8.0	5.7	7.2	6.3
2011 ^f	0.3	1.9	8.2		0.6			7.2	4.8	-3.6	-1.6	-2.8
4005						age Share of Tota			07.0			
1985 1986	5.1 7.6	2.3 3.2	0.1 0.2		7.6 11.0			59.7 45.9	67.3 56.9			32.7 43.1
1987	12.1	3.5	0.3		15.9			35.3	51.3			48.7
1988 1989	15.7 17.6	2.0 1.6	0.3 0.3		18.1 19.6			42.0 48.5	60.0 68.1			40.0 31.9
1990	18.2	1.8	0.3		20.3			50.1	70.4			29.6
1991	19.1	1.8	0.3		21.2			44.1	65.2			34.8
1992 1993	17.3 15.6	1.5 1.7	0.9 0.7		19.7 18.0			42.9 45.6	62.6 63.6	19.6 18.8	17.8 17.6	37.4 36.4
1994	15.2	1.8	0.7		17.6			47.1	64.7	18.1	17.2	35.3
1995	15.4	1.8	0.7		17.8			51.6	69.5	15.5	15.1	30.5
1996 1997	16.1 17.0	1.8 1.9	0.7 0.8		18.7 19.8			56.5 54.0	75.1 73.8	12.9 13.4	12.0 12.9	24.9 26.2
1998	16.8	1.9	0.9		19.5			53.0	72.5	13.9	13.6	27.5
1999	18.4	2.1	0.9		21.4			51.6	73.0	14.0	13.0	27.0
2000 2001	20.0 19.6	3.3 3.3	1.1 1.0		24.4 23.9			51.6 53.6	76.0 77.5	12.6 12.1	11.4 10.5	24.0 22.5
2002	21.7	3.5	0.9		26.1			49.0	75.1	13.4	11.6	24.9
2003 2004	21.6 21.9	3.3 3.2	0.8 0.7		25.8 25.8			51.2 52.6	77.0 78.4	12.5 11.8	10.6 9.8	23.0 21.6
2005 2006	23.1 23.3	3.0 2.7	0.8 0.8		26.8 26.7			54.0 54.6	80.9 81.4	10.5 10.2	8.6 8.4	19.1 18.6
2007	24.1	2.6	0.8		27.6			53.3	80.9	10.6	8.5	19.1
2008 2009	25.9 26.6	2.5 2.3	0.9 0.7		29.2 29.6			51.1 52.3	80.3 81.9	11.0 10.3	8.7 7.8	19.7 18.1
2010 ^f	26.5	2.1	0.7		29.2			52.9	82.1	10.1	7.8	17.9
2011 ^f f: forecast.	25.7	2.1	0.7		28.4			54.8	83.2	9.4	7.4	16.8

f: forecast.

* Confidentiality precludes reporting provincial-level insurance data.

Table B P.E.I.—Total

Total

18.0 15.0 14.2

13.4 12.9

13.8

14.9 15.4

16.2

16.8

15.5 15.7

17.2 17.2

16.9

16.9

16.8

16.7 16.3 15.9

15.6 15.5 P.E.I

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, Prince Edward Island, 1985 to 2011 (cont'd)

Share of Drugs in Public, Private and Total Health Expenditures All Drugs Private Health Expenditure Public Total Public Total Public Year (\$ Millions) (Percentage Share) 1985 1986 1987 2.5 3.1 4.6 30.2 25.0 24.2 128.3 138.0 149.7 52.9 49.6 53.3 57.1 50.3 45.4 32.7 28.0 181.2 187.6 1.9 2.2 3.1 28.8 202.9 1988 1989 5.3 6.0 24.1 24.9 29.4 30.9 163.0 174.4 56.5 64.9 219.5 239.3 3.3 3.5 42.6 38.3 1990 7.3 28.6 35.9 186.3 70.0 256.2 3.9 40.9 8.2 8.6 8.6 1991 30.6 38.8 203.8 76.8 280.6 4.0 39.9 1992 1993 35.2 43.9 47.9 209.2 295.0 4.1 4.0 41.1 39.3 93.5 311.7 42.0 1994 8.9 41.8 50.7 217.0 96.7 313.7 4.1 43.2 9.8 9.8 10.6 4.4 4.2 4.6 45.2 55.1 222.8 104.6 327.4 43.2 1995 1996 1997 42.7 42.8 229.9 110.4 340.3 38.8 12.2 13.9 50.1 51.2 62.2 65.2 245.5 259.0 115.9 119.7 361.4 378.7 5.0 5.4 43.2 42.8 2000 52.8 277.7 5.8 41.4 2001 19.1 61.1 80.2 328.5 147.5 475.9 57.5 63.4 67.4 41.1 39.3 41.5 365.6 505.4 5.6 5.8 6.2 2003 22.0 541.0 2004 23.4 90.8 375.9 162.3 538.2 2005 25.9 70.7 96.6 412.8 163.2 576.0 6.3 43.3 103.9 106.7 110.9 2006 27.8 29.4 76.1 77.3 434.0 465.9 187.7 188.4 621.7 654.3 40.5 41.0 6.4 6.3 78.5 85.7 2008 32.4 510.4 185.2 695.6 6.3 42.4 2010^f 2011^f 38.3 38.6 92.8 97.1 131.1 135.6 624.5 640.7 842.5 873.1 42.5 41.8 218.0 232.3 (Annual Percentage Change) 1985 1986 1987 24.4 48.5 -17.3 -3.1 7.6 8.5 -6.3 7.4 3.5 8.2 -14.2 2.6 16.1 13.7 -0.3 3.1 8.9 7.0 1988 2.3 6.2 8.2 14.8 5.0 1990 20.7 12.7 14.9 16.0 6.8 9.4 7.7 9.8 7.0 9.5 1991 7.2 8.3 1992 1993 5.2 -0.3 15.1 11.4 13.0 9.1 2.7 4.3 11.6 9.0 5.1 5.7 1994 3.5 6.3 5.8 -0.6 3.4 0.6 1995 10.0 8.4 8.7 2.7 8.2 4.4 1996 -0.2 7.8 -5.6 -4.6 4.6 1.4 3.5 0.4 0.2 17.0 2.3 6.2 4.8 1998 15.1 16.6 6.8 5.5 5.0 2000 22.1 3.1 15.7 7.2 18.3 3.3 19.3 6.0 12.6 14.9 18.6 2001 2002 6.0 -6.0 -3.1 11.3 -5.2 6.2 8.4 6.5 10.3 9.8 3.8 2004 0.6 -0.5 10.7 4.9 6.4 7.0 2005 9.8 0.6 7.6 1.6 1.5 2006 7.1 5.9 7.5 2.7 15.0 7.9 5.2 2007 0.3 10.1 2008 3.9 9.6 -1.7 6.3 12.1 11.7 12.0 2010^f 6.5 0.6 8.2 4.7 7.7 3.5 5.4 6.6 8.1 3.6 (Percentage Share of Total Drug Expenditure) 7.6 11.0 92.4 89.0 100.0 100.0 1985 1986 15.9 18.1 84.1 81.9 1987 100.0 1989 19.6 80.4 100.0 79.7 20.3 1990 100.0 1991 1992 21.2 19.7 78.8 80.3 100.0 100.0 18.0 1993 82.0 100.0 1994 17.6 82.4 100.0 17.8 1995 82.2 100.0 18.7 81.3 1996 100.0 19.8 1997 80.2 100.0 1999 21.4 78.6 100.0 2000 24.4 75.6 100.0 23.9 26.1 25.8 76.1 73.9 74.2 2001 2002 100.0 100.0 2003 2004 25.8 74.2 2005 26.8 73.2 100.0

100.0

100.0

100.0

100.0

100.0

2011^f f: forecast

2006

2007

2009

27.6

29.6

29.2

72.4

70.4

70.8

Table B P.E.I.—Per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Prince Edward Island, 1985 to 2011

					Prescribed	Drugs				Non-Prescribed Drug Private (Out of Pocke		
	Provincial	Federal	Public Social Securit WCBs Dru	y Funds ug Insurance Funds	Subtotal Public	Insurers*	Out of Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	te (Out of Poci Personal Health Supplies	tet) Total Non-Presc. Drugs
Year			(Premi	um Component)		(\$ per Ca	nita)		• •	Drugs		
1985	13.08	6.01	0.33		19.42	(ψ pc) Ou		152.95	172.37			83.63
1986	16.61	6.94	0.47		24.02			100.25	124.27			94.14 109.04
1987 1988	27.17 35.77	7.80 4.59	0.66 0.79		35.62 41.15			79.09 95.54	114.72 136.69			90.98
1989	41.92	3.77	0.79		46.48			115.34	161.82			75.86
1990	50.03	4.91	0.95		55.88			137.70	193.59			81.26
1991 1992	56.89	5.26 5.01	0.94 2.99		63.09 66.12			131.41	194.50	 CE 70		103.63
1992	58.12 56.53	6.18	2.56		65.27			144.08 165.28	210.20 230.55	65.73 68.24	59.68 63.70	125.41 131.94
1994	57.56	6.86	2.49		66.91			178.75	245.65	68.75	65.44	134.19
1995	62.95	7.39	2.72		73.06			211.56	284.62	63.37	61.67	125.04
1996 1997	62.35 66.82	7.04 7.61	2.81 3.21		72.20 77.64			218.51 211.50	290.71 289.13	49.84 52.38	46.35 50.46	96.19 102.85
1998	76.76	8.86	3.90		89.52			242.67	332.19	63.65	62.32	125.97
1999	87.75	10.07	4.35		102.17			246.71	348.88	67.05	62.19	129.24
2000	102.36	16.74	5.48		124.58			264.09	388.67	64.46	58.37	122.84
2001 2002	114.85 123.41	19.53 19.63	5.72 5.17		140.10 148.21			314.79 278.01	454.89 426.22	70.80 75.90	61.36 65.64	132.16 141.54
2002	134.35	20.82	5.08		160.24			318.33	478.57	77.57	65.60	143.17
2004	144.18	20.83	4.91		169.92			346.45	516.37	77.74	64.73	142.46
2005	161.68	20.75	5.28		187.71			377.81	565.52	73.51	60.35	133.86
2006	175.23	20.49	5.80		201.52			411.68	613.20	76.85	63.33	140.18
2007 2008	186.53 205.58	20.26 19.76	6.20 6.80		212.98 232.14			412.01 406.27	624.99 638.41	82.11 87.34	65.36 68.90	147.47 156.24
2009	229.39	19.67	6.19		255.24			451.46	706.71	88.77	67.21	155.98
2010 ^f	243.90	19.55	6.03		269.48			487.45	756.93	93.04	71.46	164.50
2011 ^f	243.79	19.85	6.50		270.14			520.59	790.73	89.34	70.05	159.38
						(Annual Percenta	ge Change)					
1985	27.0	15.4	43.2		23.7			-34.5	 -27.9			12.6
1986 1987	63.5	12.4	43.2 39.5		48.3			-34.5	-27.9 -7.7			15.8
1988	31.7	-41.2	19.5		15.5			20.8	19.2			-16.6
1989	17.2	-17.9	0.3		13.0			20.7	18.4			-16.6
1990	19.3	30.2	20.1		20.2			19.4	19.6			7.1
1991 1992	13.7 2.2	7.2 -4.8	-0.2 216.8		12.9 4.8			-4.6 9.6	0.5 8.1			27.5 21.0
1993	-2.7	23.5	-14.6		-1.3			14.7	9.7	3.8	6.7	5.2
1994	1.8	10.9	-2.4		2.5			8.1	6.6	0.8	2.7	1.7
1995 1996	9.4 -0.9	7.8 -4.7	9.0 3.4		9.2 -1.2			18.4 3.3	15.9 2.1	-7.8 -21.4	-5.8 -24.8	-6.8 -23.1
1996	7.2	-4.7 8.0	14.4		7.5			-3.2	-0.5	-21.4 5.1	-24.6 8.9	6.9
1998	14.9	16.5	21.3		15.3			14.7	14.9	21.5	23.5	22.5
1999	14.3	13.6	11.5		14.1			1.7	5.0	5.3	-0.2	2.6
2000	16.7	66.2	26.2		21.9			7.0	11.4	-3.9	-6.1	-5.0
2001 2002	12.2 7.5	16.7 0.5	4.3 -9.6		12.5 5.8			19.2 -11.7	17.0 -6.3	9.8 7.2	5.1 7.0	7.6 7.1
2003	8.9	6.1	-1.8		8.1			14.5	12.3	2.2	-0.1	1.2
2004	7.3	0.0	-3.2		6.0			8.8	7.9	0.2	-1.3	-0.5
2005	12.1	-0.3	7.4		10.5			9.1	9.5	-5.4	-6.8	-6.0
2006 2007	8.4 6.4	-1.3 -1.2	9.9 6.9		7.4 5.7			9.0 0.1	8.4 1.9	4.5 6.8	4.9 3.2	4.7 5.2
2008	10.2	-2.4	9.7		9.0			-1.4	2.1	6.4	5.4	6.0
2009	11.6	-0.5	-8.9		10.0			11.1	10.7	1.6	-2.5	-0.2
2010 ^f	6.3	-0.6	-2.6		5.6			8.0	7.1	4.8	6.3	5.5
2011 [†]	0.0	1.5	7.8	 (Annual	0.2	 nac in Evere of	 Inflation in the	6.8	4.5	-4.0	-2.0	-3.1
1985				(Annual		nge in Excess of	innation in the					
1986	24.2	12.6	40.4		20.9			-37.3	-30.7			9.8
1987 1988	58.8 27.2	7.7 -45.7	34.8 15.0		43.6 11.0			-25.8 16.3	-12.4 14.6			11.1 -21.1
1989	12.6	-22.4	-4.3		8.4			16.2	13.8			-21.2
1990	16.3	27.2	17.1		17.2			16.4	16.6			4.1
1991	10.9	4.4	-3.0		10.1			-7.3	-2.3			24.8
1992 1993	0.9 -4.2	-6.1 22.1	215.6 -16.1		3.5 -2.7			8.4 13.3	6.8 8.2	2.4	5.3	19.8 3.8
1993	0.7	9.8	-3.5		1.4			7.0	5.5	-0.3	1.6	0.6
1995	7.0	5.5	6.7		6.9			16.0	13.5	-10.2	-8.1	-9.2
1996	-2.6	-6.4	1.7		-2.8			1.6	0.5	-23.0	-26.5	-24.7
1997	6.2	7.1	13.4		6.5			-4.2 15.2	-1.5	4.1	7.9	5.9 22.9
1998 1999	15.3 12.5	16.9 11.8	21.7 9.7		15.7 12.3			15.2 -0.1	15.3 3.2	21.9 3.5	23.9 -2.0	0.8
2000	12.5	62.1	22.1		17.8			2.9	7.3	-8.0	-10.2	-9.1
2001	10.8	15.3	3.0		11.1			17.8	15.7	8.5	3.8	6.2
2002	6.4	-0.6	-10.6		4.7			-12.7	-7.3	6.1	5.9	6.1
2003 2004	6.0 4.7	3.2 -2.6	-4.7 -5.8		5.2 3.5			11.6 6.2	9.4 5.3	-0.7 -2.4	-3.0 -3.9	-1.7 -3.1
2005	9.1	-3.4	4.4		7.5			6.0	6.5	-8.4	-9.8	-9.0
2006	5.6	-4.1	7.1		4.6			6.2	5.6	1.7	2.1	1.9
2007	2.8	-4.8	3.2		2.0			-3.6	-1.8	3.2	-0.5	1.5
2008 2009	5.3 14.3	-7.3 2.2	4.8 -6.2		4.1 12.7			-6.3 13.8	-2.7 13.4	1.5 4.3	0.6	1.1 2.5
2010 ^f	3.4	-3.5	-5.6		2.6			5.0	4.2	1.9	3.4	2.5
2011 ^f	-4.0	-2.5	3.8		-3.7			2.8	0.5	-8.0	-6.0	-7.1
f: forecast.												

t: forecast.
* Confidentiality precludes reporting provincial-level insurance data.

Table B P.E.I.—Per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Prince Edward Island, 1985 to 2011 (cont'd)

GDP Implicit
All Drugs

Health Expenditure

Price Index—Canada

		All Drugs		F	Health Expenditure		Price Index—Canada
	Public	Private	Total	Public	Private	Total	
Year			(\$ per Capi	ta)			(1997 = 100)
1985	19.42	236.58	256.00	1,004.74	414.66	1,419.40	73.6
1986	24.02	194.39	218.41	1,074.57	386.13	1,460.70	75.6
1987	35.62	188.13	223.76	1,164.10	414.24	1,578.34	79.2
1988	41.15	186.53	227.67	1,260.71	437.42	1,698.12	82.8
1989	46.48	191.20	237.68	1,340.84	499.18	1,840.01	86.6
1000	EE 00	240.00	274.04	4 400 00	E2E 04	4.000.74	90.0
1990 1991	55.88 63.09	218.96 235.04	274.84 298.14	1,426.83 1,563.81	535.91 589.69	1,962.74 2,153.50	89.2 91.6
1992	66.12	269.50	335.62	1,599.57	655.88	2,153.50	92.8
1993	65.27	297.22			707.51		92.6
		312.94	362.49	1,651.43		2,358.94	95.2
1994	66.91	312.54	379.85	1,626.43	724.66	2,351.09	93.2
1995	73.06	336.60	409.66	1,657.77	778.40	2,436.16	97.4
1996	72.20	314.70	386.90	1,716.36	781.25	2,497.61	99.0
1997	77.64	314.34	391.98	1,689.18	811.16	2,500.34	100.0
1998	89.52	368.63	458.15	1,807.78	853.14	2,660.92	99.6
1999	102.17	375.95	478.12	1,900.33	878.29	2,778.63	101.4
2000	124.58	386.93	511.51	2,034.62	905.97	2,940.60	105.5
2001	140.10	446.95	587.05	2,403.43	1,078.93	3,482.35	106.9
2002	148.21	419.55	567.76	2,669.89	1,020.75	3,690.64	108.1
2003	160.24	461.50	621.74	2,764.67	1,174.86	3,939.54	111.2
2004	169.92	488.91	658.83	2,726.81	1,176.96	3,903.77	114.1
2005	187.71	511.68	699.38	2,987.19	1,180.97	4,168.16	117.5
2006	201.52	551.86	753.38	3,146.58	1,361.24	4,507.83	120.8
2007	212.98	559.48	772.46	3,372.06	1,363.48	4,735.54	125.2
2008	232.14	562.51	794.65	3,657.60	1,327.39	4,984.99	131.3
2009	255.24	607.44	862.69	4,056.11	1,466.43	5,522.54	127.8
2010 ^f	260.40	6E4 0E	024.42	4,389.61	4 520 05	E 004 07	404.5
2010 2011 ^f	269.48	651.95 679.97	921.43		1,532.25 1,627.41	5,921.87 6.115.31	131.5
2011	270.14	679.97	950.11	4,487.90		6,115.31	136.8
			(Ar	nnual Percentage Ch	hange)		
1985							
1986	23.7	-17.8	-14.7	7.0	-6.9	2.9	2.8
1987	48.3	-3.2	2.4	8.3	7.3	8.1	4.7
1988	15.5	-0.9	1.7	8.3	5.6	7.6	4.5
1989	13.0	2.5	4.4	6.4	14.1	8.4	4.6
1990	20.2	14.5	15.6	6.4	7.4	6.7	3.0
1991	12.9	7.3	8.5	9.6	10.0	9.7	2.8
1992	4.8	14.7	12.6	2.3	11.2	4.7	1.3
1993	-1.3	10.3	8.0	3.2	7.9	4.6	1.4
1994	2.5	5.3	4.8	-1.5	2.4	-0.3	1.1
1995	9.2	7.6	7.8	1.9	7.4	3.6	2.3
1996	-1.2	-6.5	-5.6	3.5	0.4	2.5	1.7
1997	7.5	-0.1	1.3	-1.6	3.8	0.1	1.0
1998	15.3	17.3	16.9	7.0	5.2	6.4	-0.4
1999	14.1	2.0	4.4	5.1	2.9	4.4	1.8

2000	21.9	2.9	7.0	7.1	3.2	5.8	4.1
2001	12.5	15.5	14.8	18.1	19.1	18.4	1.4
2002	5.8	-6.1	-3.3	11.1	-5.4	6.0	1.0
2003	8.1	10.0	9.5	3.6	15.1	6.7	2.9
2004	6.0	5.9	6.0	-1.4	0.2	-0.9	2.6
2005	10.5	4.7		0.5	0.0		2.0
2005	10.5	4.7	6.2	9.5	0.3	6.8	3.0
2006 2007	7.4 5.7	7.9 1.4	7.7 2.5	5.3 7.2	15.3 0.2	8.1 5.1	2.8 3.7
2008	9.0	0.5	2.9	8.5	-2.6	5.3	4.9
2009	10.0	8.0	8.6	10.9	10.5	10.8	-2.7
2009	10.0	6.0	0.0	10.5	10.5	10.6	-2.1
2010 ^f	5.6	7.3	6.8	8.2	4.5	7.2	2.9
2011 ^f	0.2	4.3	3.1	2.2	6.2	3.3	4.0
		(Annual Percentage	Change in Excess of Ir	nflation in the Canad	dian Economy)		
1985						-	
1986	20.9	-20.6	-17.5	4.1	-9.7	0.1	
1987	43.6	-8.0	-2.3	3.6	2.5	3.3	
1988	11.0	-5.4	-2.8	3.8	1.1	3.1	
1989	8.4	-2.1	-0.2	1.8	9.6	3.8	
1990	17.2	11.5	12.6	3.4	4.3	3.6	
1991	10.1	4.6	5.7	6.8	7.3	7.0	
1992	3.5	13.4	11.3	1.0	10.0	3.5	
1993	-2.7	8.8	6.6	1.8	6.4	3.1	
1994	1.4	4.2	3.7	-2.6	1.3	-1.4	
1995	6.9	5.2	5.5	-0.4	5.1	1.3	
1996	-2.8	-8.2	-7.2	1.9	-1.3	0.9	
1997	6.5	-1.1	0.3	-2.6	2.8	-0.9	
1998	15.7	17.7	17.3	7.5	5.6	6.9	
1999	12.3	0.2	2.5	3.3	1.1	2.6	
2000	17.8	-1.2	2.9	3.0	-1.0	1.7	
2001	11.1	14.2	13.4	16.8	17.7	17.1	
2002	4.7	-7.2	-4.3	10.0	-6.4	4.9	
2003	5.2	7.1	6.6	0.7	12.2	3.8	
2004	3.5	3.3	3.4	-4.0	-2.4	-3.5	
2005	7.5	1.6	3.1	6.5	-2.7	3.8	
2006	4.6	5.1	4.9	2.5	12.5	5.4	
2007	2.0	-2.3	-1.1	3.5	-3.5	1.4	
2008	4.1	-4.3	-2.0	3.6	-7.5	0.4	
2009	12.7	10.7	11.3	13.6	13.2	13.5	
2010 ^f	2.6	4.4	3.9	5.3	1.5	4.3	
2011 ^f	-3.7	0.3	-0.9	-1.8	2.2	-0.7	
f: forecast.							al Health Expenditure Database, 201

P.E.I

Table B N.S.—Total

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, Nova Scotia, 1985 to 2011

			Public		Prescribed	Drugs	Private				Prescribed Druite (Out of Pock	
	Provincial	Federal	Social Security WCBs Drug	Funds Insurance Funds	Subtotal Public	Insurers*	Out of Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	Personal Health Supplies	Total Non-Presc. Drugs
				m Component)		/A ==::::			Diugs	Drugs	опрыса	Diags
Year 1985	45.5	2.3	0.2		48.0	(\$ Million	is) 	38.7	86.7			61.1
1986	53.1	2.3	0.2		55.7			59.6	115.3			69.2
1987	62.3	2.6	0.2		65.1			67.7	132.8			80.2
1988 _ 1989	72.2 82.1	3.4 4.2	0.3 0.3		76.0 86.6			74.8 82.5	150.8 169.1			78.9 77.7
1990 1991	83.0 83.0	5.0 5.6	0.3 0.5		88.3 89.1			96.0 106.2	184.2 195.3			79.3 80.6
1992	89.0	5.9	0.5		95.4			118.4	213.8	48.7	44.3	93.0
1993 1994	88.5 83.2	6.8	0.6 0.6		95.9 91.1			132.7	228.6 228.9	51.3	47.9 49.3	99.1 101.1
		7.3						137.8		51.8		
1995 1996	83.9 83.3	8.9 8.4	0.7 0.7		93.5 92.5			148.7 159.4	242.2 251.8	47.8 53.8	46.5 50.0	94.2 103.8
1997	86.8	9.8	0.7		97.3			170.5	267.9	49.6	47.4	96.9
1998	99.5	14.4	0.8		114.7			198.7	313.4	54.8	53.7	108.5
1999	110.7	14.8	1.1		126.5			201.5	328.0	55.5	51.5	107.0
2000 2001	117.3 128.7	18.8 22.3	1.4 1.9		137.4 152.9			227.3 247.5	364.7 400.4	55.3 60.5	50.1 52.4	105.4 112.9
2002	140.8	24.2	2.2		167.2			282.2	449.5	64.6	55.9	120.5
2003	156.2	25.9	2.5		184.6			299.5	484.1	68.7	58.1	126.9
2004	170.0	26.4	3.0		199.4			324.5	523.9	72.1	60.0	132.1
2005 2006	186.1 231.8	27.4 34.7	3.4 4.8		216.8 271.3			359.9 396.8	576.7 668.1	71.6 73.7	58.8 60.8	130.4 134.5
2006	251.8 252.3	34.7	4.8 5.6		288.3			396.8 423.5	711.8	73.7 80.1	63.7	134.5
2008	269.0	28.2	6.8		304.1			423.0	727.0	80.4	63.4	143.9
2009	293.0	28.9	6.9		328.9			459.5	788.5	76.8	58.1	134.9
2010 ^f 2011 ^f	307.2	29.1	9.7		346.0			526.3	872.3	81.6	62.7	144.3
2011	311.3	29.7	10.6		351.6			576.9	928.6	81.7	63.8	145.4
1985						(Annual Percenta	ge Change)					
1986	16.7	3.8	16.4		16.1			54.0	33.0			13.2
1987	17.2	8.3	4.2		16.8			13.6	15.1			16.0
1988 1989	16.0 13.7	32.7 21.9	48.7 -7.8		16.8 14.0			10.4 10.4	13.5 12.2			-1.6 -1.6
1990	1.0	20.1	6.4		1.9			16.3	8.9			2.1
1991	0.1	12.4	41.5		0.9			10.6	6.0			1.7
1992	7.2	5.3	2.6		7.1			11.5	9.5			15.4
1993 1994	-0.5 -6.0	15.4 6.6	20.2 6.1		0.6 -5.0			12.1 3.9	6.9 0.1	5.2 1.0	8.1 3.0	6.6 1.9
1995 1996	0.8 -0.7	21.6 -5.0	15.7 5.2		2.6 -1.1			7.9 7.2	5.8 4.0	-7.8 12.7	-5.7 7.7	-6.8 10.2
1997	4.2	16.2	-1.0		5.3			7.0	6.4	-7.9	-5.4	-6.7
1998	14.5	47.4	16.2		17.9			16.5	17.0	10.7	13.4	12.0
1999	11.3	2.5	27.0		10.3			1.4	4.7	1.2	-4.1	-1.5
2000 2001	5.9 9.8	27.1 18.6	28.6 39.0		8.6 11.3			12.8 8.9	11.2 9.8	-0.3 9.3	-2.7 4.6	-1.5 7.1
2002	9.4	8.6	18.0		9.4			14.0	12.2	6.8	6.6	6.7
2003	10.9	7.0	12.3		10.4			6.1	7.7	6.4	4.0	5.3
2004	8.8	2.0	19.2		8.0			8.4	8.2	4.9	3.3	4.2
2005 2006	9.5 24.6	3.7 26.9	12.0 41.6		8.7 25.1			10.9 10.2	10.1 15.8	-0.7 3.0	-2.1 3.4	-1.3
2006	24.6 8.9	-12.5	41.6 17.6		6.3			6.7	15.8 6.5	3.0 8.6	4.9	3.2 6.9
2008	6.6	-7.1	21.3		5.4			-0.1	2.1	0.4	-0.5	0.0
2009	8.9	2.5	2.0		8.2			8.6	8.5	-4.5	-8.3	-6.2
2010 ^f	4.8	0.6	39.8		5.2			14.5	10.6	6.3	7.8	6.9
2011 [†]	1.3	1.9	9.7		1.6	 age Share of Tota	 I Drug Evnend	9.6	6.5	0.1	1.7	0.8
1985	30.8	1.5	0.1		32.5	age Share of Tota		26.2	58.7			41.3
1986	28.8	1.3	0.1		30.2			32.3	62.5			37.5
1987 1988	29.2	1.2	0.1		30.5			31.8	62.3 65.6			37.7 34.4
1988 1989	31.5 33.3	1.5 1.7	0.1 0.1		33.1 35.1			32.5 33.4	65.6 68.5			34.4 31.5
1990	31.5	1.9	0.1		33.5			36.4	69.9			30.1
1990	30.1	2.0	0.1		32.3			38.5	70.8			29.2
1992	29.0	1.9	0.2		31.1			38.6	69.7	15.9	14.4	30.3
1993 1994	27.0 25.2	2.1 2.2	0.2 0.2		29.3 27.6			40.5 41.8	69.8 69.4	15.6 15.7	14.6 14.9	30.2 30.6
1995	24.9	2.6	0.2		27.8			44.2	72.0	14.2	13.8	28.0
1995 1996	24.9 23.4	2.6	0.2 0.2		27.8 26.0			44.2 44.8	72.0 70.8	14.2 15.1	13.8 14.1	28.0 29.2
1997	23.8	2.7	0.2		26.7			46.7	73.4	13.6	13.0	26.6
1998 1999	23.6 25.4	3.4 3.4	0.2 0.2		27.2 29.1			47.1 46.3	74.3 75.4	13.0 12.8	12.7 11.8	25.7 24.6
2000 2001	24.9 25.1	4.0 4.3	0.3 0.4		29.2 29.8			48.4 48.2	77.6 78.0	11.8 11.8	10.7 10.2	22.4 22.0
2001	24.7	4.3	0.4		29.8			49.5	78.9	11.3	9.8	21.1
2003	25.6	4.2	0.4		30.2			49.0	79.2	11.2	9.5	20.8
2004	25.9	4.0	0.5		30.4			49.5	79.9	11.0	9.2	20.1
2005	26.3	3.9	0.5		30.7			50.9	81.6	10.1	8.3	18.4
2006 2007	28.9 29.5	4.3 3.6	0.6 0.7		33.8 33.7			49.4 49.5	83.2 83.2	9.2 9.4	7.6 7.4	16.8 16.8
2008	30.9	3.2	0.8		34.9			48.6	83.5	9.2	7.3	16.5
2009	31.7	3.1	0.8		35.6			49.8	85.4	8.3	6.3	14.6
2010 ^f	30.2	2.9	1.0		34.0			51.8 53.7	85.8 86.5	8.0 7.6	6.2	14.2
2010 2011 ^f	29.0	2.8	1.0		32.7						5.9	13.5

f: forecast.

* Confidentiality precludes reporting provincial-level insurance data.

Table B N.S.—Total

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, Nova Scotia, 1985 to 2011 (cont'd)

			otal Health Ex	penditures, Nova	i Scotia, 198	5 to 2011 (cont ^a)	Share of Drugs in Pul	olic, Private and	
=	Public	All Drugs Private	Total		Expenditure Private	Total	Total Health Ex	penditures rivate	Total
	1 45.10	·····		. 42.10		10.00			
Year			(\$ Million	s)			(Percentage	Share)	
1985 1986	48.0 55.7	99.8 128.8	147.8 184.5	947.2 1,023.2	285.3 353.7	1,232.5 1,376.9	5.1 5.4	35.0 36.4	12.0 13.4
1987	65.1	147.9	213.0	1,165.5	395.0	1,560.6	5.6	37.4	13.6
1988	76.0	153.7	229.7	1,165.0	420.3	1,585.2	6.5	36.6	14.5
1989	86.6	160.2	246.8	1,281.5	470.3	1,751.8	6.8	34.1	14.1
1990 1991	88.3 89.1	175.3 186.8	263.5 275.9	1,376.6 1,451.2	490.4 518.8	1,866.9 1,970.0	6.4 6.1	35.7 36.0	14.1 14.0
1992	95.4	211.4	306.8	1,477.0	554.5	2,031.6	6.5	38.1	15.1
1993	95.9	231.8	327.7	1,445.5	579.5	2,025.0	6.6	40.0	16.2
1994	91.1	238.9	330.0	1,413.1	610.2	2,023.4	6.4	39.1	16.3
1995 1996	93.5 92.5	242.9 263.2	336.4 355.7	1,440.0 1,438.2	621.3 650.8	2,061.3 2,089.0	6.5 6.4	39.1 40.4	16.3 17.0
1997	97.3	267.5	364.8	1,669.3	694.9	2,364.2	5.8	38.5	15.4
1998	114.7	307.2	421.9	1,786.8	766.1	2,552.9	6.4	40.1	16.5
1999	126.5	308.5	435.0	1,899.7	778.2	2,677.9	6.7	39.6	16.2
2000 2001	137.4 152.9	332.7 360.4	470.1 513.3	1,968.4 2,082.7	868.2 930.6	2,836.6 3,013.3	7.0 7.3	38.3 38.7	16.6 17.0
2002	167.2	402.7	569.9	2,264.3	1,042.5	3,306.8	7.4	38.6	17.2
2003	184.6	426.4	611.0	2,483.8	1,111.7	3,595.5	7.4	38.4	17.0
2004	199.4	456.7	656.1	2,588.0	1,137.0	3,725.0	7.7	40.2	17.6
2005 2006	216.8 271.3	490.3 531.3	707.1 802.6	2,822.7 3,178.6	1,207.8 1,333.1	4,030.5 4,511.7	7.7 8.5	40.6 39.9	17.5 17.8
2007	288.3	567.3	855.6	3,407.1	1,413.2	4,820.3	8.5	40.1	17.8
2008	304.1	566.8	870.9	3,586.4	1,484.5	5,071.0	8.5	38.2	17.2
2009	328.9	594.5	923.4	3,680.3	1,652.0	5,332.3	8.9	36.0	17.3
2010 ^f 2011 ^f	346.0 351.6	670.6 722.4	1,016.5 1,074.0	3,951.8 4,069.6	1,738.9 1,860.5	5,690.7 5,930.1	8.8 8.6	38.6 38.8	17.9 18.1
	301.0	,	(Annual Percentag		1,000.0	0,000.1	0.0	00.0	10.1
1985									
1986	16.1	29.1	24.9	8.0	24.0	11.7			
1987 1988	16.8 16.8	14.9 3.9	15.4 7.8	13.9 -0.1	11.7 6.4	13.3 1.6			
1989	14.0	4.2	7.5	10.0	11.9	10.5			
1990	1.9	9.4	6.8	7.4	4.3	6.6			
1991	0.9	6.6	4.7	5.4	5.8	5.5			
1992 1993	7.1 0.6	13.2 9.6	11.2 6.8	1.8 -2.1	6.9 4.5	3.1 -0.3			
1994	-5.0	3.1	0.7	-2.2	5.3	-0.1			
1995	2.6	1.7	2.0	1.9	1.8	1.9			
1996 1997	-1.1 5.3	8.3 1.6	5.7 2.6	-0.1 16.1	4.7 6.8	1.3 13.2			
1998	17.9	14.9	15.7	7.0	10.2	8.0			
1999	10.3	0.4	3.1	6.3	1.6	4.9			
2000	8.6	7.9	8.1	3.6	11.6	5.9			
2001 2002	11.3 9.4	8.3 11.7	9.2 11.0	5.8 8.7	7.2 12.0	6.2 9.7			
2003	10.4	5.9	7.2	9.7	6.6	8.7			
2004	8.0	7.1	7.4	4.2	2.3	3.6			
2005	8.7	7.4	7.8	9.1	6.2	8.2			
2006 2007	25.1 6.3	8.4 6.8	13.5 6.6	12.6 7.2	10.4 6.0	11.9 6.8			
2008	5.4	-0.1	1.8	5.3	5.0	5.2			
2009	8.2	4.9	6.0	2.6	11.3	5.2			
2010 ^f	5.2	12.8	10.1	7.4	5.3	6.7			
2011	1.6 (Percentage Sha	7.7 are of Total Drug Ex	5.7 penditure)	3.0	7.0	4.2			
1985	32.5	67.5	100.0						
1986	30.2	69.8	100.0						
1987 1988	30.5 33.1	69.5 66.9	100.0 100.0						
1989	35.1	64.9	100.0						
1990	33.5	66.5	100.0						
1991 1992	32.3	67.7 68.9	100.0 100.0						
1992	31.1 29.3	70.7	100.0						
1994	27.6	72.4	100.0						
1995	27.8	72.2	100.0						
1996	26.0	74.0	100.0						
1997 1998	26.7 27.2	73.3 72.8	100.0 100.0						
1999	29.1	70.9	100.0						
2000	29.2	70.8	100.0						
2001	29.8	70.2	100.0						
2002 2003	29.3 30.2	70.7 69.8	100.0 100.0						
2004	30.4	69.6	100.0						
2005	30.7	69.3	100.0						
2006	33.8	66.2	100.0						
2007 2008	33.7 34.9	66.3 65.1	100.0 100.0						
2009	35.6	64.4	100.0						
2010 ^f	34.0	66.0	100.0						
2011 ^f	32.7	67.3	100.0						

f: forecast.

Table B N.S.—Per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Nova Scotia, 1985 to 2011

Polymore	-			Public		Prescribed	Drugs	Private				Prescribed Dru	
Part	Pr	rovincial	Federal		Funds	Subtotal	Insurers*		Subtotal	Total			
			_			Public		Pocket	Private				Non-Presc. Drugs
9 144 226 127 442 - 424 - 424 - 424 - 77 - 80 -										•	Drugs	••	•
1972 207			0.50	0.04		54.04	-		40.74	07.04			20.04
1988 2.28 0.25													77.77
1969													89.77
14.20													87.95
1905													85.92
9,980 844 0.51													87.16 88.07
## 1981 7.36											53.01		101.14
90.00 98.4 0.75		95.81	7.39	0.61		103.82			143.56	247.38	55.48	51.79	107.28
8966 800 070 - 19220 - 11112 20020 1016 1014 1046 10 0 070 - 19220 - 11112 20020 1016 1015 1016 1016 1016 1016 1016 1016 1016		89.76	7.86	0.65		98.27			148.69	246.96	55.85	53.16	109.01
\$\frac{8}{10}\$ \$10.66 \ 0.76													101.52
106.74 15.86 0.00													111.49 103.94
19255 2011 147													116.48
1900 2300 200 - 10300 20546 49846 9485 5520 121 1907 2500 2500 2501 - 17630 30201 49846 9485 5520 121 1907 2501 321 - 72559 3800 5580 7686 6782 121 1907 2501 321 - 72559 3800 5580 7686 6782 121 2017 2501 321 22559 4220 77286 7728 6847 144 2018 2501 321 22559 4220 77286 7728 6847 144 2018 2501 321 4520 77286 7728 77804 6873 144 2019 2501 321 4520 77804 6873 6871 143 2017 2501 321 4520 77804 6873 6874 672 144 2019 2501 321 4520 77804 6874 672 144 2019 2501 321 145 127 38430 4513 77804 6874 672 143 2017 2501 321 145 127 38430 4513 77804 6874 672 143 2017 2501 321 145 127 38430 4513 77804 6874 672 143 2017 2501 321 145 127 38430 4513 77807 6864 672 143 2017 2501 321 145 127 38430 4513 77807 6864 672 143 2017 2501 321 145 127 38430 4513 7880 6870 143 2017 2501 321 145 127 533 3874 533 3874 533 3874 533 3874 533 3874		118.53	15.82	1.14		135.49			215.75	351.24	59.42	55.12	114.55
150.06 25.06 24.1			20.11									53.64	112.88
18673 27.63 27.0													121.05
1811 22 28.16 2.21													135.45
247.14 37.04 5.09 - 398.77 - 422.99 712.06 713.09 64.77 14.8 20.99 32.47 60.09 - 308.13 - 462.19 700.04 60.07 60.11 15.5 31.20 15.20													140.88
247.14 370/4 500		198.78	29.26	3.60		231.64			384.51	616.15	76.49	62.80	139.29
987-19		247.14	37.04	5.09		289.27			422.99	712.26	78.60	64.77	143.38
315.04 30.06 7.30 - 399.23 469.34 895.7 81.7 61.81 14.3 205.20 30.88 10.30 - 397.36 563.37 20.54 81.7 61.81 14.8													153.69 153.57
255.82 20.08 10.30													143.68
Solution													153.09
102													154.24
162							(Annual Percenta	ige Change)					
167 7.8 3.7 163 130 148													
155													12.7
129 210 4.6 132													15.4 -2.0
10													-2.3
0.5		0.3	19.3	5.8		1.3			15.6	8.2			1.4
-100 14.8 197 0.1 11.5 6.4 4.7 7.6 6.3 6.3 6.3 5.7 5.3 3.6 6.2 0.7 2.8 6.3 6.3 6.3 5.7 5.3 3.6 6.2 0.7 2.8 6.3 6.3 6.3 5.7 5.3 3.6 6.2 0.7 2.8 6.3 6.3 6.3 6.3 5.7 5.3 3.6 6.2 0.7 2.8 6.3 6.3 6.3 6.3 6.3 6.3 6.3 6.3 6.3 6.3													1.0
63													14.8
07													6.1 1.6
1-10						2.5							-6.9
14.6													9.8
110													-6.8
59 27.1 28.5 — 8.6 — — 12.8 11.2 — 0.3 —2.7 —9.9 — — 13.8 12.0 6.8 6.4 — — 13.8 12.0 6.6 6.4 — — — 13.8 12.0 6.6 6.4 — — — 13.8 12.0 6.6 6.4 — — — — 5.9 7.5 6.2 3.8 — — — 5.9 7.5 6.2 3.8 3.1 — — — — — — — 6.2 8.1 4.8 3.1 —													12.1 -1.7
99 188 393 393 11.4 9.1 10.0 9.5 48 8 91 8.8 10.7 9.1 10.2 10.3 10.2 10.3 10.2 10.3 10.2 10.3 10.2 10.3 10.2 10.3 10.2 10.3 10.2 10.3 10.2 10.3 10.2 10.3 10.2 10.3 10.2 10.3 10.2 10.3 10.2 10.3 10.2 10.3 10.2 10.3 10.3 10.2 10.3 10.3 10.2 10.3 10.3 10.3 10.2 10.3 10.3 10.3 10.2 10.3													
9.1 8.4 177 9.1 138 12.0 6.6 6.4 8.8 17.7 6.6 2.38 8.8 8.7 1.9 1.9 1.90 7.9 8.2 8.1 4.8 3.1 9.7 3.9 12.2 9.0 11.1 10.3 0.5 1.1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1.9 1													-1.5 7.2
8.7													6.5
9.7 3.9 122 9.0 11.1 10.3 0.5 1.9													5.1
24.3 26.6 41.2 — 24.9 — — 10.0 15.6 2.8 3.1 3.1 3.1 3.1 3.1 3.2 3.1 3.2 3.2 3.3 3.0 4.8 8.9 5.2 3.3 3.0 6.6 4.4 4.3 3.93 — 4.8 — — 14.1 10.2 5.9 7.4 4.1 1.3 1.8 9.7 — — 8.6 6.4 0.0 1.7 —									8.2				4.0
9.1													-1.1
6.5													2.9 7.2
4.4		6.5	-7.2	21.2		5.3			-0.2	2.0	0.3	-0.6	-0.1
1.3		8.7	2.2	1.7		7.9			8.4	8.2	-4.7	-8.6	-6.4
CANNUAL Percentage Change in Excess of Inflation in the Canadian Economy													6.5
		1.3	1.8	9.7			 nge in Everer	Inflation in 4b -			0.0	1.7	0.7
11.9 3.1 -1.0 11.5 8.3 9.9 1 11.0 27.6 43.6 11.8 5.4 8.5					,		•			•			
11.0													9.9
8.3													10.7 -6.5
-2.7													-6.9
-3.3 9.0 37.9 2.4 7.2 2.6 5.4 3.6 0.9 5.3 9.7 7.7 9.7 7.7 1.		-27	16.3	2.7		-1.8			12.5	5.2	_		-1.6
-25 13.4 18.21.4 10.1 5.0 3.2 6.2 -1.3 -0.4 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5													-1.7
-7.4 5.2 4.6 6.4 2.5 1.3 -0.4 1.5 1.5 1.6 1.9 1 13.3 0.1 5.4 3.3 1.0.2 8.2 -2.7 7.0 3.1 3.1 5.1 2.0 10.6 5.6 3.1 15.1 -2.1 4.2 5.9 5.3 9.0 -6.5 -3 1.5 0.4 8.0 16.7 18.4 17.0 17.5 11.2 13.9 1.9 9.2 0.5 24.9 8.2 0.6 2.6 0.8 -6.2 -3 1.8 23.0 24.4 4.5 8.2 0.6 2.6 0.8 -6.2 -3 1.8 23.0 24.4 4.5 8.7 7.1 4.4 4.6 8 4.8 1.7 3 16.7 8.1 17.0 17.5 8.6 8.1 3.4 8.1 7.3 16.7 8.1 17.0 17.5 11.0 5.6 5.3 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0		5.4	3.6	0.9		5.3			9.7	7.7			13.6
-1.6													4.6 0.5
-27 -7.0 3.13.15.1 2.0 10.6 5.6 3.1 15.1 -2.1 4.2 5.9 5.3 -9.0 -6.5 -15.0 48.0 16.7 18.4 17.0 17.5 11.2 13.9 1.0 15.0 48.0 16.7 18.4 17.0 17.5 11.2 13.9 11.2 13.9 13.9 11.2 13.9 13.9 11.2 13.9 13.9 11.2 13.9 13.9 13.9 13.9 13.9 13.9 13.9 13.9													
3.1 15.1 -2.1 4.2 -5.9 5.3 -9.0 -6.5 -1.5 15.0 48.0 16.7 18.4 17.0 17.5 11.2 13.9 1 9.2 0.5 24.9 8.2 -0.6 2.6 -0.8 -6.2 1.8 23.0 24.4 4.5 8.7 7.1 -4.4 -6.8 8.6 17.4 37.9 10.1 7.7 8.6 8.1 3.4 12.7 11.0 5.6 5.3 3.3 3.4 12.7 11.0 5.6 5.5 3.3 3.9 9.1 7.3 3.0 4.6 3.3 0.9 3.3 3.0 9.6 5.1 -0.7 16.4 5.3 5.6 5.5 2.2 0.5 6.7 0.9 9.2 6.0 8.1													-9.2 8.2
9.2 0.5 24.9 8.2 0.6 2.6 0.8 6.2 1.8 23.0 24.4 4.5 8.7 7.1 4.4 6.8 8.6 17.4 37.9 10.1 7.7 8.6 8.1 3.4 1 12.7 11.0 5.6 5.3 1 15.7 8.8 3.9 9.1 7.3 3.0 4.6 3.3 0.9 6.1 -0.7 16.4 5.3 5.6 5.5 2.2 0.5 1 5.6 5.5 2.2 0.5 1 15.6 1.			15.1										-7.8
1.8 23.0 24.4 4.5 8.7 7.1 4.4 -6.8 8.6 17.4 37.9 10.1 7.7 8.6 8.1 3.4 8.1 7.3 16.7 8.1 12.7 11.0 5.6 5.3 7.8 3.9 9.1 7.3 3.0 4.6 3.3 0.9 6.1 -0.7 16.4 5.3 5.6 5.5 2.2 0.5 6.7 0.9 9.2 6.0 8.1 7.3 -3.5 -4.9 21.5 23.8 38.4 22.1 7.2 12.8 0.0 0.3 5.4 -16.0 14.2 2.8 3.3 3.1 5.2 1.5 1.5 1.6 -12.1 16.3 0.5 5.1 -2.8 1.1 10.9 -2.0 -5.9 11.4 4.9 4.4													12.5
8.6 17.4 37.9 10.1 7.7 8.6 8.1 3.4 8.1 7.3 16.7 8.1 12.7 11.0 5.6 5.3 1.7 8 3.9 9.1 7.3 3.0 4.6 3.3 0.9 6.1 0.07 16.4 5.3 5.6 5.5 2.2 0.5 6.7 0.9 9.2 6.0 5.6 5.5 2.2 0.5 6.7 0.9 9.2 6.0 8.1 7.3 3.5 4.9 21.5 23.8 38.4 22.1 7.2 12.8 0.0 0.3 6.4 6.5 4 16.0 14.2 2.8 3.3 3.1 5.2 1.5 6.4 16.0 14.2 2.8 5.6 6.5 1.2 1.5 6.1 1.6 12.1 16.3 0.5 0.5 5.1 2.8 4.6 5.4 11.4 4.9 4.4 10.6 10.6 11.1 10.9 2.2 5.9 5.9 1.5 1.5 2.7 3.6 3 1.9 11.1 10.9 2.2 5.9 2.0 5.9 2.1 1.5 2.7 2.7 2.2 5.7 2.4 5.6 2.4 4.0 2.3 2.3 2.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1													-3.5
8.1 7.3 16.7 8.1 12.7 11.0 5.6 5.3 7.8 3.9 9.1 7.3 7.3 3.0 4.6 3.3 0.9 5.6 6.1 0.7 16.4 5.3 5.6 5.5 2.2 0.5 6.7 0.9 9.2 6.0 8.1 7.3 3.5 4.9 21.5 23.8 38.4 22.1 7.2 12.8 0.0 0.3 5.4 16.0 14.2 2.8 7.2 12.8 0.0 0.3 5.4 16.0 14.2 2.8 5.5 1.5 1.5 1.6 12.1 16.3 0.5 5.5 1.2 4.6 5.4 11.4 4.9 4.4 10.6 10.6 11.1 10.9 2.0 5.9 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5													-5.6
7.8 3.9 9.1 7.3 3.0 4.6 3.3 0.9 6.1 -0.7 16.4 5.3 5.6 5.5 2.2 0.5 6.7 0.9 9.2 6.0 5.8 1 7.3 3.5 4.9 -21.5 23.8 38.4 22.1 7.2 12.8 0.0 0.3 5.4 16.0 14.2 2.8 3.3 3.1 5.2 1.5 1.5 1.6 12.1 16.3 0.5 5.1 2.8 4.6 5.4 4.6 5.4 11.4 4.9 4.4 10.6 10.6 11.1 10.9 2.0 5.9 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5													5.9 5.5
6.7 0.9 9.2 6.0 8.1 7.3 3.5 4.9 21.5 23.8 38.4 22.1 7.2 12.8 0.0 0.3 5.4 1-6.0 14.2 2.8 3.3 3.1 5.2 1.5 1.6 1-2.1 16.3 0.5 5.1 2.8 4.6 5.4 11.4 4.9 4.4 10.6 11.1 10.9 2.0 5.9 1.5 2.7 36.3 1.9 11.2 7.3 3.0 4.5 2.7 2.2 5.7 2.4 5.6 2.4 4.0 2.3		7.8	3.9	9.1		7.3			3.0	4.6	3.3	0.9	2.2
21.5 23.8 38.4 22.1 7.2 12.8 0.0 0.3 15.4 16.0 14.2 28 33 3.1 52 1.5 1.6 12.1 16.3 0.5 5.1 2.8 4.6 5.4 11.4 4.9 4.4 10.6 11.1 10.9 2.0 5.9 1.5 1.5 2.7 36.3 1.9 11.2 7.3 3.0 4.5 2.7 2.2 5.7 2.4 5.6 2.4 4.0 2.3		6.1	-0.7	16.4		5.3			5.6	5.5	2.2	0.5	1.4
5.4													-4.1
1.6 -12.1 16.3 0.55.1 -2.8 -4.6 -5.4 11.4 4.9 4.4 10.6 11.1 10.9 -2.0 -5.9 1.5 -2.7 36.3 1.9 11.2 7.3 3.0 4.5 2.7 -2.2 5.72.4 5.6 2.4 -4.0 -2.3 t.													0.1 3.5
11.4 4.9 4.4 10.6 11.1 10.9 -2.0 -5.9 1.5 -2.7 36.3 1.9 11.2 7.3 3.0 4.5 -2.7 -2.2 5.72.4 5.6 2.4 -4.0 -2.3 it.													3.5 -4.9
-2.7 -2.2 5.72.4 5.6 2.4 -4.0 -2.3 st.													-3.7
-2.7 -2.2 5.72.4 5.6 2.4 -4.0 -2.3 t.		1.5	-2.7	36.3		1.9			11.2	7.3	3.0	4.5	3.6
		-2.7	-2.2	5.7		-2.4			5.6		-4.0	-2.3	-3.2
entiality precludes reporting provincial-level insurance data. National Health Expenditure Database, 2011, Canadian Institute for Health Informa		ides renortina	nrovincial-level ico	urance data					National Ho	alth Evnenditure De	tahasa 2011 Cana	dian Instituto for L	loolth Information

Table B N.S.—Per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Nova Scotia, 1985 to 2011 (cont'd)

				•	•	,	GDP Implicit
_	Public	All Drugs Private	Total	Public	lealth Expenditure Private	Total	Price Index—Canada
Year 1985	54.21	112.74	(\$ per Cap 166.95	1,070.18	322.36	1,392.54	(1997 = 100) 73.6
1986	62.63	144.82	207.46	1,150.53	397.71	1,548.24	75.6 75.6
1987	72.82	165.57	238.39	1,304.53	442.14	1,746.68	79.2
1988	84.68	171.26	255.94	1,298.16	468.32	1,766.48	82.8
1989	95.83	177.23	273.06	1,417.87	520.32	1,938.19	86.6
1990	97.05	192.66	289.71	1,513.31	539.08	2,052.39	89.2
1991 1992	97.37 103.75	204.11 229.88	301.48 333.62	1,585.86 1,606.22	566.94 603.05	2,152.81 2,209.26	91.6 92.8
1993	103.82	250.84	354.66	1,564.33	627.19	2,191.52	94.1
1994	98.27	257.70	355.97	1,524.47	658.31	2,182.78	95.2
1995	100.69	261.74	362.43	1,551.41	669.35	2,220.76	97.4
1996	99.28	282.61	381.89	1,544.13	698.71	2,242.84	99.0
1997 1998	104.39 123.11	286.83 329.67	391.22 452.78	1,790.15 1,917.40	745.24 822.05	2,535.39 2,739.45	100.0 99.6
1999	135.49	330.30	465.79	2,034.29	833.35	2,867.64	101.4
2000	147.13	356.30	503.43	2,107.72	929.70	3,037.42	105.5
2001	163.96	386.53	550.50	2,233.74	998.07	3,231.81	106.9
2002	178.95	430.93	609.88	2,422.95	1,115.60	3,538.56	108.1
2003 2004	197.11 212.59	455.28 486.90	652.40 699.49	2,652.19 2,759.19	1,187.04 1,212.20	3,839.23 3,971.38	111.2 114.1
2005 2006	231.64 289.27	523.80 566.37	755.44 855.64	3,015.69 3,388.67	1,290.40 1,421.18	4,306.09 4,809.85	117.5 120.8
2007	308.13	606.20	914.33	3,640.86	1,510.17	5,151.03	125.2
2008	324.59	605.10	929.69	3,828.63	1,584.80	5,413.43	131.3
2009	350.23	633.02	983.25	3,918.88	1,759.07	5,677.95	127.8
2010 ^f	367.10	711.46	1,078.56	4,192.86	1,844.97	6,037.83	131.5
2011	372.86	766.05	1,138.91	4,315.55	1,972.94	6,288.49	136.8
				Annual Percentage Ch			
1985 1986	 15.5	28.5	24.3	7.5	23.4	11.2	2.8
1987	16.3	14.3	14.9	13.4	11.2	12.8	4.7
1988 1989	16.3 13.2	3.4 3.5	7.4 6.7	-0.5 9.2	5.9 11.1	1.1 9.7	4.5 4.6
1990 1991	1.3 0.3	8.7 5.9	6.1 4.1	6.7 4.8	3.6 5.2	5.9 4.9	3.0 2.8
1992	6.5	12.6	10.7	1.3	6.4	2.6	1.3
1993	0.1	9.1	6.3	-2.6	4.0	-0.8	1.4
1994	-5.3	2.7	0.4	-2.5	5.0	-0.4	1.1
1995 1996	2.5 -1.4	1.6 8.0	1.8 5.4	1.8 -0.5	1.7 4.4	1.7 1.0	2.3 1.7
1996	5.2	1.5	2.4	-0.5 15.9	6.7	13.0	1.0
1998	17.9	14.9	15.7	7.1	10.3	8.0	-0.4
1999	10.1	0.2	2.9	6.1	1.4	4.7	1.8
2000	8.6	7.9	8.1	3.6	11.6	5.9	4.1
2001 2002	11.4 9.1	8.5 11.5	9.3 10.8	6.0 8.5	7.4 11.8	6.4 9.5	1.4 1.0
2003	10.2	5.7	7.0	9.5	6.4	8.5	2.9
2004	7.9	6.9	7.2	4.0	2.1	3.4	2.6
2005	9.0	7.6	8.0	9.3	6.5	8.4	3.0
2006	24.9	8.1	13.3	12.4	10.1	11.7	2.8
2007	6.5	7.0	6.9	7.4	6.3	7.1	3.7
2008 2009	5.3 7.9	-0.2 4.6	1.7 5.8	5.2 2.4	4.9 11.0	5.1 4.9	4.9 -2.7
2010 ^f	4.8	12.4	9.7	7.0	4.9	6.3	2.9
2010 2011 ^f	1.6	7.7	5.6	2.9	6.9	4.2	4.0
_	((Annual Percentage	Change in Excess of	Inflation in the Canad	lian Economy)		
1985	 12.7	 25.7	21.5	 47	20.6		
1986 1987	12.7 11.5	25.7 9.6	21.5 10.2	4.7 8.6	20.6 6.4	8.4 8.1	
1988	11.8	-1.1	2.8	-5.0	1.4	-3.4	
1989	8.6	-1.1	2.1	4.7	6.5	5.2	
1990	-1.8	5.7	3.1	3.7	0.6	2.9	
1991	-2.4	3.2	1.3	2.0	2.4	2.1	
1992 1993	5.3 -1.4	11.4 7.7	9.4 4.9	0.0 -4.0	5.1 2.6	1.4 -2.2	
1994	-6.4	1.6	-0.7	-3.6	3.9	-1.5	
1995	0.1	-0.8	-0.5	-0.6	-0.7	-0.6	
1996	-3.1	6.3	3.7	-2.1	2.7	-0.7	
1997 1998	4.2 18.4	0.5 15.4	1.5 16.2	14.9 7.5	5.7 10.7	12.1 8.5	
1999	8.2	-1.6	1.1	4.3	-0.4	2.9	
2000	4.5	3.8	4.0	-0.5	7.5	1.8	
2001	10.1	7.1	8.0	4.6	6.0	5.0	
2002 2003	8.1 7.3	10.4 2.8	9.7 4.1	7.4 6.6	10.7 3.5	8.4 5.6	
2003	7.3 5.3	4.4	4.6	1.4	-0.5	0.9	
2005	6.0	4.6	5.0	6.3	3.4	5.4	
2006	22.1	5.3	10.5	9.6	7.3	8.9	
2007	2.8	3.4	3.2	3.8	2.6	3.4	
2008 2009	0.5 10.6	-5.0 7.3	-3.2 8.5	0.3 5.1	0.1 13.7	0.2 7.6	
2010 ^f	1.9	9.4	6.7	4.0	1.9	3.4	
2011 ^f	-2.4	3.7	1.6	-1.1	2.9	0.2	
f: forecast.						National	Health Expenditure Database, 20

f: forecast.

N.S.

Table B N.B.—Total

N.B.

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, New Brunswick, 1985 to 2011

		Public		Prescribed		Private			Priva	Prescribed Dru te (Out of Pock	ket)
Provincial	Federal	Social Security WCBs Drug	Funds g Insurance Funds	Subtotal Public	Insurers*	Out of Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	Personal Health Supplies	Total Non-Presc. Drugs
		(Premiu	m Component)		(\$ Million	ns)			Drugs		
33.9	1.7	0.1		35.7			38.8	74.4			48.4
39.6	1.8	0.2		41.5			45.6	87.1			54.8
46.2 48.5	1.9 2.7	0.2 0.2		48.4 51.4			56.1 61.4	104.5 112.7			63.6 61.6
52.7	3.1	0.3		56.0			67.1	123.1			59.6
58.3	3.7	0.4		62.4			80.3	142.7			61.0
62.4	4.1	0.4		67.0			88.8	155.8			66.1
60.0	4.2	0.5		64.8			102.2	167.0	35.6	32.3	67.9
56.8 56.0	5.2 5.7	0.6 0.6		62.5 62.3			111.3 118.4	173.8 180.7	37.0 37.3	34.5 35.5	71.5 72.8
58.3 54.8	6.4 6.4	0.6 0.7		65.4 61.9			127.8 126.7	193.1 188.6	34.4 32.9	33.5 30.6	67.9 63.6
56.1	7.1	0.7		64.0			143.9	207.9	44.5	42.6	87.1
62.1	8.6	0.9		71.6			149.7	221.3	42.5	41.6	84.2
69.0	10.8	1.1		80.8			167.0	247.8	47.6	44.1	91.7
78.4	14.2	1.4		94.0			187.7	281.6	47.6	43.1	90.7
90.1 101.3	17.2 18.8	1.7 2.1		109.0 122.2			218.9 241.9	327.9 364.1	46.5 49.7	40.3 43.0	86.9 92.6
112.3	21.0	2.6		135.9			271.4	407.2	50.6	42.8	93.4
124.4	21.6	3.3		149.3			276.1	425.4	52.2	43.5	95.7
135.8	22.3	3.7		161.9			327.0	488.9	50.1	41.1	91.2
146.4	22.7	4.0		173.0			343.7	516.7	52.7	43.4	96.0
152.7 160.9	23.3 24.3	4.0 4.2		180.0 189.4			349.6 378.3	529.6 567.8	56.8 57.8	45.2 45.6	102.1 103.4
175.2	24.3	4.4		203.3			378.3 407.0	610.3	57.8 70.3	45.6 53.2	103.4
187.5	23.5	4.4		215.4			455.0	670.4	74.1	56.9	130.9
180.9	24.0	4.8		209.7			495.3	705.0	76.9	58.1	135.0
					(Annual Percenta						
16.9	7.6	14.5		16.4			17.6	17.1			13.2
16.8	9.3	15.9		16.4			23.0	19.9			16.0
5.0	36.1	18.5		6.3			9.3	7.9			-3.1
8.6	17.3	15.6		9.1			9.3	9.2			-3.1
10.7	18.6	56.5		11.4			19.7	15.9			2.2
7.0 -3.9	12.5 2.0	11.2 24.7		7.4 -3.4			10.6 15.1	9.2 7.1			8.3 2.8
-5.4	22.5	3.7		-3.5			8.9	4.1	3.9	6.8	5.3
-1.4	10.6	5.4		-0.4			6.4	4.0	0.9	2.9	1.8
4.2	11.6	8.4		4.9			7.9	6.9	-7.8	-5.7	-6.8
-6.0	0.1 11.0	13.1		-5.2 3.3			-0.8	-2.3	-4.2 35.2	-8.5 38.9	-6.3 37.0
2.5 10.7	21.1	0.1 19.3		12.0			13.6 4.0	10.2 6.4	-4.5	-2.1	-3.4
11.0	25.2	23.4		12.9			11.6	12.0	11.8	6.0	8.9
13.6	31.9	28.3		16.2			12.4	13.6	0.1	-2.3	-1.0
14.9	20.8	25.8		16.0			16.6	16.4	-2.3	-6.5	-4.2
12.5 10.8	9.3 11.7	19.0 25.8		12.1 11.2			10.5 12.2	11.0	6.7	6.5 -0.3	6.6 0.9
10.8	3.1	25.8		9.9			12.2	11.8 4.5	1.9 3.2	-0.3 1.6	2.4
9.2	3.3	13.9		8.4			18.4	14.9	-4.1	-5.4	-4.7
7.8	1.7	6.6		6.9			5.1	5.7	5.1	5.5	5.3
4.3	2.4	1.5		4.0			1.7	2.5	8.0	4.3	6.3
5.4 8.8	4.3 -1.9	5.7 2.7		5.3 7.3			8.2 7.6	7.2 7.5	1.7 21.6	0.8 16.7	1.3 19.4
7.0 -3.5	-1.1 1.9	0.9 9.0		5.9 -2.6			11.8 8.9	9.8 5.2	5.4 3.9	6.9 2.1	6.1 3.1
	***				age Share of Tota						
27.6	1.3	0.1		29.0			31.6	60.6			39.4
27.9 27.5	1.3 1.2	0.1 0.1		29.2 28.8			32.1 33.4	61.4 62.2			38.6 37.8
27.5	1.5	0.1		29.5			35.2	64.7			35.3
28.8	1.7	0.1		30.7			36.7	67.4			32.6
28.6	1.8	0.2		30.6			39.4	70.1			29.9
28.1	1.9	0.2		30.2			40.0	70.2			29.8
25.5	1.8	0.2		27.6			43.5	71.1	15.2	13.8	28.9
23.1 22.1	2.1 2.3	0.2 0.2		25.5 24.6			45.4 46.7	70.9 71.3	15.1 14.7	14.1 14.0	29.1 28.7
22.3	2.5						49.0	74.0			26.0
22.3 21.7	2.5 2.5	0.2 0.3		25.0 24.6			49.0 50.2	74.0 74.8	13.2 13.1	12.8 12.1	26.0 25.2
19.0	2.4	0.2		21.7			48.8	70.5	15.1	14.4	29.5
20.3	2.8	0.3		23.4			49.0	72.4	13.9	13.6	27.6
20.3	3.2	0.3		23.8			49.2	73.0	14.0	13.0	27.0
21.0	3.8	0.4		25.2			50.4	75.6	12.8	11.6	24.4
21.7 22.2	4.1 4.1	0.4 0.5		26.3 26.7			52.8 53.0	79.1 79.7	11.2 10.9	9.7 9.4	20.9 20.3
22.4	4.2	0.5		27.1			54.2	81.3	10.1	8.6	18.7
23.9	4.1	0.6		28.6			53.0	81.6	10.0	8.3	18.4
23.4	3.9	0.6		27.9			56.4	84.3	8.6	7.1	15.7
	3.7	0.6		28.2			56.1	84.3	8.6	7.1	15.7
23.9							55.3	83.8	9.0	7.2	16.2
24.2	3.7 3.6	0.6 0.6		28.5 28.2							
	3.7 3.6 3.2	0.6 0.6 0.6		28.2 27.7			56.4 55.5	84.6 83.2	8.6 9.6	6.8	15.4 16.8
24.2 24.0	3.6	0.6		28.2			56.4	84.6	8.6	6.8	15.4

f: forecast.

* Confidentiality precludes reporting provincial-level insurance data.

Table B N.B.—Total

12.0 13.0 14.1 13.5 13.1

13.3 13.6 13.8 14.1 14.1

14.3 13.9 15.9 15.9 16.4

16.8 16.8 17.5 18.0 17.5

17.6 17.1 17.0 16.8 17.1

17.6 17.6 N.B.

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, New Brunswick, 1985 to 2011 (cont'd)

Share of Drugs in Public, Private and
All Drugs Health Expenditure Total Health Expenditures
Public Private Total Public Private Total Public Private Total

	Public	Private	Total	Public	Private	Total	Public	Private To
	rubiic	Filvate	iotai	rublic	riivate	iotai	rubiic	Private To
Year			(\$ Million	••)			(Percenta	es Chara)
	-		•	•				
1985	35.7	87.2	122.9	752.2	274.1	1,026.2	4.7	31.8
1986 1987	41.5 48.4	100.4 119.7	142.0 168.1	805.3 888.9	285.9 305.1	1,091.1 1,194.0	5.2 5.4	35.1 39.2
1988	51.4	122.9	174.3	961.0	330.5	1,291.5	5.3	37.2
1989	56.0	126.7	182.8	1,047.7	352.4	1,400.1	5.3	36.0
1990 1991	62.4 67.0	141.2 154.9	203.7 221.9	1,136.1	397.4 442.4	1,533.5	5.5	35.5 35.0
1991	64.8	170.1	234.9	1,186.9 1,233.1	466.7	1,629.3 1,699.8	5.6 5.3	36.4
1993	62.5	182.8	245.3	1,236.1	503.0	1,739.1	5.1	36.3
1994	62.3	191.2	253.5	1,272.2	520.8	1,793.0	4.9	36.7
1995	65.4	195.6	261.0	1,323.0	496.4	1,819.3	4.9	39.4
1996 1997	61.9 64.0	190.3 231.0	252.2 295.0	1,325.3	488.4 551.4	1,813.7 1,857.2	4.7 4.9	39.0 41.9
1998	71.6	233.8	305.5	1,305.7 1,370.6	553.6	1,924.2	5.2	42.2
1999	80.8	258.7	339.5	1,469.5	607.0	2,076.5	5.5	42.6
2000	94.0	278.4	372.3	1,580.0	638.6	2,218.6	5.9	43.6
2001	109.0	305.8	414.7	1,740.0	727.8	2,467.8	6.3	42.0
2002 2003	122.2 135.9	334.6 364.8	456.7 500.7	1,829.1	786.5 840.9	2,615.6 2,788.5	6.7 7.0	42.5 43.4
2004	149.3	371.8	521.1	1,947.6 2,115.3	864.5	2,768.5	7.0	43.0
2005	161.9	418.2	580.0	2,309.8	984.2	3,294.0	7.0	42.5
2006	173.0	439.7	612.7	2,526.9	1,054.7	3,581.6	6.8	41.7
2007 2008	180.0 189.4	451.7 481.7	631.6 671.1	2,647.5 2,841.7	1,075.5 1,141.6	3,723.0 3,983.2	6.8 6.7	42.0 42.2
2009	203.3	530.4	733.7	3,005.4	1,296.9	4,302.3	6.8	40.9
2010 ^f	215.4	585.9	801.3	3,165.3	1,384.9	4,550.2	6.8	42.3
2011 ^f	209.7	630.3	840.0	3,266.2	1,518.0	4,784.2	6.4	41.5
			(Annual Percenta	ge Change)		-		
1985								
1986	16.4	15.2	15.6	7.1	4.3	6.3		
1987	16.4	19.2	18.4	10.4	6.7	9.4		
1988	6.3	2.7	3.7	8.1	8.3	8.2		
1989	9.1	3.1	4.8	9.0	6.6	8.4		
1990	11.4	11.5	11.4	8.4	12.8	9.5		
1991	7.4	9.6	9.0	4.5	11.3	6.2		
1992	-3.4	9.8	5.8	3.9	5.5	4.3		
1993	-3.5	7.4	4.4	0.2	7.8	2.3		
1994	-0.4	4.6	3.3	2.9	3.5	3.1		
1995	4.9	2.3	3.0	4.0	-4.7	1.5		
1996	-5.2	-2.7	-3.3	0.2	-1.6	-0.3		
1997	3.3	21.4	17.0	-1.5	12.9	2.4		
1998	12.0	1.2	3.5	5.0	0.4	3.6		
1999	12.9	10.6	11.1	7.2	9.6	7.9		
2000	16.2	7.6	9.7	7.5	5.2	6.8		
2001	16.0	9.8	11.4	10.1	14.0	11.2		
2002	12.1	9.4	10.1	5.1	8.1	6.0		
2003	11.2	9.0	9.6	6.5	6.9	6.6		
2004	9.9	1.9	4.1	8.6	2.8	6.9		
2005	8.4	12.5	11.3	9.2	13.8	10.5		
2006	6.9	5.1	5.6	9.4	7.2	8.7		
2007	4.0	2.7	3.1	4.8	2.0	3.9		
2008	5.3	6.6	6.3	7.3	6.1	7.0		
2009	7.3	10.1	9.3	5.8	13.6	8.0		
2010 ^f	5.9	10.5	9.2	5.3	6.8	5.8		
2011 ^f	-2.6	7.6	4.8	3.2	9.6	5.1		
	(Percentage S	Share of Total Drug Ex	(penditure)					
1985	29.0	71.0	100.0					
1986	29.2	70.8	100.0					
1987	28.8	71.2	100.0					
1988	29.5	70.5	100.0					
1989	30.7	69.3	100.0					
1990	30.6	69.4	100.0					
1991	30.2	69.8	100.0					
1992	27.6	72.4	100.0					
1993 1994	25.5	74.5	100.0					
1994	24.6	75.4	100.0					
1995	25.0	75.0	100.0					
1996	24.6	75.4	100.0					
1997	21.7	78.3	100.0					
1998	23.4	76.6	100.0					
1999	23.8	76.2	100.0					
2000	25.2	74.8	100.0					
2001	26.3	73.7	100.0					
2002	26.7	73.3	100.0					
2003	27.1	72.9	100.0					
2004	28.6	71.4	100.0					
2005	27.9	72.1	100.0					
2006	28.2	71.8	100.0					
2007	28.5	71.5	100.0					
2008	28.2	71.8	100.0					
2009	27.7	72.3	100.0					
2010 ^f	26.9	73.1	100.0					
2011 ^f	25.0	75.0	100.0					

f: forecast.

Table B N.B.—Per Capita

N.B.

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, New Brunswick, 1985 to 2011

-		Public		Prescribed	Drugs	Private				Prescribed Dru	
Provincial	Federal	Social Security WCBs Drug	Funds Insurance Funds	Subtotal Public	Insurers*	Out of Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	ete (Out of Pock Personal Health Supplies	Total Non-Presc. Drugs
		(Premiu	m Component)		(\$ per Ca	nita)			Drugs		
46.80	2.29	0.19		49.28	(ψ ρει ου		53.60	102.88			66.8
54.59	2.46	0.22		57.26			62.92	120.18			75.5
63.50	2.68	0.25		66.43			77.12	143.55			87.3
66.43	3.63	0.30		70.36			84.01	154.37			84.3
71.66	4.23	0.34		76.23			91.22	167.45			81.1
78.82	4.99	0.53		84.34			108.44	192.78			82.4
83.75	5.57	0.59		89.90			119.11	209.01	47.57	42.20	88.6 90.7
80.19 75.83	5.66 6.92	0.73 0.75		86.57 83.50			136.60 148.60	223.17 232.11	47.57 49.37	43.20 46.09	95.4
74.59	7.64	0.79		83.03			157.80	240.84	49.72	47.33	97.0
77.65	8.52	0.86		87.02			170.11	257.14	45.80	44.57	90.3
72.83	8.51	0.97		82.31			168.45	250.76	43.79	40.72	84.5
74.59	9.45	0.97		85.01			191.27	276.28	59.18	56.54	115.7
82.80	11.47	1.16		95.43			199.42	294.85	56.66	55.47	112.1
91.89	14.36	1.43		107.68			222.50	330.18	63.36	58.77	122.1
104.41	18.94	1.84		125.19			250.06	375.25	63.43	57.44	120.8
120.09	22.90	2.31		145.31			291.92	437.23	62.06	53.78	115.8
135.05 149.49	25.01 27.91	2.75 3.46		162.81 180.86			322.44 361.25	485.25 542.11	66.19 67.38	57.25 56.99	123.4 124.3
165.45	28.74	4.33		198.52			367.17	565.69	69.43	57.81	124.3
180.77 196.29	29.73 30.47	4.93 5.30		215.43 232.05			435.23 460.87	650.66 692.93	66.65 70.61	54.72 58.18	121.3 128.7
204.81	31.21	5.38		241.39			468.93	710.33	76.24	60.69	136.9
215.47	32.47	5.68		253.62			506.53	760.15	77.37	61.04	138.4
233.78	31.76	5.81		271.35			543.11	814.46	93.75	70.99	164.7
249.38	31.30	5.84		286.52			605.22	891.74	98.51	75.66	174.1
240.48	31.86	6.37		278.70			658.22	936.92	102.23	77.18	179.
					Annual Percenta	ge Change)					
16.6	7.4	14.3		16.2			17.4	16.8			13.
16.3	8.9 35.6	15.5 18.1		16.0 5.9			22.6 8.9	19.4 7.5			15. -3.
4.6 7.9	16.6	14.8		8.3			8.6	8.5			-3.
10.0 6.3	17.8 11.6	55.5 10.4		10.6 6.6			18.9 9.8	15.1 8.4			1. 7.
-4.3	1.6	24.3		-3.7			14.7	6.8			2
-5.4	22.4	3.6		-3.5			8.8	4.0	3.8	6.7	5.
-1.6	10.4	5.2		-0.6			6.2	3.8	0.7	2.7	1.
4.1	11.5	8.3		4.8			7.8	6.8	-7.9	-5.8	-6
-6.2	-0.1	12.9		-5.4			-1.0	-2.5	-4.4	-8.6	-6
2.4 11.0	11.0 21.4	0.1 19.6		3.3 12.3			13.5 4.3	10.2 6.7	35.1 -4.3	38.8 -1.9	36. -3.
11.0	25.2	23.4		12.8			11.6	12.0	11.8	5.9	-3.
13.6 15.0	31.9 20.9	28.3 25.9		16.3 16.1			12.4 16.7	13.6 16.5	0.1 -2.2	-2.3 -6.4	-1. -4.
12.5	9.2	18.9		12.0			10.5	11.0	6.7	6.5	6.
10.7	11.6	25.7		11.1			12.0	11.7	1.8	-0.5	0.
10.7	3.0	25.0		9.8			1.6	4.4	3.0	1.5	2.
9.3	3.4	14.0		8.5			18.5	15.0	-4.0	-5.4	-4
8.6	2.5	7.4		7.7			5.9	6.5	5.9	6.3	6
4.3	2.4	1.5		4.0			1.7	2.5	8.0	4.3	6.
5.2	4.1	5.5		5.1			8.0	7.0	1.5	0.6	1
8.5	-2.2	2.3		7.0			7.2	7.1	21.2	16.3	19
6.7	-1.5	0.6		5.6			11.4	9.5	5.1	6.6	5
-3.6	1.8	8.9		-2.7			8.8	5.1	3.8	2.0	3
			(Annual I	ercentage Cha	nge in Excess of	Inflation in the	Canadian Econ	omy) 			-
13.8	4.6	11.5		13.4			14.6	14.0			10
11.6	4.2	10.7		11.3			17.8	14.7			10
0.1	31.1	13.6		1.4			4.4	3.0			-8
3.3	12.0	10.3		3.8			4.0	3.9			-1
7.0	14.8	52.5		7.6			15.8	12.1			-
3.5	8.9	7.6		3.8			7.1	5.7			4
-5.5 -6.9	0.3 21.0	23.0 2.2		-5.0 -5.0			13.4 7.3	5.5 2.6	2.3	5.3	1
-0.9	9.3	4.1		-1.7			5.1	2.7	-0.4	1.6	0
1.8 -7.9	9.1 -1.8	6.0 11.2		2.5 -7.1			5.5 -2.7	4.4 -4.2	-10.2 -6.1	-8.2 -10.3	9- 8-
1.4	10.0	-0.9		2.3			12.6	9.2	34.2	37.9	35
11.4	21.8	20.1		12.7			4.7	7.2	-3.8	-1.5	-2
9.2	23.4	21.5		11.0			9.8	10.2	10.0	4.1	7
9.5	27.8	24.2		12.2			8.3	9.5	-4.0	-6.4	-5
5.0	19.6	24.6		14.7			15.4	15.2	-3.5	-7.7	-5
13.7	8.2	17.9		11.0			9.4	9.9	5.6	5.4	5
13.7 11.4	8.7	22.8		8.2			9.1	8.8	-1.1	-3.4	
11.4 7.8		22.4		7.2			-0.9	1.8	0.5	-1.1	-4
11.4	0.4										
11.4 7.8 8.1 6.2	0.4	11.0		5.5			15.5	12.0	-7.0	-8.4	
11.4 7.8 8.1 6.2 5.8	0.4 -0.3	11.0 4.6		4.9			3.1	3.7	3.1	3.5	3
11.4 7.8 8.1 6.2 5.8 0.7	0.4 -0.3 -1.3	11.0 4.6 -2.1		4.9 0.3			3.1 -1.9	3.7 -1.2	3.1 4.3	3.5 0.6	3
11.4 7.8 8.1 6.2 5.8	0.4 -0.3	11.0 4.6		4.9			3.1	3.7	3.1	3.5	-7 3 2 -3 21
11.4 7.8 8.1 6.2 5.8 0.7 0.3	0.4 -0.3 -1.3 -0.8	11.0 4.6 -2.1 0.6		4.9 0.3 0.2			3.1 -1.9 3.2	3.7 -1.2 2.1	3.1 4.3 -3.4	3.5 0.6 -4.3	3 2 -3

* Confidentiality precludes reporting provincial-level insurance data.

Table B N.B.—Per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, New Brunswick, 1985 to 2011 (cont'd)

		All Davino			Joolth Evnonditure		GDP Implicit Price Index—Canada
	Public	All Drugs Private	Total	Public	Health Expenditure Private	Total	Price index—Canada
Year			(\$ per 0	Capita)			(1997 = 100)
1985	49.28	120.48	169.76	1,039.37	378.68	1,418.05	73.6
1986 1987	57.26 66.43	138.51 164.45	195.77 230.88	1,110.46 1,221.26	394.24 419.14	1,504.71 1,640.40	75.6 79.2
1988	70.36	168.31	238.67	1,315.80	452.46	1,768.26	82.8
1989	76.23	172.34	248.57	1,425.04	479.28	1,904.32	86.6
1990	84.34	190.84	275.18	1,535.00	536.96	2,071.96	89.2
1991	89.90	207.73	297.63	1,592.01	593.38	2,185.39	91.6
1992	86.57	227.37	313.94	1,648.30	623.91	2,272.21	92.8
1993 1994	83.50 83.03	244.07 254.85	327.57 337.88	1,650.79 1,695.79	671.67 694.18	2,322.46 2,389.97	94.1 95.2
1995 1996	87.02 82.31	260.48 252.96	347.50 335.27	1,761.67 1,761.66	660.95 649.20	2,422.62 2,410.86	97.4 99.0
1997	85.01	306.99	392.00	1,735.08	732.76	2,467.84	100.0
1998	95.43	311.55	406.98	1,826.14	737.64	2,563.77	99.6
1999	107.68	344.63	452.31	1,957.71	808.66	2,766.37	101.4
2000	125.19	370.93	496.12	2,105.17	850.90	2,956.07	105.5
2001	145.31	407.76	553.07	2,320.35	970.56	3,290.91	106.9
2002 2003	162.81 180.86	445.88 485.62	608.69 666.48	2,437.73 2,592.58	1,048.19 1,119.37	3,485.93 3,711.94	108.1 111.2
2004	198.52	494.42	692.94	2,812.70	1,149.59	3,962.29	114.1
2005	215.43	556.60	772.03	3,074.33	1,309.94	4,384.27	117.5
2006	232.05	589.67	821.72	3,388.73	1,414.38	4,803.11	120.8
2007	241.39	605.86	847.26	3,551.24	1,442.58	4,993.82	125.2
2008 2009	253.62 271.35	644.95 707.85	898.57 979.20	3,804.63 4,010.78	1,528.39 1,730.77	5,333.01 5,741.55	131.3 127.8
2010 [†] 2011 [†]	286.52 278.70	779.38 837.64	1,065.90 1,116.34	4,210.50 4,340.71	1,842.26 2,017.37	6,052.75 6,358.08	131.5 136.8
2011	210.10	037.04	1,110.34			0,350.06	130.8
1985				(Annual Percentage Cl	nange)		
1986	16.2	15.0	15.3	6.8	4.1	6.1	2.8
1987	16.0	18.7	17.9	10.0	6.3	9.0	4.7
1988	5.9	2.4	3.4	7.7	7.9	7.8	4.5
1989	8.3	2.4	4.1	8.3	5.9	7.7	4.6
1990	10.6	10.7	10.7	7.7	12.0	8.8	3.0
1991 1992	6.6 -3.7	8.9 9.5	8.2 5.5	3.7 3.5	10.5 5.1	5.5 4.0	2.8 1.3
1993	-3.5	7.3	4.3	0.2	7.7	2.2	1.4
1994	-0.6	4.4	3.1	2.7	3.4	2.9	1.1
1995	4.8	2.2	2.8	3.9	-4.8	1.4	2.3
1996	-5.4	-2.9	-3.5	0.0	-1.8	-0.5	1.7
1997 1998	3.3 12.3	21.4 1.5	16.9 3.8	-1.5 5.2	12.9 0.7	2.4 3.9	1.0 -0.4
1999	12.8	10.6	11.1	7.2	9.6	7.9	1.8
2000	16.3	7.6	9.7	7.5	5.2	6.9	4.1
2001	16.1	9.9	11.5	10.2	14.1	11.3	1.4
2002	12.0	9.3	10.1	5.1	8.0	5.9	1.0
2003	11.1	8.9	9.5	6.4	6.8	6.5	2.9
2004	9.8	1.8	4.0	8.5	2.7	6.7	2.6
2005 2006	8.5 7.7	12.6 5.9	11.4 6.4	9.3 10.2	13.9 8.0	10.6 9.6	3.0 2.8
2006	4.0	2.7	3.1	4.8	2.0	9.6 4.0	3.7
2008	5.1	6.5	6.1	7.1	5.9	6.8	4.9
2009	7.0	9.8	9.0	5.4	13.2	7.7	-2.7
2010 ^f	5.6	10.1	8.9	5.0	6.4	5.4	2.9
2011	-2.7	7.5	4.7	3.1	9.5	5.0	4.0
1985		(Annual Percentage	Change in Excess	of Inflation in the Canad	dian Economy)		
1986	13.4	12.2	12.5	4.0	1.3	3.3	
1987	11.3	14.0	13.2	5.2	1.6	4.3	
1988	1.4	-2.2	-1.1	3.2	3.4	3.3	
1989	3.8	-2.2	-0.4	3.7	1.4	3.1	
1990	7.6	7.7	7.7	4.7	9.0	5.8	
1991 1992	3.8 -5.0	6.1 8.2	5.4 4.2	1.0 2.3	7.7 3.9	2.7 2.7	
1993	-5.0	5.9	2.9	-1.3	6.2	0.8	
1994	-1.7	3.3	2.0	1.6	2.3	1.8	
1995	2.5	-0.1	0.5	1.5	-7.1	-1.0	
1996	-7.1	-4.6	-5.2	-1.7	-3.4	-2.2	
1997 1998	2.3 12.7	20.4 1.9	15.9 4.3	-2.5 5.7	11.9 1.1	1.4 4.3	
1999	11.0	8.8	9.3	5.7	7.8	6.1	
2000	12.2	3.5	5.6	3.4	1.1	2.8	
2001	14.7	8.6	10.1	8.9	12.7	10.0	
2002	11.0	8.3	9.0	4.0	7.0	4.9	
2003 2004	8.2 7.2	6.0 -0.8	6.6 1.4	3.5 5.9	3.9 0.1	3.6 4.2	
2005 2006	5.5 4.9	9.6 3.1	8.4 3.6	6.3 7.4	10.9 5.2	7.6 6.8	
2007	0.3	-0.9	-0.6	1.1	-1.7	0.3	
2008	0.2	1.6	1.2	2.3	1.1	1.9	
2009	9.7	12.5	11.7	8.1	15.9	10.4	
2010 ^f	2.6	7.2	5.9	2.0	3.5	2.5	
2011 ^f	-6.7	3.5	0.7	-0.9	5.5	1.1	
6.6						NI-C	111 B-1-1

N.B.

f: forecast.

Table B Que.—Total

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, Quebec, 1985 to 2011

					Prescribed	d Drugs					Prescribed Dr	
	Provincial	Federal	Public Social Sec	urity Funds	Subtotal	Insurers*	Private Out of	Subtotal	Total	Over-	ete (Out of Poc Personal	ket) Total
		_	WCBs	Drug Insurance Funds	Public		Pocket	Private	Prescribed Drugs	the- Counter	Health Supplies	Non-Presc. Drugs
Year			(Pr	emium Component)		(\$ Millior	ns)			Drugs		
1985	250.4	7.4	2.1		260.0			342.6	602.6			230.5
1986	291.2	8.1	2.7		301.9			463.0	764.9			261.0
1987	333.8	8.8	3.2		345.8			466.6	812.4			302.7
1988 1989	384.1 437.1	10.7 12.8	3.2 3.5		398.0 453.4			523.3 582.4	921.4 1,035.8			366.9 444.8
1990 1991	502.9 604.0	15.3 16.7	4.2 4.9		522.4 625.6			638.9 709.4	1,161.2 1,335.0			468.3 534.5
1992	650.5	18.1	5.1		673.7			770.9	1,444.6	306.5	264.2	570.7
1993	686.1	21.1	5.0		712.3			882.3	1,594.6	312.4	280.8	593.1
1994	742.1	23.0	5.6		770.7			898.5	1,669.2	326.8	306.6	633.4
1995	807.0	24.1	6.3		837.4			1,005.9	1,843.3	334.4	314.5	649.0
1996 1997	733.4 700.3	24.0 26.0	6.9 7.4	169.1	764.3 902.7			1,079.9 1,227.2	1,844.1 2,129.9	322.1 293.5	314.6 294.6	636.7 588.1
1997	779.8	29.5	8.1	213.4	1,030.8			1,227.2	2,129.9	312.2	316.7	628.9
1999	918.6	34.4	9.3	262.4	1,224.7			1,433.5	2,658.2	334.1	332.4	666.6
2000	1,118.4	35.0	11.1	327.8	1,492.4			1,612.8	3,105.2	321.2	324.3	645.4
2001	1,309.4	38.4	13.5	367.4	1,728.6			1,752.2	3,480.8	337.0	331.7	668.7
2002	1,439.5	44.7	15.4	433.2	1,932.8			1,968.7	3,901.6	347.1	340.6	687.6
2003 2004	1,538.9 1,678.1	50.7 53.5	18.0 21.1	577.8 615.5	2,185.4 2,368.2			2,130.9 2,357.0	4,316.3 4,725.2	350.7 371.7	340.4 352.4	691.0 724.1
2005 2006	1,798.7 1,955.6	57.3 62.2	23.0 26.4	618.7 669.0	2,497.8 2,713.1			2,492.4 2,706.9	4,990.2 5,420.1	426.3 439.4	385.1 399.1	811.4 838.5
2006	2,164.9	66.2	29.6	712.1	2,713.1			2,706.9	5,866.6	464.2	402.4	866.6
2008	2,297.2	71.1	32.8	774.7	3,175.8			3,017.1	6,192.9	491.7	421.8	913.5
2009	2,443.5	69.5	36.1	744.0	3,293.0			3,195.2	6,488.2	538.5	440.9	979.4
2010 ^f	2,460.6	68.4	38.7	779.0	3,346.7			3,553.4	6,900.1	537.4	444.4	981.8
2011 ^f	2,395.5	69.7	42.0	793.5	3,300.7			3,970.9	7,271.7	525.8	443.1	968.9
						(Annual Percenta	ge Change)					
1985 1986	16.3	8.4	27.3		16.1			35.1	26.9			13.2
1987	14.6	9.1	19.2		14.5			0.8	6.2			16.0
1988	15.1	21.6	1.0		15.1			12.2	13.4			21.2
1989	13.8	20.0	7.2		13.9			11.3	12.4			21.2
1990	15.0	19.2	20.8		15.2			9.7	12.1			5.3
1991	20.1	9.4	16.6		19.8			11.0	15.0			14.1
1992 1993	7.7 5.5	8.2 16.7	3.3 -0.1		7.7 5.7			8.7 14.4	8.2 10.4		6.3	6.8 3.9
1993	8.2	8.7	11.7		8.2			1.8	4.7	1.9 4.6	9.2	6.8
1995 1996	8.7 -9.1	5.0 -0.7	12.1 9.7		8.7 -8.7			11.9 7.4	10.4 0.0	2.3 -3.7	2.6 0.0	2.5 -1.9
1997	-4.5	8.5	6.2		18.1			13.6	15.5	-8.9	-6.4	-7.6
1998	11.4	13.4	10.0	26.2	14.2			0.1	6.1	6.4	7.5	6.9
1999	17.8	16.6	15.1	23.0	18.8			16.7	17.7	7.0	5.0	6.0
2000	21.8	1.9	19.7	24.9	21.9			12.5	16.8	-3.9	-2.5	-3.2
2001	17.1	9.6	20.8	12.1	15.8			8.6	12.1	4.9	2.3	3.6
2002 2003	9.9 6.9	16.6 13.4	14.3 17.1	17.9 33.4	11.8 13.1			12.4 8.2	12.1 10.6	3.0 1.0	2.7 -0.1	2.8 0.5
2004	9.0	5.5	17.3	6.5	8.4			10.6	9.5	6.0	3.5	4.8
2005	7.2	7.0	9.0	0.5	5.5			5.7	5.6	14.7	9.3	12.1
2006	8.7	8.6	14.7	8.1	8.6			8.6	8.6	3.1	3.6	3.3
2007	10.7	6.4	11.9	6.4	9.6			6.9	8.2	5.6	0.8	3.3
2008 2009	6.1 6.4	7.5 -2.3	10.8 10.1	8.8 -4.0	6.8 3.7			4.3 5.9	5.6 4.8	5.9 9.5	4.8 4.5	5.4 7.2
2010 [†] 2011 ^f	0.7 -2.6	-1.6 1.9	7.4 8.6	4.7 1.9	1.6 -1.4			11.2 11.7	6.3 5.4	-0.2 -2.2	0.8 -0.3	0.2 -1.3
2011	-2.0	1.5	0.0	1.9		tage Share of Tota	l Drug Expend		5.4	*2.2	*0.3	-1.5
1985	30.1	0.9	0.3		31.2			41.1	72.3			27.7
1986	28.4	0.8	0.3		29.4			45.1	74.6			25.4
1987	29.9	0.8	0.3		31.0			41.8	72.9			27.1
1988 1989	29.8 29.5	0.8 0.9	0.3 0.2		30.9 30.6			40.6 39.3	71.5 70.0			28.5 30.0
1990 1991	30.9 32.3	0.9 0.9	0.3		32.1 33.5			39.2 37.9	71.3 71.4			28.7 28.6
1992	32.3	0.9	0.3		33.4			38.3	71.7	15.2	13.1	28.3
1993	31.4	1.0	0.2		32.6			40.3	72.9	14.3	12.8	27.1
1994	32.2	1.0	0.2		33.5			39.0	72.5	14.2	13.3	27.5
1995	32.4	1.0	0.3		33.6			40.4	74.0	13.4	12.6	26.0
1996	29.6	1.0	0.3		30.8			43.5	74.3	13.0	12.7	25.7
1997 1998	25.8 27.0	1.0 1.0	0.3	6.2 7.4	33.2 35.7			45.2 42.5	78.4 78.2	10.8 10.8	10.8 11.0	21.6 21.8
1998	27.6	1.0	0.3	7.4	36.8			42.5	80.0	10.0	10.0	20.0
	29.8	0.9	0.3	8.7	39.8			43.0	82.8		8.6	17.2
2000 2001	29.8 31.6	0.9	0.3	8.7	39.8 41.7			43.0 42.2	82.8 83.9	8.6 8.1	8.0	17.2
2002	31.4	1.0	0.3	9.4	42.1			42.2	85.0	7.6	7.4	15.0
2003	30.7	1.0	0.4	11.5	43.6			42.6	86.2	7.0	6.8	13.8
2004	30.8	1.0	0.4	11.3	43.5			43.3	86.7	6.8	6.5	13.3
2005	31.0	1.0	0.4	10.7	43.1			43.0	86.0	7.3	6.6	14.0
2006	31.2	1.0	0.4	10.7	43.4			43.3	86.6	7.0	6.4	13.4
2007 2008	32.2 32.3	1.0 1.0	0.4 0.5	10.6 10.9	44.1 44.7			43.0 42.5	87.1 87.1	6.9 6.9	6.0 5.9	12.9 12.9
2008	32.3 32.7	0.9	0.5	10.0	44.7			42.5	86.9	7.2	5.9	13.1
2010 ^f	31.2	0.9	0.5	9.9	42.5			45.1	87.5	6.8	5.6	12.5
2010 2011 ^f	31.2 29.1	0.9	0.5	9.9	42.5 40.1			45.1	87.5 88.2	6.4	5.6	12.5
f: forecast			2.0	2.0							J. 1	

f: forecast.
* Confidentiality precludes reporting provincial-level insurance data.

Table B Que.—Total

Que.

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, Quebec, 1985 to 2011 (cont'd)

Share of Drugs in Public, Private and Total Health Expenditures Health Expenditure Private All Drugs Public Total Public Total Public Total (\$ Millions) Year (Percentage Share) 260.0 301.9 573.1 724.0 7,927.6 8,051.3 2,104.4 2,486.1 27.2 29.1 8.3 9.7 1985 833.0 10,031.9 3.3 3.7 1986 1,025.9 10,537.4 1987 345.8 769.3 1,115.1 8,636.4 2,632.2 11,268.6 4.0 29.2 9.9 2,850.8 12,279.2 4.2 453.4 1,027.2 1,480.7 10,108.6 3,181.7 13,290.3 32.3 11.1 1989 1990 522.4 1,629.5 10,814.1 3,497.4 14,311.5 4.8 31.7 11.4 32.6 32.4 1991 625.6 1.243.8 1.869.5 11.815.3 3.819.3 15.634.6 5.3 12.0 2,015.3 12,234.5 5.5 5.7 1993 712.3 1,475.4 2,187.7 12,459.6 4,444.6 16,904.2 33.2 12.9 2,302.6 12,674.4 4,653.5 17,327.9 32.9 13.3 1995 1996 12,704.3 17,367.9 35.5 36.3 14.4 14.6 837.4 1,654.9 2,492.3 4,663.6 6.6 6.2 4,727.9 16,976.4 1997 902.7 1,815.2 2,717.9 13,033.2 4,976.0 18,009.2 6.9 36.5 15.1 1,030.8 1,857.3 2,100.1 2,888.0 3,324.8 14,123.0 14,456.5 5,050.8 5,616.8 19,173.7 36.8 37.4 1999 20,073.3 8.5 16.6 2000 1,492.4 2,258.3 3,750.6 15,699.7 5,967.7 21,667.5 36.6 37.2 36.8 17.6 18.4 18.8 2001 1.728.6 2,420.9 4.149.5 16.986.3 6.621.8 23,608.1 10.2 2002 2,656.4 2,822.0 4,589.2 5,007.4 17,862.7 18,908.0 7,141.6 7,671.7 25,004.4 10.8 11.6 2,185.4 26,579.6 2004 2,368.2 3,081.0 5,449.3 20,122.9 7,888.3 28,011.2 11.8 39.1 19.5 2.497.8 5.801.6 21,217,7 8.567.8 29.785.5 11.8 38.6 19.5 2005 3.303.8 2,713.1 2,972.7 6,258.6 6,733.2 9,109.1 9,561.5 38.9 39.3 19.8 20.1 3,545.4 22,527.1 31,636.2 2007 3,760.6 23,909.9 33,471.4 12.4 3,175.8 3,293.0 7,106.4 7,467.6 25,601.8 27,440.3 10,259.4 10,750.4 35,861.2 38,190.6 38.3 38.8 2008 3,930.6 12.4 19.8 4,174.6 19.6 3,346.7 3,300.7 2010^f 4,535.2 7,881.9 28,492.7 11,517.4 40,010.2 39.4 2011 29.554.6 12.371.6 11.2 19.7 4.939.8 8.240.6 41.926.2 39.9 (Annual Percentage Change) 5.0 16.1 1.6 26.3 23.2 18.1 1986 7.3 9.2 7.2 1987 14.5 15.1 6.3 15.5 9.0 1988 8.3 1989 13.9 15.4 14.9 8.2 7.7 1990 15.2 7.8 10.0 7.0 9.9 19.8 12.3 14.7 9.3 3.5 9.2 4.7 1992 7.9 7.8 8.4 1993 1994 5.7 8.2 10.0 8.6 5.3 1.8 1.7 7.3 4.7 3.2 2.5 1995 8.7 8.2 0.2 0.2 1.4 0.2 1996 -8.7 3.7 -0.5 -3.6 -2.3 1997 1998 18.1 14.2 5.7 2.3 9.6 6.4 8.4 5.2 1.5 6.1 6.5 6.3 1999 18.8 13.1 15.1 2.4 11.2 4.7 21.9 7.5 12.8 8.6 7.9 2000 6.2 15.8 11.8 10.6 10.6 8.2 5.2 11.0 7.9 9.0 5.9 2001 7.2 9.7 2002 13.1 8.4 6.2 9.2 5.9 6.4 7.4 2.8 6.3 5.4 2004 8.8 5.5 7.2 6.5 5.4 6.3 2005 8.6 8.6 9.6 6.8 2006 7.3 7.9 6.2 6.3 6.2 2007 6.1 4.5 5.0 7.3 5.8 7.1 2008 5.5 2009 3.7 6.2 5.1 7.2 4.8 6.5 4.8 4.8 2010 1.6 -1.4 8.6 5.5 3.8 3.7 7.1 7.4 2011^f 4.5 (Percentage Share of Total Drug Expenditure) 31.2 29.4 1985 68.8 100.0 70.6 1986 100.0 1987 31.0 69.0 100.0 30.9 30.6 69.1 69.4 100.0 1989 1990 32.1 67.9 100.0 1991 33.5 66.5 100.0 66.6 67.4 100.0 100.0 1993 32.6 1994 33.5 66.5 100.0 1995 33.6 66.4 100.0 1997 33.2 66.8 100.0 35.7 36.8 64.3 63.2 1999 100.0 2000 39.8 60.2 100.0 2001 41.7 58.3 100.0 57.9 56.4 56.5 42.1 2003 43.6 100.0 2004 43.5 100.0 56.9 2005 43.1 100.0 2006 2007 44.1 55.9 100.0 2008 44.7 55.3 100.0 44.1 55.9 2009 100.0 2010^f

2011^f f: forecast. 40.1

59.9

100.0

Table B Que.—Per Capita

Que.

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Quebec, 1985 to 2011

Prescribed Drugs

Non-Prescribed Drugs
Private (Out of Pocket) Public Private Over Provincial Federal Social Security Funds Subtotal Insurers' Subtotal Total Total WCBs Health Drug Insurance Public Pocket Private Prescribed the-Non-Presc. Funds Drugs Counter Supplies Drugs ium Component) Drugs Year (\$ per Capita) 1.12 1.20 1985 37.57 0.32 39.00 51.40 90.40 34.58 1986 43.40 45.00 69.01 1987 49.21 1.30 0.47 50.98 68.80 119.78 44.62 ---64.20 1989 63.09 1.85 0.50 65.44 84.06 149.50 1990 71.80 2.18 0.60 74.58 91.21 66.86 1991 85.50 2.37 0.69 88.56 100.41 188.97 75.65 1992 37.17 1993 95.89 2.95 0.71 99.55 123.31 222.86 43.65 39.24 82.89 103.18 3.20 42.63 89.89 87.86 1995 111.78 3.34 0.88 116.00 139.34 255.33 46.32 43.57 1996 3.31 149.01 1997 96.26 3.57 1.01 23.25 124.09 168.69 292.78 40.34 40.50 80.84 106.88 309.65 86.19 125.43 4.69 45.40 1999 1.27 35.84 167.23 195.75 362.98 45.62 91.02 152.02 422.07 87.73 2001 177.02 5.19 1.82 49.67 233.69 236.88 470.57 45.56 44.84 90.40 193.33 58.19 259.59 264.41 524.00 45.74 92.35 77.10 284.32 575.92 2003 205.33 6.77 291.60 2004 222.29 7.09 2.80 81.53 313.71 312.23 625.94 49.24 46.68 95.91 2005 236.74 7.54 3.03 81.43 328.74 328.03 656.77 56.11 50.68 106.79 710.22 109.87 2007 281.61 8.61 3.84 92.63 386.69 376.45 763.15 60.39 52.34 112.73 2008 296.37 9.18 4.23 99.95 409.72 389.23 798.95 63.43 54.42 117.85 8.88 4.61 95.04 420.65 125.10 2009 68.79 2010^f 8.65 4.90 98.52 872.62 2011^f 300.59 8.75 5.28 99.57 414.18 498.28 912.46 65.98 55.60 121.58 Percentage Change) 1985 1986 15.5 7.7 26.4 15.4 34.3 26.1 12.5 1988 14.1 20.6 0.1 14.1 11.2 12.5 20.2 1989 12.3 18.4 5.8 12.4 9.8 11.0 19.7 1990 13.8 17.9 19.5 14.0 8.5 10.9 4.1 1991 1992 7.0 7.6 2.6 7.0 8.0 7.5 6.1 15.9 8.2 5.0 7.6 13.7 5.6 8.6 -0.8 11.2 3.2 6.2 4.8 7.6 1.2 4.1 1994 1995 8.3 4.6 11.7 8.2 10.0 1996 -9.5 9.2 -9.1 6.9 -0.3 -4.1 -0.3 -2.3 8.0 13.1 -9.2 6.1 -6.7 7.2 1997 17.7 13.2 15.1 11.0 25.8 13.9 -0.2 6.6 1998 5.8 1999 17.4 16.2 14.6 22.5 18.4 16.3 17.2 6.6 4.6 5.6 21.2 24.3 21.3 -2.9 -3.6 2000 1.4 19.1 12.0 16.3 -4.3 2002 9.2 15.8 13.5 17.1 11.1 11.6 11.4 2.3 2.0 2.2 2004 8.3 4.7 16.4 5.8 7.6 9.8 8.7 5.2 2.8 4.0 6.5 11.3 2005 6.3 8.3 -0.1 4.8 14.0 8.6 2006 8.2 14.2 7.6 5.7 8.1 2.6 4.9 3.2 2.9 2.6 2007 2008 5.2 6.7 9.9 7.9 6.0 3.4 4.7 5.0 4.0 4.5 -0.3 -3.4 -2.6 1.1 3.7 1.1 2010^f 6.3 0.6 10.1 5.3 -1.2 -0.2 -0.8 -2.9 2011^f 7.8 10.9 (Annua ntage Change in Excess of Inflation in the Canadian Economy) 1985 1986 12.7 4.9 9.7 1987 8.7 3.2 13.1 8.5 -5.1 0.3 10.0 1988 9.6 7.8 16.0 13.9 -4.4 1.2 9.6 7.9 6.7 8.0 6.4 15.7 15.1 5.3 1989 10.8 14.9 10.9 5.5 7.9 10.4 1991 16.3 5.7 12.9 16.0 7.3 11.2 6.3 14.5 3.3 -0.2 1.8 1993 -2.2 3.6 12.3 8.2 1994 6.5 7.1 10.1 6.5 0.2 3.0 3.0 7.5 5.2 1995 6.0 2.2 9.3 5.9 9.2 7.7 -0.4 -0.1 -0.3 -11.1 -5.9 -10.8 16.7 -2.0 14.1 -5.7 -10.2 -3.9 -9.0 -2.7 7.0 1997 12.2 1998 11.5 13.5 10.1 26.3 14.3 0.2 6.2 6.5 7.6 7.1 3.8 1999 14.5 4.8 2000 17.1 -2.7 15.0 20.2 17.2 7.9 12.2 -8.4 -7.0 2001 15.1 7.6 14.8 18.8 10.1 13.9 6.7 10.1 3.0 0.4 1.7 2002 8.2 3.3 5.7 12.5 10.0 10.6 10.3 4.6 7.2 9.8 29.6 -2.5 2.6 -3.6 0.2 -3.1 1.4 7.0 6.1 2004 13.8 5.0 2005 3.5 5.3 8.3 -3.1 1.8 2.1 1.9 11.0 2006 5.4 5.3 11.4 4.8 5.3 5.3 5.3 -0.2 0.4 0.1 2007 0.2 2008 0.4 1.8 5.0 3.0 1.1 -1.5 -0.2 -0.9 -0.3 2009 8.0 -0.6 11.7 -2.2 5.4 7.6 6.4 11.2 6.2 8.9 2010^f -3.3 -5.5 3.3 0.7 -2.3 7.2 2.3 -4.1 -3.2 -3.7 2011^f -2.9 -6.1 -6.9

Confidentiality precludes reporting provincial-level insurance data.

Table B Que.—Per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Quebec, 1985 to 2011 (cont'd) GDP Implicit

		All Davido		u.	aalth Evnanditura		GDP Implicit Price Index—Canada
	Public	All Drugs Private	Total	Public	ealth Expenditure Private	Total	Frice index—Canada
Year			(\$ per Ca				(1997 = 100)
1985 1986	39.00 45.00	85.97 107.92	124.97 152.93	1,189.31 1,200.16	315.70 370.59	1,505.01 1,570.76	73.6 75.6
1987	50.98	113.42	164.40	1,273.33	388.08	1,661.41	79.2
1988	58.20	130.18	188.37	1,378.61	416.85	1,795.46	82.8
1989	65.44	148.26	213.70	1,458.95	459.21	1,918.16	86.6
1990	74.58	158.07	232.66	1,544.02	499.35	2,043.36	89.2
1991	88.56	176.07	264.62	1,672.46	540.63	2,213.09	91.6
1992	94.78	188.75	283.53	1,721.23	582.66	2,303.89	92.8
1993 1994	99.55 107.16	206.20 213.01	305.75 320.17	1,741.32 1,762.32	621.16 647.05	2,362.48 2,409.37	94.1 95.2
1995 1996	116.00 105.46	229.23 236.87	345.22 342.33	1,759.73 1,690.17	645.98 652.41	2,405.71 2,342.58	97.4 99.0
1997	124.09	249.53	373.62	1,791.60	684.03	2,475.62	100.0
1998	141.28	254.56	395.84	1,935.72	692.27	2,627.99	99.6
1999	167.23	286.77	454.00	1,974.04	766.97	2,741.01	101.4
2000	202.85	306.95	509.80	2,133.98	811.16	2,945.14	105.5
2001	233.69	327.28	560.97	2,296.37	895.20	3,191.58	106.9
2002 2003	259.59 291.60	356.76 376.53	616.35 668.13	2,399.05 2,522.85	959.16 1,023.61	3,358.21 3,546.46	108.1 111.2
2004	313.71	408.14	721.85	2,665.65	1,044.95	3,710.60	114.1
2005	328.74	434.82	763.56	2,792.53	1,127.63	3,920.16	117.5
2006	355.52	464.57	820.09	2,951.83	1,193.61	4,145.45	120.8
2007	386.69	489.18	875.88	3,110.26	1,243.78	4,354.05	125.2
2008	409.72	507.08	916.80	3,302.90	1,323.57	4,626.46	131.3
2009	420.65	533.26	953.92	3,505.24	1,373.26	4,878.50	127.8
2010 ^f	423.24	573.54	996.78	3,603.31	1,456.54	5,059.85	131.5
2011 ^r	414.18	619.86	1,034.04	3,708.56	1,552.41	5,260.97	136.8
				Annual Percentage Cha			
1985 1986	15.4	25.5	22.4	0.9	17.4	4.4	2.8
1987	13.3	25.5 5.1	7.5	6.1	4.7	5.8	4.7
1988	14.1	14.8	14.6	8.3	7.4	8.1	4.5
1989	12.4	13.9	13.4	5.8	10.2	6.8	4.6
1990	14.0	6.6	8.9	5.8	8.7	6.5	3.0
1991	18.7	11.4	13.7	8.3	8.3	8.3	2.8
1992	7.0	7.2	7.1	2.9	7.8	4.1	1.3
1993 1994	5.0 7.6	9.2 3.3	7.8 4.7	1.2 1.2	6.6 4.2	2.5 2.0	1.4 1.1
1995 1996	8.2 -9.1	7.6 3.3	7.8 -0.8	-0.1 -4.0	-0.2 1.0	-0.2 -2.6	2.3 1.7
1997	17.7	5.3	9.1	6.0	4.8	5.7	1.0
1998	13.9	2.0	5.9	8.0	1.2	6.2	-0.4
1999	18.4	12.7	14.7	2.0	10.8	4.3	1.8
2000	21.3	7.0	12.3	8.1	5.8	7.4	4.1
2001	15.2	6.6	10.0	7.6	10.4	8.4	1.4
2002 2003	11.1 12.3	9.0	9.9 8.4	4.5 5.2	7.1 6.7	5.2 5.6	1.0 2.9
2004	7.6	5.5 8.4	8.0	5.2	2.1	4.6	2.9
2005 2006	4.8 8.1	6.5 6.8	5.8 7.4	4.8 5.7	7.9 5.9	5.6 5.7	3.0 2.8
2007	8.8	5.3	6.8	5.4	4.2	5.0	3.7
2008	6.0	3.7	4.7	6.2	6.4	6.3	4.9
2009	2.7	5.2	4.0	6.1	3.8	5.4	-2.7
2010 ^f	0.6	7.6	4.5	2.8	6.1	3.7	2.9
2011	-2.1	8.1	3.7	2.9	6.6	4.0	4.0
1985		(Annual Percentage	Change in Excess of	Inflation in the Canadi	ian Economy)		
1986	12.6	22.7	19.6	-1.9	14.6	1.6	
1987	8.5	0.4	2.8	1.4	0.0	1.0	
1988	9.6	10.3	10.1	3.7	2.9	3.5	
1989	7.9	9.3	8.9	1.3	5.6	2.3	
1990	10.9	3.6	5.8	2.8	5.7	3.5	
1991 1992	16.0 5.8	8.6 5.9	11.0 5.9	5.6 1.7	5.5 6.5	5.5 2.8	
1993	3.6	7.8	6.4	-0.3	5.2	1.1	
1994	6.5	2.2	3.6	0.1	3.1	0.9	
1995	5.9	5.3	5.5	-2.5	-2.5	-2.5	
1996	-10.8	1.7	-2.5	-5.6	-0.7	-4.3	
1997	16.7	4.4	8.1	5.0	3.9	4.7	
1998 1999	14.3 16.6	2.5 10.8	6.4 12.9	8.5 0.2	1.6 9.0	6.6 2.5	
2000 2001	17.2 13.9	2.9 5.3	8.2 8.7	4.0 6.3	1.7 9.0	3.3 7.0	
2002	10.0	8.0	8.8	3.4	6.1	4.2	
2003	9.4	2.6	5.5	2.3	3.8	2.7	
2004	5.0	5.8	5.5	3.1	-0.5	2.0	
2005	1.8	3.5	2.8	1.8	4.9	2.6	
2006	5.3	4.0	4.6	2.9	3.1	3.0	
2007 2008	5.1 1.1	1.6 -1.2	3.1 -0.2	1.7 1.3	0.5 1.5	1.4 1.4	
2009	5.4	7.9	6.8	8.8	6.5	8.2	
2010 ^f	-2.3	4.6	1.5	-0.1	3.1	0.8	
2011 ^f	-6.1	4.1	-0.3	-1.1	2.6	0.0	
						Negovo	

Que

Table B Ont.—Total

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, Ontario, 1985 to 2011

			Public		Prescribed	Drugs	Private				Prescribed Druate (Out of Poc	
	Provincial	Federal	Social Security WCBs Drug	Funds Insurance Funds	Subtotal Public	Insurers*	Out of Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	Personal Health Supplies	Total Non-Presc. Drugs
Year			(Premiu	m Component)		(\$ Million	ns)			Drugs		
1985	399.4	13.8	7.2		420.5			579.4	999.9			487.9
1986	481.2	14.5	8.8		504.5			706.8	1,211.2			552.4
1987 1988	574.4 663.8	15.4 24.5	10.1 12.0		599.9 700.4			748.2 845.3	1,348.1 1,545.6			640.6 711.0
1989	749.5	30.7	13.5		793.8			951.9	1,745.7			789.2
1990	881.2	36.2	16.2		933.6			1,089.7	2,023.3			816.5
1991	1,012.7	37.9	20.2		1,070.8			1,201.1	2,271.9			883.5
1992 1993	1,183.6	41.0	23.3		1,247.8			1,376.9	2,624.8	521.5	455.3	976.7
1993	1,248.0 1,235.8	46.7 50.7	24.2 18.5		1,318.9 1,305.1			1,482.1 1,508.7	2,801.0 2,813.7	558.9 616.3	478.5 516.1	1,037.5 1,132.4
1995	1,379.6	52.9	19.5		1,452.0			1,660.0	3,112.0	615.7	528.8	1,144.5
1996	1,362.7	53.9	21.6		1,432.0			1,735.3	3,173.5	641.2	540.5	1,181.7
1997	1,407.6	57.6	22.3		1,487.5			2,103.4	3,590.9	710.3	603.4	1,313.7
1998 1999	1,550.0	65.9 73.7	23.9 25.4		1,639.8 1,799.2			2,466.3	4,106.1	750.6 799.7	646.0 679.7	1,396.6 1,479.4
	1,700.0							2,387.7	4,186.9			
2000 2001	1,943.4 2,212.6	72.6 83.0	31.1 35.4		2,047.0 2,330.9			2,719.9 3,016.0	4,767.0 5,346.9	824.7 840.5	699.8 719.6	1,524.6 1,560.1
2001	2,536.2	94.5	41.4		2,672.1			3,344.4	6,016.5	887.8	740.5	1,628.3
2003	2,829.4	106.6	51.9		2,987.8			3,766.1	6,753.9	910.1	728.3	1,638.4
2004	3,141.0	108.8	63.3		3,313.0			4,034.1	7,347.1	954.0	750.1	1,704.1
2005	3,439.1	121.4	71.7		3,632.1			4,290.8	7,922.9	978.4	770.5	1,748.9
2006 2007	3,693.4 3,813.7	131.2 135.1	79.4 83.5		3,904.0 4,032.3			4,637.8 4,905.2	8,541.8 8,937.5	1,017.9 1,104.2	800.6 852.7	1,818.4 1,956.9
2008	4,063.1	135.8	88.8		4,287.6			5,353.2	9,640.9	1,101.9	842.6	1,944.5
2009	4,405.8	134.3	95.3		4,635.4			5,471.8	10,107.2	1,165.9	869.1	2,035.0
2010 ^f	4,354.7	133.7	102.3		4,590.7			5,581.3	10,172.0	1,169.2	887.3	2,056.5
2011 [†]	4,475.2	136.2	112.8		4,724.2			5,770.4	10,494.6	1,167.8	897.1	2,064.9
						(Annual Percenta						
1985 1986	20.5	4.8	20.8		20.0			22.0	21.1			13.2
1987	19.4	5.9	15.2		18.9			5.9	11.3			16.0
1988	15.6	59.4	19.2		16.7			13.0	14.6			11.0
1989	12.9	25.3	12.6		13.3			12.6	12.9			11.0
1990	17.6	18.0	19.8		17.6			14.5	15.9			3.5
1991 1992	14.9 16.9	4.8 8.0	24.4 15.4		14.7 16.5			10.2 14.6	12.3 15.5			8.2 10.6
1993	5.4	13.9	3.9		5.7			7.6	6.7	7.2	5.1	6.2
1994	-1.0	8.7	-23.3		-1.0			1.8	0.5	10.3	7.8	9.1
1995	11.6	4.3	5.1		11.3			10.0	10.6	-0.1	2.5	1.1
1996	-1.2	1.8	10.9		-1.0			4.5	2.0	4.1	2.2	3.3
1997 1998	3.3 10.1	7.0 14.4	2.9 7.4		3.4 10.2			21.2 17.3	13.2 14.3	10.8 5.7	11.6 7.1	11.2 6.3
1999	9.7	11.9	6.3		9.7			-3.2	2.0	6.5	5.2	5.9
2000	14.3	-1.6	22.3		13.8			13.9	13.9	3.1	3.0	3.1
2001	13.9	14.3	13.8		13.9			10.9	12.2	1.9	2.8	2.3
2002 2003	14.6	13.9	17.0		14.6 11.8			10.9 12.6	12.5	5.6 2.5	2.9 -1.6	4.4
2003	11.6 11.0	12.8 2.0	25.2 22.0		10.9			7.1	12.3 8.8	4.8	3.0	0.6 4.0
2005	9.5	11.6	13.3		9.6			6.4	7.8	2.6	2.7	2.6
2005	9.5 7.4	8.1	10.7		7.5			8.1	7.8	4.0	3.9	4.0
2007	3.3	3.0	5.2		3.3			5.8	4.6	8.5	6.5	7.6
2008	6.5	0.5	6.3		6.3			9.1	7.9	-0.2	-1.2	-0.6
2009	8.4	-1.1	7.4		8.1			2.2	4.8	5.8	3.1	4.7
2010 ^t 2011 ^f	-1.2 2.8	-0.5 1.9	7.4 10.3		-1.0 2.9			2.0 3.4	0.6 3.2	0.3 -0.1	2.1 1.1	1.1 0.4
2011	2.0	1.9	10.3			age Share of Tota	I Drug Expend		3.2	-0.1	1.1	0.4
1985	26.8	0.9	0.5		28.3		D. ug Expone	38.9	67.2			32.8
1986	27.3	0.8	0.5		28.6			40.1	68.7			31.3
1987	28.9	0.8	0.5		30.2			37.6	67.8			32.2
1988 1989	29.4 29.6	1.1 1.2	0.5 0.5		31.0 31.3			37.5 37.6	68.5 68.9			31.5 31.1
1990 1991	31.0 32.1	1.3 1.2	0.6 0.6		32.9 33.9			38.4 38.1	71.2 72.0			28.8 28.0
1992	32.9	1.1	0.6		34.6			38.2	72.9	14.5	12.6	27.1
1993	32.5	1.2	0.6		34.4			38.6	73.0	14.6	12.5	27.0
1994	31.3	1.3	0.5		33.1			38.2	71.3	15.6	13.1	28.7
1995 1996	32.4 31.3	1.2 1.2	0.5 0.5		34.1 33.0			39.0 39.8	73.1 72.9	14.5 14.7	12.4 12.4	26.9 27.1
1997	28.7	1.2	0.5		30.3			42.9	73.2	14.7	12.4	26.8
1998	28.2	1.2	0.4		29.8			44.8	74.6	13.6	11.7	25.4
1999	30.0	1.3	0.4		31.8			42.1	73.9	14.1	12.0	26.1
2000	30.9	1.2	0.5		32.5			43.2	75.8	13.1	11.1	24.2
2001	32.0	1.2	0.5		33.7			43.7	77.4	12.2	10.4	22.6
2002 2003	33.2 33.7	1.2 1.3	0.5 0.6		35.0 35.6			43.7 44.9	78.7 80.5	11.6 10.8	9.7 8.7	21.3 19.5
2003	34.7	1.3	0.7		36.6			44.6	81.2	10.5	8.3	18.8
2005	35.6	1.3	0.7		37.6			44.4	81.9	10.1	8.0	18.1
2005	35.6	1.3	0.7		37.6			44.4	82.4	9.8	7.7	17.6
2007	35.0	1.2	0.8		37.0			45.0	82.0	10.1	7.8	18.0
2008 2009	35.1 36.3	1.2 1.1	0.8 0.8		37.0 38.2			46.2 45.1	83.2 83.2	9.5 9.6	7.3 7.2	16.8 16.8
2010 [†] 2011 [†]	35.6 35.6	1.1 1.1	0.8 0.9		37.5 37.6			45.6 45.9	83.2 83.6	9.6 9.3	7.3 7.1	16.8 16.4
6. 6	55.5				37.0			10.0	30.0	0.0		

f: forecast.

* Confidentiality precludes reporting provincial-level insurance data.

Table B Ont.—Total

10.3 11.0 11.1

11.4 11.5

12.0

13.1

13.7 14.5 14.7

15.9

16.6 16.0 16.1 16.5

16.8 16.9

17.0

17.1

17.2 17.0

17.0

16.9

16.2 16.2 Ont.

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, Ontario, 1985 to 2011 (cont'd)

Share of Drugs in Public, Private and Total Health Expenditures All Drugs Health Expenditure Public Total Public Total Public Total Year (\$ Millions) (Percentage Share) 1985 1986 1987 10,443.3 11,730.2 13,011.9 3,999.5 4,367.1 4,854.5 420.5 504.5 1,067.2 1,259.2 1,487.7 1,763.7 14,442.8 16,097.2 26.7 28.8 4.3 599.9 1,388.9 1,988.8 17,866.4 28.6 1988 1989 700.4 1,556.3 1,741.1 2.256.7 14,497.9 16,093.9 5,321.9 5,876.9 19,819.8 21,970.8 4.8 4.9 29.2 29.6 793.8 2,534.9 1990 933.6 1,906.2 2,839.8 17,332.8 6,466.2 23,799.1 5.4 29.5 1991 1.070.8 2.084.6 3.155.4 19.156.1 7.038.2 26.194.3 5.6 29.6 1,247.8 1,318.9 2,353.7 2,519.6 3,601.5 20,001.5 7,573.7 27,575.2 28,074.9 6.2 6.7 31.1 30.5 1993 3,838.5 19,821.7 8,253.2 1994 1,305.1 2,641.0 3,946.1 20,008.4 8,740.7 28,749.1 6.5 30.2 1.452.0 2.804.5 4.256.5 19.875.0 9.411.7 29.286.7 29.8 1995 7.3 1,438.2 2,917.0 4,355.2 20,038.3 9,655.3 29,693.7 7.2 7.3 1997 1,487.5 3,417.2 4,904.7 20,481.1 10,314.0 30,795.1 33.1 1998 1999 1,639.8 1,799.2 3,862.9 3,867.1 5,502.8 5,666.3 22,030.1 23,344.6 11,095.5 12,094.6 33,125.6 35,439.2 7.4 7.7 34.8 32.0 2000 2,047.0 4,244.5 6,291.5 25,957.7 13,082.2 39,040.0 7.9 32.4 14.186.0 32.3 2001 2.330.9 4.576.2 6.907.1 27.606.2 41.792.2 8.4 2002 2,672.1 4,972.6 7,644.8 8,392.3 29,563.0 33,136.8 15,841.5 16,447.8 45,404.6 49,584.6 9.0 9.0 31.4 2,987.8 32.9 32.4 2003 2004 3.313.0 5.738.2 9.051.2 35,588.2 17.727.8 53,316.0 9.3 2005 3,632.1 6,039.7 9,671.8 37,852.7 18,760.6 56,613.3 9.6 32.2 3,904.0 4,032.3 6,456.3 6,862.1 10,360.3 10,894.4 40,162.8 43,068.3 19,991.2 21,052.9 60,154.0 64,121.2 32.3 32.6 9.7 9.4 2007 2008 4.287.6 7.297.7 11.585.4 46,168,1 21.821.9 67.990.0 9.3 33.4 33.2 4,590.7 4,724.2 7,637.8 7,835.3 12,228.5 12,559.5 51,676.7 52,308.3 23,792.3 25,129.3 75,468.9 77,437.6 32.1 31.2 2010 8.9 9.0 nual Percentage Change 1985 1986 1987 20.0 18.9 18.0 10.3 12.3 10.9 9.2 11.2 11.5 11.0 18.6 12.8 12.1 11.9 11.4 11.0 1988 16.7 13.5 9.6 10.9 13.3 12.3 10.4 10.9 1990 17.6 9.5 9.4 12.0 7.7 10.5 10.0 8.3 14.7 10.1 1991 8.8 16.5 5.7 -1.0 1992 1993 12.9 7.0 4.4 -0.9 5.3 1.8 14.1 7.6 9.0 6.6 1994 4.8 2.8 0.9 5.9 2.4 1995 11.3 6.2 7.9 -0.7 7.7 1.9 1996 -1.0 4.0 2.3 0.8 2.6 1.4 17.1 13.0 2.2 7.6 6.8 1998 10.2 12.2 7.6 7.6 3.0 9.0 2000 13.8 9.8 7.8 11.0 11.2 8.2 10.2 7.0 13.9 6.4 8.4 2001 9.8 2002 14.6 8.7 10.7 11.7 8.6 8.7 6.2 12.1 7.4 3.8 7.8 2004 10.9 7.9 7.5 9.6 5.3 6.4 6.2 2005 6.9 5.8 7.5 3.3 6.3 2006 6.9 7.1 5.2 6.1 7.2 6.6 6.3 2007 6.3 5.3 6.6 2008 6.3 6.3 7.2 3.7 6.0 2.9 3.6 5.6 2010 -1.0 1.7 2.6 0.7 5.0 1.2 5.2 5.6 5.1 2.9 2.7 2.6 (Percentage Share of Total Drug Expenditure) 28.3 28.6 71.7 71.4 100.0 100.0 1985 1986 30.2 31.0 1987 69.8 100.0 69.0 1989 31.3 68.7 100.0 32.9 67.1 100.0 1990 1991 1992 33.9 34.6 66.1 65.4 100.0 100.0 1993 34.4 65.6 100.0 1994 33.1 66.9 100.0 1995 34.1 65.9 100.0 33.0 67.0 1996 100.0 1997 30.3 69.7 100.0 1999 31.8 68.2 100.0 2000 32.5 67.5 100.0 66.3 65.0 64.4 2001 2002 33.7 35.0 100.0 2003 35.6 100.0 2004 36.6 63.4 100.0 2005 37.6 62.4 100.0 2006 62.3 100.0 2007 37.0 63.0 100.0 63.0 61.8 2008 37.0 100.0 2009 38.2 100.0

2011^f

f: forecast

37.6

62.4

100.0

Table B Ont.—Per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Ontario, 1985 to 2011

					Prescribed	Drugs				Non-	Prescribed Dru	ıgs
-	Provincial	Federal		Funds Insurance Funds	Subtotal Public	Insurers*	Private Out of Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	te (Out of Pock Personal Health Supplies	Total Non-Presc. Drugs
V				m Component)		/A O				Drugs		
Year 1985	42.96	1.49	0.78		45.23	(\$ per Cap	лта) 	62.31	107.54			52.47
1986	50.99	1.54	0.93		53.45			74.88	128.33			58.53
1987	59.56	1.59	1.05		62.20			77.58	139.78			66.43
1988 1989	67.45 74.16	2.49 3.04	1.22 1.34		71.16 78.53			85.88 94.18	157.04 172.71			72.24 78.08
1990 1991	85.57 97.11	3.52 3.64	1.58 1.93		90.66 102.68			105.82 115.18	196.48 217.86			79.29 84.72
1992	111.98	3.88	2.20		118.06			130.27	248.33	49.33	43.07	92.41
1993 1994	116.76 114.23	4.37 4.69	2.26 1.71		123.39 120.64			138.67 139.46	262.06 260.09	52.29 56.97	44.77 47.71	97.06 104.67
1995 1996	125.99 122.95	4.83 4.86	1.78 1.95		132.60 129.76			151.60 156.57	284.20 286.34	56.23 57.86	48.29 48.77	104.52 106.63
1997	125.36	5.13	1.98		132.48			187.33	319.81	63.26	53.74	117.00
1998 1999	136.36 147.75	5.80 6.41	2.10 2.21		144.26 156.37			216.97 207.51	361.23 363.88	66.04 69.50	56.83 59.07	122.87 128.57
2000 2001	166.31 185.97	6.21 6.97	2.66 2.97		175.18 195.91			232.76 253.50	407.94 449.41	70.58 70.64	59.89 60.49	130.47 131.13
2002	209.57	7.81	3.42		220.80			276.35	497.15	73.36	61.19	134.54
2003 2004	230.73 252.89	8.69 8.76	4.23 5.09		243.65 266.74			307.12 324.80	550.77 591.54	74.22 76.81	59.39 60.39	133.61 137.20
2005	273.69	9.66	5.71		289.06			341.47	630.53	77.86	61.32	139.18
2006	291.62	10.36	6.27		308.24			366.18	674.42	80.37	63.21	143.58
2007	298.11	10.56	6.53		315.20			383.43	698.63	86.31	66.65	152.97
2008 2009	314.18 337.22	10.50 10.28	6.86 7.29		331.54 354.80			413.94 418.82	745.49 773.62	85.21 89.24	65.15 66.52	150.36 155.76
2010 ^f												
2010 2011 ^f	329.64 334.75	10.12 10.19	7.74 8.44		347.50 353.37			422.48 431.63	769.98 785.00	88.50 87.35	67.17 67.11	155.67 154.46
_						(Annual Percenta	ge Change)					
1985												
1986 1987	18.7 16.8	3.3 3.6	19.0 12.8		18.2 16.4			20.2	19.3 8.9			11.6 13.5
1988	13.2	56.2	16.8		14.4			10.7	12.3			8.8
1989	9.9	22.0	9.6		10.4			9.7	10.0			8.1
1990	15.4	15.8	17.6		15.4			12.4	13.8			1.5
1991 1992	13.5 15.3	3.5 6.5	22.8 13.8		13.3 15.0			8.8 13.1	10.9 14.0			6.9 9.1
1993	4.3	12.6	2.7		4.5			6.4	5.5	6.0	3.9	5.0
1994	-2.2	7.4	-24.2		-2.2			0.6	-0.8	8.9	6.6	7.8
1995 1996	10.3 -2.4	3.1 0.6	3.9 9.6		9.9 -2.1			8.7 3.3	9.3 0.8	-1.3 2.9	1.2 1.0	-0.1 2.0
1997	2.0	5.6	1.6		2.1			19.6	11.7	9.3	10.2	9.7
1998	8.8	13.0	6.1		8.9			15.8	13.0	4.4	5.7	5.0
1999	8.4	10.5	5.0		8.4			-4.4	0.7	5.2	3.9	4.6
2000 2001	12.6 11.8	-3.1 12.3	20.4 11.8		12.0 11.8			12.2 8.9	12.1 10.2	1.5 0.1	1.4 1.0	1.5 0.5
2002	12.7	12.0	15.1		12.7			9.0	10.6	3.8	1.2	2.6
2003	10.1	11.3	23.6		10.4			11.1	10.8	1.2	-2.9	-0.7
2004	9.6	0.7	20.5		9.5			5.8	7.4	3.5	1.7	2.7
2005 2006	8.2 6.5	10.3 7.3	12.0 9.8		8.4 6.6			5.1 7.2	6.6 7.0	1.4 3.2	1.5 3.1	1.4 3.2
2007	2.2	1.9	4.2		2.3			4.7	3.6	7.4	5.4	6.5
2008	5.4	-0.6	5.1		5.2			8.0	6.7	-1.3	-2.2	-1.7
2009	7.3	-2.1	6.3		7.0			1.2	3.8	4.7	2.1	3.6
2010 [†] 2011 [†]	-2.3 1.6	-1.6 0.7	6.2 9.0		-2.1 1.7			0.9 2.2	-0.5 2.0	-0.8 -1.3	1.0 -0.1	-0.1 -0.8
		-		(Annual		nge in Excess of	Inflation in the					
1985	45.0	0.5	16.2		45.4			 17.4	 16.5			
1986 1987	15.9 12.1	-1.1	8.0		15.4 11.6			-1.1	4.2			8.8 8.7
1988	8.7	51.6	12.3		9.9			6.2	7.8			4.2
1989	5.4	17.4	5.0		5.8			5.1	5.4			3.5
1990 1991	12.4 10.7	12.8 0.7	14.6 20.0		12.4 10.5			9.3	10.7			-1.5 4.1
1992	14.1	5.3	12.6		13.7			6.1 11.8	8.1 12.7			7.8
1993	2.8	11.2	1.3		3.1			5.0	4.1	4.6	2.5	3.6
1994	-3.3	6.3	-25.3		-3.3			-0.5	-1.8	7.8	5.5	6.7
1995 1996	8.0 -4.1	0.7 -1.1	1.5 7.9		7.6 -3.8			6.4 1.6	6.9 -0.9	-3.6 1.2	-1.1 -0.7	-2.5 0.3
1997	1.0	4.6	0.6		-3.6 1.1			18.7	10.7	8.3	9.2	8.7
1998	9.2	13.4	6.6		9.3			16.3	13.4	4.8	6.2	5.5
1999	6.5	8.7	3.2		6.6			-6.2	-1.1	3.4	2.1	2.8
2000 2001	8.5 10.5	-7. <u>2</u> 10.9	16.3 10.4		7.9 10.5			8.1 7.6	8.0 8.8	-2.6 -1.3	-2.7 -0.4	-2.6 -0.8
2002	11.6	10.9	14.0		11.7			8.0	9.6	2.8	0.1	1.6
2003 2004	7.2 7.0	8.4 -1.9	20.7 17.9		7.5 6.9			8.2 3.2	7.9 4.8	-1.7 0.9	-5.8 -0.9	-3.6 0.1
2005 2006	5.2 3.8	7.3 4.5	9.0 7.0		5.4 3.8			2.1 4.4	3.6 4.2	-1.6 0.4	-1.5 0.3	-1.6 0.4
2007	-1.5	-1.7	0.5		-1.4			1.0	-0.1	3.7	1.8	2.9
2008 2009	0.5 10.0	-5.5 0.6	0.3 9.0		0.3 9.7			3.1 3.9	1.8 6.5	-6.2 7.4	-7.1 4.8	-6.6 6.3
2010 ^f	-5.2	-4.5	3.2		-5.0			-2.1	-3.4	-3.8	-2.0	-3.0
2011 ^f f: forecast.	-2.4	-3.3	5.0		-2.3			-1.8	-2.0	-5.3	-4.1	-4.8

f: forecast.

* Confidentiality precludes reporting provincial-level insurance data.

Table B Ont.—Per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Ontario, 1985 to 2011 (cont'd)

		All Drugo			aalth Evnanditura		GDP Implicit Price Index—Canada
	Public	All Drugs Private	Total	Public	ealth Expenditure Private	Total	Price index—Canada
Year			(\$ per Ca	apita)			(1997 = 100)
1985	45.23	114.79	160.01	1,123.23	430.17	1,553.40	73.6
1986 1987	53.45 62.20	133.42 144.01	186.87 206.21	1,242.85 1,349.18	462.71 503.36	1,705.55 1,852.54	75.6 79.2
1988	71.16	158.13	229.28	1,473.03	540.72	2,013.75	82.8
1989	78.53	172.26	250.79	1,592.27	581.43	2,173.70	86.6
1990	90.66	185.11	275.77	1,683.15	627.92	2,311.07	89.2
1991	102.68	199.90	302.58	1,836.97	674.92	2,511.89	91.6
1992	118.06	222.68	340.74	1,892.32	716.54	2,608.87	92.8
1993 1994	123.39 120.64	235.73 244.13	359.12 364.76	1,854.51 1,849.50	772.16 807.95	2,626.67 2,657.46	94.1 95.2
1995 1996	132.60 129.76	256.12 263.20	388.72 392.96	1,815.07 1,808.02	859.52 871.18	2,674.59 2,679.20	97.4 99.0
1997	132.48	304.34	436.81	1,824.07	918.57	2,742.64	100.0
1998	144.26	339.84	484.10	1,938.07	976.12	2,914.19	99.6
1999	156.37	336.08	492.45	2,028.84	1,051.12	3,079.97	101.4
2000	175.18	363.23	538.41	2,221.39	1,119.54	3,340.92	105.5
2001	195.91	384.63	580.54	2,320.31	1,192.33	3,512.64	106.9
2002 2003	220.80 243.65	410.89 440.73	631.69 684.38	2,442.81 2,702.27	1,309.00 1,341.31	3,751.81 4,043.58	108.1 111.2
2003	266.74	462.00	728.74	2,865.32	1,427.33	4,292.65	114.1
2005	289.06	480.66	769.71	3,012.44	1,493.03	4,505.47	117.5
2006	308.24	509.76	818.00	3,171.08	1,578.42	4,749.50	120.8
2007	315.20	536.39	851.59	3,366.57	1,645.67	5,012.24	125.2
2008	331.54	564.30	895.85	3,569.99	1,687.39	5,257.38	131.3
2009	354.80	574.58	929.38	3,766.03	1,730.42	5,496.46	127.8
2010 ^f	347.50	578.16	925.65	3,911.74	1,800.99	5,712.73	131.5
2011'	353.37	586.08	939.46	3,912.71	1,879.69	5,792.40	136.8
				(Annual Percentage Ch			
1985 1986	18.2	16.2	16.8	10.6	7.6	9.8	2.8
1987	16.4	7.9	10.4	8.6	8.8	8.6	4.7
1988	14.4	9.8	11.2	9.2	7.4	8.7	4.5
1989	10.4	8.9	9.4	8.1	7.5	7.9	4.6
1990	15.4	7.5	10.0	5.7	8.0	6.3	3.0
1991	13.3	8.0	9.7	9.1	7.5	8.7	2.8
1992 1993	15.0 4.5	11.4 5.9	12.6 5.4	3.0 -2.0	6.2 7.8	3.9 0.7	1.3 1.4
1994	-2.2	3.6	1.6	-0.3	4.6	1.2	1.1
1995	9.9	4.9	6.6	-1.9	6.4	0.6	2.3
1996	-2.1	2.8	1.1	-0.4	1.4	0.2	1.7
1997	2.1	15.6	11.2	0.9	5.4	2.4	1.0
1998 1999	8.9 8.4	11.7 -1.1	10.8 1.7	6.3 4.7	6.3 7.7	6.3 5.7	-0.4 1.8
2000	12.0	8.1	9.3	9.5	6.5	8.5	4.1
2001 2002	11.8 12.7	5.9 6.8	7.8 8.8	4.5 5.3	6.5 9.8	5.1 6.8	1.4 1.0
2003	10.4	7.3	8.3	10.6	2.5	7.8	2.9
2004	9.5	4.8	6.5	6.0	6.4	6.2	2.6
2005	8.4	4.0	5.6	5.1	4.6	5.0	3.0
2006	6.6	6.1	6.3	5.3	5.7	5.4	2.8
2007 2008	2.3 5.2	5.2 5.2	4.1 5.2	6.2 6.0	4.3 2.5	5.5 4.9	3.7 4.9
2009	7.0	1.8	3.7	5.5	2.6	4.5	-2.7
2010 ^f	-2.1	0.6	-0.4	3.9	4.1	3.9	2.9
2011 ^f	1.7	1.4	1.5	0.0	4.4	1.4	4.0
		(Annual Percentage	Change in Excess o	of Inflation in the Canad	ian Economy)		
1985							
1986 1987	15.4 11.6	13.4 3.2	14.0 5.6	7.8 3.8	4.8 4.0	7.0 3.9	
1988	9.9	5.3	6.7	4.7	2.9	4.2	
1989	5.8	4.4	4.8	3.5	3.0	3.4	
1990	12.4	4.4	6.9	2.7	5.0	3.3	
1991	10.5	5.2	7.0	6.4	4.7	5.9	
1992	13.7	10.1	11.3	1.8	4.9	2.6	
1993 1994	3.1 -3.3	4.4 2.5	4.0 0.5	-3.4 -1.4	6.3 3.5	-0.8 0.1	
1995 1996	7.6 -3.8	2.6 1.1	4.2 -0.6	-4.2 -2.1	4.0 -0.3	-1.7 -1.5	
1997	1.1	14.6	10.2	-0.1	4.4	1.4	
1998	9.3	12.1	11.3	6.7	6.7	6.7	
1999	6.6	-2.9	-0.1	2.9	5.9	3.9	
2000	7.9	4.0	5.2	5.4	2.4	4.4	
2001 2002	10.5 11.7	4.5 5.8	6.5 7.8	3.1 4.2	5.1 8.7	3.8 5.8	
2002	7.5	4.4	7.6 5.4	7.7	-0.4	4.9	
2004	6.9	2.2	3.9	3.4	3.8	3.6	
2005	5.4	1.0	2.6	2.1	1.6	1.9	
2006	3.8	3.3	3.5	2.5	2.9	2.6	
2007 2008	-1.4 0.3	1.5 0.3	0.4 0.3	2.5 1.2	0.6 -2.3	1.9 0.0	
2009	9.7	4.5	6.5	8.2	-2.3 5.3	7.3	
2010 ^f	-5.0	-2.3	-3.3	0.9	1.1	1.0	
2011 ^f	-2.3	-2.6	-2.5	-4.0	0.4	-2.6	
						Neces	Harlin Farancia - Baratan - 201

f: forecast.

Ont.

Table B Man.—Total

Man.

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, Manitoba, 1985 to 2011

			Public		Prescribed	Drugs	Private				Prescribed Dru	
	Provincial	Federal		Insurance	Subtotal Public	Insurers*	Out of Pocket	Subtotal Private	Total Prescribed	Over- the-	Personal Health	Total Non-Presc.
				Funds m Component)					Drugs	Counter Drugs	Supplies	Drugs
Year						(\$ Million						
1985 1986	32.5 34.6	6.5 7.2	0.3 0.4		39.2 42.2			60.0 68.2	99.2 110.4			61.0 69.1
1987	42.3	7.7	0.4		50.4			61.9	112.3			80.1
1988 1989	47.5 45.5	9.3 11.5	0.5 0.6		57.3 57.6			68.1 74.9	125.4 132.5			75.4 70.9
1990	48.5	13.8	0.7		62.9			86.2	149.1			75.3
1991	55.4	16.2	0.7		72.4			95.8	168.2			81.5
1992	68.1	18.6	0.8		87.5			101.6	189.1	51.5	41.6	93.2 92.2
1993 1994	68.1 61.1	21.9 24.6	0.7 0.8		90.7 86.5			118.5 129.1	209.2 215.6	50.4 52.3	41.9 42.5	92.2 94.8
1995	79.6	27.8	0.8		108.3			148.0	256.3	50.8	41.7	92.5
1996	73.8	28.6	0.9		103.2			163.4	266.7	54.2	47.3	101.5
1997 1998	73.7 85.9	31.3 33.7	1.0 1.0		106.0 120.5			186.7 189.0	292.7 309.5	48.1 55.3	43.7 50.9	91.8 106.3
1999	105.6	36.9	1.1		143.6			180.5	324.2	58.4	50.8	109.3
2000	130.9	38.4	1.3		170.7			205.3	376.0	60.8	52.6	113.3
2001	160.8	44.5	1.6		207.0			212.3	419.3	64.0	53.6	117.6
2002 2003	189.6 217.7	52.0 60.7	1.7 2.1		243.3 280.4			239.4 266.7	482.7 547.1	65.6 68.3	54.8 56.3	120.4 124.6
2004	234.6	65.3	2.3		302.2			277.2	579.4	71.9	58.0	129.9
2005	249.5	70.9	2.4		322.7			293.3	616.1	74.2	60.3	134.4
2006 2007	260.2 271.6	79.4 83.8	2.6 2.7		342.3 358.2			344.8 362.5	687.0 720.6	78.5 82.0	63.2 62.8	141.7 144.8
2008	279.6	85.9	3.2		368.6			375.1	743.7	87.6	66.0	153.6
2009	287.2	89.4	3.3		379.9			436.9	816.7	96.8	70.9	167.7
2010 ^f	293.1	90.3	3.6		386.9			461.5	848.5	100.0	72.4	172.4
2011 ^t	302.3	92.0	3.7		398.0	 (AI DI-		487.8	885.9	99.5	74.0	173.5
1985						(Annual Percenta	ge Change)					
1986	6.6	11.1	23.4		7.4			13.7	11.3			13.2
1987 1988	22.2 12.4	7.4 19.8	10.2 25.2		19.6 13.6			-9.3 10.1	1.7 11.7			16.0 -5.9
1989	-4.1	24.1	8.5		0.5			10.1	5.7			-5.9
1990	6.5	19.7	16.1		9.3			15.0	12.5			6.2
1991	14.3	17.8	7.1		15.0			11.2	12.8			8.2
1992 1993	22.9 -0.1	14.4 17.9	17.9 -10.4		20.9 3.6			6.1 16.6	12.5 10.6	-2.3	0.6	14.4 -1.0
1994	-10.2	12.1	5.3		-4.7			8.9	3.0	3.8	1.6	2.8
1995	30.2	13.3	9.2		25.2			14.6	18.9	-2.9	-1.9	-2.4
1996 1997	-7.3 -0.1	2.8 9.6	4.7 7.9		-4.6 2.7			10.4 14.2	4.1 9.7	6.7 -11.2	13.3 -7.6	9.7 -9.5
1998	16.5	7.4	2.5		13.7			1.2	5.7	15.0	16.6	15.8
1999	22.9	9.7	13.8		19.2			-4.5	4.7	5.6	-0.2	2.8
2000	24.0	4.0	20.6		18.8			13.7	16.0	4.1	3.4	3.7
2001 2002	22.8 17.9	16.0 16.7	18.0 7.9		21.3 17.6			3.4 12.8	11.5 15.1	5.3 2.4	2.0 2.2	3.8 2.3
2003	14.8	16.7	19.9		15.3			11.4	13.3	4.1	2.8	3.5
2004	7.7	7.7	13.0		7.8			4.0	5.9	5.3	3.0	4.3
2005	6.4	8.5	1.4		6.8			5.8	6.3	3.2	3.8	3.5
2006 2007	4.3 4.4	12.1 5.5	10.9 5.2		6.0 4.6			17.5 5.1	11.5 4.9	5.9 4.4	4.8 -0.6	5.4 2.2
2008	2.9	2.6	15.0		2.9			3.5	3.2	6.8	5.1	6.1
2009	2.7	4.1	3.7		3.0			16.5	9.8	10.5	7.5	9.2
2010 [†] 2011 [†]	2.1 3.1	1.0 1.9	8.9 4.5		1.9 2.9			5.7 5.7	3.9 4.4	3.4 -0.6	2.1 2.2	2.8 0.6
2011	5.1	1.5	4.5			age Share of Tota			7.7	-0.0	2.2	0.0
1985	20.3	4.1	0.2		24.5			37.4	61.9			38.1
1986 1987	19.3 22.0	4.0 4.0	0.2 0.2		23.5 26.2			38.0 32.2	61.5 58.4			38.5 41.6
1988	23.7	4.6	0.3		28.5			33.9	62.5			37.5
1989	22.4	5.7	0.3		28.3			36.8	65.1			34.9
1990	21.6	6.1	0.3		28.0			38.4	66.4			33.6
1991 1992	22.2 24.1	6.5 6.6	0.3 0.3		29.0 31.0			38.4 36.0	67.4 67.0	18.3	14.7	32.6 33.0
1993	22.6	7.3	0.2		30.1			39.3	69.4	16.7	13.9	30.6
1994	19.7	7.9	0.2		27.9			41.6	69.5	16.8	13.7	30.5
1995 1996	22.8 20.0	8.0 7.8	0.2 0.2		31.0 28.0			42.4 44.4	73.5 72.4	14.6 14.7	12.0 12.8	26.5 27.6
1997	19.2	8.2	0.2		27.6			48.6	76.1	12.5	11.4	23.9
1998	20.7	8.1	0.2		29.0			45.4	74.4	13.3	12.2	25.6
1999	24.4	8.5	0.3		33.1			41.7	74.8	13.5	11.7	25.2
2000 2001	26.8 30.0	7.8 8.3	0.3		34.9 38.5			42.0 39.5	76.8 78.1	12.4 11.9	10.7 10.0	23.2 21.9
2002	31.4	8.6	0.3		40.3			39.7	80.0	10.9	9.1	20.0
2003 2004	32.4 33.1	9.0 9.2	0.3 0.3		41.7 42.6			39.7 39.1	81.4 81.7	10.2 10.1	8.4 8.2	18.6 18.3
2005 2006	33.2 31.4	9.4 9.6	0.3 0.3		43.0 41.3			39.1 41.6	82.1 82.9	9.9 9.5	8.0 7.6	17.9 17.1
2007	31.4	9.7	0.3		41.4			41.9	83.3	9.5	7.3	16.7
2008 2009	31.2 29.2	9.6 9.1	0.4 0.3		41.1 38.6			41.8 44.4	82.9 83.0	9.8 9.8	7.4 7.2	17.1 17.0
2010 ^f	28.7							45.2				
2010 2011 ^f f: forecast.	28.7 28.5	8.8 8.7	0.3 0.4		37.9 37.6			45.2 46.1	83.1 83.6	9.8 9.4	7.1 7.0	16.9 16.4

f: forecast.

* Confidentiality precludes reporting provincial-level insurance data.

Table B Man.—Total

Man.

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, Manitoba, 1985 to 2011 (cont'd)

Share of Drugs in Public, Private and Total Health Expenditures All Drugs Health Expenditure Public Total Public Total Public Total Year (\$ Millions) 1985 1986 1987 39.2 42.2 50.4 121.0 137.3 141.9 160.2 179.4 192.4 1,310.9 1,425.8 1,530.2 29.1 29.6 31.5 9.3 9.5 9.7 415.6 463.9 1,726.5 1,889.7 3.0 3.0 3.3 449.9 1,980.2 1988 1989 57.3 57.6 143.4 145.8 200.7 203.4 1,634.3 1,773.2 435.4 2,069.6 2,257.4 3.5 32.9 30.1 9.7 9.0 484.2 1990 62.9 161.5 224.4 1,951.1 533.2 2,484.3 3.2 30.3 1991 72.4 249.6 2.006.0 570.0 2.576.0 3.6 31.1 9.7 1992 1993 87.5 194.8 210.8 282.3 2,099.3 2,088.9 602.6 2,701.9 2,749.1 4.2 4.3 32.3 31.9 10.4 11.0 301.5 90.7 1994 86.5 223.9 310.4 2,115.7 689.2 2,804.9 4.1 32.5 11.1 5.0 4.7 4.7 1995 108.3 240.5 2.179.4 736.1 2.915.5 32.7 12.0 348.8 1996 1997 12.4 12.4 2,972.0 106.0 278.5 384.5 2,251.9 848.6 3,100.5 32.8 1998 1999 120.5 143.6 295.2 289.8 415.8 2,388.6 2,714.9 897.7 3,286.3 3,700.8 5.0 5.3 32.9 29.4 12.7 11.7 433.4 2000 170.7 489.3 3,005.3 1,058.2 4,063.6 30.1 3.184.5 27.6 12.3 2001 207.0 329.9 536.9 1.197.1 4.381.6 6.5 2002 243.3 359.8 603.1 671.7 3,360.1 3,645.0 1,247.1 1,282.1 4,607.2 7.2 7.7 7.8 28.8 30.5 13.1 13.6 4,927.1 2003 391.3 2004 302.2 407.1 709.4 3.889.4 1.345.3 5.234.7 30.3 13.6 2005 322.7 427.8 750.5 4,188.8 1,429.5 5,618.3 7.7 29.9 13.4 2006 342.3 358.2 486.5 507.2 828.7 865.4 4,429.3 4,682.5 5,976.4 6,282.5 31.4 31.7 13.9 13.8 1.547.1 7.7 7.6 1,600.0 2008 368.6 528.7 897.3 5.020.9 1.726.8 6.747.7 7.3 30.6 13.3 5,472.5 6.9 386.9 398.0 634.0 661.3 5,697.1 6,021.0 1,958.0 2,038.4 7,655.0 8,059.4 32.4 32.4 13.3 13.1 2010^t 1,020.9 6.8 6.6 2011 1,059.3 (Annual Perce ntage Change 1985 7.4 19.6 1986 1987 13.5 3.4 9.5 4.8 12.0 8.8 7.3 11.6 7.2 -3.0 13.6 0.5 6.8 8.5 1988 1.1 1.7 4.4 -3.2 4.5 1.4 11.2 1990 9.3 15.0 10.7 10.3 10.0 10.1 10.1 1991 9.8 11.2 6.9 20.9 3.6 -4.7 1992 1993 9.9 8.2 13.1 6.8 4.7 -0.5 5.7 9.6 4.9 1.7 1994 6.2 3.0 1.3 4.4 2.0 1995 25.2 7.4 12.4 3.0 6.8 3.9 1996 -4.6 10.1 5.6 0.3 6.9 7.9 1.9 3.0 6.0 6.1 13.7 1998 13.7 8.1 5.8 6.0 19.2 4.3 9.8 2000 18.8 10.0 12.9 10.7 6.0 7.3 9.8 21.3 13.1 7.8 2001 3.5 5.5 8.5 6.7 2002 17.6 9.0 12.3 4.2 5.1 15.3 7.8 8.8 4.1 2.8 6.9 2004 5.6 6.8 5.8 7.7 7.3 2005 5.1 6.3 6.0 4.6 2.9 2006 13.7 10.4 5.7 5.7 8.2 3.4 6.4 5.1 2007 4.3 7.9 7.4 2008 4.2 3.7 7.2 3.0 14.4 2010^t 1.9 2.9 4.9 3.7 4.1 5.7 6.3 4.1 47 4.3 3.8 (Percentage Share of Total Drug Expenditure) 1985 1986 24.5 23.5 75.5 76.5 100.0 73.8 71.5 71.7 1987 1988 26.2 100.0 1989 28.3 100.0 72.0 28.0 1990 100.0 1991 1992 29.0 31.0 71.0 69.0 100.0 100.0 1993 30.1 69.9 100.0 1994 27.9 72.1 100.0 1995 31.0 69.0 100.0 1996 28.0 72.0 100.0 1997 27.6 72.4 100.0 71.0 66.9 1999 33.1 100.0 2000 34.9 65.1 100.0 38.5 40.3 41.7 61.5 59.7 58.3 2001 2002 100.0 2003 100.0 2004 42.6 57.4 100.0 2005 43.0 57.0 100.0 2006 41.3 100.0 2007 41.4 58.6 100.0 58.9 61.4 41.1 2009 38.6 100.0 62.1 100.0 2011 37.6 62.4 100.0

f: forecast.

Table B Man.—Per Capita

Man.

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Manitoba, 1985 to 2011

					Prescribed	Drugs				Non-	Prescribed Dru	ıgs
-	Provincial	Federal		Funds Insurance Funds	Subtotal Public	Insurers*	Private Out of Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	te (Out of Pock Personal Health Supplies	Total Non-Presc. Drugs
V				m Component)		/A O			2.490	Drugs	Саррисс	2.ugo
Year 1985	29.98	6.00	0.28		36.26	(\$ per Cap	лта) 	55.40	91.67			56.35
1986	31.68	6.60	0.34		38.62			62.48	101.10			63.26
1987	38.48	7.05	0.38		45.91			56.33	102.25			72.94
1988	43.10	8.42	0.47		51.99			61.78	113.77			68.38
1989	41.26	10.44	0.51		52.20			67.91	120.11			64.25
1990	43.87	12.47	0.59		56.92			77.93	134.85			68.11
1991 1992	49.95 61.22	14.63 16.69	0.63 0.74		65.21 78.65			86.34 91.33	151.55 169.98	46.32	37.42	73.41 83.73
1993	60.90	19.59	0.66		81.15			106.06	187.21	45.06	37.46	82.52
1994	54.43	21.86	0.69		76.99			114.94	191.92	46.55	37.86	84.41
1995	70.49	24.65	0.75		95.89			131.08	226.97	44.97	36.96	81.93
1996	65.03	25.22	0.78		91.03			144.10	235.13	47.77	41.69	89.46
1997 1998	64.88 75.51	27.59 29.60	0.84 0.86		93.31 105.97			164.30 166.11	257.61 272.09	42.34 48.64	38.45 44.77	80.79 93.41
1999	92.43	32.32	0.98		125.72			158.03	283.75	51.13	44.50	95.63
2000	114.11	33.47	1.17		148.75			178.93	327.68	52.97	45.82	98.79
2001	139.70	38.69	1.38		179.77			184.40	364.17	55.61	46.57	102.18
2002	164.09	45.00	1.48		210.57			207.17	417.74	56.75	47.43	104.18
2003 2004	187.38 200.39	52.22 55.82	1.77 1.98		241.36 258.19			229.51 236.82	470.87 495.01	58.77 61.42	48.48 49.58	107.26 111.00
2005	212.51	60.36	2.00		274.87			249.84	524.71	63.18	51.32	114.50
2006	219.78	67.07	2.20		289.06			291.19	580.25	66.33	53.35	119.68
2007	227.59	70.19	2.30		300.08			303.69	603.76	68.69	52.61	121.30
2008	231.90	71.27	2.61		305.79			311.15	616.94	72.65	54.74	127.39
2009	235.46	73.34	2.68		311.48			358.21	669.69	79.36	58.14	137.50
2010 ^t 2011 ^f	237.21	73.12	2.88		313.21			373.60	686.81	80.97	58.60	139.57
2011	242.38	73.81	2.98		319.17			391.20	710.37	79.77	59.32	139.09
						(Annual Percenta						
1985 1986	5.6	10.1	22.4		6.5			12.8	10.3			12.3
1987	21.5	6.8	9.5		18.9			-9.8	1.1			15.3
1988	12.0	19.4	24.8		13.2			9.7	11.3			-6.3
1989	-4.3	23.9	8.3		0.4			9.9	5.6			-6.0
1990	6.3	19.5	15.9		9.0			14.8	12.3			6.0
1991 1992	13.9 22.6	17.3 14.1	6.8 17.5		14.6 20.6			10.8 5.8	12.4 12.2			7.8 14.1
1993	-0.5	17.4	-10.8		3.2			16.1	10.1	-2.7	0.1	-1.4
1994	-10.6	11.6	4.8		-5.1			8.4	2.5	3.3	1.1	2.3
1995	29.5	12.7	8.7		24.6			14.0	18.3	-3.4	-2.4	-2.9
1996	-7.7	2.3	4.2		-5.1			9.9	3.6	6.2	12.8	9.2
1997 1998	-0.2 16.4	9.4 7.3	7.8 2.4		2.5 13.6			14.0 1.1	9.6 5.6	-11.4 14.9	-7.8 16.4	-9.7 15.6
1999	22.4	9.2	13.3		18.6			-4.9	4.3	5.1	-0.6	2.4
2000	23.5	3.5	20.1		18.3			13.2	15.5	3.6	3.0	3.3
2001	22.4	15.6	17.6		20.9			3.1	11.1	5.0	1.6	3.4
2002	17.5	16.3	7.5		17.1			12.3	14.7	2.0	1.8	2.0
2003 2004	14.2 6.9	16.1 6.9	19.2 12.1		14.6 7.0			10.8 3.2	12.7 5.1	3.6 4.5	2.2 2.3	3.0 3.5
2005 2006	6.0 3.4	8.1 11.1	1.1 9.9		6.5 5.2			5.5 16.6	6.0 10.6	2.9 5.0	3.5 3.9	3.2 4.5
2007	3.6	4.6	4.3		3.8			4.3	4.1	3.6	-1.4	1.4
2008	1.9	1.5	13.8		1.9			2.5	2.2	5.8	4.0	5.0
2009	1.5	2.9	2.5		1.9			15.1	8.6	9.2	6.2	7.9
2010 ^f	0.7	-0.3	7.5		0.6			4.3	2.6	2.0	0.8	1.5
2011 [†]	2.2	0.9	3.5	(4	1.9			4.7	3.4	-1.5	1.2	-0.3
1985				(Annual	Percentage Cha	nge in Excess of	inflation in the	Canadian Econ	оту)			
1986	2.8	7.3	19.6		3.7			10.0	7.5			9.5
1987	16.7	2.0	4.8		14.1			-14.6	-3.6			10.6
1988 1989	7.5 -8.8	14.9	20.2		8.7 -4.2			5.1	6.7			-10.8 -10.6
		19.4	3.8					5.3	1.0			
1990 1991	3.3 11.1	16.4 14.6	12.9 4.0		6.0 11.8			11.7 8.0	9.3 9.6			3.0 5.0
1992	21.3	12.8	16.3		19.4			4.5	10.9			12.8
1993	-2.0	16.0	-12.2		1.7			14.7	8.7	-4.2	-1.3	-2.9
1994	-11.7	10.5	3.7		-6.2			7.3	1.4	2.2	0.0	1.2
1995	27.2	10.4	6.3		22.2			11.7	15.9	-5.7	-4.7	-5.3
1996 1997	-9.4 -1.2	0.6 8.4	2.6 6.8		-6.7 1.5			8.3 13.0	1.9 8.6	4.6 -12.4	11.1 -8.8	7.5 -10.7
1997	16.8	7.7	2.8		14.0			1.5	6.1	15.3	16.9	16.1
1999	20.6	7.4	11.5		16.8			-6.7	2.5	3.3	-2.4	0.6
2000	19.4	-0.6	16.0		14.2			9.1	11.4	-0.5	-1.2	-0.8
2001	21.1	14.3	16.2		19.5			1.7	9.8	3.6	0.3	2.1
2002	16.4	15.2	6.4		16.1			11.3	13.7	1.0	0.8	0.9
2003 2004	11.3 4.4	13.2 4.3	16.3 9.6		11.7 4.4			7.9 0.6	9.8 2.5	0.7 1.9	-0.7 -0.3	0.1 0.9
2005	3.0	5.1	-1.9		3.5			2.5	3.0	-0.1	0.5	0.1
2005	0.6	5.1 8.3	-1.9 7.2		3.5 2.4			13.8	7.8	-0.1 2.2	1.2	1.7
2007	-0.1	1.0	0.6		0.1			0.6	0.4	-0.1	-5.1	-2.3
2008	-3.0	-3.3	9.0		-3.0			-2.4	-2.7	0.9	-0.8	0.2
2009	4.2	5.6	5.3		4.6			17.8	11.3	11.9	8.9	10.6
2010 ^f 2011 ^f	-2.2 -1.8	-3.2 -3.0	4.6 -0.5		-2.4 -2.1			1.4 0.7	-0.4 -0.6	-0.9 -5.5	-2.2 -2.8	-1.4 -4.3
f: forecast.	-1.0	-3.0	-0.3		*2.1			0.7	-0.0	-5.5	-2.0	-4.3

f: forecast.

* Confidentiality precludes reporting provincial-level insurance data.

Table B Man.—Per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Manitoba, 1985 to 2011 (cont'd)

				•		•	GDP Implicit
	Public	All Drugs Private	Total	Public	ealth Expenditure Private	Total	Price Index—Canada
Year			(\$ per Capi				(1997 = 100)
1985 1986	36.26 38.62	111.76 125.74	148.02 164.36	1,211.28 1,306.04	383.98 424.97	1,595.25 1,731.01	73.6 75.6
1987	45.91	129.27	175.18	1,393.62	409.78	1,803.40	79.2
1988	51.99	130.16	182.14	1,482.95	395.06	1,878.01	82.8
1989	52.20	132.15	184.35	1,606.82	438.77	2,045.59	86.6
1990	56.92	146.04	202.96	1,764.67	482.25	2,246.92	89.2
1991	65.21	159.76	224.97	1,807.82	513.71	2,321.53	91.6
1992	78.65	175.06	253.71	1,886.70	541.56	2,428.27	92.8
1993	81.15	188.58	269.73	1,869.05 1,883.55	590.76	2,459.81	94.1
1994	76.99	199.34	276.33	1,003.55	613.62	2,497.17	95.2
1995	95.89	213.01	308.90	1,930.11	651.90	2,582.01	97.4
1996 1997	91.03 93.31	233.57 245.09	324.60 338.40	1,926.73 1,982.07	693.69 746.91	2,620.42 2,728.98	99.0 100.0
1998	105.97	259.52	365.50	2,099.81	789.20	2,889.01	99.6
1999	125.72	253.66	379.38	2,376.29	862.92	3,239.21	101.4
2000	148.75	277.72	426.47	2,619.32	922.32	3,541.64	105.5
2001	179.77	286.58	466.36	2,766.07	1,039.77	3,805.84	106.9
2002	210.57	311.35	521.92	2,907.70	1,079.23	3,986.93	108.1
2003 2004	241.36 258.19	336.76 347.82	578.13 606.02	3,137.12 3,322.67	1,103.43 1,149.28	4,240.55 4,471.95	111.2 114.1
2005 2006	274.87 289.06	364.34 410.87	639.21 699.92	3,567.54 3,740.87	1,217.48 1,306.65	4,785.02 5,047.52	117.5 120.8
2006	300.08	410.87 424.99	725.06	3,740.87	1,340.54	5,047.52 5,263.70	120.8
2008	305.79	438.54	744.33	4,164.91	1,432.45	5,597.37	131.3
2009	311.48	495.71	807.19	4,487.29	1,509.93	5,997.22	127.8
2010 ^f	313.21	513.17	826.38	4,611.46	1,584.87	6,196.32	131.5
2011 ^f	319.17	530.30	849.46	4,828.27	1,634.61	6,462.88	136.8
			(Ar	nnual Percentage Cha	ange)		
1985							
1986	6.5	12.5	11.0	7.8	10.7	8.5	2.8
1987	18.9	2.8	6.6	6.7	-3.6	4.2	4.7
1988 1989	13.2 0.4	0.7 1.5	4.0 1.2	6.4 8.4	-3.6 11.1	4.1 8.9	4.5 4.6
1990	9.0	10.5	10.1	9.8	9.9	9.8	3.0
1991 1992	14.6 20.6	9.4 9.6	10.8 12.8	2.4 4.4	6.5 5.4	3.3 4.6	2.8 1.3
1993	3.2	7.7	6.3	-0.9	9.1	1.3	1.4
1994	-5.1	5.7	2.4	0.8	3.9	1.5	1.1
1995	24.6	6.9	11.8	2.5	6.2	3.4	2.3
1996	-5.1	9.7	5.1	-0.2	6.4	1.5	1.7
1997	2.5	4.9	4.3	2.9	7.7	4.1	1.0
1998	13.6	5.9	8.0	5.9	5.7	5.9	-0.4
1999	18.6	-2.3	3.8	13.2	9.3	12.1	1.8
2000	18.3	9.5	12.4	10.2	6.9	9.3	4.1
2001 2002	20.9	3.2	9.4	5.6	12.7	7.5	1.4 1.0
2002	17.1 14.6	8.6 8.2	11.9 10.8	5.1 7.9	3.8 2.2	4.8 6.4	2.9
2004	7.0	3.3	4.8	5.9	4.2	5.5	2.6
2005	6.5	4.7	5.5	7.4	5.9	7.0	3.0
2006	5.2	12.8	9.5	4.9	7.3	5.5	2.8
2007	3.8	3.4	3.6	4.9	2.6	4.3	3.7
2008	1.9	3.2	2.7	6.2	6.9	6.3	4.9
2009	1.9	13.0	8.4	7.7	5.4	7.1	-2.7
2010 ^f	0.6	3.5	2.4	2.8	5.0	3.3	2.9
2011 [†]	1.9	3.3	2.8	4.7	3.1	4.3	4.0
1985		(Annual Percentage	Change in Excess of Ir	nflation in the Canadi	an Economy)		
1986	3.7	9.7	8.2	5.0	7.9	5.7	
1987	14.1	-1.9	1.8	2.0	-8.3	-0.6	
1988	8.7	-3.8	-0.5	1.9	-8.1	-0.4	
1989	-4.2	-3.0	-3.4	3.8	6.5	4.4	
1990	6.0	7.5	7.1	6.8	6.9	6.8	
1991	11.8	6.6	8.1	-0.3	3.8	0.6	
1992 1993	19.4 1.7	8.3 6.3	11.5 4.9	3.1 -2.4	4.2 7.6	3.3 -0.1	
1994	-6.2	4.6	1.3	-0.3	2.8	0.4	
1995	22.2	4.5	9.4	0.1	3.9	1.1	
1995	-6.7	4.5 8.0	9.4 3.4	-1.8	3.9 4.7	1.1 -0.2	
1997	1.5	3.9	3.3	1.9	6.7	3.2	
1998	14.0	6.3	8.4	6.4	6.1	6.3	
1999	16.8	-4.1	2.0	11.4	7.5	10.3	
2000	14.2	5.4	8.3	6.1	2.8	5.2	
2001	19.5	1.8	8.0	4.2	11.4	6.1	
2002 2003	16.1 11.7	7.6 5.3	10.9 7.9	4.1 5.0	2.8 -0.7	3.7 3.5	
2004	4.4	0.7	2.2	3.3	1.6	2.9	
2005	3.5	1.7	2.5	4.4	2.9	4.0	
2006	2.4	10.0	6.7	2.1	4.5	2.7	
2007	0.1	-0.2	-0.1	1.2	-1.1	0.6	
2008	-3.0	-1.7	-2.2	1.3	2.0	1.5	
2009	4.6	15.7	11.2	10.4	8.1	9.9	
2010 ^f	-2.4	0.6	-0.6	-0.2	2.0	0.4	
2011 ^f	-2.1	-0.7	-1.2	0.7	-0.9	0.3	
f: forecast.						National	Health Expenditure Database, 20

Man.

Table B Sask.—Total

Sask.

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, Saskatchewan, 1985 to 2011

			Podella.		Prescribed	Drugs	Debasts				Prescribed Dru	
	Provincial	Federal	Public Social Security WCBs Dru	g Insurance	Subtotal Public	Insurers*	Private Out of Pocket	Subtotal Private	Total Prescribed	Over- the-	ete (Out of Pock Personal Health	Total Non-Presc.
			(Premi	Funds um Component)					Drugs	Counter Drugs	Supplies	Drugs
Year	-					(\$ Million						
1985 1986	67.6 81.1	6.3 7.1	0.1 0.1		74.0 88.3			26.8 33.8	100.8 122.1			35.3 40.0
1987	67.8	7.7	0.2		75.7			42.5	118.2			46.4
1988 1989	63.0 74.8	9.7 12.2	0.3 0.2		73.1 87.2			53.5 67.3	126.5 154.5			58.3 73.2
1990	88.7	14.5	0.3		103.5			79.5	183.0			74.4
1991	93.5	16.8	0.3		110.6			89.2	199.8			73.0
1992	85.0	19.0	0.3		104.3			99.5	203.8	40.6	35.6	76.2
1993 1994	57.8 56.2	22.4 25.0	0.4 0.4		80.6 81.6			126.7 141.3	207.3 222.9	49.9 51.7	44.9 45.5	94.8 97.2
1995	63.8	28.0	0.5		92.2			146.8	239.0	50.1	44.7	94.8
1996	66.6	28.8	0.8		96.2			148.1	244.3	47.4	44.8	92.2
1997 1998	69.3 78.9	31.2 33.7	0.8 0.9		101.3 113.6			161.2 167.4	262.5 280.9	48.9 47.6	47.3 46.7	96.2 94.4
1999	89.1	38.8	1.1		129.0			174.0	303.0	52.8	48.7	101.5
2000	100.2	42.3	1.3		143.8			185.6	329.4	55.9	51.0	106.9
2001	116.3	48.1	1.6		165.9			216.1	382.1	57.1	50.5	107.7
2002 2003	133.9 151.4	55.2 62.5	1.9 2.2		191.0 216.1			222.5 252.3	413.6 468.4	58.1 57.4	51.3 50.0	109.4 107.4
2004	168.1	64.9	2.5		235.5			274.1	509.6	60.4	51.8	112.3
2005	185.4	68.2	2.6		256.2			286.1	542.3	61.7	53.4	115.2
2006	201.9	73.1	2.8		277.9			282.5	560.4	63.0	54.0	117.0
2007 2008	241.0 269.0	75.7 78.5	3.0 3.4		319.7 350.9			300.9 289.2	620.7 640.1	65.2 69.0	53.2 54.5	118.4 123.5
2009	286.2	82.9	3.5		372.6			322.3	694.9	74.9	57.5	132.3
2010 ^f	316.4	84.0	4.1		404.5			373.9	778.4	77.5	58.8	136.2
2011 ^f	323.6	85.5	4.6		413.7			431.3	845.0	78.0	59.7	137.7
	-					(Annual Percenta						
1985 1986	20.0	13.1	2.4		19.3			25.8	21.1			13.2
1987	-16.4	8.9	42.4		-14.2			25.8	-3.2			16.0
1988	-7.1	26.1	58.9		-3.5			25.8	7.0			25.6
1989	18.7	25.3	-28.9		19.4			25.8	22.1			25.6
1990 1991	18.7 5.4	18.6 16.1	9.8 5.4		18.6 6.9			18.2 12.2	18.5 9.2			1.6 -1.9
1992	-9.1	12.9	20.3		-5.7			11.5	2.0			4.5
1993 1994	-32.0 -2.8	18.1 11.7	32.9 -2.2		-22.7			27.3 11.5	1.7 7.5	22.7 3.6	26.3 1.3	24.4 2.5
					1.3							
1995 1996	13.6 4.4	11.7 3.0	16.1 63.1		13.0 4.3			3.9 0.9	7.2 2.2	-3.0 -5.4	-1.9 0.4	-2.5 -2.7
1997	4.0	8.3	4.3		5.3			8.8	7.4	3.1	5.5	4.3
1998 1999	13.9 12.9	8.1 15.1	9.6 22.0		12.1 13.6			3.9 3.9	7.0 7.8	-2.5 10.8	-1.2 4.1	-1.9 7.5
2000 2001	12.4 16.1	9.0 13.8	16.4 18.5		11.4 15.4			6.7 16.4	8.7 16.0	5.8 2.2	4.9 -1.0	5.4 0.7
2002	15.1	14.9	20.9		15.1			3.0	8.2	1.7	1.5	1.6
2003 2004	13.1 11.0	13.1 3.8	14.4 17.3		13.1 9.0			13.4 8.6	13.2 8.8	-1.3 5.3	-2.6 3.7	-1.9 4.5
2005	10.3	5.1	2.2		8.8			4.4	6.4	2.2	3.1	2.6
2005	8.9	7.3	9.3		8.5			-1.3	3.3	2.2	1.1	1.6
2007	19.4	3.5	6.1		15.1			6.5	10.8	3.5	-1.4	1.2
2008 2009	11.6 6.4	3.7 5.6	13.8 3.2		9.7 6.2			-3.9 11.4	3.1 8.6	5.9 8.4	2.4 5.4	4.3 7.1
2010 ^f	10.5	1.3	16.6		8.5			16.0	12.0	3.5	2.2	3.0
2010 2011 ^f	2.3	1.9	12.5		2.3			15.4	8.6	0.6	1.7	1.1
					(Percent	age Share of Tota	I Drug Expend	liture)				
1985	49.6	4.6	0.1		54.4			19.7	74.1			25.9
1986 1987	50.0 41.2	4.4 4.7	0.1 0.1		54.5 46.0			20.8 25.8	75.3 71.8			24.7 28.2
1988	34.1	5.3	0.2		39.5			28.9	68.5			31.5
1989	32.8	5.4	0.1		38.3			29.5	67.9			32.1
1990 1991	34.5 34.3	5.6 6.2	0.1 0.1		40.2 40.5			30.9 32.7	71.1 73.3			28.9 26.7
1991	30.3	6.8	0.1		40.5 37.2			35.5	73.3 72.8	14.5	12.7	27.2
1993	19.1	7.4	0.1		26.7			41.9	68.6	16.5	14.9	31.4
1994	17.5	7.8	0.1		25.5			44.1	69.6	16.1	14.2	30.4
1995 1996	19.1 19.8	8.4 8.6	0.1 0.2		27.6 28.6			44.0 44.0	71.6 72.6	15.0 14.1	13.4 13.3	28.4 27.4
1997	19.3	8.7	0.2		28.2			44.0	73.2	13.6	13.2	26.8
1998	21.0	9.0	0.2		30.3			44.6	74.9	12.7	12.4	25.1
1999	22.0	9.6	0.3		31.9			43.0	74.9	13.1	12.0	25.1
2000	23.0	9.7	0.3		32.9			42.5	75.5	12.8	11.7	24.5
2001 2002	23.7 25.6	9.8 10.6	0.3 0.4		33.9 36.5			44.1 42.6	78.0 79.1	11.7 11.1	10.3 9.8	22.0 20.9
2003	26.3	10.9	0.4		37.5			43.8	81.3	10.0	8.7	18.7
2004	27.0	10.4	0.4		37.9			44.1	81.9	9.7	8.3	18.1
2005 2006	28.2	10.4 10.8	0.4 0.4		39.0			43.5	82.5 82.7	9.4 9.3	8.1	17.5
2006	29.8 32.6	10.8 10.2	0.4		41.0 43.3			41.7 40.7	82.7 84.0	9.3 8.8	8.0 7.2	17.3 16.0
2008	35.2	10.3	0.4		45.9			37.9	83.8	9.0	7.1	16.2
2009	34.6	10.0	0.4		45.0			39.0	84.0	9.1	6.9	16.0
2010 [†] 2011 [†]	34.6 32.9	9.2 8.7	0.5 0.5		44.2 42.1			40.9 43.9	85.1 86.0	8.5 7.9	6.4 6.1	14.9 14.0
f: forecast.	52.9	0.7	0.5		74.1			73.5	00.0	7.5	0.1	14.0

f: forecast.

* Confidentiality precludes reporting provincial-level insurance data.

Table B Sask.—Total

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, Saskatchewan, 1985 to 2011 (cont'd)

	-	1	otal Health Exp	enditures, Sa	skatchewan, 19	85 to 2011 (cont	L'd) Share of Drugs in Pu	blic. Private and	
		I Drugs Private	Total	Public	Health Expenditure Private	Total	Total Health E		Total
Year			(\$ Million	s)			(Percentag	e Share)	
1985	74.0	62.1	136.1	1,195.5	333.2	1,528.8	6.2	18.6	8.9
1986	88.3	73.7	162.0	1,325.9	377.7	1,703.6	6.7	19.5	9.5
1987 1988	75.7 73.1	88.9 111.7	164.6 184.8	1,372.2 1,468.3	395.5 369.3	1,767.8 1,837.6	5.5 5.0	22.5 30.2	9.3 10.1
1989	87.2	140.4	227.7	1,629.2	423.7	2,052.9	5.4	33.1	11.1
1990	103.5	153.9	257.4	1,792.1	460.1	2,252.2	5.8	33.4	11.4
1991	110.6	162.2	272.8	1,828.9	490.9	2,319.8	6.0	33.0	11.8
1992 1993	104.3 80.6	175.8 221.5	280.1 302.1	1,819.5 1,727.8	505.8 574.1	2,325.4 2,301.9	5.7 4.7	34.7 38.6	12.0 13.1
1994	81.6	238.5	320.1	1,778.8	606.4	2,385.2	4.6	39.3	13.4
1995	92.2	241.6	333.8	1,820.8	621.5	2,442.3	5.1	38.9	13.7
1996	96.2	240.4	336.6	1,862.3	627.7	2,490.0	5.2	38.3	13.5
1997	101.3	257.4	358.6	1,976.1	680.1	2,656.2	5.1	37.8	13.5
1998 1999	113.6 129.0	261.8 275.4	375.3 404.5	2,103.5 2,250.4	674.7 727.0	2,778.2 2,977.4	5.4 5.7	38.8 37.9	13.5 13.6
2000 2001	143.8 165.9	292.5 323.8	436.3 489.7	2,381.2 2,581.5	778.6 875.5	3,159.8 3,457.0	6.0 6.4	37.6 37.0	13.8 14.2
2002	191.0	332.0	523.0	2,719.3	903.8	3,623.1	7.0	36.7	14.4
2003	216.1	359.7	575.8 621.8	2,895.9	975.0 1 025.7	3,870.8	7.5	36.9 37.7	14.9
2004	235.5	386.3	621.8	3,100.3	1,025.7	4,126.0	7.6	37.7	15.1
2005	256.2 277.9	401.3	657.5 677.4	3,365.4	1,054.1	4,419.5	7.6	38.1	14.9
2006 2007	277.9 319.7	399.5 419.4	677.4 739.1	3,600.6 3,876.1	1,164.3 1,217.3	4,764.8 5,093.4	7.7 8.2	34.3 34.5	14.2 14.5
2008	350.9	412.8	763.7	4,213.0	1,223.2	5,436.2	8.3	33.7	14.0
2009	372.6	454.6	827.3	4,471.9	1,346.4	5,818.3	8.3	33.8	14.2
2010 ^f	404.5	510.1	914.6	4,812.1	1,497.2	6,309.3	8.4	34.1	14.5
2011 ^f	413.7	569.0	982.7	5,143.1	1,645.2	6,788.2	8.0	34.6	14.5
1985			(Annual Percentag	ge Change) 					
1986	19.3	18.7	19.0	10.9	13.4	11.4			
1987	-14.2	20.5	1.6	3.5	4.7	3.8			
1988 1989	-3.5 19.4	25.7 25.7	12.3 23.2	7.0 11.0	-6.6 14.7	4.0 11.7			
1990 1991	18.6 6.9	9.6 5.4	13.0 6.0	10.0 2.1	8.6 6.7	9.7 3.0			
1992	-5.7	8.4	2.7	-0.5	3.0	0.2			
1993	-22.7	26.0	7.9	-5.0	13.5	-1.0			
1994	1.3	7.7	5.9	3.0	5.6	3.6			
1995	13.0	1.3	4.3	2.4	2.5	2.4			
1996 1997	4.3 5.3	-0.5 7.1	0.8 6.6	2.3 6.1	1.0 8.3	2.0 6.7			
1998	12.1	1.7	4.6	6.4	-0.8	4.6			
1999	13.6	5.2	7.8	7.0	7.8	7.2			
2000	11.4	6.2	7.9	5.8	7.1	6.1			
2001 2002	15.4 15.1	10.7 2.5	12.2 6.8	8.4 5.3	12.4 3.2	9.4 4.8			
2002	13.1	8.3	10.1	6.5	7.9	6.8			
2004	9.0	7.4	8.0	7.1	5.2	6.6			
2005	8.8	3.9	5.7	8.5	2.8	7.1			
2006	8.5	-0.4	3.0	7.0	10.5	7.8			
2007 2008	15.1 9.7	5.0 -1.6	9.1 3.3	7.7 8.7	4.6 0.5	6.9 6.7			
2009	6.2	10.1	8.3	6.1	10.1	7.0			
2010 ^f	8.5	12.2	10.6	7.6	11.2	8.4			
2011 ^f	2.3	11.5	7.4	6.9	9.9	7.6			
	(Percentage Share								
1985 1986	54.4 54.5	45.6 45.5	100.0 100.0						
1986 1987	54.5 46.0	45.5 54.0	100.0 100.0						
1988	39.5	60.5	100.0						
1989	38.3	61.7	100.0						
1990	40.2	59.8	100.0						
1991 1992	40.5 37.2	59.5 62.8	100.0 100.0						
1992	37.2 26.7	73.3	100.0						
1994	25.5	74.5	100.0						
1995	27.6	72.4	100.0						
1996	28.6	71.4	100.0						
1997 1998	28.2 30.3	71.8 69.7	100.0 100.0						
1998	31.9	68.1	100.0						
2000	32.9	67.1	100.0						
2000	33.9	66.1	100.0						
2002	36.5	63.5	100.0						
2003 2004	37.5 37.9	62.5 62.1	100.0 100.0						
2005 2006	39.0 41.0	61.0 59.0	100.0 100.0						
2006	43.3	56.7	100.0						
2008	45.9	54.1	100.0						
2009	45.0	55.0	100.0						
2010 ^f 2011 ^f	44.2	55.8	100.0						
2011	42.1	57.9	100.0						

f: forecast.

Table B Sask.—Per Capita

Sask.

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Saskatchewan, 1985 to 2011

			D. I. II.		Prescribed	Drugs	Debeste				Prescribed Dru	
	Provincial	Federal	Public Social Secu WCBs	urity Funds Drug Insurance Funds	Subtotal Public	Insurers*	Private Out of Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	Personal Health Supplies	Total Non-Presc. Drugs
Year			(Pre	emium Component)		(\$ per Cap	oita)		· ·	Drugs	••	
1985	65.90	6.11	0.14		72.15			26.16	98.31			34.43
1986 1987	78.76 65.64	6.89 7.48	0.14 0.20		85.79 73.32			32.80 41.13	118.59 114.45			38.85 44.90
1988	61.28	9.47	0.32		71.08			52.00	123.08			56.67
1989	73.37	11.97	0.23		85.58			66.00	151.57			71.80
1990	88.11	14.37	0.26		102.73			78.97	181.70			73.85
1991 1992	93.26 84.66	16.75 18.90	0.27 0.33		110.29 103.88			89.00 99.15	199.30 203.03	40.47	35.45	72.76 75.92
1993	57.37	22.26	0.44		80.07			125.84	205.90	49.53	44.64	94.17
1994	55.63	24.80	0.43		80.85			139.94	220.79	51.18	45.12	96.29
1995	62.89	27.57	0.49		90.94			144.72	235.66	49.43	44.05	93.48
1996 1997	65.33 68.04	28.25 30.62	0.80 0.83		94.39 99.49			145.37 158.31	239.76 257.80	46.51 48.02	44.00 46.46	90.51 94.48
1998	77.57	33.12	0.91		111.61			164.51	276.11	46.83	45.92	92.75
1999	87.81	38.22	1.12		127.15			171.45	298.60	52.05	47.95	100.01
2000	99.38	41.95	1.31		142.64			184.19	326.83	55.45	50.65	106.09
2001 2002	116.26 134.44	48.10 55.48	1.56 1.90		165.92 191.82			216.10 223.47	382.02 415.28	57.12 58.36	50.52 51.52	107.64 109.88
2003	152.23	62.83	2.18		217.24			253.61	470.85	57.69	50.26	107.95
2004	168.98	65.19	2.55		236.72			275.48	512.20	60.72	52.11	112.84
2005	187.28	68.87	2.62		258.76			289.02	547.79	62.36	53.97	116.33
2006 2007	203.49 240.98	73.72 75.67	2.86 3.01		280.07 319.66			284.76 300.87	564.83 620.53	63.51 65.19	54.44 53.23	117.95 118.42
2008	265.33	77.42	3.38		346.13			285.29	631.42	68.10	53.75	121.86
2009	278.14	80.52	3.44		362.10			313.18	675.28	72.75	55.84	128.59
2010 ^f	302.59	80.29	3.94		386.82			357.59	744.40	74.12	56.19	130.30
2011 [†]	306.07	80.91	4.39		391.37			407.98	799.35	73.75	56.50	130.25
1985						(Annual Percenta	ge Change)					
1986	19.5	12.7	2.1		18.9			25.4	20.6			12.8
1987	-16.7	8.5	41.9		-14.5			25.4	-3.5			15.6
1988 1989	-6.6 19.7	26.6 26.4	59.6 -28.3		-3.1 20.4			26.4 26.9	7.5 23.2			26.2 26.7
1990	20.1	20.0	11.1		20.0			19.7	19.9			2.8
1991	5.9	16.6	5.9		7.4			12.7	9.7			-1.5
1992	-9.2	12.8	20.1		-5.8			11.4	1.9			4.3
1993 1994	-32.2 -3.0	17.8 11.4	32.6 -2.4		-22.9 1.0			26.9 11.2	1.4 7.2	22.4 3.3	25.9 1.1	24.0 2.3
1995	13.1	11.1	15.6		12.5			3.4	6.7	-3.4	-2.4	-2.9
1996	3.9	2.5	62.3		3.8			0.5	1.7	-5.9	-0.1	-3.2
1997	4.1	8.4	4.4		5.4			8.9	7.5	3.3	5.6	4.4
1998 1999	14.0 13.2	8.2 15.4	9.7 22.3		12.2 13.9			3.9 4.2	7.1 8.1	-2.5 11.1	-1.2 4.4	-1.8 7.8
2000	13.2	9.8	17.2		12.2			7.4	9.5	6.5	5.6	6.1
2001	17.0	14.6	19.4		16.3			17.3	16.9	3.0	-0.3	1.5
2002	15.6	15.3	21.4		15.6			3.4	8.7	2.2	2.0	2.1
2003 2004	13.2 11.0	13.3 3.7	14.6 17.2		13.3 9.0			13.5 8.6	13.4 8.8	-1.2 5.3	-2.4 3.7	-1.8 4.5
2005	10.8	5.6	2.7		9.3			4.9	6.9	2.7	3.6	3.1
2005	8.7	7.1	9.1		9.3 8.2			-1.5	3.1	1.8	0.9	1.4
2007	18.4	2.6	5.2		14.1			5.7	9.9	2.6	-2.2	0.4
2008 2009	10.1 4.8	2.3 4.0	12.3 1.7		8.3 4.6			-5.2 9.8	1.8 6.9	4.5 6.8	1.0 3.9	2.9 5.5
2010 ^f												
2010 2011 ^f	8.8 1.1	-0.3 0.8	14.7 11.3		6.8 1.2			14.2 14.1	10.2 7.4	1.9 -0.5	0.6 0.6	1.3 0.0
				(Annual	Percentage Cha	inge in Excess of	Inflation in the	Canadian Econ	omy)			
1985	46.7	9.9							47.0			
1986 1987	16.7 -21.4	3.7	-0.7 37.2		16.1 -19.3			22.6 20.7	17.8 -8.2			10.0 10.8
1988	-11.2	22.1	55.1		-7.6			21.9	3.0			21.7
1989	15.2	21.9	-32.9		15.8			22.4	18.6			22.1
1990	17.1	17.0	8.1		17.0			16.6	16.8			-0.2
1991 1992	3.1 -10.5	13.8 11.5	3.1 18.9		4.6 -7.1			10.0 10.1	6.9 0.6			-4.2 3.1
1993	-33.7	16.3	31.1		-24.4			25.5	0.0	20.9	24.5	22.6
1994	-4.1	10.3	-3.5		-0.1			10.1	6.1	2.2	0.0	1.2
1995 1996	10.7 2.2	8.8 0.8	13.3 60.6		10.1 2.1			1.1 -1.2	4.4 0.1	-5.7 -7.6	-4.7 -1.8	-5.3 -4.8
1997	3.2	7.4	3.4		4.4			7.9	6.5	2.3	4.6	3.4
1998	14.4	8.6	10.1		12.6			4.4	7.5	-2.0	-0.7	-1.4
1999	11.4	13.6	20.5		12.1			2.4	6.3	9.3	2.6	6.0
2000 2001	9.1 15.6	5.7 13.3	13.1 18.0		8.1 15.0			3.3 16.0	5.4 15.5	2.4 1.7	1.5 -1.6	2.0 0.1
2002	14.6	14.3	20.4		14.6			2.4	7.7	1.1	0.9	1.0
2003	10.3	10.4	11.7		10.4			10.6	10.5	-4.0	-5.3	-4.7
2004	8.4	1.2	14.6		6.4			6.0	6.2	2.7	1.1	1.9
2005 2006	7.8 5.9	2.6 4.3	-0.3 6.3		6.3 5.4			1.9 -4.3	3.9 0.3	-0.3 -1.0	0.6 -1.9	0.1 -1.4
2007	14.7	-1.0	1.6		10.5			2.0	6.2	-1.0	-5.9	-3.3
2008	5.2	-2.6	7.5		3.4			-10.0	-3.1	-0.4	-3.9	-2.0
2009	7.5	6.7	4.4		7.3			12.5	9.7	9.5	6.6	8.2
2010 ^t 2011 ^f	5.8 -2.8	-3.2 -3.2	11.8 7.3		3.9 -2.8			11.2 10.1	7.3 3.4	-1.1 -4.5	-2.3 -3.4	-1.6 -4.0
f: forecast.	2.0	0.2			2.0							

t: forecast.

* Confidentiality precludes reporting provincial-level insurance data.

Table B Sask.—Per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Saskatchewan, 1985 to 2011 (cont'd)

All Drugs Private Health Expenditure Price Index—Canada Public Public Year (\$ per Capita) (1997 = 100) 1985 1986 72.15 85.79 60.60 71.65 132.75 157.44 324.93 366.97 1,490.78 1,655.19 1,165.85 73.6 75.6 1987 73.32 86.03 159.35 1,328.72 383.01 1,711.73 79.2 85.58 223.37 1,598.43 415.71 1989 137.80 2,014.15 86.6 1990 102.73 152.81 255.54 1,779.42 456.84 2,236.27 1991 110.29 161.76 272.06 1.824.01 489.59 2.313.60 91.6 1,812.37 1,716.06 2,316.20 1993 80.07 220.01 300.07 570.20 2,286.26 94.1 80.85 317.09 2,408.26 2,443.35 1,795.42 97.4 1995 90.94 238.20 329.14 612.84 1996 235.89 1997 99.49 252.79 352.28 1,941.00 668.05 2,609.05 100.0 111.61 127.15 257.26 271.46 368.86 2,067.32 2,217.76 663.07 2,730.39 2,934.21 398.61 716.46 101.4 1999 142.64 290.28 432.93 2,362.84 772.58 3,135.42 2.581.16 2001 165.92 323.74 489.66 875.38 3.456.55 106.9 2002 191.82 333.35 525.17 578.80 2,730.52 2,911.21 907.57 3,638.09 3,891.34 217.24 361.56 980.13 2003 2004 236.72 388.31 625.04 3,116.22 1,030.97 4,147.20 114.1 664.12 3.399.24 1.064.72 4.463.96 117.5 2005 258.76 405.36 1,173.53 1,216.97 4,802.67 5,092.12 402.71 682.78 3,629.15 2007 319.66 419.29 738.95 3,875.15 125.2 407.15 441.77 4,155.66 4,345.34 1,206.56 1,308.31 2008 346.13 753.27 5,362.22 131.3 2009 4,602.11 4,864.94 1,431.88 1,556.19 6,033.99 6,421.13 2010^f 487.89 874.71 2011 391.37 538.23 929.60 136.8 (Annual Percentage Change) 1985 ---18.9 18.2 1986 18.6 10.5 12.9 11.0 2.8 3.1 7.5 1988 -3.1 26.3 12.8 -6.2 4.5 1989 20.4 26.8 24.3 11.9 15.7 12.7 4.6 10.9 14.4 11.3 1990 20.0 9.9 11.0 3.0 5.9 7.2 1991 8.2 1.3 1992 -5.8 2.5 -0.6 2.9 0.1 1993 1994 -22.9 1.0 25.7 7.4 13.2 7.6 5.7 -5.3 2.7 1.4 -1.3 3.3 2.3 1.7 1.0 1995 12.5 8.0 3.8 1.9 2.0 0.5 3.8 5.4 12.2 1996 -1.0 0.3 1.8 1.5 8.5 -0.7 8.1 7.2 1.8 1997 6.7 4.7 6.2 6.5 6.8 4.7 -0.4 1998 1999 13.9 5.5 8.1 7.3 7.5 1.8 6.9 2000 12.2 8.6 6.5 7.8 6.9 4.1 13.3 2001 13.1 1.4 15.6 3.0 2002 7.3 5.8 5.3 13.3 8.5 7.4 5.2 2.6 2004 9.0 8.0 7.0 6.6 2005 9.3 4.4 9.1 3.3 7.6 6.3 8.2 14.1 2006 -0.7 4.1 2.8 6.8 10.2 3.7 7.6 2.8 3.7 2007 6.0 -2.9 2008 8.3 4.6 1.9 7.2 -0.9 5.3 4.9 -2.7 9.4 8.7 2010 10.4 8.8 5.9 6.7 2.9 10.3 5.7 6.4 6.3 Percentage Change in Excess of Inflation in the Canad 1985 16.1 15.4 7.7 10.1 8.2 1987 -19.3 15.3 -3.5 -1.6 -0.4 -1.3 1988 1989 -7.6 15.8 21.8 22.2 8.3 19.7 3.0 7.3 -10.7 11.1 -0.1 8.1 1990 17.0 7.9 11.4 8.3 6.9 4.4 8.0 3.1 7.0 24.2 1991 4.6 3.7 -0.3 0.7 1992 -7.1 -24.4 -1.9 -6.8 1.6 -1.1 -2.7 1993 6.1 1994 -0.1 6.3 4.6 1.6 4.2 2.2 10.1 -1.5 1.5 -0.4 -0.3 -0.4 1995 1996 1997 -2.6 6.2 -1.3 5.7 0.1 5.2 -1.2 7.5 -0.2 5.8 2.2 3.7 -0.3 6.2 1998 12.6 5.1 6.9 5.1 1999 12.1 6.3 5.5 2000 8.1 2.8 4.5 2.4 3.7 2.8 15.0 14.6 10.2 7.9 4.7 12.0 2001 11.8 8.9 1.9 5.6 4.8 2.6 5.1 2.6 2002 6.2 7.3 5.4 4.2 2002 10.4 3.7 4.5 4.1 2005 6.3 3.2 6.1 0.3 7.4 4.6 5.4 10.5 3.4 2006 -3.4 0.0 4.0 4.8 2007 0.4 3.1 2.4 0.0 2.3 0.4 -7.8 -5.7 2008 -2.9 2009 7.3 11.2 9.4 7.3 11.1 8.1 2010 3.9 7.5 3.0 6.5 4.7 3.8 5.9 2011^f 2.3

Sask

f: forecast.

Table B Alta.—Total

Alta.

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, Alberta, 1985 to 2011

		Public		Prescribed	Drugs	Private				-Prescribed Dru ate (Out of Pock	
Provincial	Federal	Social Security I WCBs Drug	Insurance unds	Subtotal Public	Insurers*	Out of Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	Personal Health Supplies	Total Non-Presc. Drugs
		(Premiur	n Component)		(\$ Million	ıs)			Drugs		
69.5	6.4	0.9		76.7			134.5	211.2			113.1
83.2	7.0	1.2		91.4			147.9	239.3			128.1
95.7 108.0	7.4 9.1	1.5 1.6		104.6 118.7			153.1 172.6	257.7 291.3			148.5 163.3
159.7	11.1	1.8		172.7			194.5	367.2			179.6
179.5	13.2	2.2		194.9			219.0	413.9			184.3
189.2	15.3	2.7		207.1			241.2	448.3			192.8
205.6 205.8	17.1 20.4	3.0 3.7		225.6 229.9			256.8 297.0	482.4 526.9	103.3 114.2	91.2 98.7	194.4 213.0
208.1	22.8	3.3		234.2			309.4	543.7	119.3	106.1	225.4
212.5	26.0	3.1		241.5			323.6	565.1	119.8	108.9	228.6
232.6	26.3	3.5		262.4			360.2	622.6	128.3	112.5	240.8
254.8	29.3	3.5		287.6			403.5	691.1	144.5	125.9	270.4
278.1 328.2	32.8 41.2	4.2 5.2		315.0 374.6			430.1 494.4	745.1 869.1	153.1 167.1	135.0 136.7	288.1 303.8
387.1 451.0	45.1 51.4	5.7 7.7		437.8 510.1			556.5 617.5	994.3 1,127.7	173.4 190.6	150.0 160.8	323.4 351.4
515.2	57.7	8.7		581.7			686.9	1,268.6	199.0	169.6	368.6
588.2	64.9	10.2		663.2			754.3	1,417.5	220.0	177.3	397.3
646.8	67.8	10.9		725.5			800.9	1,526.4	236.8	187.2	424.0
709.3	71.6	10.9		791.7			848.5	1,640.2	240.8	194.9	435.6
758.9 792.5	75.3 76.8	11.6 11.3		845.8 880.6			995.1 1,045.1	1,840.9 1,925.7	270.6 292.0	212.9 222.7	483.6 514.7
827.7	77.0	11.4		916.0			1,118.0	2,034.0	302.1	227.6	529.7
1,003.3	78.8	10.9		1,093.0			1,205.5	2,298.5	320.3	231.7	552.1
1,142.4	79.3	11.2		1,232.9			1,314.3	2,547.2	327.2	231.1	558.3
1,237.9	80.8	11.2		1,330.0			1,421.1	2,751.1	322.0	240.2	562.2
					Annual Percenta						
19.8	9.8	33.7		19.1			10.0	13.3			13.2
15.1	6.1	23.4		14.5			3.5	7.7			16.0
12.7	22.8	13.0		13.5			12.7	13.0			10.0
48.0	22.5	10.2		45.5			12.7	26.1			10.0
12.4	18.0	22.6		12.9			12.6	12.7			2.7
5.4 8.7	16.1 11.8	19.6 11.9		6.3 8.9			10.1 6.5	8.3 7.6			4.6 0.8
0.1	19.6	23.9		1.9			15.7	9.2	10.6	8.3	9.5
1.1	11.9	-11.4		1.9			4.2	3.2	4.5	7.4	5.8
2.1	13.7	-5.1		3.1			4.6	3.9	0.4	2.6	1.4
9.5	1.3	11.9		8.6			11.3	10.2	7.1	3.3	5.3
9.6 9.1	11.5 11.8	-0.3 21.3		9.6 9.5			12.0 6.6	11.0 7.8	12.6 6.0	11.9 7.2	12.3 6.5
18.0	25.8	22.9		18.9			15.0	16.6	9.2	1.3	5.5
17.9	9.3	9.8		16.9			12.6	14.4	3.8	9.7	6.4
16.5	14.1	36.1		16.5			11.0	13.4	9.9	7.3	8.7
14.2 14.2	12.2 12.4	13.6 16.2		14.0 14.0			11.2 9.8	12.5 11.7	4.4 10.5	5.4 4.6	4.9 7.8
10.0	4.5	6.9		9.4			6.2	7.7	7.6	5.6	6.7
9.7	5.6	0.1		9.1			5.9	7.5	1.7	4.1	2.7
7.0	5.2	6.7		6.8			17.3	12.2	12.4	9.3	11.0
4.4	2.0	-2.6		4.1			5.0	4.6	7.9	4.6	6.4
4.4 21.2	0.3 2.4	0.6 -4.2		4.0 19.3			7.0 7.8	5.6 13.0	3.4 6.1	2.2 1.8	2.9 4.2
13.9 8.4	0.6 1.9	2.8 0.3		12.8 7.9			9.0 8.1	10.8 8.0	2.1 -1.6	-0.3 4.0	1.1 0.7
		0.5			age Share of Tota				-1.0		
21.4	2.0	0.3		23.7			41.5	65.1	-		34.9
22.6	1.9	0.3		24.9			40.3	65.1			34.9
23.6 23.7	1.8 2.0	0.4 0.4		25.8 26.1			37.7 38.0	63.4 64.1			36.6 35.9
29.2	2.0	0.3		31.6			35.6	67.2			32.8
30.0	2.2	0.4		32.6			36.6	69.2			30.8
	2.4	0.4		32.3			37.6	69.9			30.1
29.5		0.4		33.3			37.9	71.3	15.3	13.5	28.7
29.5 30.4	2.5			31.1			40.1 40.2	71.2 70.7	15.4 15.5	13.3 13.8	28.8 29.3
29.5 30.4 27.8	2.8	0.5 0.4		30.5				10.1	10.0	10.0	20.0
29.5 30.4 27.8 27.1	2.8 3.0	0.4		30.5							
29.5 30.4 27.8 27.1 26.8	2.8 3.0 3.3	0.4		30.4			40.8	71.2 72.1	15.1 14.9	13.7 13.0	28.8 27.9
29.5 30.4 27.8 27.1	2.8 3.0	0.4						71.2 72.1 71.9	15.1 14.9 15.0	13.7 13.0 13.1	28.8 27.9 28.1
29.5 30.4 27.8 27.1 26.8 26.9 26.5 26.9	2.8 3.0 3.3 3.0 3.1 3.2	0.4 0.4 0.4 0.4 0.4		30.4 30.4 29.9 30.5		 	40.8 41.7 42.0 41.6	72.1 71.9 72.1	14.9 15.0 14.8	13.0 13.1 13.1	27.9 28.1 27.9
29.5 30.4 27.8 27.1 26.8 26.9 26.5	2.8 3.0 3.3 3.0 3.1	0.4 0.4 0.4 0.4		30.4 30.4 29.9			40.8 41.7 42.0	72.1 71.9	14.9 15.0	13.0 13.1	27.9 28.1
29.5 30.4 27.8 27.1 26.8 26.9 26.5 26.9 28.0	2.8 3.0 3.3 3.0 3.1 3.2 3.5	0.4 0.4 0.4 0.4 0.4 0.4	 	30.4 30.4 29.9 30.5 31.9	 	 	40.8 41.7 42.0 41.6 42.2	72.1 71.9 72.1 74.1 75.5	14.9 15.0 14.8 14.2	13.0 13.1 13.1 11.7	27.9 28.1 27.9 25.9 24.5
29.5 30.4 27.8 27.1 26.8 26.9 26.5 26.9 28.0 29.4 30.5	2.8 3.0 3.3 3.0 3.1 3.2 3.5 3.4	0.4 0.4 0.4 0.4 0.4 0.4 0.5	 	30.4 30.4 29.9 30.5 31.9 33.2 34.5		 	40.8 41.7 42.0 41.6 42.2 42.2	72.1 71.9 72.1 74.1 75.5 76.2	14.9 15.0 14.8 14.2 13.2 12.9	13.0 13.1 13.1 11.7 11.4 10.9	27.9 28.1 27.9 25.9 24.5 23.8
29.5 30.4 27.8 27.1 26.8 26.9 26.5 26.9 28.0 29.4 30.5 31.5	2.8 3.0 3.3 3.0 3.1 3.2 3.5 3.4 3.5 3.5	0.4 0.4 0.4 0.4 0.4 0.4 0.4 0.5 0.5		30.4 30.4 29.9 30.5 31.9 33.2 34.5 35.5	 	 	40.8 41.7 42.0 41.6 42.2 42.2 41.7 42.0	72.1 71.9 72.1 74.1 75.5 76.2 77.5	14.9 15.0 14.8 14.2 13.2 12.9 12.2	13.0 13.1 13.1 11.7 11.4 10.9 10.4	27.9 28.1 27.9 25.9 24.5 23.8 22.5
29.5 30.4 27.8 27.1 26.8 26.9 26.5 26.9 28.0 29.4 30.5	2.8 3.0 3.3 3.0 3.1 3.2 3.5 3.4	0.4 0.4 0.4 0.4 0.4 0.4 0.5	 	30.4 30.4 29.9 30.5 31.9 33.2 34.5		 	40.8 41.7 42.0 41.6 42.2 42.2	72.1 71.9 72.1 74.1 75.5 76.2	14.9 15.0 14.8 14.2 13.2 12.9	13.0 13.1 13.1 11.7 11.4 10.9	27.9 28.1 27.9 25.9 24.5 23.8
29.5 30.4 27.8 27.1 26.8 26.9 26.5 26.9 28.0 29.4 30.5 31.5 32.4 33.2	2.8 3.0 3.3 3.0 3.1 3.2 3.5 3.4 3.5 3.5 3.6 3.5	0.4 0.4 0.4 0.4 0.4 0.4 0.5 0.5 0.6		30.4 30.4 29.9 30.5 31.9 33.2 34.5 35.5 36.5 37.2			40.8 41.7 42.0 41.6 42.2 42.2 41.7 42.0 41.6 41.1	72.1 71.9 72.1 74.1 75.5 76.2 77.5 78.1 78.3	14.9 15.0 14.8 14.2 13.2 12.9 12.2 12.1	13.0 13.1 13.1 11.7 11.4 10.9 10.4 9.8 9.6	27.9 28.1 27.9 25.9 24.5 23.8 22.5 21.9 21.7
29.5 30.4 27.8 27.1 26.8 26.9 26.5 26.9 28.0 29.4 30.5 31.5 31.5	2.8 3.0 3.3 3.0 3.1 3.2 3.5 3.4 3.5 3.5 3.6	0.4 0.4 0.4 0.4 0.4 0.4 0.5 0.5 0.6		30.4 30.4 29.9 30.5 31.9 33.2 34.5 35.5 36.5	 		40.8 41.7 42.0 41.6 42.2 42.2 41.7 42.0 41.6	72.1 71.9 72.1 74.1 75.5 76.2 77.5 78.1	14.9 15.0 14.8 14.2 13.2 12.9 12.2 12.1	13.0 13.1 13.1 11.7 11.4 10.9 10.4 9.8	27.9 28.1 27.9 25.9 24.5 23.8 22.5 21.9
29.5 30.4 27.8 27.1 26.8 26.9 26.5 26.9 28.0 29.4 30.5 31.5 32.4 33.2 32.4 32.6 32.5	2.8 3.0 3.1 3.2 3.5 3.4 3.5 3.6 3.5 3.4 3.2	0.4 0.4 0.4 0.4 0.4 0.5 0.5 0.6 0.6 0.5 0.5		30.4 30.4 29.9 30.5 31.9 33.2 34.5 35.5 36.5 37.2 38.1 36.4 36.1			40.8 41.7 42.0 41.6 42.2 42.2 41.7 42.0 41.6 41.1 40.9 42.8 42.8	72.1 71.9 72.1 74.1 75.5 76.2 77.5 78.1 78.3 79.0 79.2 78.9	14.9 15.0 14.8 14.2 13.2 12.9 12.1 12.1 11.6 11.6	13.0 13.1 13.1 11.7 11.4 10.9 10.4 9.8 9.6 9.4	27.9 28.1 27.9 25.9 24.5 23.8 22.5 21.9 21.7 21.0 20.8 21.1
29.5 30.4 27.8 27.1 26.8 26.9 28.0 29.4 30.5 31.5 32.4 33.2 34.2 32.5 32.5 32.3	2.8 3.0 3.3 3.0 3.1 3.2 3.5 3.4 3.5 3.6 3.5 3.6 3.5 3.3	0.4 0.4 0.4 0.4 0.4 0.5 0.5 0.6 0.6 0.5 0.5 0.5 0.5 0.5 0.6		30.4 30.4 29.9 30.5 31.9 33.2 34.5 35.5 36.5 37.2 38.1 36.4 36.1 35.7			40.8 41.7 42.0 41.6 42.2 42.2 41.7 42.0 41.6 41.1 40.9 42.8 42.8 43.6	72.1 71.9 72.1 74.1 75.5 76.2 77.5 78.1 78.3 79.0 79.2 78.9 79.3	14.9 15.0 14.8 14.2 13.2 12.9 12.2 12.1 11.6 11.6 12.0 11.8	13.0 13.1 13.1 11.7 11.4 10.9 10.4 9.8 9.6 9.4 9.2 9.1	27.9 28.1 27.9 25.9 24.5 23.8 22.5 21.9 21.7 21.0 20.8 21.1 20.7
29.5 30.4 27.8 27.1 26.8 26.9 26.5 26.9 28.0 29.4 30.5 31.5 32.4 33.2 32.4 32.6 32.5	2.8 3.0 3.1 3.2 3.5 3.4 3.5 3.6 3.5 3.4 3.2	0.4 0.4 0.4 0.4 0.4 0.5 0.5 0.6 0.6 0.5 0.5		30.4 30.4 29.9 30.5 31.9 33.2 34.5 35.5 36.5 37.2 38.1 36.4 36.1			40.8 41.7 42.0 41.6 42.2 42.2 41.7 42.0 41.6 41.1 40.9 42.8 42.8	72.1 71.9 72.1 74.1 75.5 76.2 77.5 78.1 78.3 79.0 79.2 78.9	14.9 15.0 14.8 14.2 13.2 12.9 12.1 12.1 11.6 11.6	13.0 13.1 13.1 11.7 11.4 10.9 10.4 9.8 9.6 9.4	27.9 28.1 27.9 25.9 24.5 23.8 22.5 21.9 21.7 21.0 20.8 21.1

f: forecast.

* Confidentiality precludes reporting provincial-level insurance data.

Table B Alta.—Total

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, Alberta, 1985 to 2011 (cont'd)

		All D	rotal meanin	Experiuntures, A		Share of Drugs in Public, Private and Total Health Expenditures				
	Public	All Drugs Private	Total	Public Hea	Ith Expenditure Private	Total		xpenditures Private	Total	
Year			(\$ Million	s)			(Percentag	e Share)		
1985	76.7	247.6	324.3	3,239.1	831.3	4,070.4	2.4	29.8	8.0	
1986 1987	91.4 104.6	276.0 301.6	367.4 406.2	3,537.9 3,514.4	910.6 985.5	4,448.5 4,499.9	2.6 3.0	30.3 30.6	8.3 9.0	
1988	118.7	335.9	454.6	3,645.6	1,184.9	4,830.6	3.3	28.3	9.4	
1989	172.7	374.0	546.7	4,031.0	1,318.8	5,349.8	4.3	28.4	10.2	
1990 1991	194.9 207.1	403.4 434.0	598.3 641.1	4,326.9 4,557.5	1,422.5 1,505.1	5,749.4 6,062.5	4.5 4.5	28.4 28.8	10.4 10.6	
1992	225.6	451.2	676.9	4,846.4	1,584.2	6,430.7	4.7	28.5	10.5	
1993 1994	229.9 234.2	510.0 534.8	739.8 769.1	4,800.5 4,527.8	1,719.9 1,785.7	6,520.4 6,313.4	4.8 5.2	29.7 30.0	11.3 12.2	
1995	241.5	552.2	793.8	4,283.5	1,809.0	6,092.5	5.6	30.5	13.0	
1996	262.4	601.0	863.4	4,466.5	1,854.2	6,320.6	5.9	32.4	13.7	
1997 1998	287.6 315.0	673.9 718.1	961.5 1,033.2	4,942.1 5,354.0	2,140.1 2,265.9	7,082.2 7,619.8	5.8 5.9	31.5 31.7	13.6 13.6	
1999	374.6	798.3	1,172.9	6,140.2	2,561.6	8,701.7	6.1	31.2	13.5	
2000	437.8	879.9	1,317.7	6,792.9	2,808.8	9,601.8	6.4	31.3	13.7	
2001	510.1	968.9	1,479.1	7,744.0	3,218.4	10,962.4	6.6	30.1	13.5	
2002 2003	581.7 663.2	1,055.5 1,151.6	1,637.2 1,814.8	8,456.4 9,105.3	3,337.4 3,522.5	11,793.7 12,627.7	6.9 7.3	31.6 32.7	13.9 14.4	
2004	725.5	1,224.9	1,950.4	9,950.0	3,882.3	13,832.3	7.3	31.6	14.1	
2005	791.7	1,284.1	2,075.9	11,041.0	4,129.9	15,170.8	7.2	31.1	13.7	
2006 2007	845.8 880.6	1,478.7 1,559.8	2,324.5 2,440.4	12,156.3 13,356.4	4,835.8 5,118.2	16,992.1 18,474.6	7.0 6.6	30.6 30.5	13.7 13.2	
2008	916.0	1,647.7	2,563.7	14,848.4	5,546.5	20,394.9	6.2	29.7	12.6	
2009	1,093.0	1,757.5	2,850.5	15,694.7	5,824.1	21,518.8	7.0	30.2	13.2	
2010 ^f 2011 ^f	1,232.9 1,330.0	1,872.6 1,983.3	3,105.5 3,313.3	17,722.5 18,377.5	6,168.5 6,558.2	23,891.0 24,935.7	7.0 7.2	30.4 30.2	13.0 13.3	
2011	1,330.0	1,305.5	(Annual Percentag		0,330.2	24,333.7	7.2	30.2	13.3	
1985										
1986 1987	19.1 14.5	11.5 9.3	13.3 10.6	9.2 -0.7	9.5 8.2	9.3 1.2				
1988	13.5	11.3	11.9	3.7	20.2	7.3				
1989	45.5	11.4	20.3	10.6	11.3	10.7				
1990 1991	12.9	7.8	9.4 7.2	7.3 5.3	7.9 5.8	7.5 5.4				
1991	6.3 8.9	7.6 4.0	5.6	6.3	5.3	6.1				
1993	1.9	13.0	9.3	-0.9	8.6	1.4				
1994	1.9	4.9	4.0	-5.7	3.8	-3.2				
1995 1996	3.1 8.6	3.3 8.8	3.2 8.8	-5.4 4.3	1.3 2.5	-3.5 3.7				
1997	9.6	12.1	11.4	10.6	15.4	12.0				
1998 1999	9.5 18.9	6.6 11.2	7.5 13.5	8.3 14.7	5.9 13.1	7.6 14.2				
2000	16.9	10.2	12.3	10.6	9.7	10.3				
2001	16.5	10.1	12.2	14.0	14.6	14.2				
2002 2003	14.0 14.0	8.9 9.1	10.7 10.8	9.2 7.7	3.7 5.5	7.6 7.1				
2004	9.4	6.4	7.5	9.3	10.2	9.5				
2005	9.1	4.8	6.4	11.0	6.4	9.7				
2006 2007	6.8 4.1	15.2 5.5	12.0 5.0	10.1 9.9	17.1 5.8	12.0 8.7				
2007	4.0	5.6	5.1	11.2	8.4	10.4				
2009	19.3	6.7	11.2	5.7	5.0	5.5				
2010 ^f 2011 ^f	12.8 7.9	6.5 5.9	8.9 6.7	12.9 3.7	5.9 6.3	11.0 4.4				
2011		Share of Total Drug E		3.7	0.3	4.4				
1985	23.7	76.3	100.0							
1986 1987	24.9 25.8	75.1 74.2	100.0 100.0							
1988	26.1	73.9	100.0							
1989	31.6	68.4	100.0							
1990 1991	32.6 32.3	67.4 67.7	100.0 100.0							
1992	33.3	66.7	100.0							
1993 1994	31.1 30.5	68.9 69.5	100.0 100.0							
1995 1996	30.4 30.4	69.6 69.6	100.0 100.0							
1997	29.9	70.1	100.0							
1998 1999	30.5 31.9	69.5 68.1	100.0 100.0							
2000	33.2	66.8	100.0							
2001	34.5	65.5	100.0							
2002 2003	35.5 36.5	64.5 63.5	100.0 100.0							
2003	36.5 37.2	62.8	100.0							
2005	38.1	61.9	100.0							
2006	36.4	63.6	100.0							
2007 2008	36.1 35.7	63.9 64.3	100.0 100.0							
2009	38.3	61.7	100.0							
2010 ^f	39.7	60.3	100.0							
2011 [†]	40.1	59.9	100.0							

f: forecast.

Table B Alta.—Per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Alberta, 1985 to 2011

		Prescribed Drugs								Non-Prescribed Drugs			
-	Provincial	Federal		Funds Insurance Funds	Subtotal Public	Insurers*	Private Out of Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	te (Out of Pock Personal Health Supplies	Total Non-Presc. Drugs	
Year				m Component)		(\$ per Cap	nita)		ū	Drugs		•	
1985	28.91	2.65	0.37		31.93	(\$ per Cap		55.96	87.89			47.07	
1986	34.23	2.87	0.48		37.59			60.86	98.44			52.69	
1987	39.32	3.04	0.60		42.96			62.87	105.83			60.99	
1988 _ 1989	43.98 64.01	3.71 4.47	0.67 0.73		48.36 69.20			70.31 77.94	118.67 147.14			66.53 71.96	
1990	70.48	5.16	0.87		76.52			86.00	162.51			72.36	
1991	72.98	5.89	1.02		79.89			93.03	172.92			74.37	
1992	78.09	6.48	1.13		85.70			97.53	183.24	39.22	34.62	73.84	
1993 1994	77.14 77.07	7.65 8.46	1.38 1.21		86.18 86.74			111.35 114.58	197.53 201.32	42.82 44.18	37.01 39.28	79.83 83.46	
1995 1996	77.70 83.81	9.50 9.49	1.13 1.25		88.33 94.55			118.34 129.79	206.67 224.34	43.80 46.23	39.81 40.53	83.62 86.77	
1997	90.05	10.37	1.22		101.64			142.56	244.20	51.05	44.49	95.55	
1998	95.90	11.31	1.45		108.66			148.33	256.98	52.80	46.55	99.36	
1999	111.14	13.97	1.74		126.85			167.42	294.27	56.59	46.29	102.88	
2000 2001	128.81 147.55	15.00 16.82	1.88 2.52		145.69 166.89			185.19 202.01	330.88 368.91	57.71 62.35	49.90 52.62	107.62 114.96	
2002	165.33	18.51	2.81		186.65			220.43	407.08	63.86	54.41	118.28	
2003	186.05	20.52	3.22		209.79			238.59	448.38	69.59	56.09	125.68	
2004	201.62	21.13	3.39		226.14			249.65	475.78	73.81	58.34	132.16	
2005	216.20	21.81	3.31		241.33			258.63	499.96	73.38	59.40	132.78	
2006 2007	221.83 225.61	22.00 21.85	3.39 3.22		247.22 250.68			290.87 297.53	538.09 548.22	79.10 83.13	62.24 63.39	141.34 146.52	
2008	230.46	21.43	3.17		255.06			311.31	566.36	84.11	63.37	147.48	
2009	273.31	21.47	2.97		297.76			328.40	626.16	87.27	63.13	150.39	
2010 ^f	307.01	21.32	3.01		331.34			353.23	684.56	87.94	62.10	150.04	
2011 [†]	326.16	21.30	2.96		350.42			374.44	724.86	84.85	63.29	148.14	
						(Annual Percenta							
1985 1986	18.4	8.6	32.2		 17.7			8.7	12.0			11.9	
1987	14.9	5.9	23.2		14.3			3.3	7.5			15.8	
1988	11.9	21.8	12.1		12.6			11.8	12.1			9.1	
1989	45.5	20.5	8.4		43.1			10.9	24.0			8.2	
1990 1991	10.1 3.5	15.6 14.0	20.1 17.5		10.6 4.4			10.3 8.2	10.4 6.4			0.6 2.8	
1992	7.0	10.1	10.2		7.3			4.8	6.0			-0.7	
1993	-1.2	18.0	22.3		0.6			14.2	7.8	9.2	6.9	8.1	
1994	-0.1	10.5	-12.5		0.6			2.9	1.9	3.2	6.1	4.5	
1995 1996	0.8	12.3 -0.2	-6.3		1.8 7.0			3.3	2.7	-0.8 5.5	1.4	0.2	
1996	7.9 7.4	-0.2 9.3	10.3 -2.2		7.0 7.5			9.7 9.8	8.6 8.9	5.5 10.4	1.8 9.8	3.8 10.1	
1998	6.5	9.1	18.4		6.9			4.0	5.2	3.4	4.6	4.0	
1999	15.9	23.5	20.6		16.7			12.9	14.5	7.2	-0.6	3.6	
2000	15.9	7.4	7.9		14.9			10.6	12.4	2.0	7.8	4.6	
2001 2002	14.6 12.0	12.2 10.1	33.8 11.4		14.6 11.8			9.1 9.1	11.5 10.3	8.0 2.4	5.4 3.4	6.8 2.9	
2002	12.5	10.1	14.6		12.4			8.2	10.1	9.0	3.4	6.3	
2004	8.4	3.0	5.4		7.8			4.6	6.1	6.1	4.0	5.2	
2005	7.2	3.3	-2.2		6.7			3.6	5.1	-0.6	1.8	0.5	
2006	2.6	0.8	2.3		2.4			12.5	7.6	7.8	4.8	6.4	
2007 2008	1.7 2.1	-0.7 -1.9	-5.1 -1.6		1.4 1.7			2.3 4.6	1.9 3.3	5.1 1.2	1.9 0.0	3.7 0.7	
2009	18.6	0.2	-6.3		16.7			5.5	10.6	3.8	-0.4	2.0	
2010 ^f	12.3	-0.7	1.4		11.3			7.6	9.3	0.8	-1.6	-0.2	
2011 ^f	6.2	-0.1	-1.7		5.8			6.0	5.9	-3.5	1.9	-1.3	
1985				(Annual	Percentage Cha	nge in Excess of	Inflation in the	Canadian Econ	omy)				
1986	15.6	5.8	29.4		14.9			5.9	9.2			9.1	
1987	10.1	1.1	18.5		9.5			-1.4	2.8			11.0	
1988 1989	7.3 41.0	17.3 15.9	7.6 3.8		8.1 38.5			7.3 6.3	7.6 19.4			4.6 3.6	
1990	7.1	12.6	17.1		7.5			7.3	7.4			-2.5	
1991	0.8	11.3	14.8		1.6			7.3 5.4	3.6			0.0	
1992	5.7	8.8	8.9		6.0			3.6	4.7			-2.0	
1993	-2.6	16.6	20.8		-0.9			12.7	6.4	7.7	5.5	6.7	
1994	-1.2	9.4	-13.6		-0.4			1.8	8.0	2.1	5.0	3.4	
1995 1996	-1.5 6.2	10.0 -1.9	-8.6 8.6		-0.5 5.4			0.9 8.0	0.3 6.9	-3.2 3.9	-1.0 0.1	-2.1 2.1	
1997	6.5	8.3	-3.2		6.5			8.8	7.9	9.4	8.8	9.1	
1998	6.9	9.5	18.8		7.3			4.5	5.7	3.9	5.1	4.4	
1999	14.1	21.7	18.8		14.9			11.1	12.7	5.4	-2.4	1.7	
2000	11.8	3.3	3.8		10.7			6.5	8.3	-2.1	3.7	0.5	
2001 2002	13.2 11.0	10.8 9.0	32.4 10.4		13.2 10.8			7.7 8.1	10.1 9.3	6.7 1.4	4.1 2.4	5.5 1.8	
2003	9.6	7.9	11.7		9.5			5.3	7.2	6.1	0.2	3.4	
2004	5.8	0.4	2.8		5.2			2.0	3.5	3.5	1.4	2.6	
2005	4.2	0.3	-5.2		3.7			0.6	2.1	-3.6	-1.2	-2.5	
2006 2007	-0.2 -2.0	-1.9 -4.4	-0.5 -8.8		-0.4 -2.3			9.7 -1.4	4.8 -1.8	5.0 1.4	2.0 -1.8	3.6 0.0	
2008	-2.7	-6.8	-6.5		-3.1			-0.2	-1.6	-3.7	-4.9	-4.2	
2009	21.3	2.9	-3.5		19.4			8.2	13.3	6.5	2.3	4.7	
2010 ^f	9.4	-3.7	-1.5		8.3			4.6	6.4	-2.2	-4.6	-3.2	
2011 ^f f: forecast.	2.2	-4.1	-5.7		1.8			2.0	1.9	-7.5	-2.1	-5.3	

f: forecast.

* Confidentiality precludes reporting provincial-level insurance data.

Table B Alta.—Per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Alberta, 1985 to 2011 (cont'd) GDP Implicit

	All Drugs			He	GDP Implicit Price Index—Canada			
	Public	Private	Total	Public	alth Expenditure Private	Total	THOUSAGE CANADA	
Year			(\$ per Cap				(1997 = 100)	
1985	31.93	103.03	134.95	1,347.98	345.94	1,693.92	73.6	
1986 1987	37.59 42.96	113.54 123.86	151.13 166.81	1,455.36 1,443.08	374.58 404.68	1,829.95 1,847.76	75.6 79.2	
1988	48.36	136.84	185.20	1,485.33	482.78	1,968.11	82.8	
1989	69.20	149.90	219.10	1,615.48	528.50	2,143.98	86.6	
1990	76.52	158.36	234.87	1,698.71	558.47	2,257.18	89.2	
1991	79.89	167.40	247.29	1,757.86	580.52	2,338.38	91.6	
1992	85.70	171.37	257.08	1,840.71	601.71	2,442.42	92.8	
1993	86.18	191.18	277.36	1,799.67	644.78	2,444.45	94.1	
1994	86.74	198.04	284.78	1,676.53	661.19	2,337.72	95.2	
1995	88.33	201.95	290.28	1,566.45	661.54	2,227.99	97.4	
1996 1997	94.55 101.64	216.56 238.11	311.11 339.75	1,609.45 1,746.27	668.13 756.21	2,277.57 2,502.48	99.0 100.0	
1998	108.66	247.68	356.34	1,846.55	781.48	2,628.02	99.6	
1999	126.85	270.31	397.16	2,079.12	867.37	2,946.49	101.4	
2000	145.69	292.81	438.50	2,260.59	934.74	3,195.32	105.5	
2001	166.89	316.98	483.87	2,533.41	1,052.90	3,586.31	106.9	
2002	186.65	338.71	525.36	2,713.56	1,070.93	3,784.49	108.1	
2003	209.79	364.28	574.06	2,880.16	1,114.22	3,994.38	111.2	
2004	226.14	381.80	607.94	3,101.44	1,210.13	4,311.57	114.1	
2005	241.33	391.41	632.74	3,365.41	1,258.82	4,624.23	117.5	
2006 2007	247.22 250.68	432.21 444.05	679.43 694.74	3,553.18 3,802.32	1,413.46 1,457.07	4,966.64 5,259.40	120.8 125.2	
2007	255.06	458.78	713.84	4,134.44	1,544.40	5,259.40	131.3	
2009	297.76	478.79	776.55	4,275.63	1,586.63	5,862.25	127.8	
2010 ^f	331.34	503.26	834.60	4,762.90	1,657.78	6,420.69	131.5	
2011 ^f	350.42	522.58	873.00	4,842.19	1,727.97	6,570.15	136.8	
				nnual Percentage Cha				
1985								
1986	17.7	10.2	12.0	8.0	8.3	8.0	2.8	
1987	14.3	9.1	10.4	-0.8	8.0	1.0	4.7	
1988 1989	12.6 43.1	10.5 9.5	11.0 18.3	2.9 8.8	19.3 9.5	6.5 8.9	4.5 4.6	
1990	10.6	5.6	7.2	5.2	5.7	5.3	3.0	
1991 1992	4.4 7.3	5.7 2.4	5.3 4.0	3.5 4.7	3.9 3.7	3.6 4.4	2.8 1.3	
1993	0.6	11.6	7.9	-2.2	7.2	0.1	1.4	
1994	0.6	3.6	2.7	-6.8	2.5	-4.4	1.1	
1995	1.8	2.0	1.9	-6.6	0.1	-4.7	2.3	
1996	7.0	7.2	7.2	2.7	1.0	2.2	1.7	
1997	7.5	10.0	9.2	8.5	13.2	9.9	1.0	
1998 1999	6.9 16.7	4.0 9.1	4.9 11.5	5.7 12.6	3.3 11.0	5.0 12.1	-0.4 1.8	
2000	14.9	8.3	10.4	8.7	7.8	8.4	4.1	
2001 2002	14.6 11.8	8.3 6.9	10.3 8.6	12.1 7.1	12.6 1.7	12.2 5.5	1.4 1.0	
2003	12.4	7.5	9.3	6.1	4.0	5.5	2.9	
2004	7.8	4.8	5.9	7.7	8.6	7.9	2.6	
2005	6.7	2.5	4.1	8.5	4.0	7.3	3.0	
2006	2.4	10.4	7.4	5.6	12.3	7.4	2.8	
2007	1.4	2.7	2.3	7.0	3.1	5.9	3.7	
2008	1.7	3.3	2.7	8.7	6.0	8.0	4.9	
2009	16.7	4.4	8.8	3.4	2.7	3.2	-2.7	
2010 ^f	11.3	5.1	7.5	11.4	4.5	9.5	2.9	
2011 ¹	5.8	3.8	4.6	1.7	4.2	2.3	4.0	
1985		(Annual Percentage		ntiation in the Canadia				
1986	14.9	7.4	9.2	5.2	5.5	5.2		
1987	9.5	4.3	5.6	-5.6	3.3	-3.8		
1988	8.1	6.0	6.5	-1.6 4.2	14.8	2.0		
1989	38.5	5.0	13.7	4.2	4.9	4.4		
1990	7.5	2.6	4.2	2.1	2.6	2.3		
1991 1992	1.6 6.0	3.0 1.1	2.5 2.7	0.7 3.5	1.2 2.4	0.8 3.2		
1992	-0.9	1.1	6.5	3.5 -3.7	2.4 5.7	-1.4		
1994	-0.4	2.5	1.6	-7.9	1.4	-5.5		
1995	-0.5	-0.4	-0.4	-8.9	-2.3	-7.0		
1996	5.4	5.6	5.5	1.1	-0.7	0.6		
1997	6.5	9.0	8.2	7.5	12.2	8.9		
1998	7.3	4.5	5.3	6.2	3.8	5.5		
1999	14.9	7.3	9.6	10.8	9.2	10.3		
2000	10.7	4.2	6.3	4.6	3.7	4.3		
2001 2002	13.2 10.8	6.9 5.8	9.0 7.5	10.7 6.1	11.3 0.7	10.9 4.5		
2003	9.5	4.7	6.4	3.2	1.1	2.6		
2004	5.2	2.2	3.3	5.1	6.0	5.4		
2005	3.7	-0.5	1.1	5.5	1.0	4.2		
2006	-0.4	7.6	4.6	2.8	9.5	4.6		
2007	-2.3	-0.9	-1.4	3.3	-0.6	2.2		
2008 2009	-3.1 19.4	-1.5 7.1	-2.1 11.5	3.9 6.1	1.1 5.4	3.1 5.9		
2010 ^f 2011 ^f	8.3 1.8	2.2 -0.2	4.5 0.6	8.5 -2.3	1.5 0.2	6.6 -1.7		
	1.0	-0.2	5.0	-2.0	0.2	-1.1		

Alta

f: forecast.

Table B B.C.—Total

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, British Columbia, 1985 to 2011

			Public		Prescribed	d Drugs	Private				Prescribed Dru te (Out of Pock	
Pi	rovincial	Federal	Social Security WCBs Drug	Insurance Funds	Subtotal Public	Insurers*	Out of Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	Personal Health Supplies	Total Non-Presc. Drugs
			(Premiu	n Component)		(\$ Millior	ıs)			Drugs		
	128.5	7.8	1.4		137.7			121.1	258.8			157.
	151.4	8.6	1.5		161.5			105.6	267.0			178.
	153.5 169.8	9.2 14.0	1.7 2.0		164.4 185.7			134.9 159.6	299.2 345.3			207. 219.
	196.5	18.0	2.0		216.7			188.9	405.6			219.
	232.6 275.4	21.2 24.4	2.4 2.7		256.3 302.4			216.8 241.1	473.0 543.5			248. 266.
	311.8	26.5	3.1		341.5			268.1	609.5	149.5	134.7	284.
	346.0	32.1	3.5		381.6			303.1	684.7	164.4	146.0	310.
	339.4	35.8	4.0		379.2			323.2	702.5	183.5	156.9	340.
	349.5	40.5	4.2		394.1			353.5	747.6	186.0	163.8	349.
	379.4	44.2	3.9		427.5			374.9	802.4	192.2	166.3	358.
	418.7	45.3	4.0		468.0			412.2	880.2	196.5	172.7	369.
	457.8 515.6	49.5 54.2	5.1 5.9		512.4 575.7			480.0 505.7	992.4 1,081.5	208.5 226.4	185.0 196.7	393. 423.
	595.4 659.1	58.2 65.6	6.8 7.4		660.4 732.1			570.1 641.0	1,230.5 1,373.1	235.6 245.1	199.6 209.6	435.: 454.
	670.3	76.0	7.2		753.4			759.4	1,512.8	257.5	220.3	477.
	657.7	88.0	7.6		753.3			881.4	1,634.7	278.3	225.5	503.
	700.4	92.6	9.0		801.9			1,009.6	1,811.5	295.6	231.6	527.
	750.0	96.6	9.8		856.3			1,035.5	1,891.8	299.1	239.4	538.
	793.8	101.4	10.8		906.0			1,224.0	2,130.0	308.1	244.2	552.3
	825.6	104.5	11.3		941.4			1,232.4	2,173.8	286.1	221.3	507.
	856.0	107.2	12.0		975.2			1,375.4	2,350.6	292.7	224.2	516.
	883.1	108.7	11.5		1,003.3			1,443.7	2,447.0	308.0	231.3	539.
	927.8	108.9	13.8		1,050.5			1,519.9	2,570.4	327.4	236.7	564.
	964.9	110.9	15.0		1,090.9	 (4		1,559.3	2,650.2	329.5	252.4	581.
-						(Annual Percenta	ge Change)					
	17.8	9.6	4.7		17.2			-12.8	3.2			13.
	1.4	7.3	15.5		1.8			27.8	12.1			16.
	10.6	51.5	16.5		13.0			18.4	15.4			5.
	15.8	29.1	9.0		16.7			18.4	17.5			5.
	18.3	17.9	14.0		18.2			14.7	16.6			7.
	18.4	14.6	10.1		18.0			11.3	14.9			7.
	13.2 11.0	9.0 21.0	16.1 11.6		12.9 11.7			11.2 13.1	12.1 12.3	10.0	8.4	6. 9.:
	-1.9	11.6	14.1		-0.6			6.6	2.6	11.6	7.4	9.
	3.0	12.9	5.7		3.9			9.4	6.4	1.4	4.4	2.
	8.6	9.1	-6.0		8.5			6.1	7.3	3.3	1.5	2.
	10.3	2.6	2.1		9.5			10.0	9.7	2.3	3.9	3.0
	9.4	9.2	25.6		9.5			16.4	12.7	6.1	7.1	6.0
	12.6	9.6	17.2		12.4			5.4	9.0	8.6	6.3	7.
	15.5	7.3	15.1		14.7			12.7	13.8	4.1	1.5	2.5
	10.7	12.7	8.3		10.9			12.4	11.6	4.0	5.0	4.
	1.7 -1.9	15.8 15.8	-3.0 6.4		2.9 0.0			18.5 16.1	10.2	5.1 8.1	5.1 2.3	5. 5.
	6.5	5.1	17.9		6.4			14.5	8.1 10.8	6.2	2.7	4.
	7.1 5.8	4.3 5.0	8.8 10.4		6.8 5.8			2.6 18.2	4.4 12.6	1.2 3.0	3.3 2.0	2.
	4.0	3.1	4.9		3.9			0.7	2.1	-7.2	-9.4	-8.
	3.7	2.6	5.7		3.6			11.6	8.1	2.3	1.3	1.9
	3.2	1.4	-4.3		2.9			5.0	4.1	5.2	3.2	4.3
	5.1	0.1	20.8		4.7			5.3	5.0	6.3	2.3	4.
	4.0	1.9	8.5		3.8			2.6	3.1	0.6	6.6	3.
	30.9	1.9	0.3		(Percen 33.1	tage Share of Tota	I Drug Expend	29.1	62.1			37.
	34.0	1.9	0.3		36.2			23.7	59.9			40.
	30.3	1.8	0.3		32.5			26.6	59.1			40.
	30.1	2.5	0.3		32.9			28.3	61.2			38.
	30.8	2.8	0.3		34.0			29.6	63.6			36.
	32.2	2.9	0.3		35.5			30.0	65.5			34.
	34.0	3.0	0.3		37.3			29.8	67.1			32.
	34.9 34.8	3.0 3.2	0.3 0.3		38.2 38.3			30.0 30.5	68.2 68.8	16.7 16.5	15.1 14.7	31. 31.
	32.5	3.4	0.4		36.4			31.0	67.4	17.6	15.0	32.
	31.8 32.7	3.7 3.8	0.4 0.3		35.9 36.8			32.2 32.3	68.1 69.1	16.9 16.6	14.9 14.3	31. 30.
	33.5	3.6	0.3		37.5			33.0	70.5	15.7	13.8	29.
	33.0	3.6	0.4		37.0			34.6	71.6	15.0	13.4	28.
	34.3	3.6	0.4		38.3			33.6	71.9	15.0	13.1	28.
	35.7	3.5	0.4		39.6			34.2	73.9	14.1	12.0	26.
	36.1	3.6	0.4		40.1			35.1	75.1	13.4	11.5	24.
	33.7	3.8	0.4		37.8 35.2			38.1	76.0 76.4	12.9	11.1	24.
	30.8 29.9	4.1 4.0	0.4 0.4		35.2 34.3			41.2 43.2	76.4 77.5	13.0 12.6	10.5 9.9	23. 22.
	30.9	4.0	0.4		35.2			42.6 45.6	77.8	12.3	9.9	22
	29.6	3.8 3.9	0.4 0.4		33.8 35.1			45.6 46.0	79.4 81.1	11.5 10.7	9.1 8.3	20. 18.
	30 R		U. T		30.1							
	30.8 29.9	3.7	0.4		34.0			48.0	82.0	10.2	7.8	18.
		3.7 3.6	0.4 0.4		34.0 33.6			48.0 48.3	82.0 81.9	10.2 10.3	7.8 7.7	18. 18.
	29.9 29.6	3.6	0.4		33.6			48.3	81.9	10.3	7.7	18.
	29.9											

 $\ensuremath{^{\star}}$ Confidentiality precludes reporting provincial-level insurance data.

Table B B.C.—Total

B.C.

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, British Columbia, 1985 to 2011 (cont'd)

Share of Drugs in Public, Private and Total Health Expenditures All Drugs Health Expenditure Public Total Public Total Public Total Year (\$ Millions) (Percentage Share) 1985 1986 1987 137.7 161.5 164.4 278.8 284.1 341.9 3,410.8 3,666.9 3,896.4 1,227.1 1,317.2 1,444.9 4,637.9 4,984.1 5,341.3 22.7 21.6 23.7 9.0 8.9 9.5 416.5 445.6 4.0 4.4 4.2 506.3 1988 1989 185.7 216.7 378.9 421.2 564.6 637.9 4,242.0 4,736.8 1,597.1 1,773.0 5,839.1 6,509.7 4.4 23.7 23.8 9.7 9.8 4.6 1990 256.3 465.4 721.7 5,390.4 1,986.0 7,376.3 4.8 23.4 9.8 1991 302.4 507.3 809.7 5.967.8 2.159.5 8.127.4 5.1 23.5 10.0 341.5 381.6 552.2 613.5 893.7 6,478.5 6,870.4 2,291.2 2,427.0 8,769.7 9,297.4 5.3 5.6 24.1 25.3 10.2 10.7 1993 995.1 1994 379.2 663.6 1,042.9 7,238.1 2,533.2 9,771.3 5.2 26.2 10.7 10.113.2 394.1 1.097.3 7.538.9 2.574.3 27.3 10.9 1995 703.2 5.2 11.2 11.5 427.5 2,689.4 10,378.1 5.6 5.9 27.3 1997 468.0 781.4 1,249.4 7,942.6 2,889.4 10,832.0 27.0 1998 1999 512.4 575.7 873.5 928.8 1,385.9 1,504.6 8,304.5 8,969.4 3,109.8 3,310.3 11,414.3 12,279.7 6.2 6.4 28.1 28.1 12.1 12.3 2000 1,005.4 1,665.8 9,825.8 3,586.8 13,412.6 6.7 10.819.7 12.5 2001 732.1 1.095.7 1.827.7 3.860.3 14.680.1 6.8 28.4 2002 753.4 1,237.2 1,990.6 2,138.4 11,452.1 11,922.9 4,218.0 15,670.2 6.6 6.3 29.3 12.7 2003 1,385.1 4,466.5 16,389.4 31.0 13.0 2004 801.9 1.536.8 2.338.7 12,232.3 4.893.7 17,126.0 6.6 31.4 13.7 2005 856.3 1,574.0 2,430.3 13,000.8 5,098.4 18,099.2 6.6 30.9 13.4 2006 2007 906.0 941.4 1,776.3 1,739.7 2,682.3 2,681.2 13,541.2 14,361.9 5,902.5 5,915.1 19,443.8 20,277.0 30.1 29.4 13.8 13.2 6.7 6.6 2008 975.2 1.892.2 2.867.4 15.681.3 6.611.5 22.292.8 6.2 28.6 12.9 1,003.3 22,971.5 29.8 1,050.5 1,090.9 2,084.1 2,141.1 3,134.6 3,232.0 17,225.6 17,898.1 6,805.9 7,198.8 24,031.5 25,097.0 30.6 29.7 13.0 12.9 2010^f 6.1 6.1 nual Percentage Change) 1985 1986 1987 17.2 1.8 1.9 20.3 7.5 6.3 7.3 7.5 7.2 7.0 13.6 10.8 11.2 8.9 11.7 10.5 11.0 1988 13.0 11.5 9.3 16.7 13.0 11.5 1990 18.2 18.0 10.5 13.1 12.2 13.8 10.7 12.0 13.3 10.2 1991 9.0 8.7 1992 1993 12.9 11.7 8.9 11.1 10.4 11.3 7.9 6.0 8.6 6.0 1994 -0.6 8.2 4.8 5.4 4.4 5.1 3.9 8.5 9.5 1995 6.0 5.2 4.2 1.6 3.5 1996 4.3 5.8 2.0 4.5 2.6 6.6 3.3 7.6 1998 9.5 11.8 10.9 4.6 5.4 7.6 12.4 9.2 9.4 2000 14.7 8.2 9.0 10.7 9.5 8.4 7.6 10.9 10.1 2001 5.8 4.1 2.6 2002 2.9 12.9 8.9 9.3 6.7 0.0 7.4 9.4 5.9 9.6 4.6 4.5 2004 11.0 6.8 2.4 6.3 4.2 5.7 2005 3.9 5.8 3.9 3.6 2006 12.9 10.4 4.2 15.8 7.4 2007 -2.1 0.0 0.2 4.3 2008 8.8 6.9 9.2 11.8 9.9 2.9 4.8 4.0 3.0 2010 4.7 3.8 5.1 2.7 5.0 3.1 5.6 3.9 2.2 4.6 4.4 (Percentage Share of Total Drug Expenditure) 33.1 36.2 66.9 63.8 100.0 100.0 1985 1986 1987 32.5 67.5 100.0 67.1 1989 34.0 66.0 100.0 35.5 64.5 100.0 1990 1991 1992 37.3 38.2 62.7 61.8 100.0 100.0 1993 38.3 61.7 100.0 1994 36.4 63.6 100.0 1995 35.9 64.1 100.0 36.8 63.2 1996 100.0 1997 37.5 62.5 100.0 1999 61.7 38.3 100.0 2000 39.6 60.4 100.0 59.9 62.2 64.8 2001 2002 40.1 37.8 100.0 100.0 2003 35.2 2004 34.3 65.7 100.0 2005 35.2 64.8 100.0 2006 33.8 66.2 100.0 2007 35.1 64.9 100.0 66.0 66.4 100.0 100.0 2008 33.6 2009 33.5 66.5 100.0

2011^f f: forecast 33.8

66.2

100.0

Table B B.C.—Per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, British Columbia, 1985 to 2011

					Prescribed Drugs					Non-Prescribed Drugs Private (Out of Pocket)			
	Provincial	Federal	Public Social Security	Funds	Subtotal	Insurers*	Private Out of	Subtotal	Total	Over-	Personal	(et) Total	
		_		Insurance Funds	Public		Pocket	Private	Prescribed Drugs	the- Counter	Health Supplies	Non-Presc. Drugs	
Year			(Premiu	m Component)		(\$ por Ca	nita)			Drugs			
1985	43.21	2.63	0.47		46.31	(\$ per Ca	 	40.72	87.03			53.01	
1986	50.41	2.86	0.49		53.75			35.14	88.89			59.43	
1987	50.32	3.02	0.55		53.89			44.21	98.11			67.88	
1988 1989	54.50 61.46	4.48 5.64	0.63 0.67		59.62 67.77			51.23 59.07	110.85 126.84			70.39 72.63	
1990 1991	70.67 81.63	6.46 7.22	0.74 0.79		77.87 89.64			65.87 71.48	143.74 161.12			75.56 78.90	
1992	89.90	7.65	0.90		98.45			77.29	175.73	43.10	38.83	81.93	
1993	96.98	9.01	0.97		106.96			84.97	191.93	46.07	40.93	87.01	
1994	92.34	9.75	1.08		103.18			87.94	191.11	49.92	42.69	92.60	
1995	92.52	10.72	1.11		104.35			93.59	197.94	49.24	43.36	92.59	
1996 1997	97.94 106.03	11.40 11.47	1.02 1.02		110.35 118.52			96.76 104.40	207.12 222.92	49.60 49.77	42.91 43.73	92.51 93.50	
1998	114.95	12.42	1.27		128.63			120.51	249.15	52.34	46.45	98.79	
1999	128.53	13.52	1.48		143.52			126.07	269.60	56.44	49.04	105.48	
2000	147.40	14.41	1.69		163.50			141.14	304.64	58.34	49.42	107.76	
2001 2002	161.60 162.87	16.09 18.47	1.81 1.74		179.50 183.07			157.17 184.53	336.66 367.60	60.09 62.57	51.39 53.53	111.48 116.10	
2002	158.27	21.19	1.83		181.29			212.11	393.40	66.96	54.26	121.22	
2004	166.60	22.02	2.14		190.76			240.15	430.91	70.31	55.10	125.41	
2005	176.04	22.66	2.29		201.00			243.07	444.07	70.20	56.19	126.39	
2006	187.07	23.89	2.54		213.50			288.43	501.93	72.61	57.55	130.16	
2007 2008	191.58 195.27	24.24 24.45	2.63 2.73		218.45 222.45			285.96 313.74	504.41 536.18	66.38 66.76	51.35 51.14	117.73 117.89	
2009	197.99	24.38	2.57		224.94			323.67	548.61	69.05	51.86	120.91	
2010 ^f	204.76	24.03	3.05		231.85			335.46	567.30	72.26	52.25	124.51	
2011 ^f	209.53	24.09	3.26		236.89			338.60	575.49	71.55	54.80	126.34	
						(Annual Percenta	age Change)						
1985													
1986	16.7	8.5	3.7		16.1			-13.7	2.1			12.1	
1987 1988	-0.2 8.3	5.7 48.3	13.7 14.1		0.3 10.6			25.8 15.9	10.4 13.0			14.2 3.7	
1989	12.8	25.7	6.2		13.7			15.3	14.4			3.2	
1990	15.0	14.5	10.8		14.9			11.5	13.3			4.0	
1991	15.5	11.8	7.4		15.1			8.5	12.1			4.4	
1992	10.1	6.0	12.9		9.8			8.1	9.1			3.8	
1993 1994	7.9 -4.8	17.7 8.3	8.5 10.7		8.6 -3.5			9.9 3.5	9.2 -0.4	6.9 8.3	5.4 4.3	6.2 6.4	
1995 1996	0.2 5.9	9.9 6.4	2.8 -8.4		1.1 5.8			6.4 3.4	3.6 4.6	-1.4 0.7	1.6 -1.0	0.0 -0.1	
1997	8.3	0.6	0.2		7.4			7.9	7.6	0.3	1.9	1.1	
1998	8.4	8.2	24.5		8.5			15.4	11.8	5.2	6.2	5.7	
1999	11.8	8.9	16.4		11.6			4.6	8.2	7.8	5.6	6.8	
2000	14.7	6.6	14.3		13.9			11.9	13.0	3.4	0.8	2.2	
2001 2002	9.6 0.8	11.6 14.8	7.3 -3.9		9.8 2.0			11.4 17.4	10.5 9.2	3.0 4.1	4.0 4.2	3.4 4.1	
2003	-2.8	14.7	5.3		-1.0			14.9	7.0	7.0	1.3	4.4	
2004	5.3	3.9	16.6		5.2			13.2	9.5	5.0	1.6	3.5	
2005	5.7	2.9	7.3		5.4			1.2	3.1	-0.2	2.0	0.8	
2006	6.3	5.4	10.9		6.2			18.7	13.0	3.4	2.4	3.0	
2007 2008	2.4 1.9	1.5 0.9	3.3 3.9		2.3 1.8			-0.9 9.7	0.5 6.3	-8.6 0.6	-10.8 -0.4	-9.6 0.1	
2009	1.4	-0.3	-5.9		1.1			3.2	2.3	3.4	1.4	2.6	
2010 ^f	3.4	-1.4	18.9		3.1			3.6	3.4	4.6	0.7	3.0	
2011 ^f	2.3	0.3	6.8		2.2			0.9	1.4	-1.0	4.9	1.5	
				(Annual	Percentage Cha	inge in Excess of	Inflation in the	Canadian Econo	omy)				
1985					42.2			46.5					
1986 1987	13.9 -4.9	5.7 1.0	0.9 9.0		13.3 -4.5			-16.5 21.1	-0.7 5.6			9.3 9.5	
1988	3.8	43.8	9.6		6.1			11.4	8.5			-0.8	
1989	8.2	21.2	1.6		9.1			10.7	9.9			-1.4	
1990	12.0	11.5	7.8		11.9			8.5	10.3			1.0	
1991	12.7	9.0	4.6		12.4			5.8	9.3			1.7	
1992 1993	8.9 6.4	4.8 16.3	11.6 7.0		8.6 7.2			6.9 8.5	7.8 7.8	5.5	4.0	2.6 4.8	
1994	-5.9	7.2	9.6		-4.6			2.4	-1.5	7.2	3.2	5.3	
1995	-2.1	7.6	0.5		-1.2			4.1	1.2	-3.7	-0.8	-2.3	
1996	4.2	4.7	-10.1		4.1			1.7	3.0	-0.9	-2.7	-1.8	
1997	7.3	-0.4	-0.8		6.4			6.9	6.6	-0.7	0.9	0.1	
1998 1999	8.8 10.0	8.7 7.1	25.0 14.6		9.0 9.8			15.9 2.8	12.2 6.4	5.6 6.0	6.7 3.8	6.1 5.0	
2000 2001	10.6 8.3	2.5 10.3	10.2 5.9		9.8 8.4			7.8 10.0	8.9 9.2	-0.7 1.6	-3.3 2.6	-1.9 2.1	
2002	-0.3	13.8	-4.9		0.9			16.4	8.1	3.1	3.1	3.1	
2003	-5.7	11.8	2.4		-3.9			12.1	4.1	4.1	-1.5	1.5	
2004	2.7	1.3	14.0		2.6			10.6	6.9	2.4	-1.0	0.9	
2005	2.7	-0.1	4.3		2.4			-1.8	0.0	-3.2	-1.0	-2.2	
2006 2007	3.5 -1.3	2.6 -2.2	8.1 -0.4		3.4 -1.4			15.9 -4.5	10.2 -3.2	0.6 -12.3	-0.4 -14.4	0.2 -13.2	
2008	-2.9	-4.0	-0.9		-3.0			4.8	1.4	-4.3	-5.3	-4.7	
2009	4.1	2.4	-3.2		3.8			5.9	5.0	6.1	4.1	5.3	
2010 ^f	0.5	-4.4	15.9		0.1			0.7	0.5	1.7	-2.2	0.0	
2011 [†] f: forecast.	-1.7	-3.7	2.8		-1.8			-3.1	-2.6	-5.0	0.9	-2.5	
	ity precludes reporting	provincial-level in:	surance data.					National He	alth Expenditure Da	tabase, 2011, Cana	dian Institute for H	lealth Information	

^{*} Confidentiality precludes reporting provincial-level insurance data.

Table B B.C.—Per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, British Columbia, 1985 to 2011 (cont'd)

		All Drugs		u	lealth Expenditure		GDP Implicit Price Index—Canada
	Public	Private	Total	Public	Private	Total	Frice index—Canada
Year			/\$ max C	anita)			(1997 = 100)
1985	46.31	93.73	(\$ per C	1,146.76	412.58	1,559.34	73.6
1986	53.75	94.57	148.32	1,220.62	438.48	1,659.09	75.6
1987	53.89	112.09	165.99	1,277.43	473.72	1,751.15	79.2
1988 1989	59.62 67.77	121.62 131.70	181.24 199.47	1,361.65 1,481.22	512.66 554.42	1,874.31 2,035.64	82.8 86.6
1990 1991	77.87 89.64	141.42 150.38	219.29 240.03	1,638.00 1,769.05	603.48 640.15	2,241.49 2,409.20	89.2 91.6
1992	98.45	159.22	257.66	1,867.85	660.58	2,528.43	92.8
1993	106.96	171.97	278.93	1,925.89	680.33	2,606.22 2,658.36	94.1
1994	103.18	180.54	283.72	1,969.18	689.18		95.2
1995	104.35	186.18	290.53	1,996.01	681.57	2,677.58	97.4
1996 1997	110.35 118.52	189.28 197.90	299.63 316.42	1,984.56 2,011.53	694.17 731.75	2,678.72 2,743.29	99.0 100.0
1998	128.63	219.30	347.94	2,084.94	780.76	2,865.71	99.6
1999	143.52	231.55	375.08	2,236.02	825.22	3,061.24	101.4
2000	163.50	248.90	412.40	2,432.62	887.99	3,320.61	105.5
2001 2002	179.50 183.07	268.64 300.63	448.14 483.70	2,652.91 2,782.74	946.52 1,024.93	3,599.43 3,807.68	106.9 108.1
2003	181.29	333.33	514.61	2,869.28	1,074.87	3,944.15	111.2
2004	190.76	365.57	556.32	2,909.81	1,164.12	4,073.93	114.1
2005	201.00	369.46	570.46	3,051.65	1,196.74	4,248.39	117.5
2006	213.50	418.59	632.09	3,190.99	1,390.93	4,581.93	120.8
2007 2008	218.45 222.45	403.69 431.63	622.14 654.08	3,332.50 3,577.05	1,372.54 1,508.14	4,705.04 5,085.20	125.2 131.3
2009	224.94	444.59	669.53	3,656.51	1,493.72	5,150.23	127.8
2010 ^f	231.85	459.97	691.82	3,801.76	1,502.08	5,303.84	131.5
2011 ^f	236.89	464.95	701.83	3,886.60	1,563.24	5,449.84	136.8
				(Annual Percentage Ch	nange)		
1985							
1986 1987	16.1 0.3	0.9 18.5	5.9 11.9	6.4 4.7	6.3 8.0	6.4 5.5	2.8 4.7
1988	10.6	8.5	9.2	6.6	8.2	7.0	4.7
1989	13.7	8.3	10.1	8.8	8.1	8.6	4.6
1990	14.9	7.4	9.9	10.6	8.8	10.1	3.0
1991	15.1	6.3	9.5	8.0	6.1	7.5	2.8
1992	9.8	5.9	7.3	5.6	3.2	4.9	1.3
1993 1994	8.6 -3.5	8.0 5.0	8.3 1.7	3.1 2.2	3.0 1.3	3.1 2.0	1.4 1.1
1995	1.1	3.1	2.4	1.4	-1.1	0.7	2.3
1996	5.8	1.7	3.1	-0.6	1.8	0.0	1.7
1997	7.4	4.6	5.6	1.4	5.4	2.4	1.0
1998 1999	8.5	10.8 5.6	10.0 7.8	3.6 7.2	6.7 5.7	4.5	-0.4 1.8
	11.6					6.8	
2000 2001	13.9 9.8	7.5 7.9	9.9 8.7	8.8 9.1	7.6 6.6	8.5 8.4	4.1 1.4
2001	2.0	11.9	7.9	4.9	8.3	5.8	1.0
2003	-1.0	10.9	6.4	3.1	4.9	3.6	2.9
2004	5.2	9.7	8.1	1.4	8.3	3.3	2.6
2005	5.4	1.1	2.5	4.9	2.8	4.3	3.0
2006 2007	6.2 2.3	13.3 -3.6	10.8 -1.6	4.6 4.4	16.2 -1.3	7.9 2.7	2.8 3.7
2007	1.8	6.9	5.1	7.3	9.9	8.1	4.9
2009	1.1	3.0	2.4	2.2	-1.0	1.3	-2.7
2010 ^f	3.1	3.5	3.3	4.0	0.6	3.0	2.9
2011 ^f	2.2	1.1	1.4	2.2	4.1	2.8	4.0
1985		(Annual Percentage	Change in Excess of	of Inflation in the Canad	lian Economy)		
1986	13.3	-1.9	3.1	3.6	3.5	3.6	
1987	-4.5	13.8	7.2	-0.1	3.3	0.8	
1988 1989	6.1	4.0	4.7	2.1	3.7	2.5	
	9.1	3.7	5.5	4.2	3.6	4.0	
1990 1991	11.9	4.4	6.9	7.6	5.8	7.1 4.7	
1992	12.4 8.6	3.6 4.6	6.7 6.1	5.2 4.3	3.3 1.9	3.7	
1993	7.2	6.6	6.8	1.7	1.6	1.6	
1994	-4.6	3.9	0.6	1.1	0.2	0.9	
1995	-1.2	0.8	0.1	-1.0	-3.4	-1.6	
1996 1997	4.1 6.4	0.0	1.5 4.6	-2.2	0.2 4.4	-1.6	
1998	9.0	3.6 11.3	10.4	0.4 4.1	7.1	1.4 4.9	
1999	9.8	3.8	6.0	5.4	3.9	5.0	
2000	9.8	3.4	5.8	4.7	3.5	4.4	
2001	8.4	6.6	7.3	7.7	5.2	7.0	
2002 2003	0.9 -3.9	10.9 8.0	6.9 3.5	3.8 0.2	7.2 2.0	4.7 0.7	
2004	2.6	7.1	5.5	-1.2	5.7	0.7	
2005	2.4	-1.9	-0.5	1.9	-0.2	1.3	
2006	3.4	10.5	8.0	1.8	13.4	5.1	
2007	-1.4	-7.2	-5.3	0.8	-5.0	-1.0	
2008 2009	-3.0 3.8	2.1 5.7	0.3 5.1	2.5 4.9	5.0 1.8	3.2 4.0	
2010 ^f	0.1	0.5	0.4	1.0	-2.4	0.0	
2011 ^f	-1.8	-2.9	-2.5	-1.8	0.1	-1.2	
						North	III. III. F I' B

f: forecast.

B.C.

Table B Y.T.—Total

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, Yukon, 1985 to 2011

				Public		Prescribed	Drugs	Private				-Prescribed Dr	
The color		Territorial	Federal _	Social Secur	rug Insurance		Insurers*	Out of		Prescribed	Over- the-	Personal Health	Total Non-Presc.
March Marc	Voor			(Pren			/\$ Million	ne)		Drugs		Supplies	Drugs
March Marc		0.2	0.2	0.0		0.5			1.2	1.0			12
100										1.9			1.3
1985 12													
Mail 10													
No. 1													
1941 1941 1941 1942													
18													
1986	1994	2.1	1.7	0.0		3.8			1.6	5.4	1.4	1.1	2.4
1977 19													
1989													
Sep													
190	1999	2.7	3.1	0.0		5.8			3.0	8.8	1.9		3.6
1	2000	3.3	3.0	0.1		6.4			3.2	9.6	1.9	2.1	3.9
Section Sect	2001	3.9		0.1		7.0			3.6	10.5		2.1	
194													
100													
March 10													
1975													
1909													
1													
140	2009	8.1	5.1	0.1		13.3			7.5	20.7	2.7	2.0	4.7
1886	2011	9.1	5.4	0.1					9.1	23.7	2.5	2.1	4.6
1986	4005	-											
1896													
1989													
1999													
1991 222	1989	15.4	37.4	-42.2		23.0			-0.3	14.1			0.2
1982													
1939													
1994 \$\beta \begin{array}{cccccccccccccccccccccccccccccccccccc													
1986													
1986	1995	-26.3	9.1	42.5		-10.1			8.0	-4.7	2.1	13.0	7.0
1989	1996	-2.3	3.8	4.8		1.1			27.6	10.0	19.9	20.2	20.0
1999													
200													
201													
100													
2006													
2005													
2006 10.2 1.2 4.6 6.7 13.7 9.0 6.7 7.9 7.2 2.9 7.2 2.9 19.6 2.9 3.8 4.2 2.008 9.7 7.2 4.29 3.0 1.3 7.9 2.9 5.8 4.2 2.008 9.7 7.2 4.29 3.0 1.5 8.8 3.0 0.2 2.5 1.6 2.5 2.5 1.5 2.5	2004	15.0	-1.2	3.1		8.0			3.0	6.3	6.8	4.3	5.7
2007 2-9													
2008 9.7 7.7 42.9 3.0 2.7 1.0 2.8 1.9 2.4													
2009 7.8													
1985 6.7													
1985 6.7	2010 ^f	7.8	4.2	-6.3		6.3			10.3	7.8	2.2	2.9	2.5
1885 6,7 9,5 0,3 16,6 41,3 57,8 42,2 1886 10,3 10,6 0.3 21,2 38,8 59,9 40,1 1987 20,9 10,0 0.3 31,2 38,6 64,9 35,1 1988 27,6 16,2 0.4 44,1 27,2 71,4 28,6 1990 30,0 23,1 0.4 53,5 22,6 76,1 23,9 1991 30,7 21,9 0.1 52,7 22,6 76,1 23,9 1991 30,7 21,9 0.1 52,7 22,6 76,1													
1986 10.3 10.6 0.3							tage Share of Tota	al Drug Expend					
1987 20.9 10.0 0.3 31.2 33.6 64.9 28.9 1988 27.6 16.2 0.4 44.1 22.2 71.4 28.6 1989 28.9 20.2 0.2 49.3 24.6 73.9 26.1 1990 30.0 23.1 0.4 53.5 22.6 76.1 24.3 1991 30.7 21.9 0.1 52.7 22.9 75.7 24.3 1992 29.4 19.6 0.4 49.4 20.5 66.5 17.9 15.6 33.5 1993 26.5 21.5 0.3 43.3 20.5 68.8 17.4 13.9 15.6 28.2 1995 19.8 23.7 0.5 -													
1988 27.6 16.2 0.4 44.1 27.2 71.4 28.6 1989 28.9 20.2 0.2 49.3 24.6 73.9 28.6 1990 30.0 23.1 0.4 53.5 22.6 76.1 24.3 1991 30.7 21.9 0.1 52.7 22.9 75.7 24.3 1992 29.4 19.8 0.4 48.4 17.0 66.5 17.9 15.6 33.5 1993 26.7 18.0 0.3 48.3 20.5 68.8 17.4 13.9 31.2 1996 19.8 23.7 0.5 43.9 22.5 68.8 17.4 13.9 15.9 33.8 1996 19.8 23.7 0.5 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>													
1990 30.0 23.1 0.4 53.5 22.6 76.1 23.9 1991 30.7 21.9 0.1 52.7 22.9 75.7 24.3 1992 224 19.6 0.4 49.4 17.0 66.5 17.9 15.6 33.5 1993 26.7 18.0 0.3 45.1 26.7 71.8 15.4 12.8 28.2 1994 26.5 21.5 0.3 48.3 20.5 68.8 17.4 13.9 31.2 1995 19.8 23.7 0.5 49.9 22.3 66.2 17.9 15.9 33.8 1996 17.0 21.7 0.4 39.1 39.1 22.3 66.2 17.9 15.9 33.8 1996 17.0 21.7 0.4 39.1 39.1 25.1 64.3 18.9 16.8 35.7 1997 17.7 19.1 0.4 37.2 39.1 27.2 22.3 69.4 16.2 14.4 30.6 1998 20.9 19.9 0.3 41.1 27.2 27.2 68.3 16.7 15.1 31.7 1999 21.8 24.6 0.4 41.1 41.1 27.2 27.2 68.3 16.7 15.1 31.5 28.9 2000 24.3 22.4 0.4 47.1 47.9 47.1 23.8 70.9 13.9 15.2 29.1 2001 26.5 20.8 0.6 47.9 47.9 24.4 71.1 15.4 12.6 12.9 25.5 20.3 28.5 21.5 0.6 50.2 25.8 77.2 12.5 10.3 22.8 2004 30.9 20.0 0.6 50.2 50.2 2 24.3 74.5 12.6 12.9 25.5 20.0 20.4 30.9 20.0 0.6 50.2 50.2 2 24.3 74.5 12.6 12.9 25.5 20.0 20.4 30.9 20.0 0.6 50.5 50.2 2 26.6 77.1 12.4 10.5 22.9 2004 30.9 20.0 0.6 50.5 50.2 2 26.6 77.1 12.4 10.5 22.9 2004 30.9 20.0 0.6 50.5 50.2 2 26.6 77.1 12.4 10.5 22.9 2004 30.9 20.0 0.6 50.5 50.9 26.6 77.1 12.4 10.5 22.9 2004 30.9 20.0 0.6 50.5 50.9 26.6 77.1 12.4 10.5 22.9 2004 30.9 20.0 0.6 50.5 50.9 26.6 77.1 12.4 10.5 22.9 2004 30.0 21.5 0.6 50.5 50.9 26.6 78.5 11.9 9.6 21.5 20.0 20.0 31.7 20.0 0.4 51.9 51.9 27.4 80.2 11.1 8.7 19.8 2009 31.7 20.0 0.4 51.9 51.9 27.4 80.2 11.1 8.7 19.8 2009 31.7 20.0 0.4 51.9 51.9 28.9 27.4 80.2 11.1 8.7 19.8 2009 31.7 20.0 0.4 51.9 51.9 28.9 27.4 80.2 11.1 8.7 19.8 2009 31.7 20.0 0.4 51.9 51.9 28.9 27.4 80.2 11.1 8.7 19.8 2009 31.7 20.0 0.4 51.9 51.9 28.9 27.4 80.2 11.1 8.7 19.8 20.1 11.1 8.7 19.8 20.1 11.1 8.7 19.8 20.1 11.1 8.7 19.8 2													
1991 30,7 21,9 0,1	1989	28.9	20.2	0.2		49.3			24.6	73.9			26.1
1992 294 19.6 0.4 49.4 17.0 66.5 17.9 15.6 33.5 1993 26.7 18.0 0.3 45.1 26.7 71.8 15.4 12.8 28.2 1994 26.5 21.5 0.3 48.3 26.7 77.8 15.4 12.8 28.2 1995 19.8 23.7 0.5 43.9 22.3 66.2 17.9 15.9 33.8 1996 17.0 21.7 0.4 39.1 25.1 64.3 18.9 16.8 35.7 1997 17.7 19.1 0.4 37.2 25.1 64.3 18.9 16.8 35.7 1998 20.9 19.9 0.3 46.7 27.2 68.3 16.7 15.1 31.7 1998 21.8 24.6 0.4 47.1	1990	30.0	23.1	0.4		53.5			22.6	76.1			23.9
1993 26.7 18.0 0.3													
1994 26.5 21.5 0.3													
1995													
1996 17.0 21.7 0.4 39.1 25.1 64.3 18.9 16.8 35.7 1997 17.7 19.1 0.4 37.2 32.3 69.4 16.2 14.4 30.6 1998 20.9 19.9 0.3 41.1 27.2 68.3 16.7 15.1 31.7 1999 21.8 24.6 0.4 46.7 24.4 71.1 15.4 13.5 28.9 2000 24.3 22.4 0.4 47.1 23.8 70.9 13.9 15.2 29.9 2001 26.5 20.8 0.6 47.9 24.4 72.3 13.6 14.1 27.7 2002 28.0 21.6 0.6 50.2 24.3 74.5 12.6 12.9 25.5 2003 25.5 21.5 0.6 50.5													
1997 17,7 19,1 0,4 37,2 32,3 69,4 16,2 14,4 30,6 199,8 199,9 0,3 41,1 27,2 68,3 16,7 15,1 31,6 15,1 31,6 15,1 31,7 28,9 28,9 20,0 21,8 24,6 0,4 47,1 24,4 71,1 15,4 13,5 28,9 28,9 20,0 24,3 22,4 0,4 47,1 23,8 70,9 13,9 15,2 29,1 20,1 20,1 20,2 20,1 24,4 72,3 13,6 14,1 27,7 20,2 20,2 20,0 21,6 0,6 47,9 24,4 72,3 13,6 14,1 27,7 20,2 20,0 21,6 10,6 50,5 24,3 74,5 12,6 12,9 25,6 20,7													
1999 21.8 24.6 0.4 46.7 24.4 71.1 15.4 13.5 28.9 2000 24.3 22.4 0.4 47.1 23.8 70.9 13.9 15.2 29.1 2001 26.5 20.8 0.6 47.9 24.4 72.3 13.6 14.1 27.7 2002 28.0 21.6 0.6 50.5 24.3 74.5 12.6 12.9 25.5 2003 28.5 21.5 0.6 50.5 26.6 77.1 12.4 10.5 22.9 2004 30.9 20.0 0.6 51.4 25.8 77.2 12.5 10.3 22.8 2005 32.0 20.3 0.5 52.9 25.4 78.2 12.1 9.7 21.8													
2000 24.3 22.4 0.4 47.1 23.8 70.9 13.9 15.2 29.1 2001 26.5 20.8 0.6 47.9 24.4 72.3 13.6 14.1 27.7 2002 28.0 21.6 0.6 50.2 24.3 74.5 12.6 12.9 25.5 2003 28.5 21.5 0.6 50.5 26.6 77.1 12.4 10.5 22.9 2004 30.9 20.0 0.6 51.4 25.8 77.2 12.5 10.3 22.8 2004 32.0 20.3 0.5 52.9 25.4 78.2 12.1 9.7 21.8 2006 32.5 18.9 0.5 52.0 26.6 78.5 11.9 9.6 21.5													
2001 26.5 20.8 0.6 47.9 24.4 72.3 13.6 14.1 27.7 2002 28.0 21.6 0.6 50.2 24.3 74.5 12.6 12.9 25.5 2003 28.5 21.5 0.6 50.5 26.6 77.1 12.4 10.5 22.9 2004 30.9 20.0 0.6 51.4 25.8 77.2 12.5 10.3 22.8 2005 32.0 20.3 0.5 52.9 25.4 78.2 12.1 9.7 21.8 2006 32.5 18.9 0.5 52.0 26.6 78.5 11.9 9.6 21.5 2007 30.0 21.5 0.5 52.8 28.5 80.5 10.9 8.6 19.5 2008 32.5 19.7 0.6 52.8	1999	21.8	24.6	0.4		46.7			24.4	71.1	15.4	13.5	28.9
2002 28.0 21.6 0.6 50.2 24.3 74.5 12.6 12.9 25.5 2003 28.5 21.5 0.6 50.5 26.6 77.1 12.4 10.5 22.9 2004 30.9 20.0 0.6 51.4 25.8 77.2 12.5 10.3 22.8 2005 32.0 20.3 0.5 52.9 25.4 78.2 12.1 9.7 21.8 2006 32.5 18.9 0.5 52.9 26.6 78.5 11.9 9.6 21.5 2007 30.0 21.5 0.5 51.9 26.6 78.5 11.9 9.6 21.5 2008 32.5 19.7 0.6 52.8 27.4 80.2 11.1 8.7 19.8 2009 31.7 20.0 0.4 51.9													
203 28.5 21.5 0.6 50.5 26.6 77.1 12.4 10.5 22.9 2004 30.9 20.0 0.6 51.4 25.8 77.2 12.5 10.3 22.8 2005 32.0 20.3 0.5 52.9 25.4 78.2 12.1 9.7 21.8 2006 32.5 18.9 0.5 52.9 28.6 78.5 11.9 9.6 21.5 2007 30.0 21.5 0.5 51.9 28.5 80.5 10.9 8.6 19.5 2008 32.5 19.7 0.6 52.8 27.4 80.2 11.1 8.7 19.8 2009 31.7 20.0 0.4 52.1 29.3 81.4 10.6 8.0 18.6 2010 ¹ 32.0 19.5 0.4													
2004 30.9 20.0 0.6 51.4 25.8 77.2 12.5 10.3 22.8 2005 32.0 20.3 0.5 52.9 25.4 78.2 12.1 9.7 21.8 2006 32.5 18.9 0.5 52.9 26.6 76.5 11.9 9.6 21.5 2007 30.0 21.5 0.5 51.9 26.5 80.5 10.9 8.6 19.5 2008 32.5 19.7 0.6 52.8 27.4 80.2 11.1 8.7 19.8 2009 31.7 20.0 0.4 51.9 29.3 81.4 10.6 8.0 18.6 2010 ¹ 32.0 19.5 0.4 51.6 32.1 83.7 8.9 7.4 16.3 2011 ¹ 32.1 19.1 0.4 51.6 32.1 83.7 8.9 7.4 16.3													
2005 32.0 20.3 0.5 52.9 25.4 78.2 12.1 9.7 21.8 2006 32.5 18.9 0.5 52.0 26.6 78.5 11.9 9.6 21.5 2007 30.0 21.5 0.5 51.9 51.9 28.5 80.5 10.9 8.6 19.5 2008 32.5 19.7 0.6 52.8 27.4 80.2 11.1 8.7 19.8 2009 31.7 20.0 0.4 52.8 27.4 80.2 11.1 8.7 19.8 2009 31.7 32.0 19.5 0.4 51.9 30.3 82.2 10.1 7.7 17.8 2011 32.1 19.1 0.4 51.6 32.1 83.7 8.9 7.4 16.3													
2006 32.5 18.9 0.5 52.0 26.6 78.5 11.9 9.6 21.5 2007 30.0 21.5 0.5 51.9 28.5 80.5 10.9 8.6 19.5 2008 32.5 19.7 0.6 52.8 27.4 80.2 11.1 8.7 19.8 2009 31.7 20.0 0.4 52.1 29.3 81.4 10.6 8.0 18.6 2010 ¹ 32.0 19.5 0.4 51.9 30.3 82.2 10.1 7.7 17.8 2011 ¹ 32.1 19.1 0.4 51.6 32.1 83.7 8.9 7.4 16.3	2005								25.4	79.2	191		
2007 30.0 21.5 0.5 51.9 28.5 80.5 10.9 8.6 19.5 2008 32.5 19.7 0.6 52.8 27.4 80.2 11.1 8.7 19.8 2009 31.7 20.0 0.4 52.1 29.3 81.4 10.6 8.0 18.6 2010 32.0 19.5 0.4 51.9 30.3 82.2 10.1 7.7 17.8 2011 32.1 19.1 0.4 51.6 32.1 83.7 8.9 7.4 16.3													
2009 31.7 20.0 0.4 52.1 29.3 81.4 10.6 8.0 18.6 2010 ¹ 32.0 19.5 0.4 51.9 30.3 82.2 10.1 7.7 17.8 2011 ¹ 32.1 19.1 0.4 51.6 32.1 83.7 8.9 7.4 16.3	2007	30.0	21.5	0.5		51.9			28.5	80.5	10.9	8.6	19.5
2010 ¹ 32.0 19.5 0.4 51.9 30.3 82.2 10.1 7.7 17.8 2011 ¹ 32.1 19.1 0.4 51.6 32.1 83.7 8.9 7.4 16.3													
2011 ¹ 32.1 19.1 0.4 51.6 32.1 83.7 8.9 7.4 16.3			20.0	0.4		52.1			29.3	81.4	10.6		18.6
		32.1	19.1	0.4		d.1c			32.1	63.7	8.9	1.4	16.3

f: forecast.
* Confidentiality precludes reporting territorial-level insurance data.

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, Yukon, 1985 to 2011 (cont'd)

		All Down	rotal Health	Expenditures, Y		6 2011 (cont a)	Share of Drugs in Pu		
	Public	All Drugs Private	Total	Public	th Expenditure Private	Total	Total Health Ex	Private	Total
Year			(\$ Million				(Percentage		
1985 1986	0.5 0.7	2.6 2.5	3.2 3.2	32.9 37.0	6.8 5.6	39.7 42.6	1.6 1.8	38.9 44.4	8.0 7.4
1987	1.1	2.4	3.5	39.1	5.6	44.7	2.8	43.3	7.9
1988 1989	1.7 2.1	2.1 2.1	3.8 4.2	40.6 44.2	5.2 5.3	45.8 49.5	4.1 4.7	40.8 40.3	8.3 8.5
1990	2.3	2.0	4.3	48.5	5.0	53.6	4.7	39.6	8.0
1991	2.8	2.5	5.3	56.5	6.1	62.6	4.9	41.0	8.4
1992 1993	3.4 3.8	3.4 4.7	6.8 8.5	60.6 69.5	6.9 10.6	67.5 80.1	5.6 5.5	49.7 44.1	10.1 10.6
1994	3.8	4.0	7.8	84.1	9.9	94.0	4.5	40.7	8.3
1995	3.4	4.3	7.7	85.2	10.5	95.8	4.0	41.2	8.1
1996 1997	3.4 4.0	5.3 6.7	8.8 10.6	92.0 86.0	18.2 17.3	110.2 103.3	3.7 4.6	29.3 38.7	8.0 10.3
1998	4.4	6.3	10.6	87.8	16.3	104.1	5.0	38.4	10.2
1999	5.8	6.6	12.4	92.4	16.9	109.2	6.3	39.2	11.4
2000 2001	6.4	7.1 7.6	13.5	98.4	24.8 27.5	123.2 142.7	6.5	28.8 27.7	11.0
2002	7.0 8.1	8.1	14.6 16.2	115.3 122.3	33.2	155.5	6.1 6.7	24.3	10.2 10.4
2003	9.0	8.9	17.9	124.0	32.3	156.3	7.3	27.4	11.4
2004	9.8	9.2	19.0	132.0	35.5	167.5	7.4	26.0	11.3
2005 2006	10.7 11.5	9.6 10.6	20.3 22.1	151.1 177.5	36.6 39.4	187.6 216.9	7.1 6.5	26.2 26.9	10.8 10.2
2007	12.1	11.2	23.2	179.1	51.9	231.0	6.7	21.5	10.1
2008 2009	12.4 13.3	11.1 12.2	23.5 25.4	191.0 222.1	50.3 56.0	241.3 278.1	6.5 6.0	22.1 21.8	9.8 9.1
2010 ^f	14.1	13.1	27.2	241.1	60.2	301.3	5.8	21.7	9.0
2011 ^f	14.6	13.7	28.3	248.1	66.1	314.2	5.9	20.7	9.0
			(Annual Percenta						
1985 1986	 27.7	-5.6	-0.1	12.3	-17.3	7.2			
1987	65.5	-2.1	12.2	5.8	0.4	5.1			
1988 1989	51.6 23.0	-12.9 -0.1	7.3 10.1	3.8 9.1	-7.5 1.2	2.3 8.2			
1990	10.8	-6.3	2.1	9.7	-4.8	8.2			
1991	21.5	25.1	23.2	16.4	20.9	16.8			
1992 1993	21.0 13.5	38.2 35.3	29.1 24.5	7.2 14.7	14.1 52.5	7.9 18.6			
1994	-1.0	-13.1	-7.6	20.9	-6.0	17.4			
1995	-10.1	7.4	-1.1	1.4	6.1	1.9			
1996	1.1	23.0	13.4	7.9	73.0	15.1			
1997 1998	15.2 10.5	25.0 -6.1	21.2 0.1	-6.5 2.0	-5.2 -5.4	-6.3 0.8			
1999	32.9	5.5	16.8	5.2	3.3	4.9			
2000	9.6	7.9	8.7	6.5	46.7	12.8			
2001 2002	9.8 16.4	6.4 6.3	8.0 11.1	17.1 6.1	10.9 20.8	15.9 8.9			
2003	11.1	9.7	10.4	1.4	-2.6	0.5			
2004	8.0	4.2	6.1	6.4	10.0	7.2			
2005 2006	10.0 6.7	3.7 10.7	7.0 8.6	14.5 17.5	2.8 7.8	12.0 15.6			
2007	5.3	5.4	5.3	0.9	31.7	6.5			
2008 2009	3.0 6.7	-0.6 9.8	1.3 8.1	6.6 16.3	-3.1 11.4	4.4 15.3			
2010 ^f	6.3	7.3	6.8	8.6	7.4	8.3			
2011 ^f	3.5	4.6	4.0	2.9	10.0	4.3			
1985		Share of Total Drug E	xpenditure) 100.0						
1986	16.6 21.2	83.4 78.8	100.0						
1987	31.2	68.8	100.0						
1988 1989	44.1 49.3	55.9 50.7	100.0 100.0						
1990	53.5	46.5	100.0						
1991	52.7	47.3	100.0						
1992 1993	49.4 45.1	50.6 54.9	100.0 100.0						
1994	48.3	51.7	100.0						
1995	43.9	56.1	100.0						
1996 1997	39.1 37.2	60.9 62.8	100.0 100.0						
1997	41.1	58.9	100.0						
1999	46.7	53.3	100.0						
2000	47.1	52.9	100.0						
2001 2002	47.9 50.2	52.1 49.8	100.0 100.0						
2003	50.5	49.5	100.0						
2004	51.4	48.6	100.0						
2005 2006	52.9 52.0	47.1 48.0	100.0 100.0						
2007	51.9	48.1	100.0						
2008 2009	52.8 52.1	47.2 47.9	100.0 100.0						
2009 2010 ^f	51.9	47.9	100.0						
2011 ^f	51.9 51.6	48.1 48.4	100.0						

f: forecast.

Table B Y.T.—Per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Yukon, 1985 to 2011

					Prescribed	Drugs					Prescribed Dru	
	Territorial	Federal	Public Social Secur WCBs D	ity Funds rug Insurance Funds	Subtotal Public	Insurers*	Private Out of Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	te (Out of Pock Personal Health Supplies	Total Non-Presc. Drugs
Year			(Pren	nium Component)		(\$ per Cap	nita)			Drugs		
1985	8.73	12.38	0.40		21.51			53.66	75.17			54.79
1986 1987	13.36 28.81	13.65 13.87	0.33 0.41		27.34 43.10			50.07 46.44	77.41 89.54			51.78 48.51
1988	39.46	23.14	0.53		63.12			38.94	102.06			40.97
1989	44.68	31.20	0.30		76.17			38.08	114.25			40.28
1990 1991	46.19 56.02	35.65 39.91	0.58 0.25		82.41 96.18			34.77 41.78	117.18 137.95			36.89 44.38
1992	66.44	44.31	0.97		111.72			38.47	150.19	40.52	35.28	75.80
1993 1994	74.64 69.86	50.24 56.56	0.88 0.86		125.76 127.27			74.59 53.92	200.35 181.20	42.89 45.73	35.83 36.58	78.72 82.32
1995	50.23	60.17	1.19		111.60			56.82	168.42	45.56	40.31	85.88
1996	47.63	60.58	1.21		109.43			70.33	179.76	53.00	47.00	100.00
1997 1998	59.26 71.27	63.97 67.89	1.17 1.19		124.40 140.35			107.92 92.92	232.32 233.27	54.06 57.00	48.20 51.46	102.26 108.45
1999	87.87	99.30	1.54		188.71			98.53	287.24	62.00	54.53	116.54
2000	107.91	99.59	1.66		209.16			105.64	314.79	61.61	67.49	129.10
2001	128.25	100.91	2.75		231.91			118.12	350.03	65.69	68.33	134.02
2002 2003	150.84 166.67	115.93 125.70	3.17 3.34		269.94 295.72			130.84 155.61	400.78 451.33	67.55 72.57	69.46 61.37	137.01 133.94
2004	189.79	122.99	3.41		316.19			158.79	474.98	76.78	63.36	140.14
2005	209.60	132.99	3.32		345.92			165.98	511.90	78.96	63.41	142.37
2006 2007	222.31 213.85	129.49 153.43	3.34 3.22		355.14 370.50			181.62 203.59	536.76 574.09	81.03 78.00	65.79 61.39	146.82 139.38
2008	230.77	140.01	4.52		375.30			194.81	570.11	78.84	61.52	140.36
2009	239.59	151.14	3.19		393.92			221.92	615.84	79.88	60.40	140.28
2010 [†] 2011 [†]	251.83 259.87	153.53 154.62	2.91 3.17		408.26 417.66			238.58 259.79	646.84 677.45	79.56 71.83	60.60 60.06	140.16 131.89
2011	239.07	134.02	3.17			(Annual Percenta		239.79	077.43	71.03	00.00	131.09
1985												
1986	52.9	10.3	-18.7		27.1			-6.7	3.0			-5.5
1987 1988	115.7 36.9	1.6 66.8	26.2 28.0		57.6 46.5			-7.2 -16.2	15.7 14.0			-6.3 -15.5
1989	13.2	34.8	-43.3		20.7			-2.2	12.0			-1.7
1990	3.4	14.3	93.3		8.2			-8.7	2.6			-8.4
1991 1992	21.3 18.6	11.9 11.0	-56.6 287.7		16.7 16.2			20.1 -7.9	17.7 8.9			20.3 70.8
1993	12.3	13.4	-8.6		12.6			93.9	33.4	5.8	1.6	3.9
1994	-6.4	12.6	-2.8		1.2			-27.7	-9.6	6.6	2.1	4.6
1995 1996	-28.1 -5.2	6.4 0.7	39.0 1.7		-12.3 -1.9			5.4 23.8	-7.1 6.7	-0.4 16.3	10.2 16.6	4.3 16.4
1997	24.4	5.6	-3.5		13.7			53.5	29.2	2.0	2.6	2.3
1998	20.3 23.3	6.1 46.3	2.0 28.6		12.8 34.5			-13.9	0.4 23.1	5.4 8.8	6.7	6.1 7.5
1999								6.0			6.0	
2000 2001	22.8 18.9	0.3 1.3	7.8 65.9		10.8 10.9			7.2 11.8	9.6 11.2	-0.6 6.6	23.8 1.2	10.8
2002	17.6	14.9	15.2		16.4			10.8	14.5	2.8	1.7	2.2
2003 2004	10.5 13.9	8.4 -2.2	5.4 2.1		9.5 6.9			18.9 2.0	12.6 5.2	7.4 5.8	-11.6 3.2	-2.2 4.6
2005	10.4	8.1	-2.5		9.4			4.5	7.8	2.8	0.1	1.6
2006	6.1	-2.6	0.6		2.7			9.4	4.9	2.6	3.8	3.1
2007 2008	-3.8 7.9	18.5 -8.7	-3.7 40.5		4.3 1.3			12.1 -4.3	7.0 -0.7	-3.7 1.1	-6.7 0.2	-5.1 0.7
2009	3.8	8.0	-29.5		5.0			13.9	8.0	1.3	-1.8	-0.1
2010 ^f	5.1	1.6	-8.7		3.6			7.5	5.0	-0.4	0.3	-0.1
2011 ^f	3.2	0.7	8.9		2.3			8.9	4.7	-9.7	-0.9	-5.9
1985				(Annual	Percentage Cha	nge in Excess of	Inflation in the	Canadian Econ	omy) 			
1986	50.1	7.5	-21.5		24.3			-9.5	0.2			-8.3
1987 1988	110.9 32.4	-3.2 62.3	21.5 23.5		52.9 41.9			-12.0 -20.7	10.9 9.5			-11.1 -20.1
1989	8.7	30.3	-47.9		16.1			-6.8	7.4			-6.2
1990	0.4	11.2	90.3		5.2			-11.7	-0.5			-11.4
1991 1992	18.5 17.3	9.2 9.8	-59.4 286.5		13.9 14.9			17.4 -9.2	15.0 7.6			17.5 69.5
1993	10.9	11.9	-10.1		11.1			92.5	32.0	4.4	0.1	2.4
1994	-7.5	11.5	-3.9		0.1			-28.8	-10.7	5.5	1.0	3.5
1995 1996	-30.4 -6.9	4.1 -1.0	36.6 0.0		-14.7 -3.6			3.0 22.1	-9.4 5.1	-2.7 14.6	7.9 14.9	2.0 14.8
1997	23.4	4.6	-4.5		12.7			52.5	28.2	1.0	1.6	1.3
1998 1999	20.7 21.5	6.6 44.4	2.4 26.8		13.3 32.6			-13.5 4.2	0.8 21.3	5.9 7.0	7.2 4.2	6.5 5.6
2000 2001	18.7 17.5	-3.8 0.0	3.7 64.6		6.7 9.5			3.1 10.5	5.5 9.8	-4.7 5.3	19.7 -0.1	6.7 2.5
2002	16.6	13.8	14.2		15.4			9.7	13.5	1.8	0.6	1.2
2003 2004	7.6 11.3	5.5 -4.7	2.5 -0.5		6.7 4.3			16.0 -0.6	9.7 2.7	4.5 3.2	-14.5 0.6	-5.1 2.0
2005	7.4	5.1	-5.6		6.4			1.5	4.8	-0.2	-2.9	-1.4
2006	3.3	-5.4	-2.2		-0.1			6.6	2.1	-0.2	1.0	0.3
2007 2008	-7.5 3.0	14.8 -13.6	-7.4 35.6		0.6 -3.6			8.4 -9.2	3.3 -5.6	-7.4 -3.8	-10.4 -4.7	-8.7 -4.2
2009	6.5	10.7	-26.8		7.7			16.6	10.7	4.0	0.9	2.7
2010 ^f	2.2	-1.4	-11.6		0.7			4.6	2.1	-3.3	-2.6	-3.0
2011 ^f f: forecast.	-0.8	-3.3	4.9		-1.7			4.9	0.7	-13.7	-4.9	-9.9

t: forecast.

* Confidentiality precludes reporting territorial-level insurance data.

Table B Y.T.—Per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Yukon, 1985 to 2011 (cont'd)

		All Drugs		He	ealth Expenditure		GDP Implicit Price Index—Canada
	Public	Private	Total	Public	Private	Total	
Year			(\$ per Ca	pita)			(1997 = 100)
1985	21.51	108.45	129.96	1,351.18	278.89	1,630.07	73.6
1986	27.34	101.85	129.19	1,510.29	229.51	1,739.80	75.6
1987	43.10	94.95	138.05	1,521.49	219.52	1,741.02	79.2
1988 1989	63.12 76.17	79.90 78.36	143.03 154.53	1,524.93 1,632.10	196.03 194.61	1,720.95 1,826.71	82.8 86.6
1990 1991	82.41 96.18	71.66 86.16	154.07 182.33	1,747.95 1,954.71	180.81 210.04	1,928.76 2,164.74	89.2 91.6
1992	111.72	114.27	225.99	2,011.98	230.03	2,242.01	92.8
1993	125.76	153.32	279.07	2,290.11	347.90	2,638.01	94.1
1994	127.27	136.24	263.51	2,831.14	334.47	3,165.61	95.2
1995	111.60	142.69	254.29	2,799.51	346.09	3,145.60	97.4
1996	109.43	170.33 210.18	279.76	2,930.96	580.94	3,511.90	99.0
1997 1998	124.40 140.35	210.18	334.58 341.73	2,705.48 2,818.35	543.38 524.56	3,248.86 3,342.91	100.0 99.6
1999	188.71	215.07	403.77	3,000.99	548.37	3,549.36	101.4
2000	209.16	234.73	443.89	3,234.92	813.89	4,048.81	105.5
2001	231.91	252.14	484.05	3,826.04	911.33	4,737.37	106.9
2002	269.94	267.85	537.79	4,058.32	1,100.78	5,159.10	108.1
2003 2004	295.72 316.19	289.56 298.92	585.28 615.12	4,055.76 4,274.60	1,056.96 1,151.06	5,112.71 5,425.66	111.2 114.1
2005 2006	345.92 355.14	308.35 328.44	654.27 683.58	4,865.49 5,499.54	1,177.12 1,220.89	6,042.61 6,720.43	117.5 120.8
2007	370.50	342.97	713.47	5,499.67	1,593.79	7,093.46	125.2
2008	375.30	335.17	710.47	5,766.16	1,518.95	7,285.11	131.3
2009	393.92	362.20	756.12	6,598.67	1,665.08	8,263.75	127.8
2010 ^f	408.26	378.74	787.00	6,984.49	1,742.29	8,726.79	131.5
2011 [†]	417.66	391.68	809.34	7,101.88	1,893.76	8,995.64	136.8
4005			(Annual Percentage Cha	inge)		
1985 1986	27.1	-6.1	-0.6	11.8	-17.7	6.7	2.8
1987	57.6	-6.8	6.9	0.7	-4.4	0.1	4.7
1988 1989	46.5 20.7	-15.8 -1.9	3.6 8.0	0.2 7.0	-10.7 -0.7	-1.2 6.1	4.5 4.6
1990 1991	8.2 16.7	-8.5 20.2	-0.3 18.3	7.1 11.8	-7.1 16.2	5.6 12.2	3.0 2.8
1992	16.2	32.6	23.9	2.9	9.5	3.6	1.3
1993	12.6	34.2	23.5	13.8	51.2	17.7	1.4
1994	1.2	-11.1	-5.6	23.6	-3.9	20.0	1.1
1995 1996	-12.3 -1.9	4.7 19.4	-3.5 10.0	-1.1 4.7	3.5 67.9	-0.6 11.6	2.3 1.7
1996	13.7	23.4	19.6	4.7 -7.7	-6.5	-7.5	1.7
1998	12.8	-4.2	2.1	4.2	-3.5	2.9	-0.4
1999	34.5	6.8	18.2	6.5	4.5	6.2	1.8
2000	10.8	9.1	9.9	7.8	48.4	14.1	4.1
2001	10.9	7.4	9.0	18.3	12.0	17.0	1.4
2002 2003	16.4 9.5	6.2 8.1	11.1 8.8	6.1 -0.1	20.8 -4.0	8.9 -0.9	1.0 2.9
2004	6.9	3.2	5.1	5.4	8.9	6.1	2.6
2005	9.4	3.2	6.4	13.8	2.3	11.4	3.0
2006	2.7	6.5	4.5	13.0	3.7	11.2	2.8
2007	4.3	4.4	4.4	0.0	30.5	5.6	3.7
2008 2009	1.3 5.0	-2.3 8.1	-0.4 6.4	4.8 14.4	-4.7 9.6	2.7 13.4	4.9 -2.7
2010 ^f 2011 ^f	3.6 2.3	4.6 3.4	4.1 2.8	5.8 1.7	4.6 8.7	5.6 3.1	2.9 4.0
	2.0	(Annual Percentage	Ob ! F4	Indicates to the Couracti	an Economy)	0.1	1.0
1985							
1986 1987	24.3 52.9	-8.9 -11.5	-3.4 2.1	9.0 -4.0	-20.5 -9.1	3.9 -4.7	
1988	41.9	-20.4	-0.9	-4.0	-15.2	-4.7 -5.7	
1989	16.1	-6.5	3.5	2.5	-5.3	1.6	
1990	5.2	-11.6	-3.3	4.1	-10.1	2.6	
1991	13.9	17.5	15.6	9.1	13.4	9.5	
1992	14.9	31.4	22.7	1.7	8.3	2.3	
1993 1994	11.1 0.1	32.7 -12.2	22.0 -6.7	12.4 22.5	49.8 -5.0	16.2 18.9	
1995 1996	-14.7 -3.6	2.4 17.7	-5.8 8.3	-3.5 3.0	1.1 66.2	-3.0 10.0	
1997	12.7	22.4	18.6	-8.7	-7.5	-8.5	
1998	13.3	-3.8	2.6	4.6	-3.0	3.3	
1999	32.6	5.0	16.3	4.7	2.7	4.4	
2000	6.7	5.0	5.8	3.7	44.3	10.0	
2001 2002	9.5 15.4	6.1 5.2	7.7 10.1	16.9 5.0	10.6 19.7	15.7 7.9	
2003	6.7	5.2	5.9	-3.0	-6.9	-3.8	
2004	4.3	0.6	2.5	2.8	6.3	3.5	
2005	6.4	0.1	3.4	10.8	-0.7	8.4	
2006 2007	-0.1 0.6	3.7 0.7	1.7 0.7	10.2 -3.7	0.9 26.9	8.4 1.9	
2007	-3.6	-7.1	-5.3	0.0	-9.6	-2.2	
2009	7.7	10.8	9.1	17.1	12.3	16.1	
2010 ^f	0.7	1.6	1.1	2.9	1.7	2.7	
2011 ^f	-1.7	-0.6	-1.2	-2.3	4.7	-0.9	

Y.T.

Table B N.W.T.—Total

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, Northwest Territories, 1985 to 2011

			Public		Prescribed	Drugs	Private				Prescribed Druate (Out of Pocl	
	Territorial	Federal	Social Secur	rity Funds Prug Insurance Funds	Subtotal Public	Insurers*	Out of Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	Personal Health Supplies	Total Non-Presc. Drugs
Year			(Prer	nium Component)		(\$ Million	ns)		2.490	Drugs	Саррисс	2. ago
1985	1.1	2.4	0.0		3.5			2.3	5.8			4.1
1986 1987	1.4 1.7	2.7 3.0	0.0 0.0		4.1 4.7			2.7 3.0	6.8 7.7			4.4 4.7
1988	1.9	3.2	0.0		5.1			3.4	8.6			5.1
1989	2.1	3.7	0.0		5.8			3.9	9.7			5.4
1990 1991	2.4 3.0	4.3 4.9	0.0		6.6 7.9			3.9 5.0	10.6 12.9			5.1 6.0
1992 1993	3.6 2.5	5.7 6.4	0.0 0.0		9.3 8.9			4.9 4.7	14.2 13.6	2.4 2.6	2.1 2.2	4.5 4.7
1994	1.2	7.1	0.1		8.3			3.5	11.8	2.8	2.3	5.1
1995	1.1	7.7	0.1		8.9			3.8	12.6	2.9	2.5	5.4
1996 1997	1.3 1.4	8.0 8.5	0.0		9.3 10.0			3.5 4.4	12.8 14.4	2.7 3.1	2.4 2.8	5.1 5.9
1998	1.7	8.8	0.0		10.5			4.5	15.0	3.2	2.9	6.2
1999	1.8	7.6	0.0		9.4			3.3	12.7	2.3	2.1	4.4
2000 2001	1.9 2.2	7.6 8.8	0.0		9.5 11.0			3.4 3.6	13.0 14.7	2.3 2.2	1.4 1.4	3.7 3.6
2002 2003	2.4 3.2	10.7 9.0	0.0 0.0		13.1 12.3			4.0 5.3	17.2 17.5	2.3 2.2	1.5	3.7 3.7
2003	3.6	8.1	0.0		11.8			5.4	17.5	2.2	1.5 1.4	3.7
2005	3.7	6.2	0.1		10.0			7.0	17.0	2.0	1.4	3.4
2006 2007	4.3 4.9	6.3 8.3	0.1 0.1		10.6 13.2			7.9 8.6	18.5 21.8	1.9 2.5	1.4 1.9	3.3 4.4
2008	5.1	8.5	0.1		13.8			8.4	22.2	2.5	1.9	4.4
2009	5.4	10.4	0.1		15.9			8.9	24.8	2.8	2.1	4.9
2010 [†] 2011 ^f	5.3 5.3	11.1 11.3	0.1 0.1		16.5 16.6			9.0 9.3	25.4 25.9	2.9 2.8	2.2 2.3	5.0 5.1
						(Annual Percenta	ge Change)					
1985 1986	30.3	12.3	-5.7		 17.7			14.6	 16.5			8.2
1987	22.0	8.5	6.9		13.1			12.7	12.9			6.2
1988 1989	12.6 7.6	6.9 17.3	67.7 -6.6		9.2 13.5			15.4 14.2	11.6 13.8			8.6 7.2
1990	13.9	14.8	-0.9		14.4			0.2	8.7			-6.0
1991	25.2	16.0	13.9		19.2			25.8	21.7			17.8
1992 1993	21.7 -31.8	14.9 13.3	1.0 27.0		17.4 -4.2			-1.1 -4.2	10.3 -4.2	7.3	3.0	-25.1 5.3
1994	-50.0	10.0	32.1		-6.5			-25.9	-13.2	9.0	4.3	6.9
1995	-8.1	9.1	0.9		6.5			7.8	6.9	1.5	12.3	6.3
1996 1997	15.1 9.9	3.3 6.5	-15.9 -3.6		4.7 7.0			-6.7 27.0	1.3 12.4	-6.2 15.7	-6.0 16.3	-6.1 16.0
1998	16.1	3.3 -13.7	1.1		5.1			1.7 -27.4	4.1	4.2 -27.8	5.4	4.8 -28.7
1999	9.8 6.6	-0.1	-14.2 0.1		-10.0			5.1	-15.2	-0.9	-29.6	-15.5
2001	13.6	16.2	22.9		1.2 15.7			5.8	2.2 13.1	-6.5	-32.0 2.7	-3.0
2002 2003	7.4 34.8	21.8 -15.7	4.0 1.7		18.9 -6.5			11.0 30.7	16.9 2.2	4.2 -2.3	3.0 1.4	3.7 -0.8
2004	12.8	-9.6	56.6		-3.5			1.7	-1.9	-1.9	-8.7	-4.6
2005	3.7	-24.4	-14.4		-15.7			30.9	-1.2	-7.8	1.8	-4.1
2006 2007	13.6 14.2	2.4 31.2	-2.7 13.3		6.6 24.3			11.7 10.0	8.7 18.2	-2.8 26.8	0.3 38.3	-1.5 31.6
2008	5.6	3.2	16.1		4.2			-2.8	1.4	1.4	0.5	1.0
2009	5.0	21.9	9.2		15.5			6.3	12.0	12.8	9.3	11.2
2010 ^r 2011 ^f	-1.1 -0.8	6.2 1.9	4.9 1.0		3.7 1.0			0.2 3.7	2.4 2.0	1.7 -2.5	2.4 6.5	2.0 1.4
						age Share of Tota						
1985 1986	10.9 12.6	24.5 24.3	0.2 0.1		35.6 37.1			23.4 23.7	59.0 60.7			41.0 39.3
1987	13.9	23.9	0.1		38.0			24.2	62.2			37.8
1988 1989	14.2 13.7	23.2 24.4	0.2 0.2		37.6 38.3			25.3 25.9	62.8 64.2			37.2 35.8
1990	15.1	27.1	0.2		42.4			25.1	67.5			32.5
1991 1992	15.7 19.3	26.1 30.3	0.2 0.2		41.9 49.7			26.2 26.2	68.2 75.9	12.9	 11.2	31.8 24.1
1993	13.4	34.9	0.2		48.6			25.6	74.1	14.1	11.8	25.9
1994	7.3	41.8	0.3		49.4			20.6	70.0	16.7	13.3	30.0
1995 1996	6.3 7.3	42.7 44.5	0.3 0.2		49.3 52.1			20.8 19.6	70.1 71.6	15.9 15.0	14.0 13.3	29.9 28.4
1997	7.1	41.8	0.2		49.1			21.9	71.0	15.3	13.7	29.0
1998 1999	7.9 10.7	41.4 44.2	0.2 0.2		49.5 55.1			21.4 19.2	70.9 74.3	15.3 13.7	13.8 12.0	29.1 25.7
2000	11.7	45.2	0.2		57.1			20.6	77.8	13.9	8.4	22.2
2001	12.1	48.0	0.2		60.4			19.9	80.3	11.8	7.9	19.7
2002 2003	11.4 15.1	51.2 42.4	0.2 0.2		62.8 57.7			19.4 24.9	82.1 82.6	10.8 10.4	7.1 7.1	17.9 17.4
2004	17.4	39.3	0.3		57.0			25.9	83.0	10.4	6.6	17.0
2005	18.4	30.2	0.3		48.9			34.5	83.4	9.8	6.8	16.6
2006 2007	19.5 18.5	28.9 31.5	0.3 0.3		48.7 50.3			36.0 33.0	84.7 83.3	8.9 9.4	6.4 7.4	15.3 16.7
2008	19.3	32.1	0.3		51.7			31.6	83.3	9.4	7.3	16.7
2009	18.1	35.0	0.3		53.4			30.0	83.4	9.4	7.1	16.6
2010 [†] 2011 [†] f: forecast.	17.5 17.0	36.3 36.3	0.3 0.3		54.1 53.6			29.4 29.9	83.5 83.6	9.4 9.0	7.1 7.5	16.5 16.4

f: forecast.

* Confidentiality precludes reporting territorial-level insurance data.

Table B N.W.T.—Total

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, Northwest Territories, 1985 to 2011 (cont'd) Share of Drugs in Public, Private and

			i nealth Expent			, 1905 to 2011	Share of Drugs in I		
	Public	All Drugs Private	Total	Public	ealth Expenditure Private	Total	Public Total Health	Expenditures Private	Total
Year			(\$ Million					age Share)	
1985 1986	3.5 4.1	6.4 7.0	9.9 11.2	118.9 145.2	19.6 21.7	138.5 166.9	3.0 2.9	32.4 32.5	7.1 6.7
1987	4.7	7.7	12.3	157.4	23.9	181.3	3.0	32.1	6.8
1988 1989	5.1 5.8	8.5 9.4	13.6 15.2	183.9 203.6	27.3 29.3	211.2 232.9	2.8 2.9	31.2 31.9	6.5 6.5
1990	6.6	9.0	15.7	218.5	28.4	246.8	3.0	31.9	6.4
1991	7.9	11.0	18.9	247.2	32.3	279.5	3.2	34.0	6.8
1992 1993	9.3 8.9	9.4 9.4	18.7 18.4	249.9 258.7	29.7 28.3	279.6 287.1	3.7 3.4	31.7 33.3	6.7 6.4
1994	8.3	8.6	16.9	259.5	26.8	286.3	3.2	32.0	5.9
1995	8.9	9.1	18.0	270.3	24.7	295.0	3.3	37.0	6.1
1996 1997	9.3 10.0	8.6 10.3	17.9 20.3	250.9 262.6	26.7 26.4	277.7 289.0	3.7 3.8	32.0 39.1	6.4 7.0
1998	10.5	10.7	21.1	283.8	26.0	309.8	3.7	41.0	6.8
1999	9.4	7.7	17.1	201.9	21.1	223.1	4.7	36.3	7.7
2000 2001	9.5 11.0	7.2 7.2	16.7 18.3	188.9 213.6	19.6 26.3	208.5 240.0	5.0 5.2	36.5 27.5	8.0 7.6
2002	13.1	7.8	20.9	237.0	28.7	265.7	5.5	27.1	7.9
2003 2004	12.3 11.8	9.0 8.9	21.2 20.7	233.5 253.9	29.9 30.3	263.4 284.3	5.2 4.7	30.1 29.4	8.1 7.3
2005	10.0	10.4	20.4	268.4	50.4	318.8	3.7	20.7	6.4
2006	10.6	11.2	21.8	286.1	58.2	344.3	3.7	19.2	6.3
2007 2008	13.2 13.8	13.0 12.8	26.2 26.6	316.3 344.9	68.9 62.1	385.2 407.0	4.2 4.0	18.9 20.7	6.8 6.5
2009	15.9	13.9	29.8	364.3	67.5	431.8	4.4	20.5	6.9
2010 ^f	16.5	14.0	30.5	366.5	72.2	438.7	4.5	19.4	6.9
2011 ^f	16.6	14.4	31.0	372.8	79.5	452.3	4.5	18.1	6.9
1985			(Annual Percenta	ge Change)					
1986	17.7	10.5	13.1	22.2	10.5	20.5			
1987 1988	13.1 9.2	8.7 11.3	10.3 10.5	8.4 16.8	10.0 14.4	8.6 16.5			
1989	13.5	10.0	11.3	10.7	7.5	10.3			
1990	14.4	-3.4	3.4	7.3	-3.3	6.0			
1991 1992	19.2 17.4	21.3 -14.2	20.4 -1.0	13.2 1.1	13.7 -7.9	13.2 0.1			
1993	-4.2	0.3	-1.9	3.5	-4.7	2.7			
1994	-6.5	-9.4	-8.0	0.3	-5.5	-0.3			
1995 1996	6.5 4.7	6.9 -6.4	6.7 -0.9	4.1 -7.2	-7.8 8.3	3.0 -5.9			
1997	7.0	20.5	13.4	4.6	-1.4	4.1			
1998 1999	5.1 -10.0	3.4 -28.1	4.3 -19.2	8.1 -28.9	-1.3 -18.8	7.2 -28.0			
2000	1.2	-6.7	-2.3	-6.5	-7.0	-6.5			
2001	15.7	1.2	9.5	13.1	34.1	15.1			
2002 2003	18.9 -6.5	7.4 15.6	14.3 1.7	10.9 -1.5	9.0 4.1	10.7 -0.9			
2004	-3.5	-0.9	-2.4	8.7	1.4	7.9			
2005	-15.7	17.0	-1.7	5.7	66.2	12.2			
2006 2007	6.6 24.3	7.4 16.4	7.0 20.2	6.6 10.6	15.4 18.5	8.0 11.9			
2008	4.2	-1.5	1.4	9.0	-10.0	5.6			
2009	15.5	8.0	11.9	5.6	8.8	6.1			
2010 ^f 2011 ^f	3.7 1.0	0.9 2.9	2.4 1.9	0.6 1.7	6.9 10.2	1.6 3.1			
2011		are of Total Drug E		1.7	10.2	3.1			
1985	35.6	64.4	100.0						
1986 1987	37.1 38.0	62.9 62.0	100.0 100.0						
1988	37.6	62.4	100.0						
1989	38.3	61.7	100.0						
1990 1991	42.4 41.9	57.6 58.1	100.0 100.0						
1992	49.7	50.3	100.0						
1993 1994	48.6 49.4	51.4 50.6	100.0 100.0						
1995	49.3	50.7	100.0						
1996	52.1	47.9	100.0						
1997 1998	49.1 49.5	50.9 50.5	100.0 100.0						
1999	49.5 55.1	44.9	100.0						
2000	57.1	42.9	100.0						
2001	60.4	39.6	100.0						
2002 2003	62.8 57.7	37.2 42.3	100.0 100.0						
2004	57.0	43.0	100.0						
2005	48.9	51.1	100.0						
2006 2007	48.7 50.3	51.3 49.7	100.0 100.0						
2008	51.7	48.3	100.0						
2009	53.4	46.6	100.0						
2010 ^f 2011 ^f	54.1 53.6	45.9 46.4	100.0 100.0						
	55.5								

f: forecast.

Table B N.W.T.—Per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Northwest Territories, 1985 to 2011

-	Prescribed Drugs							Non-Prescribed Drugs				
-	Territorial	Federal		Funds Insurance Funds	Subtotal Public	Insurers*	Private Out of Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	te (Out of Pock Personal Health Supplies	Total Non-Presc. Drugs
v				m Component)						Drugs		
Year 1985	19.87	44.58	0.30		64.76	(\$ per Cap	лта) 	42.52	107.28			74.63
1986	25.75	49.79	0.29		75.83			48.45	124.28			80.32
1987	31.22	53.68	0.30		85.21			54.27	139.47			84.79
1988 1989	34.75 36.51	56.71 64.93	0.50 0.46		91.96 101.90			61.91 69.02	153.87 170.93			91.01 95.30
1990 1991	40.26 48.72	72.19 80.93	0.44 0.48		112.88 130.14			66.93 81.44	179.82 211.58			86.68 98.76
1992	57.90	90.80	0.48		149.18			78.63	227.81	38.63	33.63	72.26
1993	38.77	101.02	0.60		140.39			73.95	214.34	40.71	34.01	74.73
1994	18.92	108.39	0.77		128.08			53.43	181.52	43.27	34.62	77.89
1995	17.01	115.69	0.76		133.46			56.36	189.82	43.00	38.04	81.04
1996 1997	19.28 21.15	117.78 125.16	0.63 0.60		137.69 146.92			51.79 65.59	189.48 212.51	39.74 45.87	35.24 40.90	74.98 86.77
1998	24.75	130.34	0.62		155.70			67.25	222.95	48.16	43.48	91.64
1999	44.90	185.89	0.87		231.66			80.64	312.30	57.48	50.56	108.04
2000	48.07	186.46	0.88		235.41			85.11	320.51	57.16	34.51	91.67
2001 2002	54.18 57.23	215.04 257.78	1.07 1.10		270.29 316.11			89.29 97.51	359.58 413.62	53.05 54.38	35.15 35.62	88.20 90.01
2003	75.78	213.37	1.09		290.24			125.19	415.44	52.20	35.49	87.70
2004	84.28	190.26	1.69		276.23			125.54	401.76	50.49	31.97	82.47
2005	87.63	144.25	1.45		233.33			164.70	398.02	46.65	32.61	79.27
2006	98.49	146.08	1.39		245.96			181.98	427.94	44.84	32.35	77.19
2007 2008	111.54 117.42	190.07 195.53	1.57 1.81		303.18 314.77			198.54 192.36	501.71 507.12	56.41 56.98	44.40 44.46	100.81 101.44
2009	123.31	238.42	1.98		363.71			204.68	568.39	64.29	48.61	112.90
2010 ^f	121.67	252.61	2.07		376.36			204.76	581.12	65.24	49.69	114.93
2011 ^f	119.57	255.07	2.08		376.72			210.40	587.12	63.00	52.46	115.46
-						(Annual Percenta	ge Change)					
1985					47.4				45.0			
1986 1987	29.6 21.2	11.7 7.8	-6.3 6.3		17.1 12.4			14.0 12.0	15.8 12.2			7.6 5.6
1988	11.3	5.6	65.8		7.9			14.1	10.3			7.3
1989	5.1	14.5	-8.8		10.8			11.5	11.1			4.7
1990	10.3	11.2	-4.0		10.8			-3.0	5.2			-9.1
1991 1992	21.0 18.8	12.1 12.2	10.2 -1.4		15.3 14.6			21.7 -3.4	17.7 7.7			13.9 -26.8
1993	-33.0	11.3	24.8		-5.9			-6.0	-5.9	5.4	1.1	3.4
1994	-51.2	7.3	28.8		-8.8			-27.7	-15.3	6.3	1.8	4.2
1995	-10.1	6.7	-1.3		4.2			5.5	4.6	-0.6	9.9	4.0
1996	13.4	1.8	-17.1		3.2			-8.1	-0.2	-7.6	-7.4	-7.5
1997 1998	9.7 17.0	6.3 4.1	-3.8 1.9		6.7 6.0			26.7 2.5	12.2 4.9	15.4 5.0	16.1 6.3	15.7 5.6
1999	81.4	42.6	41.8		48.8			19.9	40.1	19.3	16.3	17.9
2000	7.1	0.3	0.5		1.6			5.5	2.6	-0.6	-31.7	-15.2
2001	12.7	15.3	22.0		14.8			4.9	12.2	-7.2	1.9	-3.8
2002	5.6	19.9	2.3		17.0			9.2	15.0	2.5	1.3	2.0
2003 2004	32.4 11.2	-17.2 -10.8	-0.1 54.5		-8.2 -4.8			28.4 0.3	0.4 -3.3	-4.0 -3.3	-0.4 -9.9	-2.6 -6.0
2005	4.0	-24.2	-14.3		-15.5			31.2	-0.9	-7.6	2.0	-3.9
2006	12.4	1.3	-3.8		5.4			10.5	7.5	-3.9	-0.8	-2.6
2007	13.3	30.1	12.4		23.3			9.1	17.2	25.8	37.2	30.6
2008 2009	5.3 5.0	2.9 21.9	15.7 9.2		3.8 15.5			-3.1 6.4	1.1 12.1	1.0 12.8	0.1 9.3	0.6 11.3
2010 [†] 2011 [†]	-1.3 -1.7	6.0 1.0	4.7 0.1		3.5 0.1			0.0 2.8	2.2 1.0	1.5 -3.4	2.2 5.6	1.8 0.5
				(Annual		nge in Excess of	Inflation in the					
1985												
1986 1987	26.8 16.5	8.9 3.1	-9.1 1.5		14.3 7.6			11.2 7.3	13.0 7.5			4.8 0.8
1988	6.8	1.1	61.2		3.4			9.6	5.8			2.8
1989	0.5	9.9	-13.4		6.2			6.9	6.5			0.1
1990	7.2	8.1	-7.1		7.7			-6.1	2.2			-12.1
1991	18.3	9.4	7.4		12.5			18.9	14.9			11.2 -28.1
1992 1993	17.6 -34.5	10.9 9.8	-2.6 23.3		13.4 -7.3			-4.7 -7.4	6.4 -7.4	4.0	-0.3	2.0
1994	-52.3	6.2	27.7		-9.9			-28.8	-16.4	5.2	0.7	3.1
1995	-12.4	4.4	-3.6		1.9			3.1	2.2	-3.0	7.6	1.7
1996	11.7	0.1	-18.8		1.5			-9.8	-1.9	-9.3	-9.0	-9.1
1997 1998	8.7 17.5	5.3 4.6	-4.8 2.3		5.7 6.4			25.7 3.0	11.2 5.4	14.4 5.4	15.1 6.7	14.7 6.1
1999	79.6	40.8	40.0		47.0			18.1	38.3	17.5	14.5	16.1
2000	3.0	-3.8	-3.6		-2.5			1.4	-1.5	-4.7	-35.8	-19.3
2001	11.4	14.0	20.6		13.5			3.6	10.8	-8.5	0.5	-5.1
2002 2003	4.6 29.5	18.8 -20.1	1.2 -3.0		15.9 -11.1			8.2 25.5	14.0 -2.5	1.5 -6.9	0.3 -3.3	1.0 -5.5
2003	29.5 8.6	-20.1 -13.4	-3.0 51.9		-11.1 -7.4			-2.3	-2.5 -5.9	-6.9 -5.9	-3.3 -12.5	-5.5 -8.6
2005	1.0	-27.2	-17.3		-18.5			28.2	-3.9	-10.6	-1.0	-6.9
2006	9.6	-1.5	-6.6		2.6			7.7	4.7	-6.7	-3.6	-5.4
2007	9.6	26.4	8.7		19.6			5.4	13.6	22.1	33.5	26.9
2008 2009	0.4 7.7	-2.0 24.6	10.8 12.0		-1.0 18.3			-8.0 9.1	-3.8 14.8	-3.9 15.5	-4.7 12.0	-4.2 14.0
2010 ^f	-4.3	3.0	1.7		0.5			-2.9	-0.7	-1.5	-0.7	-1.1
2010 2011 ^f f: forecast.	-4.3 -5.7	-3.0	-3.9		-3.9			-2.9 -1.2	-3.0	-1.5 -7.4	1.6	-3.5

f: forecast.

* Confidentiality precludes reporting territorial-level insurance data.

Table B N.W.T.—Per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Northwest Territories, 1985 to 2011 (cont'd) GDP Implicit Health Expenditure Price Index—Canada

		All Drugs			Health Expenditure		Price Index—Canada
	Public	Private	Total	Public	Private	Total	
Year			(\$ per Cap	ita)			(1997 = 100)
1985	64.76	117.15	181.91	2,185.68	361.05	2,546.73	73.6
1986	75.83	128.77	204.59	2,655.45	396.69	3,052.14	75.6
1987	85.21	139.05	224.26	2,859.77	433.59	3,293.37	79.2
1988	91.96	152.93	244.89	3,302.40	490.09	3,792.49	82.8
1989	101.90	164.33	266.23	3,570.18	514.33	4,084.51	86.6
1990	112.88	153.61	266.49	3,708.35	481.64	4,190.00	89.2
1991	130.14	180.20	310.34	4,057.16	529.44	4,586.61	91.6
1992	149.18	150.89	300.07	4,004.30	476.22	4,480.52	92.8
1993	140.39	148.68	289.07	4,071.51	445.89	4,517.40	94.1
1994	128.08	131.32	259.40	3,983.42	410.95	4,394.37	95.2
1995	133.46	137.40	270.86	4,060.01	370.96	4,430.96	97.4
1996	137.69	126.77	264.46	3,713.59	395.82	4,109.41	99.0
1997	146.92	152.36	299.28	3,876.75	389.36	4,266.11	100.0
1998	155.70	158.89	314.60	4,224.30	387.25	4,611.55	99.6
1999	231.66	188.69	420.34	4,967.41	519.57	5,486.97	101.4
2000	235.41	176.78	412.19	4,664.19	484.88	5,149.06	105.5
2001	270.29	177.49	447.78	5,232.80	645.24	5,878.03	106.9
2002	316.11	187.52	503.63	5,711.56	692.07	6,403.63	108.1
2003	290.24	212.89	503.13	5,529.05	708.13	6,237.18	111.2
2004	276.23	208.00	484.23	5,929.69	708.29	6,637.98	114.1
2005	233.33	243.96	477.29	6,282.52	1,179.97	7,462.49	117.5
2006	245.96	259.17	505.13	6,623.07	1,346.79	7,969.85	120.8
2007	303.18	299.34	602.52	7,264.10	1,582.85	8,846.95	125.2
2008	314.77	293.80	608.57	7,893.52	1,420.18	9,313.70	131.3
2009	363.71	317.58	681.29	8,340.98	1,545.93	9,886.91	127.8
2010 ^f	376.36	319.70	696.05	8,375.71	1,649.11	10,024.82	131.5
2010 2011 ^f	376.72	319.70 325.86	702.58	8,375.71 8,441.38	1,800.89	10,024.82	131.5
	310.12	323.00				10,272.20	130.0
				nnual Percentage (Change)		-
1985							
1986 1987	17.1 12.4	9.9	12.5 9.6	21.5 7.7	9.9 9.3	19.8 7.9	2.8 4.7
1988	7.9	8.0 10.0	9.0	15.5	13.0	15.2	4.7
1989	10.8	7.5	8.7	8.1	4.9	7.7	4.6
1990	10.8	-6.5	0.1	3.9	-6.4	2.6	3.0
1991	15.3	17.3	16.5	9.4	9.9	9.5	2.8
1992 1993	14.6 -5.9	-16.3 -1.5	-3.3 -3.7	-1.3 1.7	-10.1 -6.4	-2.3 0.8	1.3 1.4
1994	-8.8	-11.7	-10.3	-2.2	-7.8	-2.7	1.1
1995	4.2	4.6	4.4	1.9	-9.7	0.8	2.3
1996	3.2	-7.7	-2.4	-8.5	6.7	-7.3	1.7
1997 1998	6.7 6.0	20.2 4.3	13.2 5.1	4.4 9.0	-1.6 -0.5	3.8 8.1	1.0
1999	48.8	18.8	33.6	17.6	34.2	19.0	1.8
2000	1.6	-6.3	-1.9	-6.1	-6.7	-6.2	4.1
2001	14.8	0.4	8.6	12.2	33.1	14.2	1.4
2002	17.0	5.6	12.5	9.1	7.3	8.9	1.0
2003 2004	-8.2 -4.8	13.5 -2.3	-0.1 -3.8	-3.2 7.2	2.3 0.0	-2.6 6.4	2.9 2.6
2004	-4.0	-2.3	*3.0	7.2	0.0	0.4	2.0
2005	-15.5	17.3	-1.4	6.0	66.6	12.4	3.0
2006	5.4	6.2	5.8	5.4	14.1	6.8	2.8
2007	23.3	15.5	19.3	9.7	17.5	11.0	3.7
2008	3.8	-1.9	1.0	8.7	-10.3	5.3	4.9
2009	15.5	8.1	11.9	5.7	8.9	6.2	-2.7
2010 ^f	3.5	0.7	2.2	0.4	6.7	1.4	2.9
2011 ^f	0.1	1.9	0.9	0.8	9.2	2.2	4.0
			Change in Excess of I				
1985 1986	14.3	7.1	9.7	18.7	7.1	17.0	
1986 1987	14.3 7.6	7.1 3.2	9.7 4.9	18.7 3.0	7.1 4.6	17.0 3.2	
1988	3.4	5.5	4.7	11.0	8.5	10.6	
1989	6.2	2.9	4.2	3.5	0.4	3.1	
1990	7.7	-9.5	-2.9	0.8	-9.4	-0.4	
1991	12.5	14.5	13.7	6.6	7.2	6.7	
1992 1993	13.4 -7.3	-17.5 -2.9	-4.6 -5.1	-2.6 0.2	-11.3 -7.8	-3.6 -0.6	
1993	-7.3 -9.9	-2.9 -12.8	-5.1 -11.4	-3.3	-7.8 -8.9	-0.6	
1995	1.9	2.3	2.1	-0.4	-12.1	-1.5	
1996	1.5	-9.4	-4.0	-10.2	5.0	-8.9	
1997	5.7	19.2	12.2	3.4	-2.6	2.8	
1998 1999	6.4 47.0	4.7 16.9	5.6 31.8	9.4 15.8	-0.1 32.4	8.5 17.2	
2000	-2.5	-10.4	-6.0	-10.2	-10.8	-10.3	
2001	13.5	-0.9	7.3	10.8	31.7	12.8	
2002	15.9	4.6	11.4	8.1	6.2	7.9	
2003 2004	-11.1 -7.4	10.6 -4.9	-3.0 -6.3	-6.1 4.7	-0.6 -2.6	-5.5 3.8	
2005	-18.5	14.3	-4.4	2.9	63.6	9.4	
2006	2.6	3.4	3.0	2.6	11.3	4.0	
2007	19.6	11.8	15.6	6.0	13.8	7.3	
2008	-1.0 18.3	-6.7 10.8	-3.9 14.7	3.8	-15.1 11.6	0.4	
2009	18.3	10.8	14.7	8.4	11.6	8.9	
2010 ^f	0.5	-2.3	-0.8	-2.5	3.7	-1.5	
2011 ^f	-3.9	-2.1	-3.1	-3.2	5.2	-1.8	
f: forecast						Nation	al Health Expenditure Database, 20

N.W.T.

f: forecast.

Table B Nun.—Total

Nun.

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, Nunavut, 1985 to 2011

			Public		Prescribed		Private			Priva	Prescribed Dru te (Out of Pocl	ket)
	Territorial	Federal	WCBs	Drug Insurance Funds	Subtotal Public	Insurers*	Out of Pocket	Subtotal Private	Total Prescribed Drugs	Over- the- Counter	Personal Health Supplies	Total Non-Presc. Drugs
Year			(P	remium Component)		(\$ Million	ns)			Drugs		
985												
986 987												
988												
989												
990 991												
992												
993 994												
95												
96 97												
98												
99	1.0	0.0	0.0		1.1			1.3	2.4	1.5	1.3	2.9
00 01	1.2 1.2	0.2 0.4	0.0		1.4 1.7			1.5 1.5	2.8 3.2	1.6 1.5	0.9 1.0	2.5 2.5
02	1.5	0.8	0.0		2.4			2.1	4.5	1.6	1.0	2.6
03 04	2.1 2.2	4.1 5.1	0.0 0.1		6.3 7.4			3.3 4.1	9.6 11.5	1.5 1.5	1.0 0.9	2.6 2.4
05	2.4	7.7	0.0		10.2			3.7	14.0	1.4	1.0	2.4
06	2.8	8.9	0.0		11.7			4.3	16.1	1.4	1.0	2.5
7 8	2.9 2.1	7.7 8.8	0.0 0.1		10.7 11.0			5.1 4.9	15.8 15.9	1.8 1.8	1.4 1.4	3.2 3.2
09	2.5	8.6	0.1		11.2			6.1	17.4	2.1	1.6	3.7
10 ^f	2.7	8.4	0.1		11.1			6.9	18.0	2.1	1.6	3.7
11'	2.7	8.5	0.1		11.3	 (Annual Percenta	 ge Change)	8.0	19.3	1.9	1.5	3.4
35												
86 87												
38												
89												
90 91												
92												
93 94												
95												
96												
97 98												
99												
00 01	21.7 3.7	290.0 174.4	3.1 24.7		31.3 23.1			9.4 4.7	19.1 13.6	1.1 -4.8	-30.6 4.5	-13.7 -1.3
02	23.4	88.4	4.5		39.2			36.1	37.7	6.0	4.5	5.5
)3)4	36.7 6.3	421.2 22.9	1.4 56.9		165.5 17.5			56.6 25.1	114.5 20.1	-2.7 -1.6	1.0 -8.4	-1.3 -4.4
05	8.6	52.0	-13.1		38.4			-8.5	21.7	-7.1	2.6	-3.4
06	17.2	14.3	-1.2		14.9			15.4	15.0	2.4	5.7	3.8
07 08	3.3 -27.0	-13.3 14.9	14.1 16.9		-9.2 3.4			19.1 -4.6	-1.6 0.8	23.9 2.1	35.1 1.2	28.6 1.7
09	18.1	-2.4	11.3		1.7			25.2	8.9	15.5	11.9	13.9
10 ^f	6.2	-3.0	8.0		-0.8			11.5	3.6	2.1	2.9	2.5
111 ^f	0.2	1.9	0.0		1.5 (Percent	age Share of Tota	I Drug Expend	16.3 liture)	7.1	-10.7	-10.1	-10.4
85												
86 87												
38												
89												
90 91												
92												
93 94												
95												
96												
97 98												
99	18.8	0.7	0.4		19.9			25.4	45.3	29.1	25.6	54.7
00	22.6	2.9	0.5		25.9			27.4	53.3	29.1	17.6	46.7
01 02	21.9 21.9	7.4 11.3	0.5 0.4		29.9 33.6			26.9 29.6	56.8 63.2	26.0 22.2	17.2 14.6	43.2 36.8
03	17.4	34.2	0.3		51.9			27.0	78.9	12.6	8.5	21.1
04	16.1	36.6	0.4		53.1			29.4	82.4	10.8	6.8	17.6
05 06	14.9 15.4	47.5 47.8	0.3 0.2		62.6 63.4			22.9 23.3	85.5 86.8	8.5 7.7	6.0 5.5	14.5 13.2
07	15.5	40.5	0.3		56.3			27.1	83.4	9.3	7.3	16.6
)8)9	11.2 12.1	46.1 41.0	0.3 0.3		57.6 53.4			25.6 29.2	83.2 82.6	9.4 9.9	7.3 7.5	16.8 17.4
10 ^f	12.4	38.5	0.3		51.2			31.6	82.8	9.8	7.5	17.2
11 ^f orecast.	11.9	37.7	0.3		49.9			35.3	85.2	8.4	6.4	14.8

f: forecast.

* Confidentiality precludes reporting territorial-level insurance data.

Table B Nun.—Total

Nun

Expenditure on Drugs by Type, by Source of Finance and as a Share of Public, Private and Total Health Expenditures, Nunavut, 1985 to 2011 (cont'd)

Share of Drugs in Public, Private and Total Health Expenditures All Drugs Health Expenditure Public Total Public Total Public Total Year (\$ Millions) 1985 1986 1987 1988 1989 1991 1993 1994 1995 1997 1998 1999 1.1 5.3 133.6 142.6 0.8 46.5 1.4 1.7 159.2 168.5 42.5 3.1 3.3 4.1 4.5 173.7 10.6 1.0 37.5 2001 4.0 5.7 184.3 2.4 6.3 7.4 4.7 5.8 6.5 41.9 43.8 47.0 203.8 215.0 2003 279.4 13.3 292.7 2.5 2004 13.9 294.1 13.9 308.0 6.1 6.8 8.3 2005 10.2 16.3 288.0 16.7 304.6 3.6 36.6 5.4 2006 2007 11.7 10.7 18.5 19.0 317.8 333.1 17.6 21.0 335.4 354.1 38.4 39.6 3.7 3.2 5.5 5.4 8.1 9.8 2008 11.0 19.1 346.6 21.0 367.6 3.2 38.6 5.2 2010^f 2011^f 11.1 11.3 21.7 22.6 341.3 373.7 25.8 27.4 41.1 41.3 5.9 5.6 10.6 367.1 3.3 401.1 11.3 al Percentage Change) 1985 1986 1987 1988 1990 1991 1992 1993 1994 1995 1996 1998 19.2 9.1 17.4 18.1 9.4 16.6 2000 31.3 23.1 -6.4 0.9 2.5 2001 14.4 2002 39.2 17.2 23.8 4.9 165.5 17.5 71.9 14.9 37.1 5.3 19.1 36.1 2004 12.1 38.4 -6.6 17.3 -2.1 -1.1 2005 20.0 2006 14.9 10.9 13.4 10.3 10.1 -9.2 3.4 1.7 2007 22.5 4.8 18.9 5.6 2008 -2.2 0.9 0.3 3.8 20.7 -0.8 2010^f -0.8 1.5 8.2 6.9 3.4 4.1 0.4 9.5 3.8 6.4 0.7 (Percentage Share of Total Drug Expenditure) 1985 1986 1987 1989 1990 1991 1992 1993 1994 1995 1996 1997 19.9 80.1 100.0 1999 2000 25.9 74.1 100.0 70.1 66.4 48.1 100.0 100.0 100.0 2001 2002 29.9 33.6 2003 51.9 2004 53.1 46.9 100.0 2005 62.6 37.4 100.0 2006 63.4 36.6 100.0 2007 56.3 43.7 100.0 57.6 53.4 42.4 46.6 100.0 100.0 2009 48.8 100.0 2011^f 49.9 50.1 100.0

f: forecast.

Table B Nun.—Per Capita

Nun.

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Nunavut, 1985 to 2011

					Prescribed	Drugs					Prescribed Dru	
	Territorial	Federal	Public Social Security		Subtotal	Insurers*	Private Out of	Subtotal	Total	Over-	rte (Out of Pock Personal	Total
				g Insurance Funds m Component)	Public		Pocket	Private	Prescribed Drugs	the- Counter Drugs	Health Supplies	Non-Presc. Drugs
Year			(i reillie	iii ooiiipolielit)		(\$ per Ca	pita)			Drugs		
1985 1986												
1987												
1988 1989												
1990												
1991												
1992 1993												
1994												
1995												
1996 1997												
1998 1999	36.87	1.47	0.87		39.22			49.87	89.09	 57.22	50.33	107.55
2000	43.76	5.60	0.88		50.24			53.24	103.47	56.42	34.07	90.49
2001	44.37	15.02	1.07		60.46			54.52	114.97	52.52	34.80	87.32
2002 2003	53.59 72.19	27.68 142.15	1.10 1.09		82.36 215.44			72.60 112.06	154.96 327.50	54.45 52.19	35.67 35.49	90.12 87.68
2004	75.53	172.02	1.69		249.24			137.95	387.20	50.53	32.00	82.53
2005	80.98	258.19	1.45		340.62			124.68	465.30	46.34	32.40	78.74
2006 2007	92.52 94.11	287.53 245.41	1.39 1.57		381.44 341.09			140.20 164.43	521.65 505.51	46.24 56.41	33.37 44.40	79.61 100.81
2008 2009	67.98 78.81	279.16 267.41	1.81 1.98		348.95 348.20			155.30 190.79	504.25 538.99	57.01 64.61	44.48 48.85	101.48 113.46
2010 ^f	81.10	251.48	2.07		334.66			206.25	540.90	63.96	48.72	112.68
2010 2011 ^f	80.29	253.13	2.05		335.48			237.03	572.50	56.42	43.26	99.69
						(Annual Percenta	ige Change)					
1985 1986												
1987												
1988 1989												
1990												
1991 1992												
1993												
1994												
1995 1996												
1997												
1998 1999												
2000	18.7	280.4	0.5		28.1			6.7	16.1	-1.4	-32.3	-15.9
2001 2002	1.4 20.8	168.4 84.3	22.0 2.3		20.3 36.2			2.4 33.2	11.1 34.8	-6.9 3.7	2.2 2.5	-3.5 3.2
2003	34.7	413.6	-0.1		161.6			54.4	111.3	-4.1	-0.5	-2.7
2004	4.6	21.0	54.5		15.7			23.1	18.2	-3.2	-9.8	-5.9
2005 2006	7.2 14.2	50.1 11.4	-14.3 -3.8		36.7 12.0			-9.6 12.5	20.2 12.1	-8.3 -0.2	1.2	-4.6 1.1
2007	1.7	-14.6	12.4		-10.6			17.3	-3.1	22.0	33.1	26.6
2008 2009	-27.8 15.9	13.8 -4.2	15.7 9.2		2.3 -0.2			-5.6 22.9	-0.2 6.9	1.1 13.3	0.2 9.8	0.7 11.8
2010 ^f	2.9	-6.0	4.7		-3.9			8.1	0.4	-1.0	-0.3	-0.7
2011 ^f	-1.0	0.7	-1.2		0.2	 nge in Excess of		14.9	5.8	-11.8	-11.2	-11.5
1985				(Annual	Percentage Cha	nge in Excess of	Inflation in the	Canadian Econo	omy) 	-		
1986 1987												
1988												
1989												
1990 1991												
1992												
1993 1994												
1995												
1996 1997												
1998												
1999												
2000 2001	14.6 0.0	276.3 167.0	-3.6 20.6		24.0 19.0			2.6 1.0	12.0 9.8	-5.5 -8.3	-36.4 0.8	-20.0 -4.9
2002	19.7	83.3	1.2		35.2			32.1	33.7	2.6	1.4	2.2
2003 2004	31.8 2.0	410.7 18.4	-3.0 51.9		158.7 13.1			51.5 20.5	108.4 15.6	-7.0 -5.8	-3.4 -12.4	-5.6 -8.5
2005	4.2	47.1	-17.3		33.7			-12.6	17.2	-11.3	-1.8	-7.6
2006 2007	11.4 -2.0	8.6 -18.3	-6.6 8.7		9.2 -14.3			9.7 13.6	9.3 -6.8	-3.0 18.3	0.2 29.4	-1.7 23.0
2008	-32.6	8.9	10.8		-2.6			-10.4	-5.1	-3.8	-4.7	-4.2
2009	18.6	-1.5	12.0		2.5			25.6	9.6	16.1	12.5	14.5
2010 ^f 2011 ^f f: forecast.	0.0 -5.0	-8.9 -3.3	1.7 -5.2		-6.8 -3.7			5.2 10.9	-2.6 1.8	-4.0 -15.8	-3.2 -15.2	-3.6 -15.5

2011 - 5.0 -

Table B Nun.—Per Capita

Expenditure on Drugs per Capita by Type, by Source of Finance and Public, Private and Total Health Expenditures, Nunavut, 1985 to 2011 (cont'd)

				•		•	GDP Implicit
	Public	All Drugs Private	Total		h Expenditure Private	Total	Price Index—Canada
Year			(\$ per Capit				(1997 = 100)
1985 1986							73.6 75.6
1987							79.2
1988							82.8
1989							86.6
1990 1991							89.2
1991							91.6 92.8
1993							94.1
1994							95.2
1995							97.4
1996 1997							99.0 100.0
1998							99.6
1999	39.22	157.43	196.64	4,979.28	338.43	5,317.71	101.4
2000	50.24	143.73	193.96	5,787.58	338.32	6,125.90	105.5
2001	60.46	141.83	202.29	6,175.94	378.42	6,554.36	106.9 108.1
2002 2003	82.36 215.44	162.72 199.74	245.08 415.18	7,091.92 9,579.10	388.55 456.07	7,480.48 10,035.17	111.2
2004	249.24	220.48	469.73	9,926.96	469.23	10,396.20	114.1
2005	340.62	203.41	544.04	9,594.32	556.13	10,150.45	117.5
2006	381.44	219.81	601.26	10,316.90	572.83	10,889.73	120.8
2007 2008	341.09 348.95	265.24 256.78	606.33 605.74	10,651.83 10,969.71	670.53 665.81	11,322.35 11,635.53	125.2 131.3
2009	348.20	304.26	652.46	10,556.54	771.17	11,327.71	127.8
2010 ^f	334.66	318.93	653.58	10,275.37	775.67	11,051.05	131.5
2011 ^f	335.48	336.71	672.19	11,113.19	815.45	11,928.64	136.8
			(An	nual Percentage Chang	e)		
1985							***
1986 1987							2.8 4.7
1988							4.5
1989							4.6
1990							3.0
1991							2.8
1992 1993							1.3 1.4
1994							1.1
1995							2.3
1996							1.7
1997							1.0
1998 1999							-0.4 1.8
2000 2001	28.1 20.3	-8.7 -1.3	-1.4 4.3	16.2 6.7	0.0 11.9	15.2 7.0	4.1 1.4
2002	36.2	14.7	21.2	14.8	2.7	14.1	1.0
2003	161.6	22.7	69.4	35.1	17.4	34.2	2.9
2004	15.7	10.4	13.1	3.6	2.9	3.6	2.6
2005	36.7	-7.7	15.8	-3.4	18.5	-2.4	3.0
2006 2007	12.0 -10.6	8.1 20.7	10.5 0.8	7.5 3.2	3.0 17.1	7.3 4.0	2.8 3.7
2008	2.3	-3.2	-0.1	3.0	-0.7	2.8	4.9
2009	-0.2	18.5	7.7	-3.8	15.8	-2.6	-2.7
2010 ^f	-3.9	4.8	0.2	-2.7	0.6	-2.4	2.9
2011 [†]	0.2	5.6	2.8	8.2	5.1	7.9	4.0
1985	(A)	nnual Percentage	Change in Excess of In	flation in the Canadian	Economy) 		
1986							
1987							
1988 1989							
1990							
1990							
1992							
1993 1994							
1995 1996							
1996							
1998							
1999							
2000	24.0	-12.8	-5.5	12.1	-4.1	11.1	
2001 2002	19.0 35.2	-2.7 13.7	2.9 20.1	5.4 13.8	10.5 1.6	5.6 13.1	
2003	158.7	19.9	66.5	32.2	14.5	31.3	
2004	13.1	7.8	10.5	1.0	0.3	1.0	
2005	33.7	-10.8	12.8	-6.4	15.5	-5.4	
2006 2007	9.2 -14.3	5.3 17.0	7.7 -2.8	4.7 -0.4	0.2 13.4	4.5 0.3	
2007	-14.3 -2.6	-8.1	-2.8 -5.0	-0.4 -1.9	-5.6	-2.1	
2009	2.5	21.2	10.4	-1.1	18.5	0.1	
2010 ^f	-6.8	1.9	-2.8	-5.6	-2.4	-5.4	
2011 ^f	-3.7	1.6	-1.1	4.2	1.1	3.9	
f: forecast.						National I	Health Expenditure Database, 20

f: forecast.

Nun.






Table C.1

The Share of Pharmaceutical Goods* in Total Expenditure on Health, in Descending Order, OECD Reporting Countries, 1985, 2008, 2009

1985		2008		2009	2009	
	(%)		(%)		(%)	
Portugal	25.4	Hungary	31.5	Hungary	32.6	
Korea	23.2	Mexico	28.3	Mexico	27.1	
Spain	20.3	Slovak Republic	27.6	Slovak Republic	26.6	
Japan	18.0	Korea	23.2	Estonia	23.4	
Iceland	16.6	Poland	22.6	Korea	22.5	
France	16.2	Estonia	20.7	Poland	22.4	
Belgium	15.7	Portugal	20.6	Czech Republic	19.4	
Luxembourg	14.8	Czech Republic	20.4	Spain	18.9	
United Kingdom	14.1	Japan	19.4	Slovenia	18.8	
Germany	13.8	Spain	18.7	Italy	18.2	
New Zealand	13.3	Slovenia	18.5	Ireland	17.5	
Turkey	13.0	Italy	18.3	Canada	17.0	
Switzerland	11.3	Ireland	17.3	Belgium	16.2	
Ireland	9.9	Canada	17.0	France	16.1	
Finland	9.7	Belgium	16.7	Iceland	15.7	
Canada	9.6	France	16.3	Germany	14.9	
Netherlands	9.3	Germany	15.0	Finland	14.3	
Norway	9.1	Finland	14.8	Austria	12.5	
Australia	9.0	Australia	14.6	Sweden	12.5	
United States	8.7	Iceland	14.6	United States	12.0	
Sweden	7.0	Austria	13.4	Switzerland	10.1	
Denmark	6.6	Sweden	12.9	Netherlands	9.6	
		United States	11.9	New Zealand	9.3	
		United Kingdom	11.6	Denmark	7.3	
		Switzerland	10.1	Norway	7.3	
		New Zealand	9.4			
		Luxembourg	9.1			
		Denmark	8.0			
		Norway	7.5			

Notes

Country-specific definitions differ from the OECD proposed standard definition as follows:

Greece: Excludes other medical non-durables.

Hungary: Excludes subsidies by local governments.

New Zealand: Includes cost of care provided in prisons and military facilities; excludes subsidies from

charitable not-for-profit organizations and regional and local governments.

Switzerland: Excludes other medical non-durables.

Turkey: Includes pharmaceutical consumption in hospitals.

Source

Organisation for Economic Co-operation and Development, OECD Health Data 2011(Paris, France: OECD, June 2011).

^{*} The OECD proposes the following standard definition: Includes prescribed medicines and self-medication, often referred to as over-the-counter (OTC) products. Also includes other medical non-durables comprising a wide range of items such as bandages, elasticized stockings, incontinence articles, condoms and other mechanical contraceptive devices. Excludes pharmaceutical consumption in hospitals.

Table C.2

The Share of Public Expenditure in Total Expenditure on Pharmaceutical Goods and Other Medical Non-Durables,* OECD Reporting Countries, 1985, 2008, 2009



1985	1985 2008 2009		2009		
	(%)		(%)		(%)
Turkey	90.0	United Kingdom	84.7	Netherlands	78.8
Luxembourg	86.0	Luxembourg	84.0	Germany	77.6
New Zealand	80.4	Germany	76.6	Ireland	74.7
Germany	71.9	Ireland	74.6	Spain	71.1
Sweden	70.1	Japan	72.1	Slovak Republic	69.8
France	67.1	Slovak Republic	71.4	Czech Republic	68.7
Portugal	64.7	Spain	70.0	Switzerland	68.5
United Kingdom	64.1	Switzerland	68.5	France	66.7
Netherlands	63.3	Austria	67.0	New Zealand	65.6
Spain	62.5	France	66.7	Austria	65.2
Iceland	61.9	New Zealand	63.7	Belgium	60.5
Ireland	60.8	Czech Republic	61.6	Korea	59.3
Japan	60.6	Sweden	59.7	Sweden	58.6
Belgium	51.0	Belgium	59.3	Slovenia	57.5
Australia	47.2	Slovenia	59.3	Hungary	57.3
Denmark	45.5	Korea	57.4	Finland	55.4
Finland	44.5	Hungary	56.7	Norway	53.9
Norway	43.2	Portugal	56.2	Denmark	53.3
Canada	29.4	Norway	54.8	Iceland	48.8
Korea	15.4	Finland	54.6	Italy	46.8
United States	8.4	Denmark	54.3	Estonia	41.4
		Australia	53.8	Canada	38.8
		Iceland	48.1	Poland	38.6
		Italy	47.3	United States	31.1
		Estonia	42.9	Mexico	18.9
		Canada	38.7		
		Poland	38.3		
		United States	30.3		
		Mexico	20.1		

Notes

Country-specific definitions differ from the OECD proposed standard definition as follows:

Greece: Excludes other medical non-durables.

Hungary: Excludes subsidies by local governments.

New Zealand: Includes cost of care provided in prisons and military facilities; excludes subsidies from

charitable not-for-profit organizations and regional and local governments.

Norway: Public expenditure includes expenditure by hospitals and the National Insurance Administration

(Rikstrygdeverket, RTV) only.

Switzerland: Excludes other medical non-durables.

Turkey: Includes pharmaceutical consumption in hospitals.

Source

Organisation for Economic Co-operation and Development, OECD Health Data 2011 (Paris, France: OECD, June 2011).

^{*} The OECD proposes the following standard definition: Includes prescribed medicines and self-medication, often referred to as over-the-counter (OTC) products. Also includes other medical non-durables comprising a wide range of items such as bandages, elasticized stockings, incontinence articles, condoms and other mechanical contraceptive devices. Excludes pharmaceutical consumption in hospitals.

Table C.3

The Share of Pharmaceutical Goods* in Public Expenditure on Health, in Descending Order, OECD Reporting Countries, 1985, 2008, 2009

1985		2008		2009	2009	
	(%)		(%)		(%)	
Portugal	30.1	Slovak Republic	29.1	Slovak Republic	28.2	
Turkey	23.1	Hungary	25.2	Hungary	26.8	
Spain	15.7	Korea	23.8	Korea	22.9	
Japan	15.4	Spain	18.0	Spain	18.2	
Luxembourg	14.2	Portugal	17.8	Ireland	17.4	
France	13.8	Japan	17.3	Czech Republic	15.8	
Germany	12.8	Ireland	16.8	Germany	15.0	
New Zealand	12.3	Czech Republic	15.2	Slovenia	14.7	
Iceland	11.8	Germany	15.0	France	13.8	
Korea	11.3	Slovenia	15.0	Belgium	13.0	
United Kingdom	10.5	France	14.0	Estonia	12.9	
Netherlands	8.3	Belgium	13.2	Poland	12.0	
Ireland	7.9	Mexico	12.1	Switzerland	11.6	
Australia	6.0	Poland	12.0	Italy	11.0	
Finland	5.5	United Kingdom	12.0	Finland	10.6	
Sweden	5.4	Switzerland	11.7	Mexico	10.6	
Norway	4.6	Austria	11.7	Austria	10.5	
Canada	3.8	Australia	11.6	Canada	9.4	
Denmark	3.5	Estonia	11.4	Iceland	9.3	
United States	1.8	Italy	11.2	Sweden	9.0	
		Finland	10.8	United States	7.8	
		Sweden	9.4	New Zealand	7.5	
		Canada	9.3	Chile	6.0	
		Luxembourg	9.1	Norway	4.7	
		Iceland	8.5	Denmark	4.6	
		United States	7.8			
		New Zealand	7.4			
		Chile	6.1			
		Denmark	5.1			
		Norway	4.8			



Notes

Country-specific definitions differ from the OECD proposed standard definition as follows:

Greece: Excludes other medical non-durables.

Hungary: Excludes subsidies by local governments.

New Zealand: Includes cost of care provided in prisons and military facilities; excludes subsidies from

charitable not-for-profit organizations and regional and local governments.

Norway: Public expenditure includes expenditure by hospitals and the National Insurance Administration

(Rikstrygdeverket, RTV) only.

Switzerland: Excludes other medical non-durables.

Turkey: Includes pharmaceutical consumption in hospitals.

Source

Organisation for Economic Co-operation and Development, OECD Health Data 2011 (Paris, France: OECD, June 2011).

^{*} The OECD proposes the following standard definition: Includes prescribed medicines and self-medication, often referred to as over-the-counter (OTC) products. Also includes other medical non-durables comprising a wide range of items such as bandages, elasticized stockings, incontinence articles, condoms and other mechanical contraceptive devices. Excludes pharmaceutical consumption in hospitals.

Appendix A—Comparison of Provincial and Territorial Drug Subsidy Programs

Comparison of Provincial and Territorial Drug Subsidy Programs

Table 7 gives an overview of provincial and territorial drug subsidy programs as of December 31, 2011. The table was verified for accuracy with provincial/territorial programs. Information is also available from the following websites:

British Columbia Pharmacare

www.health.gov.bc.ca/pharmacare/

Alberta Prescription Drug Program

www.health.alberta.ca/AHCIP/prescription-program.html

Saskatchewan Drug Plan

www.health.gov.sk.ca/prescription-drugs

Manitoba Pharmacare Program

www.gov.mb.ca/health/pharmacare/index.html

Ontario Drug Benefits

www.health.gov.on.ca/en/public/programs/drugs/default.aspx

Régime général d'assurance médicaments du Québec (RGAM)

www.ramq.gouv.qc.ca/en/citoyens/assurancemedicaments/index.shtml

New Brunswick Prescription Drug Program

www.gnb.ca/0212/intro-e.asp

Nova Scotia Pharmacare

http://www.gov.ns.ca/health/pharmacare/

Prince Edward Island Pharmacy Services

www.healthpei.ca/index.php3?number=1026180&lang=E

Newfoundland and Labrador Prescription Drug Program

www.health.gov.nl.ca/health/prescription/nlpdp plan overview.html

Yukon Pharmacare

www.hss.gov.yk.ca/insured_services.php

Northwest Territories

www.hlthss.gov.nt.ca/english/services/health care plan/default.htm

Nunavut

www.drugcoverage.ca/p benefit nu.asp

Table 7: Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2011

						Maximum
Province/ Territory	Program/ Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
British Columbia	Fair PharmaCare Enhanced Assistance	Families in which at least one family member is born in 1939 or earlier and is not covered by other plans		income: \$0: <\$33K 1%: \$33K to \$50K 2%: >\$50K	PharmaCare pays 75%	1.25%: <\$33K 2%: \$33K to \$50K 3%: >\$50K
	Fair PharmaCare	Families in which all family members are born in 1940 or later and are not covered by other plans		income: \$0: <\$15K 2%: \$15K to \$30K 3%: >\$30K	PharmaCare pays 70%	2%: <\$15K 3%: \$15K to \$30K 4%: >\$30K
	PharmaCare Plan B	Permanent residents of licensed residential care facilities	None	None	None	N/A
	PharmaCare Plan C	Recipients of B.C. Income Assistance	None	None	None	N/A
	PharmaCare Plan D	Cystic fibrosis patients registered with a provincial cystic fibrosis clinic	None	None	None	N/A
	PharmaCare Plan F	Severely handicapped children registered in the At Home Program	None	None	None	N/A
	PharmaCare Plan G	health service centres meeting clinical and low- income criteria	None	None	None	N/A
	PharmaCare Plan P	Palliative care patients treated at home	None	None	None	N/A
	Smoking Cessation Program		None	See applicable PharmaCare plans above	See applicable PharmaCare plans above	See applicable PharmaCare plans above

Table 7: Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2011 (cont'd)

Province/ Territory	Program/ Plan	Beneficiary	Premium	Deductible	Copay	Maximum Annual Copay
Alberta	Seniors	Seniors age 65 and older and their eligible dependants	None	None	30% of prescription to a max. of \$25 per prescription*	N/A
	Widows	Residents age 55 to 64 who qualify for Alberta Widows' Pension and eligible dependants	None	None	30% of prescription to a max. of \$25 per prescription*	N/A
	Palliative	Palliative residents treated at home	None	None	30% of prescription to a max. of \$25 per prescription*	The lifetime maximum amount palliative patients pay out of pocket is \$1,000
	Non-Group	A universal plan available to all residents under the age of 65	Monthly rate is \$63.50 for singles and \$118.00 for families. Subsidized rates are available at \$44.45 for singles and \$82.60 for families.	None	30% of prescription to a max. of \$25 per prescription*	N/A
	Province-Wide Services	Residents with specific conditions may be eligible for high-cost drugs, mostly transplant and HIV drugs via Alberta Health Services	None	None	None	N/A
	Income Support	Residents receiving social assistance and eligible dependants	None	None	None	N/A

^{*} Costs incurred by the client choosing a high-cost product where cheaper alternatives are available are borne by the client.

Table 7: Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2011 (cont'd)

Province/ Territory	Program/ Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Alberta (cont'd)		Residents receiving AISH (an income- support program for adults with a permanent disability that severely impairs their ability to earn a living) and eligible dependants	None	None	None	N/A
	Alberta Adult Health Benefit	Qualified clients leaving Income Support for work	None	None	None	N/A
	Alberta Child Health Benefit	Children in low- income families	None	None	None	N/A
	Rare Diseases Drug Program	Residents with extremely rare genetic disorders (Gaucher's disease, Fabry disease, MPS-I, Hunter disease and Pompe disease) may be eligible for rare disease drugs via Alberta Health Services	None	None	None	N/A
Saskatchewan [†]	Drug Plan—	All residents with Saskatchewan health coverage (application required)	None	(annual threshold based on 3.4% of adjusted family income)	Income-tested (based on benefit drug costs, to help spread cost out evenly over the year)	N/A
	Seniors' Drug Plan	Saskatchewan residents 65 and older. Individual annual net income must be below the limit for the federal age credit to be eligible for the cap of \$15 per prescription (application required to determine eligibility).	None	None	Maximum \$15 per prescription	N/A

[†] To be eligible for drug plan coverage, the resident must not be covered under another provincial or federal government program, such as the Non-Insured Health Benefits Program. For all residents who are eligible for more than one drug plan program, the best coverage for each prescription will be applied.

Table 7: Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2011 (cont'd)

Province/ Territory	Program/ Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Saskatchewan [†] (cont'd)	Supplement Recipients (Basic Deductible Programs) Note: May also apply for the	Seniors receiving the Seniors Income Plan supplement or receiving the federal Guaranteed Income Supplement and residing in a special care home	None	\$100 semi- annual family deductible	35% consumer copayment after deductible has been paid	N/A
	Seniors' Drug Plan and the Special Support Program	Seniors receiving the Guaranteed Income Supplement and living in the community	None	\$200 semi- annual family deductible	35% consumer copayment after deductible has been paid	N/A
	Emergency Assistance Program	Residents who require immediate treatment with covered prescription drugs and are unable to cover their share of the cost. This is a one-time benefit, and individuals are encouraged to apply for incometested coverage for future assistance.	None	None	The level of assistance provided is in accordance with the consumer's ability to pay	N/A
	Family Health Benefits	Eligibility is established by the Ministry of Social Services, based on the number of children in the family and the family's annual income	None	\$100 semi- annual family deductible	No charge for benefit prescriptions for children; 35% consumer copayment after deductible has been paid for adult benefit prescriptions	N/A

[†] To be eligible for drug plan coverage, the resident must not be covered under another provincial or federal government program, such as the Non-Insured Health Benefits Program. For all residents who are eligible for more than one drug plan program, the best coverage for each prescription will be applied.

Table 7: Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2011 (cont'd)

Province/ Territory	Program/ Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Saskatchewan' (cont'd)	Supplementary Health	Persons nominated by Saskatchewan Social Services for special coverage, including persons on social assistance, wards, inmates, etc.	None	None	Up to \$2 per prescription (some drugs covered at no charge; individuals younger than 18 and certain other categories receive benefit prescriptions at no charge)	N/A
	Saskatchewan Aids to Independent Living (SAIL)	Persons registered under the following SAIL programs receive formulary and approved nonformulary drugs at no charge: Paraplegia Program, Cystic Fibrosis Program and Chronic End-Stage Renal Disease Program	None	None	None	N/A
	Palliative Care Program	Residents who are in the late stages of a terminal illness	None	None	None	N/A
	Children's Insulin Pump Program	Type 1 diabetic children (younger than 18) who require pumps to adequately stabilize blood sugar levels and are not eligible for benefits under a federal government program (such as the Non-Insured Health Benefits Program)	None	None	No charge for insulin pump. Insulin pump supplies subject to coverage (family deductible/ copay).	N/A
	Children's Drug Plan	Children 14 and younger	None	None	Maximum \$15 per prescription	N/A

[†] To be eligible for drug plan coverage, the resident must not be covered under another provincial or federal government program, such as the Non-Insured Health Benefits Program. For all residents who are eligible for more than one drug plan program, the best coverage for each prescription will be applied.

Table 7: Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2011 (cont'd)

Province/ Territory	Program/ Plan	Beneficiary	Premium	Deductible	Copay	Maximum Annual Copay
Manitoba	Pharmacare	All provincial residents who are eligible for benefits under The Prescription Drug Cost Assistance Act	None	Ranging from 2.73% to 6.17% based on total adjusted family income. Credit of \$3,000 for a spouse and each dependant younger than 18.	None	N/A
	Employment and Income Assistance Program	Individual Manitobans who are receiving drug benefits pursuant to the Employment and Income Assistance Program	None	None	None	N/A
	Personal Care Home/Nursing Home	Manitoba residents of personal care homes	None	None	None	N/A
	Palliative Care Drug Access Program	Residents who are terminally ill and wish to remain at home	None	None	None	N/A
Ontario	Ontario Drug Benefit Program	Seniors (65 and older). Single seniors with annual income ≥\$16,018 or seniors in couples with combined annual income of ≥\$24,175.	None	\$100 per recipient	After deductible, up to \$6.11 per prescription and \$2.83 for prescriptions dispensed in outpatient hospital pharmacies	N/A
		Seniors (65 and older). Single seniors with annual income <\$16,018 or seniors in couples with combined annual income of <\$24,175.	None	None	Up to \$2 per prescription	N/A

Table 7: Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2011 (cont'd)

Province/ Territory	Program/ Plan	Beneficiary	Premium	Deductible	Copay	Maximum Annual Copay
Ontario (cont'd)		Residents of long- term care facilities	None	None	Up to \$2 per prescription	N/A
		Residents of homes for special care	None	None	Up to \$2 per prescription	N/A
		Residents receiving professional services under the home care program	None	None	Up to \$2 per prescription	N/A
		Residents receiving social assistance (Ontario Disability Support Program or Ontario Works Program)	None	None	Up to \$2 per prescription	N/A
	Trillium Drug Program	Residents with high drug costs in relation to income	None	Income-based	Up to \$2 per prescription	N/A
	Special Drugs Program	Residents with valid Ontario health insurance. Coverage is product-specific for a limited number of diseases or conditions.		None	None	N/A

Table 7: Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2011 (cont'd)

Province/ Territory	Program/ Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Quebec	Régime public	Employment assistance (welfare) recipients (EAR) and other holders of a claim slip	None	None	None	None
		Seniors (65 and older) receiving at least 94% of the maximum Guaranteed Income Supplement (GIS)	None	None	None	None
		Seniors (65 and older) receiving less than 94% of the maximum GIS	\$0 to \$563 per adult per year, depending on income		32% of prescription costs	\$49.97 per month
		Seniors (65 and older) without GIS	\$0 to \$563 per adult per year, depending on income	\$16.00 per month	32% of prescription costs	\$80.25 per month
		General clientele (residents younger than 65 without access to a group plan). Adults are subject to a premium, a deductible and a copayment. Their children (including students age 18 to 25, under certain conditions) are covered free of charge.		\$16.00 per month	32% of prescription costs	\$80.25 per month

Table 7: Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2011 (cont'd)

Province/ Territory	Program/ Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
New Brunswick	Plan A	Seniors with Guaranteed Income Supplement (GIS)		None	\$9.05 for each prescription	\$250
Plan B Plan E		Seniors without GIS who qualify for benefits based on annual income as follows: a single senior with an annual income of \$17,198 or less; a senior couple (both ≥65) with a combined annual income of \$26,955 or less; a senior couple with one spouse younger than 65, with a combined annual income of \$32,390 or less	None	None	\$15 per prescription	N/A
	Plan B	Cystic fibrosis patients or patients with juvenile or infant sclerosis of the pancreas	\$50 yearly registration fee	None	20% prescription cost up to a maximum of \$20	\$500 per family
	Plan E	Individuals residing in a licensed adult residential facility who hold a valid health card for prescription drugs issued by the Department of Social Development	None	None	\$4 for each prescription	\$250
	Plan F	Individuals holding a valid health card for prescription drugs issued by the Department of Social Development	None	None	\$4 per prescription for adults (18 and older) and \$2 for children (younger than 18)	\$250 per family

Table 7: Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2011 (cont'd)

Province/ Territory	Program/ Plan	Beneficiary	Premium	Deductible	Copay	Maximum Annual Copay
New Brunswick (cont'd)	Plan G	Special-needs children and children in the care of the Minister of Social Development	None	None	None	N/A
	Plan H	Individuals diagnosed with multiple sclerosis and in possession of a prescription written by a neurologist for the medications Avonex, Rebif, Betaseron or Copaxone are eligible to apply for assistance	\$50 yearly registration fee	None	Income-tested (ranges from 0% to 100%)	N/A
	Plan R	Recipients of an organ or bone marrow transplant who are registered and qualify with the NBPDP	\$50 yearly registration fee	None	20% prescription cost up to a maximum of \$20	\$500 per family
	Plan T	Individuals with growth hormone deficiency or hypopituitarism who are registered and qualify with the NBPDP	\$50 yearly registration fee	None	20% prescription cost up to a maximum of \$20	\$500 per family
	Plan U	Individuals who are HIV positive and are registered with the NBPDP	\$50 yearly registration fee	None	20% prescription cost up to a maximum of \$20	\$500 per family
	Plan V	Individuals who reside in a registered nursing home	None	None	None	N/A

Table 7: Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2011 (cont'd)

Province/ Territory	Program/ Plan	Beneficiary	Premium	Deductible	Copay	Maximum Annual Copay
Nova Scotia	Seniors Pharmacare Program	Residents (65 and older) who are receiving the Guaranteed Income Supplement (GIS), are covered by Medical Services Insurance (MSI) and do not have prescription drug coverage through Veterans Affairs Canada, Non-Insured Health Benefits, Nova Scotia Family Pharmacare or any other public or private plan	None	None	30% prescription cost	\$382
		Residents (65 and older) who are not receiving the GIS, are covered by MSI and do not have prescription drug coverage through Veterans Affairs Canada, Non-Insured Health Benefits, Nova Scotia Family Pharmacare or any other public or private plan	Up to \$424 per year	None	30% prescription cost	\$382
	Department of Community Services Programs	Eligible clients and their dependants in receipt of income assistance; any client and/or dependant having access to another drug plan, be it from a public or private entity, will be required to use that plan and will not be eligible for the Pharmacare Program	None	None	All income- assistance clients and dependants are required to copay a flat fee of \$5 per prescription unless the client or dependant is eligible for copay exemption	N/A

Table 7: Comparison of Prov	incial and Territorial	Drug Subsidy Programs	as of
December 2011 (co	ont'd)		

Province/ Territory	Program/ Plan	Beneficiary	Premium	Deductible	Copay	Maximum Annual Copay
Nova Scotia (cont'd)	for Čancer Patients	Residents with a valid Nova Scotia health card who are not eligible for any other drug coverage, except Nova Scotia Family Pharmacare; have a diagnosis of cancer; have a gross family income of no more than \$15,720; provide a copy of their most recent Income Tax Notice of Assessment or Reassessment from the Canada Revenue Agency (CRA) for the cancer patient, his or her parent(s) or guardian(s), spouse or common-law partner; and agree to family income verification from the CRA Notice of Assessment or Reassessment or Reassessment		None	None	N/A
	Family Pharmacare Program	Residents with a valid Nova Scotia health card who agree to provide family size verification and also agree to family income verification through the CRA	None	Income-based	20% of the total prescription cost	Income- based

Table 7: Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2011 (cont'd)

Province/ Territory	Program/ Plan	Beneficiary	Premium	Deductible	Copay	Maximum Annual Copay
Nova Scotia (cont'd)	Nova Scotia Diabetes Assistance Program (NSDAP) Effective April 1, 2010, the NSDAP will no longer be accepting new beneficiaries. Existing beneficiaries of the NSDAP are required to re-register by April 1 each year to remain in the program. Anyone newly diagnosed with diabetes who is a member of a family currently enrolled in the NSDAP will be covered.	Residents younger than 65 with a valid Nova Scotia health card who do not have drug coverage through Veterans Affairs Canada, First Nations and Inuit Health or any private drug plans that cover diabetes medications and supplies: have a confirmed diagnosis of diabetes; agree to provide family size verification; and agree to family income verification through the CRA	None	Income-based	20% of the total prescription cost	N/A
Prince Edward Island	Seniors Drug Cost Assistance Plan		None	None	First \$8.25 of the medication cost plus the pharmacy professional fee for each prescription	N/A
	Children-in- Care	Persons eligible under the Social Assistance Act and persons in the temporary or permanent care of the Director of Child Welfare	None	None	None	N/A

Table 7: Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2011 (cont'd)

Province/ Territory	Program/ Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Prince Edward Island (cont'd)	Family Health Benefit Program	Families (parents, guardians and children younger than 18 or younger than 25 and in full-time attendance at a post-secondary education institution), eligible for P.E.I. Medicare with a total net family income less than the threshold. Families must apply for coverage on an annual basis and provide income information to the program.	None	None	The pharmacy professional fee for each prescription	N/A
	Financial Assistance Program	Persons eligible under the <i>Social</i> <i>Assistance Act</i>	None	None	None	N/A
	Erythropoietin Program	Persons eligible for P.E.I. Medicare who have been diagnosed with chronic renal failure or are receiving kidney dialysis and registered with the program	None	None	None	N/A

Table 7: Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2011 (cont'd)

Province/ Territory	Program/ Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
	Diabetes Control Program	Persons eligible for P.E.I. Medicare who are registered with the diabetes program and are insulin-dependent	None	None	Blood glucose test strips: \$11 per prescription to a maximum of 100 strips every 30 days	N/A
					Oral medications and urine testing materials: \$11 per prescription	
					High-cost diabetes medications: an income- based portion of the medication plus the professional fee for each high-cost medication obtained	
	High Cost Drugs Program	Persons eligible for P.E.I. Medicare and approved for coverage of one or more of the medications included in the program. Patients must apply for coverage on an annual basis and provide income information to the program.	None	None	Income-based portion of the drug cost plus the pharmacy professional fee for each prescription	N/A
	Community Mental Health Program	Approved long-term psychiatric patients living in the community	None	None	None	N/A
		Persons diagnosed with sexually transmitted disease or identified contacts of a person with a sexually transmitted disease	None	None	None	N/A

Table 7:	Comparison of	of Provincial	and Te	erritorial	Drug	Subsidy F	Programs	as of
	December 20	11 (cont'd)						

Province/ Territory	Program/ Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Prince Edward Island (cont'd)	Nursing Home Program	Residents in government manors or private nursing homes eligible for coverage under the Long-Term Care Subsidization Act	None	None	None	N/A
	Disease-Specific Programs (AIDS/HIV, cystic fibrosis, growth hormone, hepatitis, tuberculosis, hairy cell leukemia, AIDS-related Kaposi's sarcoma, basal cell carcinoma, meningitis, phenylketonuria, transplant drug programs delivered through the government-run provincial pharmacy, Crohn's disease and rheumatic fever)	Persons eligible for P.E.I. Medicare and registered with the program who are diagnosed with specific medical conditions or at risk for exposure to communicable diseases	None	None	None	N/A
	Quit-Smoking Program	Persons eligible for P.E.I. Medicare and who have registered with the program	None	None	Patients are responsible for all medication costs approved, except for the first \$75, which will be paid by the program	N/A
	Nutrition Program	Children and high-risk pregnant women diagnosed with a nutritional deficiency	None	None	None	N/A
	Immunization Program	Children and persons at risk for exposure to various communicable diseases	None	None	None	N/A

Table 7: Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2011 (cont'd)

Province/ Territory	Program/ Plan	Beneficiary	Premium	Deductible	Copay	Maximum Annual Copay
Prince Edward Island (cont'd)	rabico i rogiam	Persons with exposure to or at risk for exposure to rabies through an animal bite	None	None	None	N/A
	Program	Persons eligible for P.E.I. Medicare and prescribed oxygen by a specialist and who meet clinical criteria	None	None	P.E.I. Medicare will pay 50% of the cost of eligible expenses up to a maximum of \$200 per month	N/A
Newfoundland and Labrador	Plan	Seniors (65 and older) who are in receipt of the Guaranteed Income Supplement and who are registered for Old Age Security benefits	None	None	Markup and professional fee for identified benefits	N/A
	Plan	Residents of the province who qualify for full benefit coverage under the Department of Human Resources, Labour and Employment, and certain individuals receiving services through the regional health authorities, including children in the care of Child, Youth and Family Services and individuals in supervised care	None	None	None	N/A

nparison of Pro ember 2011 (c	vincial and Territo ont'd)	orial Drug Sub	sidy Program	is as of	
					Maximum

	ember zum (C					
Province/ Territory	Program/ Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Newfoundland and Labrador (cont'd)	The Access Plan	Residents with low incomes who access eligible prescription medications. The amount of coverage is determined by family net income level and family status.	None	None	Based on family net income: Family (with children) Income Copay <\$30,009 20.0% \$31,000 23.9% \$32,000 27.7% \$33,000 31.6% \$34,000 35.5% \$36,000 43.3% \$37,000 47.2% \$38,000 51.1% \$39,000 55.0% \$40,000 58.8% \$41,000 62.7% \$42,000 66.6% \$42,870 70.0% Couple (with no children) Income Copay <\$21,435 20.0% \$22,000 23.3% \$23,000 29.1% \$24,000 66.6% \$27,000 52.4% \$28,000 46.6% \$27,000 52.4% \$28,000 58.3% \$29,000 64.1% \$30,000 69.9% \$30,000 70.0% Single individuals Income Copay <\$18,577 20.0% \$19,000 22.5% \$20,000 28.3% \$21,000 34.1% \$22,000 40.0% \$22,000 51.6% \$25,000 40.0% \$25,000 40.0% \$25,000 51.6% \$25,000 57.5% \$26,000 57.5% \$26,000 69.1% \$27,000 69.1% \$27,000 69.1% \$27,000 69.1% \$27,000 69.1% \$27,000 69.1%	Between 20% and 70%, depending on family net income and family status (single, couple or family)

Table 7: Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2011 (cont'd)

Province/ Territory	Program/ Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Newfoundland and Labrador (cont'd)	The Assurance Plan	Residents who experience the financial burden of eligible high drug costs, whether it be from the cost of one extremely high-cost drug or the combined cost of different drugs	None	None	Based on a combination of family net income and eligible family drug costs	Based on family net income: Income
	The Select Needs Plan	Residents with cystic fibrosis or growth hormone deficiency	None	None	None, for identified benefits	N/A
Yukon	Pharmacare	Seniors 65 or older (and seniors' spouses age 60 and older) registered with Yukon Health Care Insurance Plan and not having coverage through First Nations and Inuit Health. Residents with another third-party or group insurance must use that plan first. Program includes clients receiving palliative care.		None	None	N/A
	Chronic Disease Program	Residents who have a chronic disease or a serious functional disability as provided under the Chronic Disease and Disability Benefits Regulations and not having coverage through First Nations and Inuit Health. Residents with another third-party or group insurance must use that plan first. Program includes clients receiving palliative care.	None	Maximum \$250 per year per individual and \$500 per year per family (deductible may be waived, depending on income)	None	N/A

Table 7: Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2011 (cont'd)

Province/ Territory	Program/ Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Yukon (cont'd)	Children's Drug and Optical Program	Children younger than 19 from low- income families and not having coverage through First Nations and Inuit Health	None	Maximum \$250 per child and \$500 per year per family (deductible may be waived, depending on income)	None	N/A
Northwest Territories	Extended Health Benefits Program for Specified Diseases	Resident, non- native or Métis and have a specified disease condition	None	None	None	N/A
	Seniors' Benefit Program	Resident and non- native residents who are 60 years and older	None	None	None	N/A
	Métis Health Benefits Program	Resident, registered with territorial health care plan, descendant of Chipewyan, Slavey, Gwich'in, Dogrib, Hare or Cree people; and resided in or used and occupied the Mackenzie Basin on or before January 1, 1921, or is a Community Acceptance Member, or was adopted as a minor	None	None	None	N/A
	Indigent Health Benefits Program	Indigent individuals or families resident of the Northwest Territories, who meet the eligibility requirements according to the Indigent Health Benefits Policy	None	None	None	N/A

Table 7: Comparison of Provincial and Territorial Drug Subsidy Programs as of December 2011 (cont'd)

Province/ Territory	Program/ Plan	Beneficiary	Premium	Deductible	Сорау	Maximum Annual Copay
Nunavut	Extended Health Benefits Program		None	None	None	N/A
	Indigent Health Benefits Program	Residents receiving income support	None	None	None	N/A

References

- 1. Canadian Institute for Health Information, *National Health Expenditure Trends*, 1975 to 2011 (Ottawa, Ont.: CIHI, 2011).
- 2. S. Morgan, "Sources of Variation in Provincial Drug Spending," *CMAJ* 170, 3 (2004): pp. 329–330.
- 3. Organisation for Economic Co-operation and Development, *OECD.Stat Extracts*, accessed November 2011, from http://www.oecd.org.
- 4. Canadian Institute for Health Information, *Drug Use Among Seniors on Public Drug Programs in Canada, 2002 to 2008* (Ottawa, Ont.: CIHI, 2010).
- 5. M. Aaserud et al., "Pharmaceutical Policies: Effects of Reference Pricing, Other Pricing and Purchasing Policies (Review)," *The Cochrane Collaboration* 4 (The Cochrane Library: John Wiley & Sons, Ltd., 2006): pp. 1–66, Cochrane Library Number CD005979.
- 6. Canadian Institute for Health Information, *Health Care Cost Drivers: The Facts.* (Ottawa, Ont.: CIHI, 2011).
- 7. Health Council of Canada, *Generic Drug Pricing and Access in Canada: What Are the Implications?* (Toronto, Ont.: Health Council of Canada, June 2010), accessed on February 10, 2011, from http://healthcouncilcanada.ca.
- 8. Alberta Health and Wellness, "Alberta Pharmaceutical Strategy Phase Two," (fact sheet) (Edmonton, Alta.: Alberta Health and Wellness, January 2010), accessed on February 14, 2011, from http://www.health.alberta.ca>.
- 9. S. Morgan et al., "'Breakthrough' Drugs and Growth in Expenditure on Prescription Drugs in Canada," *BMJ* 331, 7520 (October 8, 2005): pp. 815–816, accessed on February 8, 2007, from http://www.pubmedcentral.nih.gov, catalogue no. 38582.703866.
- 10. Z. Karaca and S. Wiggins, *The Impacts of Breakthrough Drug Classes on Total Health Expenditures: Empirical Evidence From the 1996–2001 Medical Expenditure Panel Surveys*, eds. Z. Karaca and S. Wiggins (Texas: A&M University, November 11, 2006), pp. 1–40, accessed on February 14, 2007, from http://ssrn.com, catalogue no. 947603.
- 11. F. R. Lichtenberg, "Are the Benefits of Newer Drugs Worth Their Cost? Evidence From the 1996 MEPS," *Health Affairs* 20, 5 (September/October 2001): pp. 241–251.
- 12. Canadian Cancer Society, *A National Home Care Program*, accessed on February 9, 2007, from http://www.cancer.ca.
- 13. B. Mintzes et al., "Volume IV: Pills, Persuasion and Public Health Policies," in *An Assessment of the Health System Impacts of Direct-to-Consumer Advertising of Prescription Medicines (DTCA)*, eds. B. Mintzes, A. Kazanjian, K. Bassett and J. Lexchin (Report of an Expert Survey on Direct-to-Consumer Advertising of Prescription Drugs in Canada, the United States and New Zealand) (Vancouver, B.C.: Health Policy and Research Unit, Centre for Health Services and Policy Research, August 2001), pp. 1–48, accessed on February 14, 2007, from http://www.chspr.ubc.ca, catalogue no. HPRU 02:4D.

- 14. Statistics Canada, *Guide to the Income and Expenditure Accounts* (Ottawa, Ont.: Statistics Canada, 2008), p. 23, catalogue no. 13-017.
- 15. Organisation for Economic Co-operation and Development, *OECD Health Data 2011* (Paris, France: OECD, 2011).
- 16. Statistics Canada, *Family Expenditure in Canada* (Ottawa, Ont.: Statistics Canada), catalogue no. 65-555-XPB.
- 17. Statistics Canada, *Your Guide to the Consumer Price Index* (Ottawa, Ont.: Statistics Canada, 1996), pp. 7–9, accessed on February 9, 2007, from http://www.statcan.gc.ca, catalogue no. 62-557-XPB.

Production of this report is made possible by financial contributions from Health Canada and provincial and territorial governments. The views expressed herein do not necessarily represent the views of Health Canada or any provincial or territorial government.

All rights reserved.

The contents of this publication may be reproduced unaltered, in whole or in part and by any means, solely for non-commercial purposes, provided that the Canadian Institute for Health Information is properly and fully acknowledged as the copyright owner. Any reproduction or use of this publication or its contents for any commercial purpose requires the prior written authorization of the Canadian Institute for Health Information. Reproduction or use that suggests endorsement by, or affiliation with, the Canadian Institute for Health Information is prohibited.

For permission or information, please contact CIHI:

Canadian Institute for Health Information 495 Richmond Road, Suite 600 Ottawa, Ontario K2A 4H6

Phone: 613-241-7860 Fax: 613-241-8120

www.cihi.ca

copyright@cihi.ca

ISBN 978-1-77109-032-2 (PDF)

© 2012 Canadian Institute for Health Information

How to cite this document:

Canadian Institute for Health Information, *Drug Expenditure in Canada, 1985 to 2011* (Ottawa, Ont.: CIHI, 2012).

Cette publication est aussi disponible en français sous le titre *Dépenses en médicaments au Canada, de 1985 à 2011*.
ISBN 978-1-77109-033-9 (PDF)

Talk to Us

CIHI Ottawa

495 Richmond Road, Suite 600 Ottawa, Ontario K2A 4H6 Phone: 613-241-7860

CIHI Toronto 4110 Yonge Street, Suite 300 Toronto, Ontario M2P 2B7 Phone: 416-481-2002

CIHI Victoria

880 Douglas Street, Suite 600 Victoria, British Columbia V8W 2B7

Phone: 250-220-4100

CIHI Montréal

1010 Sherbrooke Street West, Suite 300 Montréal, Quebec H3A 2R7 Phone: 514-842-2226

CIHI St. John's

140 Water Street, Suite 701 St. John's, Newfoundland and Labrador A1C 6H6 Phone: 709-576-7006



www.cihi.ca At the heart of data